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Influenza A viruses (IAVs) belong to the family Orthomyxoviridae and represent major 
pathogens of both humans and animals. Swine influenza virus is an important pathogen 
that affects not only the swine industry, but also represents a constant threat to the 
turkey industry and is of particular concern to public health. In North America, H3N2 
triple reassortant (TR) IAVs first emerged in 1998 and have since become endemic in 
swine populations. In the first part of this dissertation, we focused on the role of 
surface glycoproteins and PB1-F2 to unravel their roles in the virulence of TR IAVs 
in this important natural host. We found that surface glycoproteins are necessary and 
sufficient for the lung pathology, whereas the internal genes play a major role in the 
febrile response induced by TR H3N2 IAVs in swine. With respect to PB1-F2, we 
found that PB1-F2 exerts pleiotropic effects in the swine host, which are expressed in 
a strain-dependent manner. Pathogenicity studies in swine revealed that the presence 
of PB1-F2 leads the following effects in context of three TR strains tested: no effect 
in the context of sw/99 strain; increases the virulence of pH1N1; and decreases the 
virulence of ty/04. Next, we developed temperature-sensitive live attenuated 
influenza vaccines for use in swine and shown that these vaccines are safe and 
  
efficacious against aggressive intratracheal challenge with pH1N1. Lastly, we 
rearranged the genome of an avian H9N2 influenza virus to generate replication-
competent influenza virus vectors that provide a robust system for expression and 
delivery of foreign genes. As a proof-of-principle, we expressed the hemagglutinin 
from a prototypical highly pathogenic avian influenza virus (HPAIV) H5N1 and 
shown that this vectored H5 vaccine retained its safety properties in avian and 
mammalian species, and induced excellent protection against aggressive HPAIV 
H5N1 challenges in both mice and ferrets. Taken together, these studies have 
advanced our understanding of molecular basis of pathogenesis of influenza in the 
swine host and have contributed to the development of improved vaccines and 
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Don’t lose your faith amidst the shadows of the world. 
Even if your feet bleed, keep going, raising your faith to the celestial light above you. 
Be faithful and work. 
Strive for kindness and wait patiently. 
Everything goes by and everything is renovated on Earth, but what comes from 
Heaven will remain forever. 
Out of all miserable, the unhappiest ones are those who lost faith in God and in 
themselves, because the worst misfortune is to be deprived of faith and continue 
living. 
Therefore look up and walk ahead. 
Strive and serve. Learn and step ahead. 
Dawn shines beyond the night. 
Today the storm might tighten your heart and torment your ideal, inflicting distress 
and threatening with death. 
Don’t forget, however, that tomorrow will be another day.  
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Chapter 1: Introduction 
 
1.1. General Introduction 
Influenza A viruses belong to the family Orthomyxoviridae and represent major 
pathogens of both humans and animals. There are five different genera in the 
Orthomyxoviridae family: the Influenzavirus A, B and C; Thogotovirus; and Isavirus. 
Influenza A viruses are enveloped viruses with 80-120 nm in diameter and its nucleocapsid 
form a helical symmetry. Its genome contains eight single-stranded RNA segments of 
negative polarity (vRNA), which encode 10-12 viral proteins. Each viral RNA segments 
exists as a viral ribonucleoprotein complex (vRNPs), in which the RNA is coated with NP 
and forms a helical hairpin that is bound on one end by the hererotrimeric polymerase 
complex formed by PB2, PB1, and PA. For each genomic viral RNA segment, the coding 
region is flanked by non-coding sequences on both ends. The 5’ and 3’terminal sequences of 
the vRNA molecules together constitute the promoter structure, in a stepwise interaction with 
viral RNA polymerase complex (Sorrell, Ramirez-Nieto et al. 2007).  
The virus envelope is derived from the host cellular plasma membrane and it is 
covered with about 500 projecting glycoprotein spikes with hemagglutinating and 
neuraminidase activities. These activities correspond to the two major surface viral 
glycoproteins: the hemagglutinin (HA) and neuraminidase (NA), present as homotrimers and 
homotetramers, respectively. To date, 16 HA and 9 NA subtypes have been described. These 
surface glycoproteins are the main antigenic determinants of the virus. The HA is the viral 
ligand that recognizes sialic acid receptors present on glycoproteins and glycolipids on the 
cells laying the mucosa of the respiratory and intestinal tract. Binding to host receptors is the 
first step in the viral life cycle and this property makes the HA a major contributor to the host 
range of influenza viruses. Receptor-bound viruses enter into the cell by endocytosis followed 
by acid-activated membrane fusion in endosomes. When the endosomal pH reaches 5.0, the 
viral HA protein undergoes a conformational change that exposes the fusion peptide on the 
HA and causes it to fuse with the viral envelope. When this occurs, the viral 
ribonucleoprotein particles (vRNPs) are released from matrix protein 1 (M1) and released 




replication of the influenza genome occurs. New viral RNA is encapsidated in the capsid 
protein, and together with new M1 is then transported to budding sites at the plasma 
membrane where HA and NA have been incorporated into the cell membrane. Progeny 
virions are formed and released by budding. The sialidase activity of the NA, which disrupts 
the interaction between the HA and sialic acid receptors promotes the release and spread of 
progeny viral particles following their production by infected cells (Palese and Shaw 2007). 
In cells infected with certain strains of influenza, a nonstructural protein named PB1-
F2 can be detected (Chen, Calvo et al. 2001). This protein is 87-101-amino acid long and it is 
coded by an alternate (+1) open reading frame within the PB1 gene (segment 2). PB1-F2 is 
not required for viral replication in ovo or in tissue culture. Translation of PB1-F2 is thought 
to be mediated by ribosomal scanning of the PB1 mRNA (Chen, Calvo et al. 2001). PB1-F2 
expression causes apoptotic-cell death in immune cells (mainly monocyte-derived) and 
contributes to viral pathogenicity by virtue of inhibiting mechanisms of viral clearance 
(Zamarin, Ortigoza et al. 2006; McAuley, Hornung et al. 2007). Additionally, the presence of 
PB1-F2 in both the 1918 and the mouse-adapted PR8 influenza A virus enhances secondary 
bacterial pneumonia in the mouse model (McAuley, Hornung et al. 2007). However, two 
recent studies investigating the role of PB1-F2 in the pathogenesis of clinically relevant 
viruses and the pandemic H1N1 concluded that expression of PB1-F2 has minimum effects in 
the virulence of influenza viruses in animal models (Hai, Schmolke et al. ; McAuley, Zhang 
et al. 2010). From these studies, it appears that the role of PB1-F2 in virulence of influenza 
viruses is cell-type and virus strain specific. The contribution of PB1-F2 to virulence of 
influenza viruses in the swine host is completely unknown. 
Swine influenza virus (SIV) is an infectious disease which affects not only the swine 
industry but also represents a constant threat to the turkey industry and is of particular 
concern to public health. H3N2 triple reassortant (TR) swine influenza viruses first emerged 
in the United States in 1998 and have since become endemic in swine populations. A unique 
feature shared by all of these TR influenza viruses is the maintenance of the so-called triple 
reassortant internal gene (TRIG) cassette, which consists of the avian-like PB2 and PA genes, 
the human-like PB1 gene and the classical swine NP, M and NS genes. Fever, sneezing, 
coughing, and abortion rates up to 7% in breeding sows characterize the disease caused by 
these viruses. Since 2003-2004, however, the H3N2 TR swine influenza viruses have 
emerged and spread within commercial turkey operations in the US, causing drastic declines 
in egg production. Although virulence determinants for avian and human influenza viruses 




pathogenesis of influenza viruses in swine. Therefore, there is a need to understand the 
molecular basis of pathogenesis in this important natural host (Olsen 2002; Vincent, Ma et al. 
2008). 
In the swine industry, influenza is controlled mainly by biosecurity and vaccination. 
Currently commercially available swine influenza vaccines are based on inactivated whole 
virus preparations of the H1N1 and H3N2 subtypes. The use of vaccination has become a 
common practice to control swine influenza in the US. Nonetheless, these commercially 
available vaccines provide limited protection against the antigenically diverse influenza 
viruses that circulate in North American pigs, and consequently, forced swine producers to 
use autogenous inactivated vaccines with the hope of achieving better antigenic matching. 
However, it is important to note that the use of inactivated vaccines has been associated with 
enhanced pneumonia when immunized pigs were challenged with divergent viruses (Vincent, 
Ma et al. 2008). Even though temperature-sensitive live attenuated influenza vaccines (LAIV) 
have been shown to be safe and efficacious for humans and horses, this attenuation approach 
have not yet been developed for pigs. Thus, the development of LAIV for swine has the 
potential to circumvent the drawbacks associated with commercial vaccines and improve both 
the homotypic and heterosubtypic protection of pigs against this important swine pathogen.
 The generation of viral vectors for the delivery of foreign proteins and biologically 
active molecules remains an attractive approach with broad applications in the infectious 
disease field. Since the development of reverse genetic methods for segmented negative sense 
RNA viruses, influenza has also been considered potential vaccine vectors.  The use of 
influenza viruses as vector for delivery of foreign genes with immunoprophylactic and 
therapeutic applications has several advantages:  (a) influenza viruses are known to induce 
strong cellular and humoral immune responses both at the systemic and the mucosal levels; 
(b) Because the virus has an RNA genome without a DNA phase in its replication cycle, 
safety concerns regarding chromosomal integration of viral genes into the host are virtually 
inexistent.(c) influenza viruses have 16 different HA and 9 different NA, most of which only 
circulate in wild birds and against which humans and domestic animals don’t have pre-
existing immunity (Kittel, Sereinig et al. 2004; Martínez-Sobrido and García-Sastre 2007). 
Thus, using influenza viruses with different HA/NA combinations can circumvent the 
problem of boost vaccinations in populations that have pre-existing immunity against the 
vector; (d) influenza viruses are very well characterized and attenuated strains are used as live 
vaccines for humans and livestock. Additionally, engineering of highly attenuated influenza 




that have already been mapped in the viral genome.(e) expression of foreign gene under the 
control of the NS gene segment promoters allows early and high levels of expression of the 
transgene of interest. However, all the influenza virus vectors developed to date have been 
either unstable or have tolerated only insertions of short peptides. Among all the viral 
proteins, only the HA and NA have been successfully engineered for stable expression of 
foreign epitopes (Martínez-Sobrido and García-Sastre 2007). Nevertheless, neither HA nor 
NA glycoproteins are optimal targets for the insertion of foreign sequences because of insert 
size constraints and the fact that booster immunizations would be affected by pre-existing 
immunity to the vector. Thus, both the instability of the transgene and the insert size 
limitation has precluded the progress in the development of influenza virus as a vector for 
delivery of foreign genes.  
1.2. Research Objectives and Outline 
The main goal of my dissertation research is to dissect virulence determinates of 
influenza virus for swine and develop novel live attenuated influenza vaccines. With respect 
to the first objective, we focused on the role of surface glycoproteins and PB1-F2 to study, 
for the first time, the role of these genes in virulence of triple reassortant influenza viruses in 
pigs. These studies will advance the scientific knowledge in the influenza field and will 
hopefully shed light for the rational development of vaccines against this important swine 
disease. Regarding novel vaccines, we have developed a temperature sensitive (ts) live 
attenuated vaccine for use in pigs and also rearranged the genome of an avian influenza virus 
to develop a vector-influenza vaccine against the highly pathogenic avian influenza virus 
H5N1. Reverse genetics technology will be used to introduce attenuation markers in the 
polymerase genes of a swine-like TR H3N2 influenza virus, A/turkey/Ohio/313053/04 
(H3N2) (ty/04), with the ultimate goal of developing LAIV against epidemiologically 
important viruses for swine. Lastly, we have developed a novel strategy for engineering 
influenza viruses that stably expresses foreign genes. Influenza viruses generated using this 
technology have the potential for generating improved vaccines against influenza and other 






The research objectives of my dissertation are as follows: 
 
1- Role of surface glycoproteins in the virulence of triple reassortant H3N2 influenza 
viruses in swine 
A) Development of reverse genetics system for generation of triple reassortant 
H3N2 influenza A viruses from cloned cDNAs 
B) Development of a swine model of infection to study the virulence of H3N2 triple 
reassortant influenza A viruses 
C) Role of surface proteins in the lung pathology of triple reassortant H3N2 
influenza viruses in swine 
 
2- Role of PB1-F2 in the virulence of triple reassortant H3N2 and pandemic H1N1 
influenza viruses in swine 
A) Construction and rescue of PB1-F2 recombinant viruses 
B) Effect of PB1-F2 expression in modulating polymerase activity 
C) Use of porcine respiratory explants to study the interaction of influenza with the 
respiratory tract 
D) Pathogenesis studies in swine 
 
3- Modifications in the polymerase genes of a swine-like triple reassortant influenza 
virus to generate live attenuated vaccines for humans and livestock 
A) Construction and phenotypic characterization of LAIV in vitro 
B) Safety and efficacy of LAIV against H1N1pdm in mice and swine 
 
4- Shuffling of the influenza genome to engineer vectors stably expressing foreign 
genes 
A) Engineering of influenza virus vectors by genome rearrangement 
B) Characterization of influenza virus vectors expressing foreign genes 
C) Safety studies in chickens 
D) Evaluate the safety and the efficacy of an H9N2 vector expressing the H5 HA 




Chapter 2: Literature Review 
2.1. Influenza Virus 
2.1.1. Discovery of the influenza A viruses 
The first written description of infection by Influenza A virus probably occurred in 
1878, when Perroncito described “fowl plague” as a highly pathogenic disease affecting 
chickens in Italy (Perroncito 1878). This was the first document that differentiated fowl 
plague and fowl cholera based on clinical disease. A few years later, in 1901, Centanni and 
Savonuzzi, demonstrated that fowl plague (i.e. highly pathogenic avian influenza virus) was 
caused by a filterable agent (prototype strain A/Brescia/1902 (H7N7)) (Centanni and 
Savonuzzi 1901). Influenza in swine was first recognized as an epizootic disease in 1918, 
concomitant with the worst recorded human influenza pandemic. The viral etiology of the 
disease in pigs was determined for the first time in 1930 by Richard Shope, who conclusively 
demonstrated the filterability of agent responsible for the respiratory disease in pigs and 
isolated, for the first time, an influenza A virus (prototype strain: A/swine/Iowa/15/1930 
(H1N1)) (Shope 1931; Shope 1931). Human influenza was first identified as a viral disease in 
1933 by Smith and co-workers (prototype strain A/WS/33 (H1N1)) (Smith 1933). However, 
It was not until 1955 that it was demonstrated that the genomic composition of the fowl 
plague virus was essentially identical to the human influenza virus (Schafer 1955). By then, it 
had already been shown that human influenza viruses shared many biological properties with 
their avian counterparts, including the ability to grow in embryonated chicken eggs and 
agglutinate red blood cells (Hirst 1941). Influenza’s ability to agglutinate erythrocytes is a 
feature very exploited in diagnostic tests. Equine influenza virus was first isolated in the 
former Checoslovaquia in 1956 (prototype strain: A/equine/Prague/1/56 (H7N7)) (Sovinova, 
Tumova et al. 1958) and, later, the more epidemiologically relevant H3N8 subtype of equine 
influenza virus was first isolated in 1963 during an outbreak of this disease in Miami 
(prototype strain: A/equine/Miami/1/63) (Waddell, Teigland et al. 1963). In a remarkable 
host shift event, an H3N8 of equine-origin caused severe outbreaks of respiratory disease in 
dogs in 2004 (Crawford, Dubovi et al. 2005). Since then, canine influenza virus (prototype 
strain A/canine/Florida/43/2004 (H3N8)) has become enzootic in this animal population 




2.1.2. Classification and nomenclature 
Influenza A virus (IAV) belongs to the family Orthomyxoviridae, a family of 
enveloped viruses whose members contain six to eight segmented, single-strand RNA 
genomes with negative orientation. The name of the family is derived from the Greek orthos, 
which means correct or straight, and myxa, which means mucus. The family of 
Orthomyxoviridae comprises five different genera: the Influenzavirus A, Influenzavirus B, 
Influenzavirus C, Thogotovirus, and Isovirus. Recently, three novel viruses (Quaranfil, 
Johnston Atoll, and Lake Chad viruses) have been proposed to form a novel genus of the 
family Orthomyxoviridae (Presti, Zhao et al. 2009). This recommendation was based on 
phylogenetic analyses, virion ultrastructural features, and the unique end-terminal sequences 
identified in these viruses. Influenza viruses type A, B and C are distinguished according to 
antigenic differences between their internal nucleocapsid (NP) and matrix (M) proteins. Type 
A viruses (eight RNA segments) display broad host range and these viruses can infect many 
avian and mammalian species. These viruses are responsible for worldwide respiratory 
disease epidemics in humans and are associated with thousands of deaths annually. Type B 
viruses (eight RNA segments) are mainly human pathogens, although infection has been 
described in seals (Osterhaus, Rimmelzwaan et al. 2000). Type C viruses (seven RNA 
segments) can affect humans and swine, but infection is usually of low consequence (Muraki 
and Hongo 2010). The members of the Thogotovirus genus are a group of arboviruses that are 
transmitted by ticks, which includes the thogoto virus (six RNA segments), Dhori virus 
(seven RNA segments), and a variant known as Batken virus. Thogoto virus has been 
associated with febrile encephalic disease in humans (Siebler, Haller et al. 1996). Araguari 
virus (six RNA segments), is a less studied member of the genus Thogotovirus that was 
isolated form a marsupial (Philander opossum) in the Brazilian Amazon rainforest (Da Silva, 
Da Rosa et al. 2005). Infectious salmon anemia virus is the only member of the Isovirus 
genus (eight RNA segments) and causes devastating disease in farmed Atlantic salmon. 
Infectious salmon anemia is one of just 12 viral diseases of fish reportable to the OIE, the 
World Organization for Animal Health (Clouthier, Rector et al. 2002).  
Nomenclature system for different influenza virus is based on: (1) host of origin, (2) 
geographic origin, (3) strain number, (4) year of isolation, and (5) antigenic subtype. For 
human strains, the host is omitted (Palese and Shaw 2007). For example, the nomenclature 




a virus strain number 313053 in the year of 2004. According to its HA and NA composition, 
the virus is classified as H3N2 subtype. 
2.1.3. Morphology and genome organization 
Influenza A virus (IAV) particles are pleomorphic, although filamentous virions are 
the most predominantly observed during initial virus isolation of field samples. Laboratory-
adapted propagated in eggs or cell cultures have more regular spherical morphology (Fig. 
2.1). IAV are surrounded by a host-derived lipid bilayer envelope, with protruding spikes 
formed by the two outer glycoproteins: hemagglutinin (HA) and neuraminidase (NA), and a 
small number of the M2 ion channel protein (Nayak, Hui et al. 2004). The M1 protein plays a 
pivotal role in virus architecture (Bourmakina and Garcia-Sastre 2003; Elleman and Barclay 
2004). Deletion of the cytoplasmic tail of M2, HA, or NA also alters virion morphology from 
spherical/elliptical to irregular shape (Jin, Leser et al. 1997; Iwatsuki-Horimoto, Horimoto et 
al. 2006). The interactions among M1, M2, HA, and NA are important for the formation and 
preservation of the characteristic virion shapes. Morphological alterations in virions can be 
caused by artifacts introduced during sample preparation for negative staining, such as air 
drying (Nermut and Frank 1971), low pH (Ruigrok, Hewat et al. 1992),  and 















Figure 2.1.Transmission electron microscopy of influenza A virus particles. The avian 
influenza virus strain A/Guinea Fowl/Hong Kong/WF10/99 (H9N2) was propagated in 
embryonated eggs, purified and negatively stained with 2% phosphotungstic acid (PTA). The 
arrow indicates a spherical virion (inset). The lipid bilayer is not visible in the intact particles, 




The HA is a type I transmembrane protein that forms homotrimers in mature virions. 
Each monomer consists of an outer HA1 subunit covalently linked through disulfide bonds to 
a membrane-anchoring HA2 subunit (Cross, Burleigh et al. 2001). The HA protein is a 
multifunctional protein responsible for binding to receptors on host cells, membrane fusion, 
and induction of neutralizing antibodies. Each virion has approximately 500 radial 
projections of glycoproteins spikes in its envelope (Ruigrok, Andree et al. 1984). The HA is a 
major envelope protein that accounts for about 80% of the spikes (the NA forms the 
remaining 20% of the spikes) (Cross, Burleigh et al. 2001).  
The NA is a type II transmembrane protein that is assembled as homotetramers in the 
virions. The sialidase activity of NA removes sialic acids from sialyloligosaccharides in the 
host cells and is critical for the release and spread of progeny virions at the final stage of 
infection (Gong, Xu et al. 2007). Recently, it was shown that NA also plays an important role 
early during the viral infection, presumably by removal of mucus covering the airways 
epithelium (Matrosovich, Matrosovich et al. 2004). The receptor-destroying activity of the 
NA serves to counter the receptor-binding activity of the HA. Although mutant influenza 
virus lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, 
or mice, compensatory mutations are introduced in the HA receptor-binding pocket to reduce 
the virus’s affinity for cellular receptors (Hughes, Matrosovich et al. 2000). Furthermore, the 
balance between the HA and NA activities are crucial for influenza virus replication, 
virulence, and transmission (Mitnaul, Matrosovich et al. 2000; Hulse, Webster et al. 2004; 
Lu, Zhou et al. 2005; Yen, Liang et al. 2011).  Influenza A viruses are classified into subtypes 
based on two surface antigens, the HA and NA glycoproteins. To date, 16 HA and 9 NA 
subtypes have been described (Fouchier, Munster et al. 2005). Wild aquatic birds are 
considered the natural reservoirs of all influenza A viruses, in which all the HA and NA 
subtypes have been found. In these birds, influenza viruses usually replicate in the intestinal 
tract, cause no disease, and transmit by fecal contamination of water. These viruses 
occasionally establish stable lineages in terrestrial birds as well as mammalian species such as 
humans, swine, horses, and dogs (Webster, Bean et al. 1992; Fouchier, Munster et al. 2005; 
Gibbs and Anderson 2010). 
The M2 protein, a type III transmembrane protein, is the third virus membrane 
integral protein, which is found in the form of  homotetramers (Lamb, Zebedee et al. 1985; 
Lear 2003). M2 is a minor component of the envelope, but plays a crucial role during 




of M1 matrix protein and ribonucleoprotein (RNP) with helical symmetry. The matrix protein 
(M1) is the most abundant protein in the IAV virion and is located in the inner surface of the 
lipid bilayer. By coating the inner face of the envelope, M1 gives stability to the interior 
structure of the emerging viral particle. Furthermore, M1 interacts with the cytoplasmic tails 
of the viral integral membrane proteins HA, NA, M2 and serves as a docking site for the 
recruitment of the viral RNPs (Ali, Avalos et al. 2000; Nayak, Hui et al. 2004; Chen, Leser et 
al. 2008; Rossman and Lamb 2011). 
Each of the eight viral RNP is composed of the RNA polymerase complex proteins 
(PB1, PB2 and PA) which drive transcription and replication; and the NP, which forms 
homo-oligomers and wraps the genomic vRNA (minus strand). The RNP particles are located 
inside a layer of M1 protein that lines the viral lipid membrane. During virus replication, at 
least three other nonstructural proteins are expressed into the mature virion: (1) the non-
structural protein 1 (NS1), a multi-functional protein that evades the host immune system; (2) 
NS2, also called nuclear export protein (NEP), which plays a crucial role in mediating the 
export of viral RNPs from the cell nucleus during replication as well as modulating 
transcription and replication; (3) and PB1-F2, a protein expressed by certain, but nor all, IAV 
strains that exhibits pleiotropic effects in the process of virus-host interaction, including  
induction of host-cell apoptosis, modulation of polymerase activity, viral virulence and innate 
immune responses (Krumbholz, Philipps et al. 2011; Rossman and Lamb 2011). In 2009, 
N40, an N-terminally truncated version of PB1 lacking transcriptase function was described 
for the first time, but its function remains elusive (Wise, Foeglein et al. 2009).  
The genome of influenza A virus is composed of eight vRNA segments with negative 
polarity. For each genomic viral RNA segment, the coding region is flanked by non-coding 
sequences at both ends. The 5’ and 3’terminal sequences of the vRNA molecules together 
constitute the promoter structure, in a stepwise interaction with viral RNA polymerase 
complex (Robertson 1979). Each viral RNA segment exists as an RNP complex in which the 
RNA is coated with NP and forms a helical hairpin that is bound on one end by the 
heterotrimeric polymerase complex formed by PB2, PB1, and PA. Although the first 13 and 
12 nucleotides at 5’ and 3’ end, respectively, are highly conserved among the vRNA 
segments of all influenza A viruses, the length and nucleotide composition of additional 





2.1.4. Viral RNA segments, gene products, and pathogenesis determinants  
The eight influenza A viral RNA segments encodes 12 recognized gene products. 
These proteins are PB2, PB1, PA, HA, NP, NA, M1, M2, NS1, and NEP/NS2 proteins. 
Besides PB1, segment 2 has also been show to encode PB1-F2 and N40 gene products. 
Proteins M2 and NEP/NS2 are derived from mRNA splicing of the M and NS genes, 
respectively. The major function of each viral protein is summarized in Table 2.1 Influenza 
virus virulence is considered a polygenic trait, in which disease outcome is determined by the 
gene constellation of a particular influenza virus strain within a specific host (Hatta, Gao et 
























1 2341 PB2 RNA-dependent RNA polymerase: binds to Cap 
Inhibits type I interferon 
2 2341 PB1 RNA-dependent RNA polymerase: catalysis of viral RNA 
polymerization 
  PB1-F2 Strain-dependent pleiotropic effects: modulates host innate immune 
response, apoptosis, polymerase activity, enhances primary and 
secondary viral pneumonia, antibacterial effects 
  N40 Unknown 
3 2231 PA RNA-dependent RNA polymerase: cap-snatching endonuclease activity 
4 1742 to 1778 HA Receptor binding, viral fusion, and major viral antigen 
5 1565 NP Viral encapsidation, transport of RNPs from cytoplasm to nucleus, type-
specific antigen 
6 1467 NA Receptor destroying activity: viral release, limits virus superinfection, 
antigenic site 
7 1027 M1 Assembly, type-specific antigen 
  M2 Ion channel 
8 890 NS1 Multifunctional protein: blocks host antiviral immunity, regulates 
transcription and replication, modulates RNA splicing, enhancement of 
viral mRNA translation, regulation of virus particle morphogenesis 
  NS2/NEP Assembly: nuclear export of progeny vRNPs 




Segment 1: PB2 
The RNA segment 1 (2,341 nucleotides long) encodes a single protein: the 
polymerase basic protein PB2, which is a 759-amino acid long protein. The PB2 subunit 
plays an essential role in the initiation of transcription for viral mRNA by binding to the 5' 
methylated cap of host pre-mRNAs, which are subsequently cleaved after 10-13 nucleotides 
by the endonuclease activity of PA (Dias, Bouvier et al. 2009). The PB2 has been shown to 
be an important determinant of pathogenicity of some influenza A viruses. PB2 accomplishes 
this task by several mechanisms, including enhancement of polymerase activity and 
modulation of host antiviral innate immune pathways upon its interaction with the 
mitochondrial antiviral signaling protein, MAVS (Hatta, Gao et al. 2001; Salomon, Franks et 
al. 2006; de Wit, Munster et al. 2010; Graef, Vreede et al. 2010). In particular, presence of a 
lysine (K) at position 627 is a strong determinant of pathogenicity to mammals, whereas 
glutamic acid (E) is the virulence marker in avian isolates (Subbarao, London et al. 1993; 
Baigent and McCauley 2003). However, it must be noted that avian influenza viruses with a 
typical avian PB2 at position 627 can also display high virulence in mammals further 
supporting the notion that influenza virulence is a multigenic phenomenon (Chen, Bright et 
al. 2007).   
Segment 2: PB1, PB1-F2, and N40 
 
The RNA segment 2 (2,341 nucleotides long) encodes up to three proteins: the 
polymerase basic protein PB1, the most important protein encoded by this segment; PB1-F2; 
and N40. PB1 is a 757-amino acid long protein that serves as the backbone of the viral 
polymerase complex. PB1 is responsible for the catalysis of viral RNA polymerization and 
plays a prominent role in the assembly of the polymerase complex since it contains binding 
sites for PB2 and PA subunits. PB1 is a major determinant of pathogenicity of the influenza 
A viruses (Salomon, Franks et al. 2006). 
PB1-F2 is an 87-90 amino-acid long protein encoded by an alternate (+1) open reading 
frame (ORF) within the PB1 gene. The protein was originally discovered in 2001 during a 
search for CD8+T-cell epitopes in the influenza genome (Chen, Calvo et al. 2001). 
Translation of PB1-F2 mRNA is likely mediated by ribosomal scanning and the protein is 
expressed early and transiently in infected cells (Chen, Calvo et al. 2001). Full-length PB1-F2 
is expressed by most IAV of avian origin, but the protein is truncated in the classical swine 




have been reported also in some human H3N2 isolates and North American swine triple 
reassortant (TR) viruses, which have a human-like PB1 gene (Zell, Krumbholz et al. 2007). 
Using in vitro and mouse models, several groups have shown that PB1-F2 has pleiotropic 
effects. This protein, while dispensable for viral replication in embryonated eggs, tissue 
culture, or in vivo (Conenello and Palese 2007), it enhances the replication kinetics of the 
laboratory virus, A/Puerto Rico/8/34 (H1N1; hereafter referred to as PR8), and the 1918 
H1N1 virus, but has no effects in the growth kinetics of the H5N1 or human H3N2 viruses 
(McAuley, Zhang et al. 2010; Smith, Adler et al. 2011). By interacting with the PB1 subunit, 
PB1-F2 was shown to up-regulate the PR8 polymerase activity (Mazur, Anhlan et al. 2008) 
and, more recently, the highly pathogenic H5N1 (McAuley, Zhang et al. 2010) and pH1N1 
(Chen, Chen et al. 2010). Importantly, PB1-F2 expression results in enhanced apoptotic-cell 
death in immune cells, viral pathogenicity in mice, and immunopathology (Chen, Calvo et al. 
2001; Zamarin, Ortigoza et al. 2006; Conenello, Zamarin et al. 2007; McAuley, Hornung et 
al. 2007; McAuley, Chipuk et al. 2010). Intranasal administration of PB1-F2 peptides derived 
from the 20th century pandemic strains (1918 H1N1, 1957 H2N2, 1968 H3N2) and H5N1 led 
to acute lung injury, elevation of pro-inflammatory cytokines, and the influx of inflammatory 
cells to the lungs of mice (McAuley, Chipuk et al. 2010). However, this effect seems to be 
lost in recently circulating human H3N2 strains through accumulations of point mutations in 
the PB1-F2 protein (Alymova, Green et al. 2011). A rare polymorphism (N66S) in PB1-F2 
has been associated with high lethality of the 1918 IAV and certain highly pathogenic H5N1 
strains (Conenello, Zamarin et al. 2007; Schmolke, Manicassamy et al. 2011). Surprisingly, 
two recent studies investigating the role of PB1-F2 in the pathogenicity of clinically relevant 
human viruses and the pH1N1 concluded that the expression of PB1-F2 has minimal effects 
on the virulence of these viruses in murine and ferret models (Hai, Schmolke et al. ; 
McAuley, Zhang et al. 2010). Recent publications have shown that PB1-F2 has profound 
effects in genes involving the host innate immunity responses, although these reports 
disagreed on the role of PB1-F2 in modulating type I interferons, suggesting that this function 
of PB1-F2 remains unresolved and needs further investigation (Le Goffic, Bouguyon et al. 
2010; Dudek, Wixler et al. 2011; Le Goffic, Leymarie et al. 2011; Varga, Ramos et al. 2011). 
Overall, the effects of PB1-F2 in relation to influenza-host interaction are not completely 
understood and seem to be cell-type, virus strain, and even host-specific. 
Besides PB1 and PB1-F2, RNA segment 2 also encodes N40, an N-terminally 
truncated version of PB1 that was first described in 2009. N40 interacts with PB2 and the 




for virus rescue but is detrimental for virus replication in certain viral genetic backgrounds. 
(Wise, Foeglein et al. 2009). Recent work has shown that N40 does not alter the host innate 
immune response (Le Goffic, Leymarie et al. 2011). The functional role of N40 in viral 
virulence is yet to be elucidated. 
Segment 3: PA 
The RNA segment 3 (2,231 nucleotides long) encodes a single protein: the 
polymerase acid protein PA, which is a 716-amino acid long protein. The N-terminus of PA 
directly interacts with the C-terminus of PB1, which is essential for viral transcription and 
replication (Perez and Donis 2001). Although initially attributed to PB2 and PB1, Dias el al. 
recently demonstrated that the cap-snatching endonuclease activity of influenza virus resides 
in the PA subunit. The endonuclease active site binds two manganese ions and comprises a 
histidine and a cluster of three acidic residues, which are conserved in all influenza viruses 
(Dias, Bouvier et al. 2009). Importantly, the PA subunit modulates polymerase activity, virus 
replication and the virulence of H5N1 avian influenza viruses ducks, a natural host for 
influenza virus (Song, Feng et al. 2011). 
Segment 4: HA 
The RNA segment 4 (1742 to 1778 nucleotides long) encodes a single protein: the 
hemagglutinin (HA), which is a 562 to 566-amino acid long glycoprotein. The HA protein is 
multifunctional, being responsible for binding of the virus to receptors on host cells, 
membrane fusion, and assembly (see “Influenza virus life cycle” below).  Binding to host 
receptors is the first step in the viral life cycle and this property makes the HA a major 
contributor to the host range of influenza viruses (Suzuki, Ito et al. 2000). HA also plays a 
central role in the adaptive host immune system since it contains important antigenic sites 
against which neutralizing antibodies are directed. The variability of NA and HA proteins is 
responsible for the ability of this virus persists in the population despite the immune response 
mounted by their hosts. So far, 16 different HA subtypes and 9 different NA subtypes have 
been identified. This allows the formation of hundreds of possible subtypes HA and NA 
combinations. However, only a few subtypes have established permanent lineages in 
mammalian species. For example, only three of these HA subtypes (H1, H2, and H3) have 
established stable lineages in humans. In contrast, aquatic birds harbor a large repertoire of 




pandemic threat (Webster, Bean et al. 1992; Sorrell, Ramirez-Nieto et al. 2007; Kimble, 
Sorrell et al. 2011). 
The HA is synthesized in the rough endoplasmic reticulum (RER) as a single 
polypeptide HA0. Newly synthesized HA is cleaved to remove the amino-terminal 
hydrophobic sequence of 14 to 18 amino acids, which correspond to the signal sequence for 
transport to the cell membrane. To fold properly, HA must be glycosylated and acquire its six 
intramolecular disulphide bonds (Cross, Burleigh et al. 2001). The structure of the membrane 
anchored HA molecules form homotrimers and each molecule consists of a globular head on 
a stalk. The cleavage of HA0 is accomplished by host-produced trypsin-like proteases, which 
are serine proteases secreted from a restricted number of cell types of the respiratory and 
digestive tracts. In the case of the HA-containing polybasic cleavage site of the highly 
pathogenic avian influenza viruses, processing of HA is carried out by furin, an ubiquitous 
membrane-bound protease member of the subtilisin family (Rott, Klenk et al. 1995). 
Cleavage of HA0 into HA1 and HA2 is a prerequisite for virus infectivity (Lazarowitz and 
Choppin 1975) and a major determinant of virulence and systemic dissemination of the 
highly pathogenic avian influenza strains (Horimoto and Kawaoka 1994). These two HA 
subunits are linked by a single disulphide bond (Copeland, Doms et al. 1986). 
The globular head is made up solely of HA1 and contains the receptor-binding 
domain as well as antigenic sites against which neutralizing antibodies responses are directed 
to. The stalk is composed of HA2 and the N-terminal portion of HA1. HA2 contains the 
transmembrane hydrophobic sequence which is highly conserved among different HA 
subtypes, and play an essential role in HA fusion upon virus entry (Cross, Burleigh et al. 
2001). The HA, along with the NA, undergoes  “antigenic drift” due to accumulation of 
amino acid substitutions in epitopes recognized by antibodies that neutralize viral infectivity. 
The rapid antigenic drift displayed by influenza viruses has precluded the development of 
broadly protective vaccines. It seems that the virus evolve by adjusting receptor binding 
avidity with steady alterations in antigenicity (Hensley, Das et al. 2009). Since the discovery 
that potentially more broadly neutralizing antibodies are directed against the conserved HA2 
stalk domain, ongoing research efforts from different groups are trying to re-focus influenza 
immune responses in order to develop universal influenza vaccines (Steel, Lowen et al. 2010; 
Ekiert, Friesen et al. 2011; Wrammert, Koutsonanos et al. 2011). The HA is a major virulence 




Naeve et al. 1984; Kobasa, Takada et al. 2004; Pappas, Aguilar et al. 2008; de Wit, Munster 
et al. 2010; Ping, Dankar et al. 2010).  
Segment 5: NP 
The RNA segment 5 (1565 nucleotides long) encodes a single protein: the 
nucleoprotein (NP), which is 498 amino acids in length and plays a pivotal role in viral 
encapsidation. NP is an arginine-rich protein that acts primarily as a single-strand RNA 
binding protein and serves as the structural protein in viral ribonucleoprotein particles 
(vRNPs). NP coats the RNA and is the major viral protein in the vRNPs. NP also plays a role 
in the transport of vRNPs from cytoplasm to nucleus by interacting with cellular cargo 
protein karyopherin α (Melen, Fagerlund et al. 2003) NP is also one of the type-specific 
antigens and a major target of the host cell-mediated immune responses (Yewdell, Bennink et 
al. 1985) (Yewdell, Bennink et al. 1985). Numerous studies suggest that NP plays a role in 
host range (Scholtissek, Koennecke et al. 1978; Scholtissek, Burger et al. 1985; Naffakh, 
Tomoiu et al. 2008) and virulence (Wasilenko, Lee et al. 2008; Tada, Suzuki et al. 2011). 
Segment 6: NA 
The RNA segment 6 (1413 nucleotides long, for A/Puerto Rico/8/34 (H1N1) strain) 
encodes a single protein: the neuraminidase (NA), which is a 454 amino acid long type II 
membrane glycoprotein. The NA’s sialidase activity plays a role in virion release, facilitating 
budding of progeny virions from infected cells and contributing to the spread of progeny 
virions on the airway epithelium. Recently, it was shown that NA also plays an important role 
early during viral infection, presumably by removal of mucus covering the airways 
epithelium (Matrosovich, Matrosovich et al. 2004). By removing surface sialic acid receptors 
from the virion-producing cell, the NA also limits influenza A virus superinfection (Huang, 
Li et al. 2008). The NA monomer consists of four domains: a globular head, a stalk, a 
transmembrane and cytoplasmic domains. The NA catalytic and major antigenic sites are 
located in the globular head. Similarly to the HA, NA contains highly variable regions 
considered as antigenic sites targeted by the host immune system that contributes to antigenic 
drift. Even though NA-specific antibodies are not neutralizing, they have protective effects 
since they interfere with virus replication by preventing the release of new virus particles. As 
mentioned earlier, antigenic drift in NA can contributes for influenza evasion from 




vaccination (Subbarao and Joseph 2007; Nayak, Kumar et al. 2010). In addition, the NA has 
also been associated with the virulence of several influenza viruses of avian and mammalian 
origin (Schulman and Palese 1977; Li, Schulman et al. 1993; Pappas, Aguilar et al. 2008; 
Matsuoka, Swayne et al. 2009; Sorrell, Song et al. 2010). 
Segment 7: M1 and M2 
The RNA segment 7 (1027 nucleotides long) is bicistronic and encodes the matrix 
protein M1 and the ion channel M2 protein. The M1 is a 252-amino acid long protein that is 
expressed late in the viral life cycle and is the most abundant polypeptide in the influenza 
virion. The M1 is located on the inner surface of the lipid bilayer. By coating the inner face of 
the envelope, M1 gives rigidity to the virion. M1 is crucial for the assembly of progeny 
virions and it has been shown that M1 is the only viral component which is absolutely 
essential for the formation of virus-like particles (VLPs) (Gomez-Puertas, Albo et al. 2000). 
M1 also interacts with both vRNPs and NEP/NS2 mediating the export of newly synthesized 
vRNPs from the nucleus to the cytoplasm (Ma, Roy et al. 2001). 
M2 is 97-amino acid long protein that is expressed from splicing of the M mRNA. 
M2 mRNA splicing is controlled by both the viral polymerase and cellular splicing factors, 
such as the serine/arginine-rich splicing factor SF2/ASF (Shih, Nemeroff et al. 1995; Shih 
and Krug 1996). The M2 is a tetrameric type III integral membrane protein whose ion 
channel activity is essential for the uncoating process M2 also plays a role in assembly and 
budding of virus particles (Rossman and Lamb 2011). In addition, M2 has also been 
considered a vaccine candidate or as an adjuvant for inactivated vaccines because antibodies 
specific for M2 have been shown to be protective in vivo in the mouse model (Schotsaert, De 
Filette et al. 2009; Guo, Yao et al. 2010; Song, Van Rooijen et al. 2011).  
The M segment has been recently identified as a major determinant for aerosol 
transmissibility of the 2009 pandemic H1N1 virus (Chou, Albrecht et al. 2011), although it is 
not clear whether M1 or M2 or both contribute to this phenotype. 
 
Segment 8: NS1 and NEP/NS2 
The RNA segment 8 (890 nucleotides long) is bicistronic and encodes the 
nonstructural protein 1 (NS1) and the nuclear export protein (NEP/NS2). NS1 is a ~230-




during the viral life cycle. NS1 blocks the host’s antiviral response by inhibiting the IFN 
production as well as the antiviral effects of IFN-induced proteins, such as dsRNA-dependent 
protein kinase R (PKR) and 2'5'-oligoadenylate synthetase (OAS)/RNase L. By interacting 
with cellular factors, NS1 also modulates a variety of cellular processes during viral infection, 
including inhibition of host mRNA polyadenylation, inhibition of nuclear export of 
polyadenylated host mRNA, regulation of viral RNA transcription and replication, 
modulation of viral RNA splicing, enhancement of viral mRNA translation, regulation of 
virus particle morphogenesis, and activation of phosphoinositide 3-kinase (PI3K) (Hale, 
Randall et al. 2008). In addition, a large body of work has shown that NS1 is an important 
virulence factor (Lipatov, Andreansky et al. 2005; Fernandez-Sesma, Marukian et al. 2006; 
Li, Jiang et al. 2006; Jackson, Hossain et al. 2008; Jiao, Tian et al. 2008). 
NEP/NS2 is a 121-amino acid long protein that interacts with both M1 protein and 
the cellular export machinery to participate in the assembly of virus particles (Yasuda, 
Nakada et al. 1993). This interaction is essential in the virus life cycle for the export of the 
new vRNP complex from the nucleus (O'Neill, Talon et al. 1998). Recent mapping of 
NEP/NS2 domains showed that its C-terminal domain (residues 81–100) is essential for M1 
binding and the nuclear export of progeny vRNPs (Shimizu, Takizawa et al. 2011). In 
addition, NEP/NS2 has also been implicated in playing a role in the regulation of influenza 
virus transcription and replication (Robb, Smith et al. 2009).  
2.1.5. Influenza virus life cycle 
The replication cycle of influenza virus is initiated when a viral particle comes into 
contact with the target cell. The association between the virus and the cell is possible due to 
the affinity of the activated HA to sialic-acid-containing receptors present on cell surface 
glycoproteins or glycolipids. N-acetyl neuraminic acid  (sialic acid) is bound to galactose 
(Gal) through α2-3, α2-6, or α2-8 glycosidic linkage by sialyltransferases, which are 
expressed in a cell type and species-specific fashion (Angata and Varki 2002; Gagneux, 
Cheriyan et al. 2003). The ability of different HA proteins to bind to SA receptors with either 
a2-3 or a2-6 linkages is a major determinant of the host range and tissue tropism of the 
influenza A viruses (Bean, Schell et al. 1992; Matrosovich, Tuzikov et al. 2000; Ibricevic, 
Pekosz et al. 2006). For example, avian and equine influenza strains preferentially bind cell 




swine origin binds preferably to SAa2-6Gal receptors (Ito and Kawaoka 2000; Gambaryan, 
Karasin et al. 2005).  
The binding of the membrane-distal region of influenza HA to SA receptors induces 
the entry of the virus in the cell by receptor-mediated endocytosis. The cleavage of the HA0 
molecule into HA1 and HA2 is a prerequisite for the membrane fusion and therefore a 
condition for viral infectivity. Virus entry is mediated by invagination of clathrin coated-pits 
on the host plasma membrane. As the endosomal vesicles containing influenza virus move 
towards the nucleus, their pH is acidified. When the endosome reaches pH 5.0, the HA 
undergoes a conformational change that exposes the fusion peptide located on HA2. The 
fusion peptide is a short hydrophobic sequence that inserts itself into the endosomal 
membrane and triggers the fusion with the viral envelope resulting in the release of vRNPs 
into the cytoplasm. Acidification of the endosome also activates the M2 protein, which 
pumps H+ protons into the viral particle, thus destabilizing the M1 interaction with RNP 
complex and freeing it from the viral envelope (Cross, Burleigh et al. 2001).  
The viral RNPs are then transported into the cell nucleus where transcription and 
replication occurs (Cross, Burleigh et al. 2001). Nuclear localization signals (NLS) located on 
NP, the major component of the RNPs, binds to NLS receptors (e.g., karyopherin family 
members), which are responsible for the transport of vRNP to the nucleus (Wang, Palese et 
al. 1997). A unique feature of influenza viruses among other RNA viruses is that all vRNA 
synthesis takes place in the nucleus by use of the nuclear machinery of the host cells.  As 
mentioned earlier, the genome of influenza virus consists of an eight-segmented, single-
stranded, negative-sense RNA. Similar to all viruses with a negative-sense genome, the 
influenza vRNA serves both as a template for mRNA synthesis and as a template for the 
synthesis of positive-sense (cRNA) replicated intermediates, which in turn serve as a template 
for the synthesis of progeny genomic vRNA. The heterotrimeric polymerase complex 
composed of PB2, PB1, and PA protein subunits carries out the transcription and replication 
of the eight separate segments of influenza vRNA. To initiate synthesis of its mRNA, 
influenza virus depends on cellular RNA polymerase II activity because the influenza RNA 
polymerase complex is a primer-dependent enzyme (Palese and Shaw 2007). Thus, the virus 
cannibalizes 5’-capped primer (5’-methyguanosine cap plus 10-13 nucleotides) from 
heterogeneous host pre-mRNA transcripts to initiate viral mRNA synthesis ('cap-snatching' 
mechanism). To accomplish this, the virus uses the cap-binding function of PB2 and the 




continuous supply of cellular RNA polymerase II and justifies fully functional inhibition of 
mRNA synthesis by actinomycin D. Polyadenylation of viral mRNA is catalyzed by the 
polymerase complex via a sttutering mechanism when it reaches a polyuridine strech 
approximately 17 to 22 nucleotides from the 5' end of each vRNA segment (Robertson, 
Schubert et al. 1981). Mature mRNAs are then transported to the cytoplasm, where they 
direct the synthesis of viral proteins using the cellular machinery. Unlike mRNA synthesis, 
cRNA (+ sense) synthesis occurs in a primer-independent manner. The cRNAs lack 5’cap 
and poly-A tail. The cRNAs are not transported to the cytoplasm during viral infection and 
serve as templates for the synthesis of negative-sense genomic vRNA. Synthesis of all three 
RNA species (mRNA, cRNA, and vRNA) takes place in the nucleus. It is not completely 
understood how the switch between transcription and replication occurs, although it has been 
reported that the NP protein has an important function in this switching (Portela and Digard 
2002). Recently, Perez and co-workers reported that influenza A virus generates small RNAs 
(22–27 nucleotide oligomers corresponding to the 5′ end of each vRNA) that regulates the 
switch from transcription to replication (Perez, Varble et al. 2010).  
Progeny vRNPs are exported out of the nucleus into the cytoplasm associated with 
the M1 and NEP/NS2 proteins. These complexes are transported to the assembly site on the 
plasma membrane either via cytoskeleton elements or by piggybacking on the cytoplasmic 
tail of HA and NA through interactions with the M1 protein. Newly synthesized HA and NA 
glycoproteins are targeted to lipid rafts domains on the apical membrane of polarized cells, 
where budding of progeny viral particles takes place. Lipid raft domains are regions of the 
plasma membrane rich in cholesterol and sphingolipids. Expression of lipid raft-associated 
proteins, such as the influenza virus HA and NA, causes the coalescence and enlargement of 
the raft domains. This clustering of HA and NA may cause a deformation of the membrane 
and the initiation of the virus budding event. M2, which is not a raft-associated protein, is 
recruited to the periphery of the budding virus though interactions with M1 (Rossman and 
Lamb 2011). M2 initially stabilizes the site of budding, possibly enabling the polymerization 
of the matrix protein and the formation of filamentous virions. Subsequently, M2 is able to 
alter membrane curvature at the neck of the budding virus, causing membrane scission 
(“pinching off””) and the release of the budding virus (Leser and Lamb 2005; Schmitt and 
Lamb 2005; Chen, Leser et al. 2008; Rossman and Lamb 2011).  
At the final stage of viral assembly, vRNAs are likely selectively (rather than 




of vRNPs into virions typically involves the recognition of packaging signals in the vRNA. 
These packaging signals are cis-acting sequences that span both the untranslated regions 
(UTR) and regions of the ORF at both ends of the vRNA segments. The UTR’s and 
packaging signals are unique to each gene segment but conserved amongst gene segments 
across influenza A viruses (Watanabe, Watanabe et al. 2003; Fujii, Fujii et al. 2005; Liang, 
Hong et al. 2005; Hutchinson, von Kirchbach et al. 2010). In addition to the 8 RNA segments 
and nine viral structural proteins, influenza virus has been shown to package 36 host derived 
proteins in the virion (Shaw, Stone et al. 2008). The implications of these host-derived 
proteins for the interactions of influenza virus with its host are yet to be deciphered. 
2.1.6. Advancements in influenza virus reverse genetics and its use as a vector  
Because influenza viruses contain a negative strand RNA, transfection of the naked 
vRNA, without the replication complex, cannot initiate transcription or translation. Rather, 
the vRNA must be transcribed into positive-sense mRNA and cRNA by the viral RNA 
polymerase complex in order to initiate an infection. This limitation of negative-sense RNA 
viruses compared with positive-sense RNA viruses hampered the progress in developing 
reverse genetics systems to manipulate the IAV genome. For example, the first reverse 
genetic system for a virus was developed in 1981 by Racaniello and Baltimore, who were 
able to rescue poliovirus entirely from cloned cDNAs (Racaniello and Baltimore 1981).  
The first reverse genetics system for negative-strand RNA viruses was described in 
1989 by Luytjes and co-workers, who engineered an IAV vector expressing foreign 
sequences (Luytjes, Krystal et al. 1989). The authors engineered a plasmid expressing the 
chloramphenicol-acetyltransferase (CAT) gene in negative polarity flanked by the NS UTR 
under the transcriptional control of a T7 promoter. The influenza-like CAT reporter gene was 
then transfected into cells along with purified vRNP protein components (PB2, PB1, PA, and 
NP) to transcribe the added RNA. The transfected cells were previously infected with an 
influenza helper virus, which was able to replicate, transcribe, and package the foreign CAT 
gene. Although this allowed the production of influenza viruses with transgenic RNA, the 
purification of the RNPs was troublesome and required the use of a helper influenza virus, 
which required specialized methods to select the virus with the foreign gene. Furthermore, 
expression of the foreign CAT transgene was significantly reduced after a few passages 
suggesting that the segment encoding CAT was not stably preserved. To distinguish the wild 




developed including host-range growth restrictions (Enami, Luytjes et al. 1990; Subbarao, 
Kawaoka et al. 1993), temperature sensitive mutations (Enami, Sharma et al. 1991), or plaque 
purification in the presence of antibodies (Enami and Palese 1991; Barclay and Palese 1995) 
or amantadine (Castrucci and Kawaoka 1995). 
Subsequent work demonstrated successful vRNP formation of viral model RNAs in 
influenza virus-infected cells using a influenza-reporter replicon under the control of the 
RNA polymerase I (Pol-I) promoter. The Pol-I complex is involved in transcription of 
ribosomal RNA that lacks both a 5′ cap and a 3′ poly (A) tail.  In addition, the hepatitis delta 
virus ribozyme was incorporated downstream of the vRNA in order to ensure adequate 
processing of the 3’end of the vRNA (Neumann, Zobel et al. 1994; Neumann and Hobom 
1995; Pleschka, Jaskunas et al. 1996). Although this system eliminated the need to purify 
viral NP and polymerase proteins for RNP reconstitution in vitro, it still relied on the co-
infection with a helper virus for generation of recombinant influenza viruses (Pleschka, 
Jaskunas et al. 1996). In 1999, two independent groups succeeded, for the first time, in the 
generation of influenza A viruses entirely from cloned cDNAs (Fodor, Devenish et al. 1999; 
Neumann, Watanabe et al. 1999). This technique was a major breakthrough in influenza virus 
research since it eliminated the need for purified RNPs and helper viruses. In this 12-plasmid 
rescue system, virus rescue was accomplished by transfecting cells with eight plasmids 
encoding authentic sequences of each vRNA and four expression plasmids encoding the NP 
and polymerase proteins needed for transcription and replication. To generate vRNA-
expressing plasmids, vRNA extracted from the virus is cloned in a negative sense, flanked by 
a truncated RNA polymerase I promoter and the hepatitis delta virus ribozyme, or a RNA 
polymerase I terminator. The use of these flanking sequences assures the intracellular 
expression of viral RNAs with correct start and end sequences as described above. In contrast 
to the RNAs generated by cellular RNA polymerase II, these vRNAs lack the 5’cap. Upon 
transfection, authentic vRNAs are transcribed by the cellular RNA polymerase I and then 
recognized and amplified by viral polymerase (PB1, PB2 and PA) expressed from the cellular 
RNA polymerase II coding plasmids. Because NP is required for both replication and 
encapsidation of the viral RNA, an NP expression plasmid is also included. This method 
reliably produces recombinant influenza viruses without the need of further selection 
methods. 
This initial plasmid-based reverse genetics was further improved to an eight-plasmid 




(Hoffmann, Neumann et al. 2000). Using this approach, the cDNA encoding each vRNA was 
cloned in the negative–sense orientation between human RNA polymerase I promoter at the 
5’ end and the mouse RNA polymerase I terminator at the 3’end. This entire gene cassette 
was then cloned in the positive-sense orientation between an RNA polymerase II promoter 
and polyadenilation site. The orientation of the two transcription units allows the synthesis of 
negative sense vRNA by RNA polymerase I and positive-sense mRNA by RNA polymerase 
II from one cDNA. This system is commonly referred to as the bidirectional (dual promoters: 
Pol-I and Pol-II) reverse genetic system to differentiate form the unidirectional (single 
promoter: Pol-I) system described above.   
In 2005, a one-plasmid-based rescue system was first developed with the goal of 
improving transfection efficiency by reducing the number of plasmids required for viruses 
rescue. In this system, the eight RNA polymerase I transcription cassettes for viral RNA 
synthesis were combined on one plasmid. The authors suggested that protein synthesis from a 
cryptic RNA polymerase II promoter, present in the vector or in the RNA polymerase I 
promoter or terminator region, was responsible for the generation of recombinant virus from 
one-plasmid-transfected cells (Neumann, Fujii et al. 2005). 
A limitation of all the previously described reverse genetics systems is the species 
specificity of the RNA polymerase I promoter systems, which impede virus recovery from a 
heterologous host either in vitro or in vivo and can lead to host adaptation when generating 
recombinant viruses from cloned cDNAs. These limitations were partly circumvented by the 
use of a species-independent T7 promoter rescue system (de Wit, Spronken et al. 2007) or by 
the development of the chicken (Zhang, Kong et al. 2009) and the canine Pol-I reverse 
genetics systems (Wang and Duke 2007; Murakami, Horimoto et al. 2008). Although the T7 
RNA polymerase-based reverse-genetics can be use for virus rescue in cells from different 
species, rescue efficiency with this system is inferior to the bidirectional eight-plasmid rescue 
system and therefore have not gained much popularity (de Wit, Spronken et al. 2007). Even 
though the draft swine genome sequence has been released, the porcine Pol-I reverse genetics 
system is yet to be developed.  
The use of viral vectors for the delivery of traceable reporter genes and bioactive 
molecules has broad applications in the fields of gene therapy and infectious disease. A 
number of live recombinant viral vectored vaccines have been licensed for veterinary use and 




features of DNA vaccines with those of live attenuated vaccines. Similarly to DNA vaccines, 
viral vectors deliver the DNA encoding protein immunogens into target host cells, but with 
the added advantage of inducing more robust immune by the replicating viral entity (Draper 
and Heeney 2010). Since the development of reverse genetic methods for segmented negative 
sense RNA viruses, influenza A viruses (IAV) have also been considered as potential vaccine 
vectors (Hoffmann, Neumann et al. 2000). Martínez-Sobrido and García-Sastre have 
reviewed in details the use of IAV as a vector (Martínez-Sobrido and García-Sastre 2007) . 
The engineering of IAV as expression and delivery vectors offers several advantage: (i) 
induce strong cellular and humoral immune responses both systemically and at the mucosal 
surfaces (Garulli, Kawaoka et al. 2004), (ii) the virus does not have a DNA phase during 
replication, eliminating thus safety concerns regarding integration of viral DNA into the hosts 
genome, (iii) IAV have 16 different HA and 9 different NA surface protein genes, which 
readily permits reconstitution of the vector surface proteins, making boost vaccinations 
feasible(Fouchier, Munster et al. 2005), and (iv) IAV are well characterized with attenuated 
strains already used as vaccines for humans and livestock (Belshe, Edwards et al. 2007). 
However, most of the AIV vectors developed to date have either been unstable or tolerated 
only short gene inserts. Thus, both the instability of the transgene and the insert size 
limitation has prevented IAV vectors from being used as vaccines (Martínez-Sobrido and 
García-Sastre 2007). 
Among all the IAV proteins, the surface glycoproteins HA and NA have been 
successfully engineered for expression of small protein epitopes (Li, Mueller et al. 2005; 
Martínez-Sobrido and García-Sastre 2007; Martina, van den Doel et al. 2011). Nevertheless, 
neither HA nor NA glycoproteins are optimal targets for the insertion of foreign sequences 
because of insert size constraints and the fact that booster immunizations could be affected by 
pre-existing immunity to the vector or the transgene itself.  Another approach that has been 
attempted is the incorporation of the foreign gene as an additional gene segment. Several 
groups have successfully expressed transgenes as additional influenza segments, including 
the CAT reporter gene (Luytjes, Krystal et al. 1989), the ectodomain of the classical swine 
fever virus E2 protein (Zhou, Konig et al. 1998) , GFP or the tumor-associated antigen 
MAGE-3 (Strobel, Krumbholz et al. 2000), or even an additional HA protein to generate an 
influenza virus expressing two HA proteins from the H1 and H3 (Gao, Lowen et al. 2010) or  




Additionally, expression of foreign genes has also been achieved by fusion or co-
expression of foreign proteins downstream of the NS1 protein, but expression of NEP is still 
dependent of splicing of segment 8 RNA (Ferko, Stasakova et al. 2001; Kittel, Ferko et al. 
2005; Sereinig, Stukova et al. 2006; Wolschek, Samm et al. 2011). Recently, Manicassamy 
and collaborators adapted a previously developed strategy to express NEP as a single ORF 
(Basler, Reid et al. 2001) and constructed IAV expressing GFP reporter gene fused to viral 
NS1 protein via a linker sequence. Nevertheless, the stability of the GFP-expressing virus 
was compromised during multicycle replication (Manicassamy, Manicassamy et al. 2010).  
Alternatively, IAV expressing foreign genes have been constructed by replacing the 
NA (Shinya, Fujii et al. 2004) or the PB2 (Ozawa, Victor et al. 2011) ORF with the gene of 
interest. Although this approach is interesting, it requires the use of specialized cell lines that 
express reduced levels of sialic acid or provides the essential PB2 protein in trans. 
Bicistronic influenza virus RNA segments have been constructed with two open 
reading frames as fusion proteins (Kittel, Ferko et al. 2005) or as discrete gene products 
separated by either an internal ribosomal entry site (IRES) (Garcia-Sastre, Muster et al. 
1994); by use of an internal influenza promoter (Fujii, Ozawa et al. 2009);  by a putative 
caspase cleavage site (Kittel, Sereinig et al. 2004), by a linker sequence (Manicassamy, 
Manicassamy et al. 2010) or connected to each other via a cleavage recognition signal, such 
as the foot-and-mouth disease virus 2A cis-acting hydrolase element (CHYSEL) (Percy, 
Barclay et al. 1994). 
Although these strategies have contributed to advances in the field, further 
developments in influenza virus vector design are needed to improve foreign gene stability as 
well as the packaging capacity of these viruses. This knowledge will permit the development 
of alternative safe and effective influenza-based vectors against influenza as well as other 
diseases. Furthermore, the generation of non-attenuated influenza viruses stably carrying 
traceable reporter genes will serve as an important tool to more effective tracking of the 






2.2. Influenza virus infection of domestic swine 
2.2.1. Overview 
Swine influenza is an acute respiratory disease of pigs. The disease has a high 
morbidity rate, but mortality is generally low. However, severe outbreaks can be seen 
depending on many factors, including animal’s age, virus strain, and secondary bacterial 
infections. Swine influenza not only affects the swine industry, but also represents a constant 
threat to the turkey industry and is of particular concern to public health (OIE 2008). The 
emergence of the 2009 pH1N1 containing all eight RNA segments derived from swine 
viruses provided further evidence of the pivotal role of domestic pigs in the ecology of 
influenza A virus infections. 
The causative agent of swine influenza is the type A influenza virus of the 
Orthomyxoviridae family. The genetic, structural and biologic characteristics of SIVs are 
identical to other type A influenza viruses characterized by negative-sense, segmented RNA 
genomes and were described in detail above. 
2.2.2. Epidemiology 
Influenza A viruses (IAV) display a remarkable ability to infect a variety of animal 
species, including humans, pigs, wild and domestic birds, horses, cats, dogs, ferrets, and sea 
mammals (Palese and Shaw 2007). Among these animals, wild aquatic birds are thought to be 
the primordial reservoir from which all IAV have emerged (Webster, Bean et al. 1992). 
IAV of three different subtypes: H1N1, H1N2 and H3N2 are endemic in swine 
populations worldwide. Other subtypes that have been identified in pigs include H1N7, 
H3N1, H2N3, H4N6, H3N3, and H9N2 (OIE 2008). Equine-origin H3N8 influenza viruses 
have also been isolated from pigs in central China (Tu, Zhou et al. 2009). In addition, wholly 
H5N1 avian influenza viruses have been isolated from asymptomatic pigs in Korea and 
Indonesia (Lee, Pascua et al. 2009; Nidom, Takano et al. 2010). Moreover, an H7N2 
influenza virus reassortant between avian H7N2 and H5N3 influenza viruses has been 




Despite the same subtype classification, swine influenza viruses in Europe and North 
America are antigenically and genetically distinct (Vincent, Ma et al. 2008). In Europe, an 
avian-like H1N1 virus and human-like H3N2 swine influenza viruses have been considered 
widespread among pigs since the 1980s. Furthermore, a novel H1N2 reassortant emerged in 
the mid 1990s and is also endemic in European swine populations (Van Reeth, Brown et al. 
2008). This virus has a human-like H1 HA, a human-like swine H3N2 viruses NA and its 
internal genes are most closely related to avian H1N1 viruses (Brown, Harris et al. 1998). 
In North America, classical H1N1 viruses (cH1N1), descendents of the 1918 
“Spanish flu” pandemic, were the predominant subtype circulating in swine populations since 
their first isolation in 1930. The classical H1N1 swine influenza viruses in the United States 
remained antigenically and genetically highly conserved for almost 70 years (Sheerar, 
Easterday et al. 1989; Luoh, McGregor et al. 1992; Noble, McGregor et al. 1993). In 1998, 
however, the epidemiology of swine influenza infection in North American pigs changed 
dramatically. A new genotype of H3N2 triple reassortant IAV (TR) emerged in the U.S. 
swine population and established permanent lineages. TR swine IAV have demonstrated 
exceptional ability to further reassort with either classical swine H1N1 and human H1N1 and 
H3N2 viruses, generating at least seven different reassortant lineages in the last decade 
(Karasin, Olsen et al. 2000; Karasin, Schutten et al. 2000; Webby, Rossow et al. 2004; 
Karasin, Carman et al. 2006; Lekcharoensuk, Lager et al. 2006; Ma, Gramer et al. 2006; 
Olsen, Karasin et al. 2006; Ma, Vincent et al. 2007). Currently, TR strains of the H3N2, 
H1N2, H1N1, and the pH1N1 subtypes predominate in the US swine population (Vincent, 
Ma et al. 2008). Interestingly, some of these viruses have expanded their host range and cause 
outbreaks in turkeys in North Carolina, Minnesota, and Ohio in 2003-2004 (Choi, Lee et al. 
2004). A unique feature shared by all of these endemic reassortants is the maintenance of the 
triple reassortant internal gene (TRIG) cassette, which consists of the avian-like (PA and 
PB2), swine-like (M, NP, and NS), and human-like (PB1) gene segments. The TRIG cassette 
appears to accept multiple HA and NA types, which could provide a selective advantage to 
swine viruses possessing this internal gene constellation (Vincent, Ma et al. 2008; Ma, Lager 
et al. 2009).  
In addition, the 2009 pandemic H1N1 virus (pH1N1), which is also a TR, have been 
commonly isolated from commercial swine operations throughout the world. In all incidents, 
epidemiological investigations have linked humans as the possible source of the infection to 




reassortants between pH1N1 and circulating influenza A viruses have been isolated from pigs 
in several countries (Vijaykrishna, Poon et al. 2010; Howard, Essen et al. 2011; Moreno, Di 
Trani et al. 2011; Pereda, Rimondi et al. 2011; Starick, Lange et al. 2011). In the US alone, 
pH1N1 have reassorted promiscuously with endemic TR strains given rise to at least 7 
distinct and novel viral genotypes in this animal species (Ducatez, Hause et al. 2011).  
 
2.2.3. The pig as an intermediate host and sialic acid receptor distribution 
For many years, pigs have been considered a “mixing vessel” for the generation of 
novel influenza viruses (Scholtissek, Burger et al. 1983; Scholtissek, Burger et al. 1985; 
Scholtissek 1995). Pigs are susceptible to human influenza viruses, and to a wide range of 
avian influenza viruses. Experimental infection studies showed that pigs were susceptible to 
13 different influenza virus subtypes (H1-H3 and non-human-type HA types H4-H13). From 
these studies, a reassortant virus was generated in pigs upon co-infection with a parental SIV 
strain and an avian strain; the latter naturally unable to replicate by itself in pigs (Kida, Ito et 
al. 1994). The mixing vessel attribute is consistent with the presence in the respiratory tract of 
pigs of prototypical human-like and avian-like influenza receptors, N-acetylneuraminic acid-
α2,6-galactose (SAα2,6Gal) and N-acetylneuraminic acid-α2,3-galactose (SAα2,3Gal), 
respectively (Ito, Couceiro et al. 1998). However, several recent studies have questioned the 
“mixing vessel” hypothesis. First, comprehensive mapping of the sialic acid distribution 
showed that despite SAα2,3Gal and SAα2,6Gal receptors in pig respiratory tracts, SAα2,3Gal 
is found only in the smaller airways (bronchiole and alveoli) and not in the trachea or nose 
(Nelli, Kuchipudi et al. 2010; Van Poucke, Nicholls et al. 2010; Trebbien, Larsen et al. 2011), 
which is in disagreement with a previous report by Ito et al that found both type of receptors 
in pig trachea (Ito, Couceiro et al. 1998). Experimentally, pigs display low susceptibility to 
infection with low and highly pathogenic H5N1 avian influenza viruses (Choi, Nguyen et al. 
2005; Lipatov, Kwon et al. 2008; De Vleeschauwer, Atanasova et al. 2009). Moreover, the 
prevalence of H5N1 avian influenza virus infection in Asia appears to very low relative to 
prevalence in bird populations (Choi, Nguyen et al. 2005) and swine H5N1 isolates are less 
virulent to mice than avian isolates, suggesting that these viruses may become less virulent 
during their replication in pigs (Takano, Nidom et al. 2009). 
The receptor specificity theory alone does not explain the apparently increased 
susceptibility of this species since both types of receptors are also found in the respiratory 




and humans (Shinya, Ebina et al. 2006), implying that these species can also serve as 
intermediate hosts for influenza reassortment. Nevertheless, the hypothesis that the pig acts as 
a mixing vessel between human and avian influenza viruses cannot be rejected since pigs 
have been commonly associated with two-way transmission of influenza viruses to and from 
humans (Myers, Olsen et al. 2007; Robinson, Lee et al. 2007; Newman, Reisdorf et al. 2008; 
Vincent, Swenson et al. 2009). In addition, pigs were involved in the genesis of the 2009 
pH1N1 (Garten, Davis et al. 2009) and a greater number of reassortants between pH1N1 and 
circulating IAV have been isolated from pigs than from any other species that have been 
infected by pH1N1(Vijaykrishna, Poon et al. 2010; Howard, Essen et al. 2011; Moreno, Di 
Trani et al. 2011; Pereda, Rimondi et al. 2011; Starick, Lange et al. 2011, Gramer, Lee et al. 
2007; Kumar, Deflube et al. 2011; Nfon, Berhane et al. 2011).  
In addition, there have been at least 50 cases described in the literature of zoonotic 
swine influenza virus infection with a case-fatality rate of 14% (Myers, Olsen et al. 2007).  In 
fact, an epidemiological study conducted in swine workers from Iowa, the US largest pork 
producing state, concluded that occupational exposure to pigs greatly increases workers' risk 
of swine influenza virus infection (Myers, Olsen et al. 2006).  A 2-year prospective study of 
zoonotic influenza transmission in Iowa concluded that swine workers and their nonswine-
exposed relatives are at increased risk of zoonotic influenza virus infections (Gray, McCarthy 
et al. 2007). Thus, these studies highlight the importance of swine in the ecology and 
evolution of the influenza A viruses and suggest that systematic swine surveillance may allow 
the early detection of potentially pandemic strains in this reservoir. 
2.2.4. Pathogenesis, pathology, and clinical features 
The pathogenesis of swine influenza is well known and bears remarkable 
resemblance to human influenza with respect to the clinical presentations and pathologic 
features. Swine influenza infection follows a typical pattern of respiratory viral infections 
without systemic spread. Viral replication takes place in cells of the nasal mucosa, tonsils, 
trachea, lungs and tracheobronchial lymph nodes (Brown, Done et al. 1993). Consistent with 
the sialic acid receptor distribution, immunohistochemistry studies in influenza virus infected 
pigs have revealed that swine influenza antigens are widespread in the respiratory tract 
(alveoli, bronchioles, bronchi as well as nasal and tracheal epithelium) of pigs, whereas avian 
influenza antigens are located only in the lower respiratory tract (alveoli and bronchioles) 
(Trebbien, Larsen et al. 2011). Under experimental conditions, reproduction of typical swine 




inoculation of high viral doses, as opposed to less invasive methods such as intranasal 
inoculation, which usually result in mild or subclinical infection (Maes 1984). 
In uncomplicated infections, the gross lesions are mainly those of a primary viral 
pneumonia. Animals develop bronchointerstitical pneumonia that is characterized by 
depressed dark red to purple-red and sharply demarcated areas in the lungs. Lesions may be 
found throughout the lungs but they are usually more extensive in the cranio-ventral portions 
of the lung (Fig. 2.2A). Other parts of the lungs may be pale and emphysematous. The 
airways are often dilated and filled with mucopurulent exudate. The bronchial and 
mediastinal lymph nodes are typically edematous but not congested (Brown, Done et al. 
1993; Van Reeth, Van Gucht et al. 2002; Vincent, Ma et al. 2008). Microscopically, the 
hallmark of swine influenza infection is necrosis and desquamation of epithelial cells lining 
the airways. In addition, epithelium attenuation in the bronchioles and interstitial pneumonia 
may be present (Fig. 2.2B). Mild to moderate peribronchiolar and perivascular lymphocytic 
infiltration occurs at nearly all levels of the airways. The influx of inflammatory cells in the 
airways causes obstruction of the bronchi, bronchiole and significant lung damage due to 
release of enzymes (Van Reeth 2000; Barbe, Atanasova et al. 2011). As mentioned earlier, 
viral antigen can be detected throughout the respiratory tree, but is predominantly detected in 
the luminal, rather than the basal epithelial cells (Fig. 2.2C). Infection with influenza viruses 
induces the production of pro-inflammatory cytokines mediators in pigs that are thought to be 
key players in developing disease. Specifically, experimental infection with representative 
swine influenza virus strains demonstrated highly significant correlations between clinical 
signs and the levels of IL-1, IL-6, IL-12, IFN-α, IFN-γ, TNF-α, and acute phase protein in 
















Figure 2.2. Lung pathology induced by influenza in pigs. Pigs were infected with 
A/turkey/Ohio/313053/04 (H3N2) and pneumonia was assessed at 3 dpi. (A) Gross lung 
pathology. There are multifocal dark red areas of consolidation, which are consistent with 
bronchointerstitial pneumonia. (B) Microscopic pneumonia. The bronchus contains 
neutrophils. The epithelium is infiltrated by neutrophils and there is a loss of cilia and goblet 
cells.  The adjacent BALT is present. (C) Immunohistochemistry. The brown spots indicate 
the presence of the virus (NP antigen) in the bronchial epithelium.	   The bronchus is also 








Typical signs of influenza in pigs include abrupt onset fever, anorexia, inactivity and 
respiratory signs (sneezing, coughing, irregular abdominal breathing and ocular and nasal 
discharges). Although mortality is relatively low (1-3%), it can be higher in piglets and in 
breeding females, where the abortion rate can reach up to 7% (Easterday 1999; Zhou, Senne 
et al. 1999). Morbidity can be as high as 100% and can precipitate outbreaks of more serious 
respiratory diseases causing increased mortality. Outbreaks of swine influenza can have 
serious economic consequences because of the increased time needed for convalescent 
animals to attain slaughter weight (Kay, Done et al. 1994). Swine influenza virus is spread 
via aerosolized respiratory secretions and fomites, including contaminated inanimate objects 
and people moving between infected and uninfected swine. Outbreaks of swine influenza are 
most commonly associated with the introduction of new animals into a herd. The incubation 
period is usually one to three days. Pigs begin excreting the virus within 24 hours of 
infection, and may shed the virus for seven to ten days (OIE 2008). With respect to the 2009 
pH1N1, pigs inoculated with this strain virus show clinical disease signs and pathology 
similar to infection with other swine influenza viruses (Brookes, Irvine et al. 2009; Itoh, 
Shinya et al. 2009; Lange, Kalthoff et al. 2009; Weingartl, Albrecht et al. 2009; Vincent, 
Lager et al. 2010). 
2.2.5. Diagnosis 
According to clinical and pathologic findings only a presumptive diagnosis can be 
made since there are no pathognomonic signs of the disease and the clinical signs may be 
confused with other respiratory diseases of pigs including porcine reproductive and 
respiratory syndrome virus (PRRSV), Aujeszky’s disease (pseudorabies) virus, porcine 
respiratory coronavirus, Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, and 
other bacterial agents. Moreover, in outbreaks of primary influenza virus infection, clinical 
signs many be mild or absent. Virus isolation is carried out on embryonated chicken eggs 
and/or in MDCK cell lines using nasal or pharyngeal swabs collected of live animals in the 
febrile phase. Tissue samples from trachea and lungs can be used to isolate viruses from 
animals that were euthanized or died during the acute stage of the disease. For routine 
diagnosis, however, RT-PCR and quantitative real time RT-PCR (qPCR) has replaced virus 
isolation, thanks to their speed, sensitivity, automation, and for enabling rapid diagnosis on 
samples where the virus is no longer viable. Nevertheless, virus isolation is still used to 
provide enough material for genome sequencing (Richt, Lager et al. 2004; OIE 2008; 




Serology on paired samples can diagnose swine influenza, retrospectively. However, 
the presence of maternal antibodies may limit the applicability of antibody-based assays. The 
presence of swine influenza specific antibodies can be determined by serological assays such 
as the hemagglutination inhibition test (HI), which is subtype specific. Additionally, serum 
neutralization and ELISA can also be used. Virus present in fixed tissue samples can be 
detected by immunofluorescence or immunohistochemistry methods (Vincent, Janke et al. 
1997; OIE 2008). Recent developments in metagenomics-based strategies, such as pan-viral 
microarrays and deep sequencing, may potentially transform the way clinical microbiology 
laboratories approach the diagnosis and genetic characterization swine influenza as well as 
other respiratory diseases of swine (Greninger, Chen et al. 2010; Nicholson, Kukielka et al. 
2011).  
2.2.6. Prevention and control 
Vaccine and strict biosecurity practices are the primary means of preventing and 
controlling swine influenza in pig populations. Because influenza can be introduced into a 
facility in an infected animal, strict quarantine of newly acquired pigs can decrease the risk of 
transmission to the rest of the herd. Segregation and partial depopulation of early-weaned 
piglets, “all-in/all-out” system and rigorous hygiene, are considered essential steps to control 
the spread of the swine influenza within the farm and minimize the economical effects of the 
disease. Infected swine herds can be cleared of influenza viruses by depopulation. Where 
exclusion is not feasible, vaccines can be used to control the disease (Kothalawala, Toussaint 
et al. 2006; Vincent, Ma et al. 2008). Currently, commercially available swine influenza 
vaccines are based on inactivated whole virus preparations of the H1N1 and H3N2 subtypes. 
The use of vaccination has become a common practice to control swine influenza in the US. 
Nonetheless, these commercially available vaccines provide limited protection against the 
antigenically diverse influenza viruses that circulate in North American pigs, and 
consequently, forced swine producers to use autogenous inactivated vaccines with the hope of 
achieving better antigenic matching (Vincent, Lager et al. 2007). These vaccines do not 
always prevent infection or virus shedding, but the disease is usually milder if it occurs. 
However, it is important to note that the use of inactivated vaccines has been associated with 
enhanced pneumonia when immunized pigs were challenged with divergent viruses (Vincent, 
Lager et al. 2007). 
Experimental live attenuated influenza vaccines (LAIV) have been shown to induce 




challenge (Vincent, Ma et al. 2007; Masic, Booth et al. 2009). However, the attenuation 
mechanism used in these platforms was not temperature-sensitive (ts), the attenuation 
mechanism used in vaccines currently available for humans (Belshe 2004) and horses 
(Townsend, Penner et al. 2001). Recently, a LAIV using ts genetic markers for attenuation 
was developed using a contemporary IAV strain with the triple reassortant backbone and 
shown to be efficacious in swine. Importantly, these vaccines provided sterilizing immunity 
in pigs (Pena, Vincent et al. 2011). LAIV closely mimic natural infection and have several 
advantages over inactivated vaccines. LAIVs trigger cell-mediated immunity and mucosal 
immune responses, thereby providing longer-lasting immunity and broader antigenic 
coverage than conventional inactivated vaccines (Cox, Brokstad et al. 2004; He, Holmes et al. 
2006; Horimoto and Kawaoka 2009). Additionally, LAIV are more cost effective to produce 
than inactivated vaccines since there are inherently less processing steps during production.  
In general, the antigenic evolution (antigenic drift) of swine viruses occurs at a rate 
approximately six times slower than the rate in human viruses, suggesting that swine 
influenza vaccines may be changed less often than their human counterparts (de Jong, Smith 
et al. 2007). Nevertheless, the high genetic and antigenic diversity of influenza viruses 
circulating in swine populations underscores the need for effective vaccines to mitigate the 
impact of swine influenza in pigs as well as in populations at risk such as workers with 
occupational exposure to swine.  
 




Chapter 3: Role of Surface Glycoproteins in the Virulence of 




H3N2 triple reassortant (TR) swine influenza viruses first emerged in the United 
States in 1998 and have since become endemic in swine populations. Little is known about 
the molecular markers that modulate the pathogenesis of influenza viruses in swine. 
Therefore, there is a need to understand the molecular basis of pathogenesis in this important 
natural host. Here we focused on the role of surface glycoproteins in the virulence of TR 
H3N2 influenza virus in pigs. Two closely related H3N2 TR influenza viruses were chosen 
for these studies. These strains are influenza A/swine/WI/14094/99 (H3N2) and 
A/turkey/OH/313053/04 (H3N2), referred herein as sw/99 and ty/04, respectively. By using 
reverse genetics, we exchanged the HA and NA genes between the low virulent (sw/99) and 
the highly virulent (ty/04) viruses to prepare 6:2 reassortant and determine whether the 
surface proteins are responsible for the differential virulence seen in pigs. The clinical signs 
when present were milder than with infection ty/04 WT virus and none of the animals had 
respiratory signs of disease, suggesting that the surface genes are necessary but not sufficient 
for the clinical disease. Interestingly, the 6 ty/04:2 sw/99 reassortant had higher body 
temperature than the 6 sw/99:2 ty/04, suggesting that the internal genes from the ty/04 are the 
major contributors for the febrile response. Remarkably, swapping the surface genes was 
sufficient for reverting the lung pathology phenotype. Taken together, these studies suggest 
that surface glycoproteins are responsible for the macroscopic pneumonia induced by TR 












Influenza A viruses (IAV) are single-stranded RNA viruses with negative polarity 
that belong to the family Orthomyxoviridae. Its genome contains eight RNA segments, which 
encode 10-12 viral proteins. Two major viral glycoproteins, the hemagglutinin (HA) and the 
neuraminidase (NA), are present in the viral envelope. To date, 16 HA and 9 NA subtypes 
have been described (Fouchier, Munster et al. 2005). These surface glycoproteins are the 
main antigenic determinants of the virus. The HA is the viral ligand that recognizes sialic 
acid receptors present on glycoproteins and glycolipids on host cells. Binding to host 
receptors is the first step in the viral life cycle and this property makes the HA a major 
contributor to the host range of influenza viruses (Suzuki, Ito et al. 2000). The NA 
glycoprotein virus promotes the release of virus particles from infected cells contributing to 
the spread of progeny virions at the final stage of infection. Recently, it was formally proven 
that NA also plays an important role early during the viral infection, presumably by removal 
of mucus covering the airways epithelium (Matrosovich, Matrosovich et al. 2004). 
IAV display a remarkable ability to infect a variety of animal species, including 
humans, pigs, wild and domestic birds, horses, cats, dogs, ferrets, and sea mammals (Palese 
and Shaw 2007). Among these animals, wild aquatic birds are thought to be the primordial 
reservoir from which all IAV have emerged (Webster, Bean et al. 1992). Little is known 
about the molecular markers that lead to the emergence of novel viruses subtypes with the 
ability to cross the species barrier and spread efficiently among humans. However, genetic 
reassortment played a role in the genesis of the last three influenza pandemics. In both the 
1957 Asian (H2N2) and 1968 Hong Kong (H3N2) pandemics, reassortment occurred 
between human and avian viruses. The 2009 (H1N1) pandemic (pH1N1), besides having 
gene segments derived from avian and human IAV, also acquired gene segments from the 
swine IAV.  
Pigs have been suggested as intermediate hosts for the generation of novel influenza 
viruses because they are susceptible to infection with avian and human influenza viruses 
(Scholtissek, Burger et al. 1983; Scholtissek, Burger et al. 1985; Scholtissek 1995) and have 
both the human and avian type sialic acid receptors (Ito, Couceiro et al. 1998). Since both 
types of receptors are also found in the respiratory tract of quail, pheasant, turkey, guinea 
fowl (Wan and Perez 2006; Kimble, Nieto et al. 2010) and humans (Shinya, Ebina et al. 
2006), the receptor specificity does not explain the increased susceptibility of this species.  




viruses to and from humans (Myers, Olsen et al. 2007; Robinson, Lee et al. 2007; Newman, 
Reisdorf et al. 2008; Vincent, Swenson et al. 2009) and a greater number of reassortants 
between pH1N1 and circulating IAV have been isolated from pigs than from any other 
species (Vijaykrishna, Poon et al. 2010; Howard, Essen et al. 2011; Moreno, Di Trani et al. 
2011; Pereda, Rimondi et al. 2011; Starick, Lange et al. 2011; Zhu, Zhou et al. 2011). 
Three influenza subtypes circulate in the swine populations of the world: H1N1, 
H3N2, and H1N2. In North America, classical H1N1 viruses (cH1N1), descendents of the 
1918 “Spanish flu” pandemic, were the predominant subtype circulating in swine populations 
since their first isolation in 1930. In 1998, however, the epidemiology of swine influenza 
infection in North American pigs changed dramatically. A new genotype of H3N2 triple 
reassortant IAV (TR) emerged in the U.S. swine population and established permanent 
lineages. TR swine IAV have demonstrated an exceptional ability to reassort with classical 
swine H1N1, human H1N1, and H3N2 viruses, generating at least seven different reassortant 
lineages in the last decade (Karasin, Olsen et al. 2000; Karasin, Schutten et al. 2000; Webby, 
Rossow et al. 2004; Karasin, Carman et al. 2006; Lekcharoensuk, Lager et al. 2006; Ma, 
Gramer et al. 2006; Olsen, Karasin et al. 2006; Ma, Vincent et al. 2007). Currently, TR 
strains of the H3N2, H1N2, H1N1, and the pH1N1 subtypes are predominant in the US swine 
population (Vincent, Ma et al. 2008). These viruses are not just limited to swine hosts: 
between 2003-2004, turkeys experienced outbreaks in North Carolina, Minnesota, and Ohio 
(Choi, Lee et al. 2004). A unique feature shared by all of these endemic reassortants is the 
maintenance of the triple reassortant internal gene (TRIG) cassette, which consists of the 
avian-like (PA and PB2), swine-like (M, NP, and NS), and human-like (PB1) gene segments. 
The TRIG cassette appears to accept multiple HA and NA types, which could provide a 
selective advantage to swine viruses possessing this internal gene constellation (Vincent, Ma 
et al. 2008; Ma, Lager et al. 2009) .  
Typical signs of influenza in pigs include abrupt onset fever, anorexia, inactivity and 
respiratory signs (sneezing, coughing, irregular abdominal breathing, and ocular and nasal 
discharges). Although mortality is relatively low (1-3%), it can be higher in piglets and in 
breeding females, where the abortion rate can reach up to 7% (Easterday 1999; Zhou, Senne 
et al. 1999). Morbidity can be as high as 100% and can precipitate outbreaks of more serious 
respiratory diseases causing increased mortality. Outbreaks of swine influenza can have 
serious economic consequences because of the increased time needed for convalescent 




The genetic, antigenic, and pathobiological attributes of TR H3N2 swine influenza 
virus have been evaluated. At the genetic level, at least three introductions of human H3-
subtype viruses, leading to phylogenetic clusters I, II, and III, have been documented (Richt, 
Lager et al. 2003; Webby, Rossow et al. 2004). The cluster III has evolved into cluster III 
variants, also known as cluster IV, which are now the predominant H3N2 viruses circulating 
in swine populations in North America (Gramer, Lee et al. 2007; Kumar, Deflube et al. 2011; 
Nfon, Berhane et al. 2011). Experimental infection of swine with viruses belonging to 
clusters I to III were able to induce clinical disease and pneumonia, whose severity varied 
between individual strains even within one antigenic cluster (Richt, Lager et al. 2003). 
However, to our knowledge there have been no studies investigating the molecular basis for 
strain-dependent virulence of the TR H3N2 swine influenza virus.  
Virulence of IAV is considered a polygenic trait, in which disease outcome is 
determined by the gene constellation of a particular influenza virus strain within a specific 
host (Hatta, Gao et al. 2001; Chen, Bright et al. 2007; Basler and Aguilar 2008). Several 
virulence determinants in the genome of IAV have been described, including the HA 
(Kawaoka, Naeve et al. 1984; Kobasa, Takada et al. 2004; Pappas, Aguilar et al. 2008; de 
Wit, Munster et al. 2010; Ping, Dankar et al. 2010), NA (Pappas, Aguilar et al. 2008; 
Matsuoka, Swayne et al. 2009) , NS1 (Lipatov, Andreansky et al. 2005; Fernandez-Sesma, 
Marukian et al. 2006; Li, Jiang et al. 2006; Jiao, Tian et al. 2008), NP and the polymerase 
complex formed by PB2, PB1, and PA proteins (Snyder, Buckler-White et al. 1987; Hatta, 
Gao et al. 2001; Fouchier, Schneeberger et al. 2004; de Jong, Simmons et al. 2006; Salomon, 
Franks et al. 2006; de Wit, Munster et al. 2010; Ping, Dankar et al. 2010; Song, Feng et al. 
2011). The balance between the HA and NA activities are crucial for influenza virus 
replication, virulence, and transmission (Mitnaul, Matrosovich et al. 2000; Hulse, Webster et 
al. 2004; Lu, Zhou et al. 2005; Yen, Liang et al. 2011). 
To understand the molecular mechanism underlying the strain-specific virulence of 
the TR H3N2 swine influenza virus in pigs, two genetically related H3N2 TR IAV were 
selected for these studies. These strains are A/swine/Wisconsin/14094/99(H3N2) [sw/99] and 
A/turkey/OH/313053/04(H3N2) [ty/04], a relative of sw/99 virus that caused an outbreak on 
a turkey farm. Because these viruses displayed different pathotypes in pigs, we used reverse 
genetics to decipher the role of their surface glycoproteins in virulence for swine. We found 
that although the HA and NA genes were not sufficient for reverting the clinical disease 




lung pathology. These results demonstrate that surface glycoproteins play a major role in the 





3.3. Material and Methods 
3.3. 1. Ethics Statement 
 Swine studies were conducted under BSL-2 conditions approved by USDA and 
performed according to protocols R-08-16 “Transmissibility of Influenza A Viruses in 
Swine", approved by the Institutional Animal Care and Use Committee of the University of 
Maryland. Animal studies adhere strictly to the US Animal Welfare Act (AWA) laws and 
regulations. 
3.3. 2. Cells and viruses  
 Human embryonic kidney cells (293-T) were cultured in OptiMEM I (GIBCO, 
Grand Island, NY) containing 10% FBS and antibiotics. Madin-Darby canine kidney 
(MDCK) cells were maintained in modified Eagle's medium (MEM) (Sigma-Aldrich, St. 
Louis, MO) supplemented with 5% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, 
MO), L-glutamine and antibiotics.  
 A/swine/Wisconsin/14094/99 (H3N2) (Genbank taxonomy 136472) was a kind 
gift from Dr. Sagar Goyal, University of Minnesota. A/turkey/Ohio/313053/04 (Genbank 
taxonomy ID 533026) was kindly provided by Dr. Yehia Saif, Ohio State University. Both 
viruses were successfully rescued from cloned cDNAs as described below and amplified in 
either MDCK cells (sw/99) or embryonated eggs (ty/04) following the same substrates used 
for isolation of the WT viruses. Surface reassortants between sw/99 and ty/04 were generated 
by reverse genetics and amplified in MDCK cells.  
 
3.3. 3. Reverse genetics 
 The eight-plasmid-based reverse genetics (RG) system (Hoffmann, Neumann et al. 
2000) was used to rescue WT A/swine/Wisconsin/14094/99 (H3N2) (sw/99), 
A/turkey/Ohio/313053/04 (H3N2) (ty/04) and their 2:6 surface reassortant. Briefly, viral 
RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer's instructions and reverse-transcribed to cDNA using the uni-12 primer (5′-
AGCAAAAGCAAAGG-3′) and the AMV reverse transcriptase (Promega, Madison, WI, 




Stech et al. 2001). Purified amplicons were digested with either BsaI or BsmBI (NEB, 
Ipswich, MA) and cloned into the pDP2002 vector (Song, Nieto et al. 2007). The resulting 
clones were fully sequenced and compared to the WT viral consensus. Mutations found in 
plasmid clones were corrected by site-directed mutagenesis using a commercially available 
kit (Stratagene, La Jolla, CA). 
 The recombinant WT viruses as well as the 6:2 surface gene reassortants were 
generated by transfecting the RG plasmids into co-cultured 293-T and MDCK cells as 
previously reported (Hoffmann, Neumann et al. 2000). 6 ty/04:2sw/99 is a 6:2 reassortant 
with the 6 internal genes from ty/04 and 2 surface genes from the sw/99, whereas the 6 
sw/99:2 ty/04 has the 6 internal genes from sw/99 and 2 surface genes from the ty/04. 
3.3. 4. Swine studies 
To evaluate the pathogenicity of the sw/99 and ty/04 strains in swine, two 
independent experiments were carried out. A total of 14 female Yorkshire swine (5 weeks old 
and weighing approximately 40 lbs each) were obtained from a commercial farm and shown 
to be negative for antibodies against influenza A viruses by a commercially available NP 
ELISA (Synbiotics/Pfizer, Kansas City, MO). Pigs were sedated by intramuscular injection of 
6 mg/kg of tiletamine-zolazepam (Telazol®, Pfizer Animal Health, NY) and 2.2 mg/kg of 
xylazine. In each experiment, groups of 3 pigs each were infected intratracheally with 1x108 
TCID50 with either sw/99 or ty/04 virus diluted in 4 mL of sterile PBS. Two pigs served as an 
uninfected control and were inoculated through the same route with 4 mL of PBS. For five 
days post inoculation, pigs were monitored daily for hyperthermia and clinical signs of 
disease and virus shedding in nasal secretions were measured. At the end of the experiment, 
the animals were euthanized and necropsied.  Nasal swabs were collected daily in 1 mL of 
Brain-Heart Infusion (BHI) media containing antibiotics and stored at -80°C until further 
analysis. During necropsy, lungs were removed in toto and a score was given based on the 
percentage of gross lesions of lobes showing the purple-red consolidation. Bronchoalveolar 
lavage fluid (BALF) and sections of the pulmonary lobes were also obtained for virus 
isolation.  
To evaluate the virulence of the surface reassortants between sw/99 and ty/04, two 
groups of pigs (n=3) were infected with each of the reassortants following the same 




3.3. 5. Virus titration 
Viral stocks and viruses present in biological samples (clarified lung homogenates, 
nasal swabs or BALF) were titrated on MDCK cells and the TCID50/ml was determined by 
the method of Reed and Muench (Reed and Muench 1938). Briefly, samples were serially 
diluted 10-fold in OptiMEM I media (GIBCO, Grand Island, NY) containing antibiotics and 
1 µg/ml TPCK-trypsin (SIGMA, Saint Louis, MO). Next, 200 µL of the inoculum were 
overlaid onto confluent monolayers of MDCK cells seeded in 96-well plates. Plates were 
incubated for 3 days and the endpoint viral titer was determined by an HA assay readout 
using 0.5% turkey red blood cells. 
3.3. 6. Cytokine levels in porcine BALF 
The levels of nine porcine cytokines (IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12, and TNFα) in BALF samples were determined by multiplex sandwich ELISA following 
the manufacter’s protocol (Aushon Biosystems, MA). 
3.3. 7. Alignment and phylogenetic analysis 
The surface glycoproteins of the sw/99 and ty/04 viruses were aligned with other 
North American H3N2 swine IAV using ClustalW method in MegAlign (Lasergene v.8.1.5., 
DNAStar, Madison, WI).  The phylogenetic tree was generated by Neighboor-Joining method 
using the using PAUP 4.0b10 program (Sinauer Associates, Inc., Sunderland, MA). 
Robustness of phylogenetic trees was tested by performing 1000 bootstrap replicates with 
111 random seeds. 
3.3. 8. Statistical analysis 
All statistical analyses were performed using GraphPad Prism Software Version 5.00 
(GraphPad Software Inc., San Diego, CA). Comparison between two treatment means was 
achieved using a two-tailed Student t-test, whereas multiple comparisons were carried out by 
analysis of variance (ANOVA) using Tukey’s post hoc test, unless otherwise specified. The 




3.4. Results  
3.4.1. Evolutionary relationships and sequence alignment of the sw/99 and ty/04 
surface glycoproteins 
The A/swine/Wisconsin/14094/99 (H3N2) belongs to cluster III of the North 
America TR H3N2 swine IAV based on the nucleotide sequence of its HA gene. Initially, 
phylogenetic analysis of the HA gene of A/turkey/Ohio/313053/04 (H3N2) suggested that the 
virus also belonged to cluster III and was closely related to A/Swine/WI/14094/99 (H3N2) 
(Tang, Lee et al. 2005). However, the cluster III viruses have continued to evolve into cluster 
III variants, also known as cluster IV.  With the inclusion of more recent TR H3N2 strains 
isolated from different hosts, it has become clear that the ty/04 strain is a variant belonging to 
cluster IV of TR H3N2 IAV, not to cluster III (Fig. 3.1A). Deduced amino acid sequences of 
the HA protein of both the sw/99 and ty/04 viruses showed that these viruses differ by 26 
amino acids (95.4% similarity), whereas their NA differ by 27 amino acids (94.2% 
similarity). Major amino acid changes were shown at the antigenic sites of sw/99 and ty/04 
HA1 molecule. Furthermore, there are drastic changes in receptor binding and glycosylation 





























Figure 3.1. Phylogenetic analysis and alignment of of the HA derived from the TR H3N2 
viruses used in this study. (A) Phylogenetic relationships of sw/99 and ty/04 with other 
H3N2 IAV. Analysis was based on the nucleotide sequences of the HA genes. The 
phylogenetic tree was generated by Neighboor-Joining method using the PAUP 4.0 beta 10 
program. (B) Alignment of the HA1 protein. Shaded residues indicate amino acids that differ 
from the consensus. Boxed residues represent antigenic sites in the H3 molecule. Underlined 























3.4.2. Genetically related triple reassortant H3N2 influenza viruses display distinct 
pathotypes in swine 
 
To determine the pathotypes of the two parental WT TR H3N2 viruses used in this 
study, we initially inoculated groups of pigs with 1x108 TCID50 with either sw/99 or ty/04 
virus through the intratracheal route because experimental reproduction of typical signs of 
influenza in pigs is most consistently accomplished by intratracheal inoculation with high 
doses of virus (Maes 1984). After inoculation with sw/99, none of the pigs had fever or other 
clinical signs, with exception of a single pig that had a transient cough and a two-day 
decrease in food consumption. This suggests that this virus is of low virulence for pigs under 
experimental conditions. In contrast, pigs inoculated with ty/04-developed signs of severe 
clinical disease, which were characterized by high fever, hyporexia, inactivity, huddling, 
nasal and ocular discharge, coughing, and dyspnea. Fifty percent (3 out of 6) of pigs 




Figure 3.2. Rectal temperature of pigs intratracheally infected with H3N2 triple 
reassortant Influenza A viruses. Daily mean rectal temperatures of pigs following 
inoculation with either sw/99, ty/04, or PBS control (Values are shown as the mean ± SEM. * 




At necropsy, pigs infected with sw/99 had discrete lung lesions, which were 
characterized by small areas and scarce with purple-red consolidation. In sharp 
contrast, pigs infected with ty/04 virus had pneumonia, which was characterized by 
multiple areas of purple-red lung consolidation (Fig.3.3), airways filled with blood-
tinged fibrinous exudates, and enlargement of the tracheobronchial lymph nodes (data 
not shown). The severity of macroscopic lung lesions correlated with the clinical 
outcome of the infection by these two viruses. As expected, mock-infected animals 












Figure 3.3. Gross pathology of pigs infected with H3N2 triple reassortant Influenza A 
viruses. On day 5 post-infection, pigs were euthanized and the gross pathology was 
evaluated. Representative lungs from pigs infected with either sw/99 (A) or ty/04 (B) are 
shown. Lungs from pigs infected with sw/99 display minimum pathology, whereas lungs 






The degrees of macroscopic lung pathology were mirrored by the changes 
found at the microscopic levels. Pigs infected with the sw/99 virus generally showed 
only mild histopathological lesions as opposed to the ty/04-inoculated pigs that had 
severe bronchopneumonia. In general, pulmonary lesions were typical of influenza 
virus infection in pigs and were characterized by multifocal to widespread necrotizing 
bronchitis and bronchiolitis, light peribronchiolar lymphocytic cuffing, mild 
multifocal interstitial pneumonia and varying degrees of alveolar involvement (data 
not shown). These results suggest that in spite of the genetic similarity between ty/04 
and sw/99, the two viruses display different signs of clinical disease and lung 
pathology in swine. 
 
3.4.3. Pneumonia caused by ty/04 does not correlate with levels of viral replication in 
the respiratory tract 
 
We then compared the levels of virus shedding in the upper respiratory tract 
and the viral lung load in both the sw/99 and the ty/04-infected pigs. There was no 
statistical significant difference in the kinetics and absolute levels of virus shedding 
between the two viruses during the first five days of infection. Nasal shedding was 
first detected at 1 dpi and peaked at 4 dpi, reaching 5-6 log10 TCID50/mL (Fig. 3.4A). 
Virus titers in BALF and lung homogenate ranged from 104 to 105 TCID50 /ml 
of BALF or gram of tissue and the differences were not statistically significant 
between two viruses (Fig. 3.4B). In conclusion, these results suggest that both viruses 
replicate similarly in the respiratory tract of pigs and the levels of replication do not 















Figure 3.4. Shedding and viral lung load following inoculation of pigs with H3N2 triple 
reassortant Influenza A viruses. Groups of pigs (n=6) were inoculated intratracheally with 
108 TCID50/animal of either sw/99 or ty/04 diluted in 4 ml of PBS. A third group (n=3) was 
mock vaccinated with PBS alone. (A) Viral shedding in nasal secretions of pigs infected with 
either WT sw/99 or ty/04 (B) Viral lung load. Viral titers in bronchoalveolar lavage fluid 
(BALF) and in the right cranial lobe collected at 5 dpi. Viral titers were determined by 





3.4.4. Febrile response induced by ty/04 correlates with pulmonary levels of IL-1β 
Cytokine production after influenza infection has been implicated in the pathogenesis 
of influenza in mammals, including pigs (Van Reeth 2000). To further understand the host 
response following infection with sw/99 or ty/04 in swine, we measured the protein levels of 
nine porcine cytokines/chemokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNF-α, 
and IFN-γ) in BALF collected at 5 dpi necropsies. The concentrations of IL-2 were elevated 
in infected pigs relative to mock controls, but there was no statistical significant difference 
between the two viruses. Interestingly, ty/04-infecteded pigs exhibited statistically significant 
higher levels of the proinflammatory cytokine IL1-β as compared to sw/99 group (Fig.3.5). 
The high levels of IL1-β in the ty/04 group correlated with the fever induced by the infection 
with this virus strain. These results indicate that ty/04 infection induces higher expression 
levels of IL1-β relative to sw/99 and this heightened production of pro-inflammatory 





Figure 3.5. Cytokine profile in the lungs of pigs infected with WT H3N2 TR viruses. The 
levels of nine porcine cytokines in BALF samples were determined by multiplex sandwich 





3.4.5. Surface glycoproteins modulate the lung pathology of TR H3N2 influenza 
viruses in swine 
We next attempted to determine the molecular attributes that led to enhanced 
virulence of the ty/04 strain compared to sw/99. By using reverse genetics, we exchanged the 
HA and NA genes between the less virulent (sw/99) and the more virulent (ty/04) viruses to 
determine whether the surface proteins are responsible for the differential virulence seen in 
pigs. We focused on HA and NA surface proteins because of their pivotal role in influenza 
virulence for other species and the fact that they co-evolve (Mitnaul, Matrosovich et al. 2000; 
Pappas, Aguilar et al. 2008). 
Six female Yorkshire swine were divided in two groups of three pigs each and 
infected with the 6:2 surface reassortants between sw/99 and ty/04 using the same dose and 
route as described above for infection with the parental WT viruses. The clinical signs, when 
present, were milder than with infection WT viruses and none of the animals had respiratory 
signs of disease, suggesting that the surface genes are necessary but not sufficient for the 
clinical disease induced by ty/04 (Table 3.1).  
Table 3.1. Clinical signs of pigs infected with H3N2 triple reassortant Influenza A 
viruses and their 6:2 surface reassortants. 
 
 Viruses 
Clinical signs  sw/99 ty/04 6 ty/04:2 sw/99 6 sw/99:2 ty/04 
hyporexia  6/6 6/6 3/3 3/3 
inactivity  0/6 6/6 3/3 3/3 
huddling  0/6 6/6 0/3 0/3 
nasal discharge  0/6 6/6 0/3 0/3 
conjunctivitis  0/6 3/6 0/3 3/3 
coughing  1/6 6/6 0/3 0/3 





Strikingly, swapping the surface genes was sufficient for reverting the lung pathology 
phenotype (compare Fig. 3.6 with 3.2). Pigs infected 6sw/99:2ty/04 had the same percentage 
of lung involvement than pigs infected with the WT ty/04, suggesting that the surface genes 
from H3N2 TR influenza viruses are necessary and sufficient for induction of macroscopic 
pneumonia in pigs. The severity of lung pathology did not correlate with viral burden in the 
lungs since there was no statistically significant difference in lung and BALF viral titers 
among the groups (Fig. 3.7). In addition, the levels of viral shedding in nasal secretions were 
similar between the two viruses. Taken together, these studies suggest that the surface genes 
are involved in the macroscopic pneumonia in pigs. 
Figure 3.6. Gross pathology of pigs infected with 6:2 surface reassortants between ty/04 
and sw/99. Groups of pigs (n=3) were inoculated intratracheally with 108 TCID50/animal of 
with 6:2 surface reassortants between sw/99 and ty/04viruses. At 5dpi, pigs were euthanized 
and their lungs were removed to evaluate gross pathology. Lungs from pigs infected with 
6ty/04:2sw/99 (top panels) display minimum pathology, whereas lungs from 6sw/99:2ty/04-
infected pigs (bottom panels) have multifocal areas of dark red consolidation that are 





Figure 3.7. Virus lung load after infection with 6:2 surface reassortants between sw/99 
and ty/04 viruses. Groups of pigs (n=3) were inoculated intratracheally with 108 
TCID50/animal of with 6:2 surface reassortants between sw/99 and ty/04 viruses. At 5 dpi, 
pigs were euthanized and viral load in all lung lobes (A) and BALF (B) were determined by 






3.4.6. The internal genes from ty/04 play a major role in the febrile response 
Because infection with WT ty/04 caused sustained high body temperatures during the 
acute phase of the infection, we sought to study the role of surface and internal genes in this 
parameter of disease. Replacing both the HA and NA genes in ty/04 with those of sw/99 did 
not affect body temperature because animals infected with 6ty/04:2sw/99 reassortant had a 
higher body temperature (p<0.05, two-way ANOVA) than those animals infected with the 6 
sw/99:2 ty/04 (Fig. 3.8). This suggests that ty/04 internal genes are the major contributors for 
the febrile response. The levels of IL1-β in 6ty/04:2sw/99 were not statistically different from 
the levels of IL1-β in 6 sw/99:2 ty/04 (data not shown), which may have been caused by the 
small number of animals used and the variability among them. Taken together, these 
experiments suggest that although surface genes are critical for the lung pathology, the 






Figure 3.8. Rectal temperature of pigs infected with 6:2 surface reassortants. Groups of 
pigs (n=3) were inoculated intratracheally with 108 TCID50/animal of 6:2 surface reassortants 
between sw/99 and ty/04 viruses diluted in 4 ml of PBS. Values are shown as the mean ± 
SEM of the daily mean rectal temperatures of pigs following infection. The differences 








The emergence of TR H3N2 influenza A viruses (IAV) in swine populations in 1998 
has significantly affected the epidemiology of animal influenza in North America. 
Importantly, TR H3N2 IAV have expanded their host range and caused outbreaks in turkeys 
in North Carolina and Minnesota in 2003 (Choi, Lee et al. 2004), and Ohio in 2004 (Tang, 
Lee et al. 2005). Usually, infection of turkey flocks with swine influenza viruses is associated 
with close proximity to swine herds (Tang, Lee et al. 2005). In 2007, swine-like TR H3N2 
viruses were isolated, for the first time, from migratory waterfowl in South Dakota, 
highlighting their potential for interspecies transmission (Ramakrishnan, Wang et al. 2010). 
Currently, TR H3N2 IAV, belonging to phylogenetic cluster IV, is the most prevalent TR 
H3N2 genotype circulating in North America animal populations, including swine, turkey, 
quails, and waterfowl (Ramakrishnan, Wang et al. 2010; Kumar, Deflube et al. 2011; Nfon, 
Berhane et al. 2011). TR swine IAV have demonstrated the ability to reassort with either 
classical swine H1N1 or human H1N1 and H3N2 viruses, generating at least seven different 
reassortant lineages in the last decade. Remarkably, the 2009 pandemic H1N1 resulted from 
genetic reassortment between TR swine IAV circulating in North America and Eurasia swine 
H1N1 IAV (Garten, Davis et al. 2009).  
In our current study, we used reverse genetics with the goal of identifying molecular 
attributes responsible for the enhanced virulence of certain TR H3N2 IAV. We chose two 
representative strains, sw/99 and ty/04, because the ty/04 is a derivative of the sw/99 strain, a 
virus that had been circulating among pigs in the United States since 1998 (Tang, Lee et al. 
2005). The evolutionary pathways and transmission events that led to the emergence of ty/04 
had been hindered by a lack of systematic surveillance in turkey and swine populations. It has 
been shown that the ty/04 isolate is fully adapted to replication and transmission in both 
turkeys and swine (Yassine, Al-Natour et al. 2007). With respect to the sw/99 virus, to our 
knowledge, no studies have characterized this strain in pigs. Although both viruses were 
initially classified into genetic cluster III, it has become evident that the ty/04 virus is a 
cluster III variant, which is now denominated cluster IV (Fig. 3.1A). Richt and collaborators 
studied the pathogenesis of TR H3N2 swine IAV belonging from clusters I to III with respect 
to their ability to replicate and induce clinical signs and influenza-specific lesions in pigs. 
Pigs infected with H3N2 cluster I, II, or III virus demonstrated macroscopic pneumonia and 




cluster III (Richt, Lager et al. 2003). Although these studies have been important for the 
characterization of field isolates in vivo, the genetic basis of virulence of TR H3N2 IAV is yet 
to be elucidated. 
To further characterize the pathotype of WT viruses in swine, we used an aggressive 
intratracheal challenge model. Only mild changes in the clinical appearances and lung 
pathology were observed in pigs infected with sw/99 strain. Fever was not observed in these 
animals. In sharp contrast, infection with ty/04 was associated with severe clinical disease, 
extensive gross pathological and histological pulmonary lesions, and sustained fever 
throughout the experimental period. Thus, our challenge protocol using high doses of virus 
(1x108 TCID50) successfully reproduced disease manifestations under laboratory conditions. 
We have previously shown that intranasal infection with low dose (1x105 TCID50) of ty/04 
only caused mild clinical signs of disease (Pena, Vincent et al. 2011).  
Surprisingly, the enhanced pneumonia caused by viruses containing the ty/04 surface 
glycoproteins (ty/04 WT and 6sw/99:2ty/04) did not correlate with either levels of viral 
shedding in nasal secretions or the viral lung load. This lack of correlation between viral 
burden and pneumonia may be due to the high infectious dose used in these experiments. It is 
possible that the use of a high infectious dose led to the synchronous infection of a large 
number of respiratory cells, which did not allow for the detection of modest differences in the 
levels of viral replication. Interestingly, when we used lower viral dose for infection (105 
TCID50), ty/04 replicated to higher titers than sw/99 (Pena et al, manuscript in preparation). 
Furthermore, Yassine et al. reported that ty/04 replicated more efficiently than a TR H3N2 
swine IAV (A/swine/North Carolina/03 (H3N2) in vitro and in vivo and displayed better 
binding affinity to plasma membrane preparations from pig tracheas (Yassine, Khatri et al. 
2011).  
 
The infectivity of IAV is mainly determined by the presence of sialic acid receptors 
on susceptible host cells to which the HA is able to bind and internalize. Recently, a study 
investigating the distribution of human-like (α2,6Gal) and avian-like (α2,3Gal) influenza 
receptors (Nelli, Kuchipudi et al. 2010; Van Poucke, Nicholls et al. 2010; Trebbien, Larsen et 
al. 2011) challenged an earlier work that suggested that the presence of both types of 
receptors in the porcine trachea made pigs more susceptible to IAV and allowed them to 
serve as "mixing vessels" for human-avian influenza A virus reassortants (Ito, Couceiro et al. 
1998). The current model suggests that the distribution of the two type sialic acid receptors in 




α2,6Gal is the predominant receptor species in all areas of the respiratory tract and the 
α2,3Gal receptor is found in small amounts exclusively in the lower respiratory tract 
(bronchioles and alveoli) (Nelli, Kuchipudi et al. 2010; Van Poucke, Nicholls et al. 2010; 
Trebbien, Larsen et al. 2011). Additionally, the avidity with which the ty/04 HA binds to each 
sialic acid species may determine its enhanced pneumonia in vivo. In agreement with this, 
titration of either ty/04 or sw/99 or their surface reassortants, using turkey red blood cells 
(RBC) yield the same titer, but when chicken RBC was used in these experiments, ty/04-
containing viruses had a titer four-fold higher than sw/99 (data not shown). Since turkey RBC 
has predominantly α2,6Gal type receptor, whereas α2,3Gal is the preponderant sialic acid 
moiety in chicken RBC (Thompson, Barclay et al. 2004), it is conceivable that ty/04 may 
reach the deeper respiratory tract more effectively than sw/99 to cause bronchopneumonia.  
Although introduction of ty/04 surface glycoproteins into the sw/99 backbone 
reproduced pneumonia caused by parental ty/04, the typical clinical disease induced by ty/04 
could not be duplicated by this 6:2 reassortant. Here, we demonstrated that ty/04 internal 
genes, but not the surface genes, are responsible for the febrile response. Rescue and 
characterization of reassortant viruses containing the ty/04 surface genes and additional IAV 
virulence determinants located in the internal segments may shed light into the constellation 
of genes responsible for the clinical expression of disease. These studies are beyond the scope 
of this work and warrant further investigation. 
In summary, we have shown that genetically related TR H3N2 IAV display distinct 
pathotypes in the swine host. Our current study indicates that the surface glycoproteins are 
necessary and sufficient for the induction of severe pneumonia, while their internal genes are 
responsible for the fever. The ability of pathogenic surface glycoproteins to induce 
pneumonia in the background of a low virulent virus has implications for the development of 
safer vaccines for this target species. Given the similarities between pigs and humans 
regarding the distribution of sialic acid receptors, cytokine production, and clinical-
pathological outcomes after influenza infection (Van Reeth, Van Gucht et al. 2002; Barnard 
2009; Barbe, Atanasova et al. 2010; Barbe, Saelens et al. 2010), our findings may be relevant 
for human medicine. Knowledge gained from understanding the molecular basis of virulence 





Chapter 4: Restoring PB1-F2 into the 2009 Pandemic H1N1 
Influenza Virus Enhances Viral Replication, Histopathology, 
and Cytokine Responses in Swine. 
 
4.1. Abstract 
PB1-F2 is an 87-90 amino acid long protein expressed by certain influenza A viruses. 
Previous studies have shown that PB1-F2 contributes to virulence in the mouse model; 
however, its role in natural hosts - pigs, humans, or birds - remains largely unknown. 
Outbreaks of domestic pigs infected with the 2009 pandemic H1N1 influenza virus (pH1N1) 
have been detected worldwide. Unlike previous pandemic strains, pH1N1 viruses do not 
encode a functional PB1-F2 due to the presence of three stop codons resulting in premature 
truncation after codon 11. However, pH1N1s have the potential to acquire the full-length 
form of PB1-F2 through mutation or reassortment. In this study, we assessed whether 
restoring the full-length PB1-F2 ORF in the pH1N1 background would have an effect in virus 
replication and virulence in pigs. Restoring the PB1-F2 ORF resulted in up-regulation of viral 
polymerase activity at early time points in vitro and enhanced virus yields in porcine 
respiratory explants and in the lungs of infected pigs. There was a significant increase in the 
severity of pneumonia in pigs infected with isogenic virus expressing PB1-F2 as compared to 
the WT pH1N1. The extent of microscopic pneumonia correlated with increased pulmonary 
levels of IFN-α and IL-1β in pigs infected with pH1N1 encoding a functional PB1-F2. 
Together, our results indicate that PB1-F2 in the context of pH1N1 modulates viral 









 4.2. Introduction 
Influenza A viruses (IAV) belong to the family Orthomyxoviridae and represent 
important pathogens of humans and animals. In the 20th century, humans experienced three 
IAV pandemics (1918, 1957, and 1968) that resulted in significant morbidity and mortality 
(Taubenberger and Kash 2010). These pandemic strains emerged through genetic 
reassortment between influenza viruses of avian origin and the circulating human strain. 
These events resulted in antigenic shift and the successful dissemination, in an 
immunologically naïve population, of a virus carrying a novel hemagglutinin (HA). In 
addition to the new HA, pandemic strains inherited the PB1 gene segment from the avian 
influenza donor virus  (and the NA gene in 1957) (Smith, Vijaykrishna et al. 2009). Like 
most avian influenza viruses, these previous pandemic strains encoded a full-length PB1-F2 
gene. However, human influenza strains have invariably evolved to introduce truncations in 
the PB1-F2 open reading frame (ORF). It is tempting to speculate that PB1-F2 function is 
necessary for virus survival in birds but unnecessary or detrimental in humans. Its 
significance in pandemic strains remains obscure. 
In the spring of 2009, a novel H1N1 IAV emerged in North America causing acute 
respiratory disease in humans. The virus quickly spread throughout most regions of the 
world, prompting the World Health Organization (WHO) to declare an influenza pandemic 
on June 11th, 2009 (Dawood, Jain et al. 2009; Garten, Davis et al. 2009). The new virus 
(pH1N1) resulted from genetic reassortment between swine influenza viruses (SIVs) 
circulating in North America and Eurasia. Specifically, six of its RNA segments (PB2, PB1, 
PA, HA, NP, and NS) are closely related to North American triple-reassortant (TR) H1N1 
SIVs, whereas the NA and M gene segments are related to Eurasian H1N1 SIVs (Garten, 
Davis et al. 2009). This unique gene constellation has never been described among influenza 
isolates from anywhere in the world and the precise evolutionary history of the 2009 pH1N1 
is unknown (Dawood, Jain et al. 2009; Gibbs, Armstrong et al. 2009; Smith, Vijaykrishna et 
al. 2009; Al Hajjar and McIntosh 2010). Several outbreaks of pH1N1 virus infections in 
animals have been reported worldwide. These outbreaks were predominantly documented in 
pigs, but incidental infection in turkeys, cats, ferrets, dogs and wild animals has been 
described (Howden, Brockhoff et al. 2009; Nofs, Abd-Eldaim et al. 2009; Britton, Sojonky et 
al. 2010; Dundon, De Benedictis et al. 2010; Mathieu, Moreno et al. 2010; Pereda, Cappuccio 
et al. 2010; Song, Lee et al. 2010; Sponseller, Strait et al. 2010; Swenson, Koster et al. 2010; 




than 20 countries and epidemiological investigations have linked humans as the probable 
source (Hofshagen, Gjerset et al. 2009; Howden, Brockhoff et al. 2009). Experimentally, pigs 
are susceptible to human pH1N1 viruses and the virus is highly transmissible in swine 
(Brookes, Irvine et al. 2009; Itoh, Shinya et al. 2009; Lange, Kalthoff et al. 2009; Weingartl, 
Albrecht et al. 2009; Vincent, Lager et al. 2010). Pigs inoculated with the pH1N1 virus show 
clinical disease signs and pathology similar to infection with other SIVs (Brookes, Irvine et 
al. 2009; Itoh, Shinya et al. 2009; Lange, Kalthoff et al. 2009; Weingartl, Albrecht et al. 
2009; Vincent, Lager et al. 2010).  
Pigs have been historically considered a “mixing vessel” for the generation of novel 
influenza viruses (Scholtissek, Burger et al. 1983; Scholtissek, Burger et al. 1985; Scholtissek 
1995). Pigs are susceptible to human influenza viruses; however, and perhaps unlike humans, 
they appear susceptible to a wide range of avian influenza viruses. Experimental infection 
studies showed that pigs were susceptible to 13 different influenza virus subtypes (H1-H3 and 
non-human-type HA types H4-H13). From these studies, a reassortant virus was generated in 
pigs upon co-infection with a parental SIV strain and an avian strain; the latter naturally 
unable to replicate by itself in pigs (Kida, Ito et al. 1994). The mixing vessel attribute is 
consistent with the presence in the respiratory tract of pigs of prototypical human-like and 
avian-like influenza receptors, N-acetylneuraminic acid-α2,6-galactose (α2,6Gal) and N-
acetylneuraminic acid-α2,3-galactose (α2,3Gal), respectively (Ito, Couceiro et al. 1998). 
Although subsequent studies have shown both types of receptors are also found in the 
respiratory tract of quail, pheasant, turkey, guinea fowl (Wan and Perez 2006; Kimble, Nieto 
et al. 2010) and humans (Shinya, Ebina et al. 2006), pigs have been commonly associated 
with two-way transmission of influenza viruses to and from humans (Myers, Olsen et al. 
2007; Robinson, Lee et al. 2007; Newman, Reisdorf et al. 2008; Vincent, Swenson et al. 
2009). Pigs were undoubtedly involved in the genesis of the 2009 pH1N1 (Garten, Davis et 
al. 2009). Since then, several reassortants between pH1N1 and circulating influenza A viruses 
have been isolated from pigs in several countries (Vijaykrishna, Poon et al. 2010; Howard, 
Essen et al. 2011; Moreno, Di Trani et al. 2011; Pereda, Rimondi et al. 2011; Starick, Lange 
et al. 2011), raising great concerns about the potential acquisition of virulence markers by the 
pH1N1 virus upon reassortment with other strains in the swine host. 
Among the virulence factors that could be acquired by pH1N1 is the non-structural 
protein PB1-F2. In contrast to the three previous pandemic influenza viruses, pH1N1 does not 
encode a functional PB1-F2 due to the presence of three stop codons that causes a premature 




encoded by an alternate (+1) open reading frame (ORF) within the PB1 gene. Translation of 
PB1-F2 mRNA is likely mediated by ribosomal scanning and the protein is expressed early 
and transiently in infected cells (Chen, Calvo et al. 2001). PB1-F2 is expressed mostly by 
IAVs of avian origin (Zell, Krumbholz et al. 2007) and its presence is not required for viral 
replication in embryonated eggs, tissue culture, or in vivo (Conenello and Palese 2007). 
However, PB1-F2 expression results in enhanced apoptotic-cell death in immune cells, viral 
pathogenicity in mice, and immunopathology (Chen, Calvo et al. 2001; Zamarin, Ortigoza et 
al. 2006; Conenello, Zamarin et al. 2007; McAuley, Hornung et al. 2007; McAuley, Chipuk 
et al. 2010). Additionally, the presence of PB1-F2 in both the 1918 and the mouse-adapted 
PR8 influenza A virus enhances secondary bacterial pneumonia in the mouse model 
(McAuley, Hornung et al. 2007). Surprisingly, two recent studies investigating the role of 
PB1-F2 in the pathogenicity of clinically relevant human viruses and the pH1N1 concluded 
that the expression of PB1-F2 has minimal effects on the virulence of these viruses in murine 
and ferret models (Hai, Schmolke et al. ; McAuley, Zhang et al. 2010). From these studies, it 
appears that the role of PB1-F2 in modulating influenza virus pathogenicity is cell-type and 
virus strain-specific and/or species-dependent. The contribution of PB1-F2 to the virulence of 
influenza viruses in swine has yet to be determined. 
Here, we restored the PB1-F2 ORF in pH1N1 and studied its effects on viral 
pathogenicity and host responses in pigs. Restoring PB1-F2 in the pH1N1 virus resulted in 
increased virus replication in swine respiratory explants. More importantly, in pigs, a pH1N1 
virus encoding a complete PB1-F2 ORF increased virus replication in the lung, enhanced 
lung histopathology, and induced higher pulmonary levels of IFN-α and IL-1β than the WT 
virus. These findings suggest that PB1-F2 modulates pH1N1 pathogenicity and cytokine 





4.3. Material and Methods 
4.3.1. Ethics Statement 
Pig explants were prepared according to protocol R-08-16 “Transmissibility of 
Influenza A Viruses in Swine" approved by the Institutional Animal Care and Use 
Committee, University of Maryland, College Park. Swine pathogenicity studies were 
conducted in the high containment facilities at the National Animal Disease Center in Ames, 
IA under protocol 3950 "Influenza A virus pathogenesis and host response in swine" 
approved by the USDA- ARS Animal Care and Use Committee. Animal studies adhered 
strictly to the US Animal Welfare Act (AWA) laws and regulations. 
 
4.3.2. Cell lines and virus strains 
Madin-Darby canine kidney (MDCK) cells were maintained in modified Eagle's 
medium (MEM) (Sigma-Aldrich, St. Louis, MO) supplemented with 5% fetal bovine serum 
(FBS) (Sigma-Aldrich, St. Louis, MO), L-glutamine.and antibiotics. Human embryonic 
kidney cells (293-T) were cultured in OptiMEM I (GIBCO, Grand Island, NY) containing 5% 
FBS and antibiotics. A/California/04/09 (H1N1) (Ca/04) was kindly provided by the Centers 
for Disease Control and Prevention (CDC), Atlanta, Georgia. Ca/04 wild type (WT) and the 
recombinants thereof were propagated in MDCK cells for 3 days at 35°C to produce viral 
stocks. The recombinant Ca/04 viruses used in this study were generated from cloned cDNAs 
and are described below. 
4.3.3. Mutagenesis and rescue of recombinant influenza viruses 
The eight gene segments of Ca/04 were amplified by RT-PCR and cloned in the 
bidirectional reverse genetics (RG) plasmid derived from pHW2000 (Hoffmann, Neumann et 
al. 2000). The QuikChange II site-directed mutagenesis kit (Stratagene, Inc., La Jolla, CA) 
was used according to manufacturer’s protocols to introduce changes in the PB1-F2 open 
reading frame (ORF). The PB1-F2 ORF in the PB1 segment was restored by mutating the 
stop codons at positions 12, to encode for serine, and at positions 58 and 88, to encode for 
tryptophan (Fig.1). The mutations did not change the PB1 ORF. The recombinant viruses 
were generated by transfecting co-cultured 293-T and MDCK cells as previously described 




culture, the HA gene from the mouse-adapted Ca/04 (Ye, Sorrell et al. 2010) was used in 
these experiments. All RG plasmids and recovered recombinant viruses were fully sequenced 
to confirm their identity. 
 
 4.3.4. Alignment and phylogenetic analysis 
The restored Ca/04 PB1-F2 was aligned with the 20th century pandemic strains (1918 
H1N1, 1957 H2N2, and 1968 H3N2), some of the ancestors of the 2009 Influenza A H1N1 
strain, and previously characterized PR8 and A/VietNam/1203/04 (H5N1) PB1-F2 protein 
using ClustalW method in MegAlign (Lasergene v.8.1.5., DNAStar, Madison, WI).  The 
phylogenetic tree was generated by Neighboor-Joining method using the MegAlign program. 
Robustness of phylogenetic trees was tested by performing 1000 bootstrap replicates with 
111 random seeds.  
4.3.5. Minigenome assay to study polymerase activity 
The minigenome assay was performed as described previously (Pena, Vincent et al.). 
Briefly, 1 µg of the plasmid encoding the influenza virus-like NS vRNA carrying the Gaussia 
Luciferase (GLuc) reporter gene was transfected in 293-T cells along with 1 µg of each of the 
RG plasmids encoding Ca/04 PB2, PB1, PA and NP plasmids using the TransIT-LT1 (Mirus, 
Madison, WI) reagent following the manufacturer’s recommendations. The Ca/04 PB1 
plasmid encoded either the WT PB1-F2 (truncated after codon position 11) or the artificially 
restored PB1-F2 ORF. The pCMV/SEAP (SEAP) plasmid, which expresses the secreted 
alkaline phosphatase, was co-transfected into cells to normalize the transfection efficiency. 
Alternatively, MDCK cells were transfected with GLuc reporter under the control of the 
canine Polymerase I promoter (PolI) for 12 hours followed by infection with Ca/04 (WT or 
KI) virus at an MOI of 1 or 0.01. At the indicated time points, supernatant from transfected 
cells was harvested and assayed for both luciferase and secreted alkaline phosphatase 
activities using the BioLux™ Gaussia Luciferase Assay Kit (NEB, Ipswich, MA) and the 
Phospha-Light™ Secreted Alkaline Phosphatase Reporter Gene Assay System (A&D, Foster 
City, CA) according to the manufacturers’ instructions. Relative polymerase activity was 





4.3.6. Isolation, culture, and infection of porcine respiratory explants 
Porcine nasal turbinates (NT), tracheal, and lung explants were prepared as described 
previously (Van Poucke, Nicholls et al. 2010), with some modifications. All respiratory 
explants were cultivated at an air-liquid interface in an incubator at 37°C and 5% CO2. NT 
and trachea explants were cultivated in 50% DMEM (Gibco)/50% RPMI (Gibco) media 
supplemented with 100 U/ml penicillin (Gibco), 100 µg/ml of streptomycin (Gibco), 0.1 
mg/ml gentamycin (Gibco), 25 µg/ml Amphotericin B (Gibco), 0.3 mg/ml glutamine (BDH 
Biochemical) and nonessential amino acids (Sigma). Media for lung explants consisted of 
M199 (Sigma) containing the same antibiotics as above, nonessential amino acids (Sigma). 
Vitamin supplement (ATCC, Rockville, MD), 0.5 µg/ml hydrocortisone and ITS supplement 
(Insulin, Transferrin, Selenium) added at 10 ml/L medium. A five-week-old swine donor 
obtained from a high-health status farm whose animals are negative for IAV was used for this 
study. The animal was humanely euthanized with Beuthanasia®-D (Intervet/Schering-
Plough, Summit, NJ) at a dosage of 1 ml/4.5 Kg of body weight and the respiratory tissues 
were collected. NT and trachea explants were dissected and washed 10 times with PBS 
containing antibiotics to remove bacterial contamination. Tissues were then cut into squares 
of 25 mm2 each and placed with the epithelial surface upwards onto the filter membrane of 
the polyester tissue culture-treated inserts (Transwells®, Corning, Lowell, MA) at an air-
liquid interface in 12-well plates. The lower compartment was filled with 1 ml of explant 
media. The right apical lung lobe was expanded with a 1% type VII-A low gelling 
temperature agarose solution (Sigma, St. Louis, MO) that had been dissolved in lung explants 
media and cooled down to 37°C. The expanded lung was placed at 4°C for 10 min in a sterile 
container until the agarose solidified. The embedded lung tissue was then cut into 1 mm thick 
slices using a microtome blade and hand microtome. Two sections of the lungs were 
obtained: the proximal lung (close to the start of bronchial tree) and distal lung (close to the 
lung alveoli). The procedure for cultivation of lung explants was similar to the procedure 
used for the NT and tracheal explants. After 24 h, lung explants were washed with warm PBS 
to remove most of the agarose before infection. At 24 h of culture, explants were washed with 
PBS and 106 tissue culture infectious dose 50% (TCID50) of the recombinant viruses diluted 
in 500 µl of explants media were deposited in the upper compartment of Transwells® for 1 h. 
After the 1 h adsorption at 37°C, explants were washed three times with PBS and the culture 




bathing media was collected at 24, 48, and 72 h post inoculation to assess virus yields. Virus 
titers in respiratory explants were determined by standard TCID50 in MDCK cells. 
 
4.3.7. Virus titration 
Viral stocks and virus present in biological samples were titrated on MDCK cells and 
the TCID50/ml was determined by the Reed and Muench method (Reed and Muench 1938). 
Briefly, samples were serially diluted 10-fold in serum-free media containing antibiotics and 
1 µg/ml TPCK-trypsin (SIGMA) and 100 or 200 µl of the inoculum were overlaid onto 
confluent monolayers of MDCK cells seeded in 96-well plates. The cells with the sample 
were incubated for 3 days and the endpoint viral titer was determined by an HA assay using 
0.5% turkey red blood cells. 
4.3.8. Swine pathogenicity experiment 
Three-week-old cross-bred pigs were obtained from a high-health herd free of SIV 
and porcine reproductive and respiratory syndrome virus. All pigs were treated with ceftiofur 
crystalline free acid (Pfizer Animal Health, New York, NY) to reduce bacterial contaminants 
prior to the start of the experiment. Twenty pigs were randomly divided in two groups (n=10) 
and housed in separate isolation rooms. Pigs were infected intratracheally with 1×105 TCID50 
of either Ca/04 WT or an isogenic virus expressing PB1-F2 (Ca/04 KI) diluted in 2 ml of 
MEM using previously described protocols (Vincent, Lager et al. 2010). Following 
inoculation, pigs were monitored daily for clinical signs of disease and nasal swabs were 
collected to measure viral shedding. Five pigs from each group were euthanized on day 1 and 
the remaining five animals were euthanized at 3 dpi for evaluation of viral lung load, 
pathology, and host response to infection. Five additional pigs were inoculated with 2 ml 
MEM as above and served as mock-controls. Control pigs were euthanized at 3 days post 
infection (dpi). 
4.3.9. Pathologic examination of swine lungs  
At necropsy, lungs were removed in toto and evaluated to determine the percentage 
of the lung affected by purple-red, consolidated lesions that are typical of influenza virus 
infection in pigs. The percentage of the surface affected with pneumonia was visually 




weighted proportions of each lobe to the total lung volume as previously described (Halbur, 
Paul et al. 1995). Each lung was then lavaged with 50 ml MEM to obtain bronchoalveolar 
lavage fluid (BALF). A veterinary pathologist scored all lungs and was blinded to the 
treatment groups. 
4.3.10. Histopathology and immunohistochemistry 
Tissue samples from the trachea and right middle lung lobe were taken and fixed in 
10% buffered formalin for histopathological examination. Tissues were routinely processed 
and stained with hematoxylin and eosin. A board-certified veterinary pathologist blinded to 
treatment groups evaluated microscopic lesions.  Scoring of lesions was based on scales 
adapted from Gauger et al (Gauger, Vincent et al. 2011). Individual scores were assigned to 
four parameters: bronchial and bronchiolar epithelial changes, bronchitis/bronchiolitis, 
peribronchiolar lymphocytic cuffing and interstitial pneumonia.  Scores were based on 
percentage of airways with lesions that included epithelial changes and inflammation on a 5-
point scale: 0: No lesions, 1: 1-25%, 2: 26 to 50%, 3: 51-75%, 4: greater than 75% of airways 
affected with airway epithelial damage and inflammation.  Peribronchiolar cuffing by 
lymphocytes was graded on a 4-point scale:  0: None, 1: Mild, loosely formed cuff, 2:  
Moderate, well formed cuffs, and 3:  Prominent, thick well formed cuffs.  Interstitial 
pneumonia was graded on 5-point scale based on severity and distribution:  0:  No lesions, 1:  
Mild, focal to multifocal, 2:  Moderate, locally extensive to multifocal, 3:  Moderate, 
multifocal to coalescing, and 4:  Severe, coalescing to diffuse. 
Trachea sections were scored similar to the bronchi and bronchioles and were based 
on epithelial changes and degree of inflammation. Tracheal epithelial changes were graded on 
a 5-point scale: 0:  No lesions, 1:  Early epithelial changes characterized by focal to 
multifocal loss of cilia and epithelial degenerative changes, 2:  Mild epithelial flattening with 
loss of cilia and goblet cells, 3:  Moderate epithelial flattening with decreased thickness of 
respiratory epithelium, loss of cilia and goblet cells, 4:  Flattened epithelium with areas of 
mucosa covered by a single layer of cuboidal epithelium and epithelial loss (necrosis).  
Degree of tracheitis was graded on a simple 4-point scale:  0: None, 1: Mild, 2: Moderate, 
and 3: Severe. 
  Influenza virus Type A-specific antigen was detected in lung tissues using a 
previously described immunohistochemical (IHC) method with minor modification (Vincent, 
Janke et al. 1997). Briefly, tissue sections were deparaffinized and hydrated in distilled water. 




water and treated in 0.05% protease for 2 min. Slides were then rinsed three times in de-
ionized water and once in Tris-buffered saline (TBS). Influenza A virus-specific monoclonal 
antibody (MAb) HB65 (ATCC, Manassas, VA), specific for the nucleoprotein (NP) of 
influenza A viruses, was applied at 1:100 dilution and slides were incubated at room 
temperature for 1 h.  Bound MAbs were stained with peroxidase-labeled anti-mouse IgG 
followed by chromogen using the DAKO LSAB2-HRP Detection System (DAKO, 
Carpinteria, CA) according to the manufacturer’s instructions. The slides were rinsed in 
deionized water and counterstained with Gill’s hematoxylin.  Antigen detection was given 
two scores:  1) airway epithelial labeling and 2) alveolar/interstitial labeling.  In airway 
epithelium a 5-point scale was used:  0:  None,1:  Few  cells with positive labeling, 2:  Mild 
scattered labeling, 3:  Moderate scattered labeling, 4:  Abundant scattered labeling (greater 
than 50% epithelium positive in affected airways).  In the interstitium/alveoli, a 4-point scale 
was used:  0:  None, 1:  Minimal focal signals, 2:  Mild multifocal signals, 3:  Abundant 
signals. 
 
4.3.11. Quantification of cytokine/chemokine protein levels in bronchoalveolar 
lavage fluid 
 Levels of nine porcine cytokines/chemokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12p70, TNF-α, and IFN-γ) in BALF were determined by multiplex ELISA following the 
manufacturer’s recommendations (SearchLight, Aushon Biosystems). Levels of IFN-α 
protein were measured by ELISA using F17 monoclonal antibody, K9 MAb and recombinant 
porcine IFN-α (R&D Systems Inc., Minneapolis, MN) as previously described (Brockmeier, 
Lager et al. 2009). 
 
4.3.12. Statistical analysis 
All statistical analyses were performed using GraphPad Prism Software Version 5.00 
(GraphPad Software Inc., San Diego, CA). Comparison between two treatment means was 
achieved using a two-tailed Student t-test, whereas multiple comparisons were carried out by 







4.4.1. Restoring PB1-F2 in the Ca/04 pH1N1 background up-regulates early 
polymerase activity 
It has been shown that PB1-F2 derived from the laboratory strain A/Puerto Rico/8/34 
(H1N1) (PR8) interacts with the polymerase subunit PB1 and increases polymerase activity 
(Mazur, Anhlan et al. 2008). We wanted to determine if polymerase activity of a pH1N1 
virus would be affected when the PB1-F2 ORF was restored. To this end, we first developed 
the entire reverse genetic system for the Ca/04 strain. The three stop codons present in the 
Ca/04 WT PB1-F2 were changed to encode for serine (codon 12) and tryptophan (codons 58 
and 88) and thus allowing translation of the full-length PB1-F2 (Ca/04 KI), as previously 
described (Hai, Schmolke et al. ; Ozawa, Basnet et al. 2011) (Fig 4.1). These point mutations 
were silent in the PB1 ORF.  
 
Figure 4.1. Alignment and phylogenetic analysis of artificially restored PB1-F2 full-
length ORF in Ca/04 pH1N1. (A) Alignment of the PB1-F2 open reading frames. The three 
stop codons (asterisks) present in the Ca/04 PB1-F2 gene were replaced to serine (12), and 
tryptophan (58 and 88). Ca/04 PB1-F2 ORF was aligned to those of the 20th century 
pandemic strains (1918 H1N1, 1957 H2N2, and 1968 H3N2), the ancestors of the 2009 




(H5N1) strains. Boxed residue highlights amino acid residues that have been associated with 
increased virulence: 51(T), 56(V), 66(S), and 87(E) (Marjuki, Scholtissek et al. ; Conenello, 
Zamarin et al. 2007). (B) Phylogenetic relationships of Ca/04 PB1-F2 with other relevant 
PB1-F2 proteins. The phylogenetic tree was generated by Neighboor-Joining method using 
the MegAlign program. 
 
To study viral polymerase activity in the absence or presence of PB1-F2, we used an 
influenza minigenome assay as previously described (Pena, Vincent et al.). Co-transfection of 
293-T cells was performed with plasmids encoding the Ca/04 PB2, PB1 (with or without full-
length PB1-F2), PA, and NP genes and the influenza replicon carrying GLuc. Transfection 
efficiency was normalized using a plasmid encoding the SEAP reporter gene under a RNA 
pol II promoter. Polymerase activity is monitored by the ratio of Gluc/SEAP. These 
experiments revealed that the presence of PB1-F2 led to significantly higher polymerase 
activities at 12 h post transfection than in its absence (Fig. 4.2A). At latter time points, no 
such difference was observed, suggesting that pH1N1 PB1-F2 modulates early polymerase 
activity in mammalian cells. Although the mingenome assay has become the method of 
choice for studying IAV polymerase activity, this method does not reflect all of the regulatory 
events that occur during the course of infection since it involves only the minimal 
components required for viral transcription and replication (Robb, Smith et al. 2009). To 
overcome this drawback and study the effect of PB1-F2 on polymerase activity in the context 
of the viral life cycle, we transfected MDCK cells with GLuc reporter under the control of the 
canine Pol-I followed by infection with Ca/04 (WT or KI) virus at an MOI of 1 or 0.01. 
Consistent with the results from the minigenome, the presence of PB1-F2 enhanced early 
viral polymerase activity. The enhancement in polymerase activity was statistically 
significant (p<0.01) between 6 and 12 hpi when MOI 0.01 was employed (Fig. 4.2B) and 
between 1 and 10 hpi when MOI 1 was used (Fig. 4.2C). Together, these results imply that 



















Figure 4.2. PB1-F2 up-regulates early polymerase activity. (A) Minigenome assay. 293-T 
cells were transfected with plasmids encoding the minimal components required for viral 
transcription and replication (PB2, PB1, and PA polymerase subunits, NP and a vRNA 
influenza driven-luciferase reporter replicon expressing GLuc) and pCMV/SEAP, plasmid to  
normalize transfection efficiency as previously described (Pena, Vincent et al.). At the 
indicated time points post transfection, the supernatant was harvested and assayed for both 
luciferase and phosphatase activities. (B) and (C) Kinetics of polymerase activity after virus 
infection. MDCK cells were transfected with 1 µg of GLuc reporter under the control of the 




(C). Data are expressed as polymerase activities (mean ± SE) determined from four 
independent experiments. 
4.4.2. PB1-F2 enhances Ca/04 replication in porcine respiratory explants 
 
It has been demonstrated that expression of full-length wild type PB1-F2 by the 
pH1N1 has no effects on viral replication in human A549 cells or MDCK cells (Hai, 
Schmolke et al. ; Ozawa, Basnet et al. 2011). However, cell lines do not exhibit the natural 
physiological conditions and cellular complexity present in the respiratory tract. To address 
this limitation and study the impact of PB1-F2 expression in a relevant biological system, we 
developed an ex vivo organ culture model of the pig respiratory tract maintained at an air–
liquid interface. These tissue explants retained their cytoarchitecture (data not shown) and 
supported productive replication of the recombinant Ca/04 influenza viruses (Fig. 4.3). 
Restoring PB1-F2 in Ca/04 improved virus replication in explants of nasal turbinates (Fig. 
4.3A), trachea (Fig. 4.3B), and proximal lung (Fig. 4.3C). No differences were observed in 
explants of the distal lung (Fig. 4.3D). This enhancing effect of PB1-F2 in virus production 
was mainly seen at early time points. These data indicate that PB1-F2 modulates early viral 








Figure 4.3. Replication of PB1-F2 recombinant viruses in porcine respiratory explants. 
Explants from nasal turbinates (A), trachea (B), and proximal (C), and distal lung (D) were 
infected with 106 TCID50 of either Ca/04 WT or KI. The bathing media was collected at the 
indicated time points and titrated by the TCID50 method in MDCK cells. Values shown are 
the mean ± SEM of virus titer (log10 TCID50/ml) from four independent experiments. * p< 
0.05. 
 
4.4.3. Restored PB1-F2 ORF increases virus replication in swine lungs 
To evaluate whether the enhanced viral yields in porcine respiratory explants 
displayed by Ca/04 KI would correlate with increased viral replication in vivo, we inoculated 
groups of pigs (n=10/group) with the Ca/04 WT or Ca/04 KI viruses. From each group, 5 pigs 
were euthanized at days 1 and 3 pi and viral titers in BALF were determined. Consistent with 
the explants data, restoring the PB1-F2 ORF resulted in statistically significant increases in 
viral loads in the lungs at either time point (Fig. 4.4A). Increased Ca/04 KI replication in the 
lungs was further corroborated by the more pronounced pulmonary expression of influenza 
NP antigen by IHC analysis (Fig. 4.4B-C). As expected, mock-inoculated pigs had neither 




Collectively, these results suggest that restoring the PB1-F2 ORF in the Ca/04 virus leads to 




Figure 4.4. Replication and immunohistochemical analysis of PB1-F2 recombinant viruses in 
swine lungs. Groups of pigs (n=10) were infected with 105 TCID50 of PB1-F2 recombinant viruses and 
five animals from each group were euthanized either at 1 or 3 dpi. The lungs were collected and 
processed for virus titration and immunohistochemical analysis. (A) Pulmonary replication of PB1-F2 
isogenic viruses in pigs. Values are mean ± SEM of virus titer (log10 TCID50/ml) in bronchoalveolar 




influenza A virus nucleoprotein (NP) in the lungs of infected pigs. Values given are the mean ± SEM 
IHC scores based on the percent of influenza-positive cells in the airway and lung interstitium. (C) 
Representative IHC slides depicting viral antigen primarily in airway epithelium at 1 and 3 dpi. 
Scattered labeling in the interstitium at 3 dpi is present. 
 
4.4.4. PB1-F2 aggravates microscopic pneumonia despite no differences in nasal 
virus shedding or macroscopic lesions in pigs 
To determine if PB1-F2 affects the kinetics of viral shedding in pigs, nasal swabs 
collected from each pig from 1 to 3 dpi were titrated in MDCK cells. Virus shedding in nasal 
secretions was only detected at 3 dpi and there was no difference between the Ca/04 WT and 
Ca/04 KI viruses (Fig. 4.5A). Infected pigs did not show any overt clinical signs of disease 
regardless of the virus used. At necropsy, pigs in both the Ca/04 WT and Ca/04 KI had 
cranioventral lung consolidation; with 5% to 10% of lung involvement at 3 dpi (Fig. 4.5B-C). 
There were no differences between the two virus groups, indicating that PB1-F2 has no effect 
on the macroscopic lung pathology caused by Ca/04 in swine.   
 
 
Figure 4.5. Viral shedding and macroscopic pneumonia are unaltered by PB1-F2 
expression in swine. Groups of pigs (n=10) were infected with 105 TCID50 of PB1-F2 
recombinant viruses and nasal swabs were collected from 1-3 dpi for measuring virus 
shedding. At 1 and 3 dpi, five animals from each group were euthanized and the lungs were 
scored for gross pneumonia. (A) Viral shedding in nasal secretions of pigs.  Viral titers in 
nasal swabs were determined by TCID50 on MDCK cells. (B) Percentage of macroscopic lung 
lesions. Values are shown as the mean ± SEM.   
 
 
However, differences in lung inflammation were detected at the microscopic level. 




in pigs in the Ca/04 KI group as compared to the Ca/04 WT group (Fig. 4.6A and 4.6C). 
Unlike the mock-inoculated animals that had normal histological features, the lesions in 
virus-infected pigs were typical of influenza virus pneumonia in pigs and were characterized 
by multifocal to widespread necrotizing bronchitis and bronchiolitis, light peribronchiolar 
lymphocytic cuffing, and multifocal interstitial pneumonia. Both viruses induced similar 





Figure 4.6. PB1-F2 exacerbates microscopic pneumonia in swine. Groups of pigs (n=10) 
were infected with 105 TCID50 of PB1-F2 recombinant viruses. At 1 and 3 dpi, five animals 
from each group were euthanized and the histopathological changes in the lower respiratory 
tract was evaluated. (A) Histopathologic scores in the lungs. (B) Histopathologic scores of 
trachea. (C) Photomicrographs representing microscopic pneumonia in Ca/04 KI and Ca/04 
WT virus. 
 
4.4.5. PB1-F2 exacerbates the pulmonary levels of IFN-α and IL-1β in swine 
Cytokine production after influenza infection has been implicated in the pathogenesis 
of influenza in mammals, including pigs (Van Reeth 2000). To further characterize the effect 
of PB1-F2 in the pathological manifestations of pH1N in swine, we measured the protein 
levels of ten porcine cytokines/chemokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, 
TNF-α, IFN-α, and IFN-γ) in BALF collected at 1 and 3 dpi necropsies. The production of 
the cytokines/chemokines IL-6, IL-8, and IFN-γ was similar between the two groups infected 
with the PB1-F2 recombinants viruses (Fig. 4.7). However, pulmonary levels of IFN-α and 
IL-1β were significantly higher at 1 dpi in pigs infected with Ca/04 KI than with Ca/04 WT 
(Fig. 8). IL-2, IL-4, IL-10, IL-12p70, and TNF-α did not reach detectable levels in this 
experimental infection (data not shown). Collectively, these results indicate that PB1-F2 
induces higher expression levels of IFN-α and IL-1β early during pH1N1 infection in pigs 
and this heightened production of pro-inflammatory mediators may have contributed to the 
more severe microscopic pneumonia developed in Ca/04 KI-infected animals (Fig. 4.6). 
 
 
Figure 4.7. PB1-F2 exacerbates the pulmonary levels of IFN-α and IL-1β in swine. 
Groups of pigs (n=10) were infected intratracheally with 105 TCID50 of PB1-F2 recombinant 
viruses. On days 1 and 3 post-infection, animals from each group were euthanized and the 
cytokines/chemokines levels in BALF were determined by ELISA. Data are shown as mean ± 
SEM of four animals in each challenge group. A one-way analysis of variance (ANOVA) was 






Outbreaks of influenza A viruses (IAV) are among the most significant causes of 
respiratory disease in both humans and animals. Occasionally, pandemic influenza viruses 
emerge when a virus acquires a new HA molecule to which the majority of the population is 
immunologically naïve, resulting in devastating levels of morbidity and mortality (Tscherne 
and Garcia-Sastre 2011). Virulence of influenza viruses is considered a polygenic trait. 
Molecular studies in different animal models have determined that the gene constellation of a 
particular influenza virus strain within a specific host plays a pivotal role in disease outcome 
(Hatta, Gao et al. 2001; Chen, Bright et al. 2007; Basler and Aguilar 2008). Several proteins 
in the viral genome have clearly identified roles in virulence: the surface glycoproteins 
hemagglutinin (HA) and neuraminidase (NA) that are responsible for viral binding, entry and 
release (Pappas, Aguilar et al. 2008); the polymerase protein complex formed by PB2, PB1, 
and PA proteins that drives genome transcription and translation (Watanabe, Watanabe et al. 
2009; Graef, Vreede et al. 2010); and the nonstructural protein NS1 that disarms the 
interferon-based defense system of the host and also modulates other important aspects of the 
virus replication cycle (Hale, Randall et al. 2008).   
A recently added member to the family of IAV proteins with a role in virulence is 
PB1-F2. Unlike other influenza viruses that have become adapted to humans, the 2009 
pH1N1 virus lacks most of the known hallmarks of influenza virulence, including PB1-F2 
(Trifonov and Rabadan 2009). However, with the continued circulation of pH1N1 in humans 
and animals, especially in swine, there are opportunities for acquisition of PB1-F2 through 
mutations or genetic reassortment with co-circulating animal influenza viruses. We examined 
the functional significance of PB1-F2 acquisition by pH1N1 on polymerase activity, viral 
replication, pathogenicity, and host response to infection in its natural host, the pig. The data 
demonstrated that the full-length PB1-F2 in a pH1N1 virus impacts polymerase activity, viral 
replication efficiency both ex vivo and in vivo, lung inflammation, and local cytokine 
responses to infection. Evolutionarily, the full-length PB1-F2 was lost in some humans and 
swine influenza viruses through incorporation of premature stop codons. This is in contrast to 
avian influenza viruses in which the entire PB1-F2 ORF is highly conserved (Zell, 
Krumbholz et al. 2007). Thus, PB1-F2 may have comparable functional roles in humans and 




humans, given the outbred nature of this species, the comparable distribution of sialic acid 
receptors, and the similarities of influenza clinical signs, pathology, and cytokine response 
between the two species (Van Reeth, Van Gucht et al. 2002; Barnard 2009; Nelli, Kuchipudi 
et al. 2010).  
In an attempt to characterize the molecular mechanisms by which PB1-F2 might 
affect viral replication, we studied the effects of Ca/04 PB1-F2 on polymerase activity using 
an IAV UTR-driven GLuc reporter gene. We found that PB1-F2 up-regulates early (12 hpt) 
viral polymerase activity, but not at later time points (24-72 hpt). These results contrast with 
those reported by Chen et al that indicated that Ca/04 PB1-F2 enhanced polymerase activity 
at 48 hpt (Chen, Chen et al. 2010). The discrepancy between this and the previous study with 
regard to polymerase function may be due to differences in the reporter gene used as 
polymerase activity readout and the length of the restored PB1-F2 ORF. Chen et al, used a 
chloramphenicol acetyltransferase (CAT) reporter system and mutated only 2 stop codons in 
PB1-F2 ORF generating an 87-aa product instead of a 90 peptide product (Hai, Schmolke et 
al.). It must be noted, however, that polymerase activity in our assay was evaluated in humans 
and canine cells; however, it appears to correlate well with the replication of these viruses in 
ex vivo swine respiratory explants and in vivo in swine lungs.  
As the presence of PB1-F2 augmented replication of some viral strains in tissue 
culture (McAuley, Zhang et al. 2010; Smith, Adler et al. 2011), we studied the growth 
kinetics of PB1-F2 Ca/04 recombinant viruses in porcine respiratory explants. Respiratory 
explants have proved to be a valuable system to study influenza-host interaction in a scalable, 
well-defined and controlled experimental setting (Chan, Chan et al. 2010; Van Poucke, 
Nicholls et al. 2010). Our results are in harmony with the hypothesis that PB1-F2 modulates 
viral replication since higher viral yields were observed in explants derived from both the 
upper and lower respiratory tracts (Fig. 3). Interestingly, this effect of PB1-F2 in virus 
production (and polymerase activity, Fig 2) was mainly observed at early time points, 
consistent with the early and transient expression of PB1-F2 in the course of infection (Chen, 
Calvo et al. 2001; McAuley, Hornung et al. 2007; Le Goffic, Bouguyon et al. 2010). 
Furthermore, the increased ex vivo viral replication paralleled with lung viral load in pigs 
infected with Ca/04 KI (Fig. 5). In contrast, viral shedding in nasal secretions was not 
affected by PB1-F2. This may be explained by the route of inoculation used in our in vivo 
studies. Pigs were infected intratracheally, a route that deposits the virus in the lower 




was detected only at 3 dpi, which could be a time point that makes it difficult to distinguish 
modest differences in shedding. However, we cannot rule out the possibility that PB1-F2 
could affect viral shedding beyond 3 dpi and/or in intranasally infected animals. These 
studies are beyond the scope of this work and warrant further investigation. 
Even though PB1-F2 had no effect on the gross lung pathology or clinical disease, 
Ca/04 KI-infected pigs developed more severe microscopic pneumonia as early as 1 dpi. This 
finding fit with previous reports that demonstrated that PB1-F2 increases the severity of 
pulmonary lesions in mouse models, either in the context of viral infection (McAuley, 
Hornung et al. 2007) or simply by administration of peptides (McAuley, Chipuk et al. 2010). 
Moreover, our results are in agreement with ferret studies by Hai et al that reported no 
changes in clinical outcome by a PB1-F2-expressing Ca/04 compared to WT controls, 
although the authors did not assess lung pathology (Hai, Schmolke et al.). Thus, it could be 
postulated that during primary viral infection the microscopic pulmonary changes induced by 
PB1-F2 are not sufficiently large enough to be manifested clinically or detected 
macroscopically. However, the effects of PB1-F2 enhancement of virulence might be seen 
under field conditions, where immunosuppressive conditions and secondary bacterial 
infections can aggravate the outcome of influenza infections.  
The pro-inflammatory cytokine response is critical for recruiting effector cells to the 
site of an infection. However, elevated or prolonged cytokine production can also contribute 
to the pathological changes observed during infection. To better understand the mechanism of 
lesion severity in Ca/04 KI-infected pigs, we measured the pulmonary concentration of ten 
cytokines/chemokines during the acute stage of infection. Increased levels of IFN-α and IL-
1β proteins were found in the lungs of pigs infected with Ca/04 KI compared to the Ca/04 
WT (Fig. 7). This exacerbation of the host innate response was observed at 24 hpi, but not at 
72 hpi, adding to the notion that changes mediated by PB1-F2 occur shortly after infection. 
To our knowledge, this is the first report that shows that PB1-F2 enhances type I IFN in vivo. 
Our results are consistent with a recent study that demonstrated that the WSN PB1-F2 
exacerbates type I IFN expression in human respiratory epithelial cells (Le Goffic, Bouguyon 
et al. 2010). In both pigs and humans, there is a strong positive correlation between local 
IFN-α levels and viral titers in nasal secretions and clinical disease (Hayden, Fritz et al. 1998; 
Van Reeth, Van Gucht et al. 2002). In addition, increased levels of IL-1β have also been 
linked to neutrophil infiltration in the lungs and the severity of pneumonia in pigs (Van 




response in pigs could be a direct effect of PB1-F2 early during infection. Thus, it is possible 
that enhanced expression of IFN-α and IL-1β are not the cause of respiratory disease, but 
markers of the extent of viral replication. The modulation of the porcine immune system by 
PB1-F2 and its interaction with host factors warrants further investigation and should shed 
light into the molecular mechanisms of PB1-F2 in strain and host-dependent manner. It 
remains to be determined whether the phenotypic differences observe with these two isogenic 
pH1N1 viruses are common features of other swine influenza viruses. 
 In summary, we have shown that PB1-F2 modulates several aspects of pH1N1 
influenza virus interaction with swine, both ex vivo and in vivo. The present study fills a 
critical gap regarding the virulence determinants for influenza virus in swine. Our studies 
provide important insights into the impact that genetic changes may have on the virulence of 




Chapter 5:  Role of PB1-F2 in the Replication and Virulence of 
Triple Reassortant H3N2 Influenza Viruses in Swine 
 
5.1. Abstract 
PB1-F2 acts as a virulence factor for the influenza A viruses (IAV) in the mouse 
model of infection. However, its contribution to the virulence of IAV in swine remains 
largely unexplored. In this study, we chose two genetically related H3N2 triple reassortant 
(TR) IAV to assess the impact of PB1-F2 in viral replication and virulence for pigs. Using 
reverse genetics, we disrupted the PB1-F2 open reading frame (ORF) of both the 
A/swine/WI/14094/99(H3N2)[Sw/99] and A/turkey/OH/313053/04(H3N2)[Ty/04]. In the 
Sw/99 strain we also introduced the N66S mutation, which has been shown to increase the 
virulence of H5N1 and 1918 influenza viruses. Knocking out PB1-F2 in the Ty/04 strain 
decreased its replication in swine respiratory explants, but did not affect its replication or 
viability in alveolar macrophage. In the context of the Sw/99 strain, PB1-F2 had no effect in 
virus yields in respiratory explants, though its presence increased viral yields and cell death in 
freshly isolated macrophages. In vivo, the expression PB1-F2 did not affect viral shedding or 
viral lung load of any of these strains. Upon necropsy, PB1-F2 had no effect on the lung 
pathology caused by Sw/99. Surprisingly, knocking out PB1-F2 from the Ty/04 strain 
significantly increased the lung pathology caused by this virus at 3 dpi. The polymorphism at 
position 66 had no effect in viral replication or virulence of the Sw/99 strain. The pulmonary 
levels of IL-6, IL-8, and IFN-γ were differentially regulated by the expression of PB1-F2. 
Together, our results indicate that PB1-F2 modulates viral replication, virulence, and innate 











Each year, infections with influenza A viruses (IAV) cause highly contagious 
respiratory diseases that are a major burden to human health, resulting in 250,000 to 500,000 
deaths around the world (WHO 2009). Furthermore, IAV have caused three IAV pandemics 
(1918, 1957, and 1968) in the 20th century and, in 2009-2010, a worldwide epidemic caused 
by the swine-origin H1N1 virus resulted in major public health and economic losses. 
Importantly, IAV display a remarkable ability to infect a variety of animal species, including 
pigs, horses, cats, dogs, ferrets, sea mammals, and a wide variety of wild and domestic avian 
species (Palese and Shaw 2007). Among these species, swine are of particular importance, 
given the financial hardship resulting from natural IAV outbreaks in swine operations and the 
fact that pigs play important role in the generation of novel IAV with pandemic potential 
(Ma, Lager et al. 2009).  
In pigs, AIV infection bears remarkable resemblance to human influenza with respect 
to the clinical presentations and pathologic features. In 1930, the first IAV to be isolated, 
A/swine/IA/15/30 (H1N1), was shown to be the etiologic agent of influenza in this species 
(Shope 1931). This virus, the so-called classical swine H1N1 viruses (cH1N1), is thought to 
be partially derived from the human 1918 pandemic H1N1 virus and evolved independently 
from other IAV in the swine population resulting in a distinct phylogenetic lineage (Smith, 
Bahl et al. 2009). cH1N1 was the only predominant IAV subtype circulating in North 
American swine populations for nearly 70 years (Vincent, Ma et al. 2008). In 1998, however, 
the epidemiology of swine influenza in North American pigs changed dramatically. H3N2 
triple reassortant (TR) IAV, containing genes from human (HA, NA, and PB1), avian (PB2 
and PA), and swine cH1N1 (NS, NP, and M) viral lineages emerged in the U.S. swine 
population and established permanent lineages. Over the next decade, these H3N2 TR IAV 
further reassorted with the co-circulating cH1N1 as well as with human H1N1 and H3N2 
viruses, generating at least seven different reassortant lineages (Vincent, Ma et al. 2008). 
Interestingly, some of these viruses have expanded their host range and cause outbreaks in 
turkeys in North Carolina, Minnesota, and Ohio in 2003-2004 (Choi, Lee et al. 2004). A 
unique feature shared by all of these endemic reassortants is the maintenance of the triple 
reassortant internal gene (TRIG) constellation, which consists of the avian-like (PA and 
PB2), swine-like (M, NP, and NS), and human-like (PB1) gene segments. The TRIG cassette 




swine viruses possessing this internal gene constellation (Vincent, Ma et al. 2008; Ma, Lager 
et al. 2009).  
Currently, TR strains of the H3N2, H1N2, and H1N1 subtypes are endemic in the US 
swine population (Vincent, Ma et al. 2008). With respect to the H3N2 TR IAV, at least three 
introductions of human H3-subtype viruses, leading to phylogenetic clusters I, II, and III, 
have been documented (Richt, Lager et al. 2003; Webby, Rossow et al. 2004). The cluster III 
has evolved into cluster III variants, also known as cluster IV, which are now the 
predominant H3N2 viruses circulating in swine populations in North America (Gramer, Lee 
et al. 2007; Kumar, Deflube et al. 2011; Nfon, Berhane et al. 2011). In addition, the 2009 
pandemic H1N1virus (pH1N1), which is also a TR, have been commonly isolated from US 
pigs and reassorted promiscuously with endemic TR strains given rise to at least 7 distinct 
and novel viral genotypes (Ducatez, Hause et al. 2011).  
IAV belongs to the family Orthomyxoviridae, a family of enveloped viruses whose 
members contain a segmented, single-strand RNA genome with negative orientation. IAV 
genome contains eight RNA segments, which encode 10-12 viral proteins. Several virulence 
factors in the genome of IAV have been identified, including the surface glycoproteins HA 
and NA ; the multifunctional NS1 protein that inhibits the host immune responses; and the 
components of the ribonucleoprotein (RNP) complex (NP and the polymerase complex 
formed by PB2, PB1, and PA proteins), which drives genome transcription and translation. 
Virulence of IAV is considered a polygenic trait, in which disease outcome is determined by 
the gene constellation of a particular influenza virus strain within a specific host (Fukuyama 
and Kawaoka 2011). 
Since the discovery of PB1-F2 in 2001 (Chen, Calvo et al. 2001), research has 
focused on using reverse genetics technology to elucidate the role of this small protein in the 
virulence of IAV. PB1-F2 is an 87-90 amino-acid long protein encoded by an alternate (+1) 
open reading frame (ORF) within the PB1 gene (RNA segment 2). Full-length PB1-F2 is 
expressed by most IAV of avian origin, but the protein is truncated in both cH1N1 and human 
H1N1 viruses isolated after 1950. Also, truncated versions of PB1-F2 have been reported in a 
some human H3N2 isolates and North American swine TR viruses, which have a human-like 
PB1 gene (Zell, Krumbholz et al. 2007). Using in vitro and mouse models, several groups 
have shown that PB1-F2 has pleiotropic effects. This protein, while dispensable for viral 
replication in embryonated eggs, tissue culture, or in vivo (Conenello and Palese 2007), it 
enhances the replication kinetics of the laboratory virus, A/Puerto Rico/8/34 (H1N1; hereafter 




human H3N2 viruses (McAuley, Zhang et al. 2010; Smith, Adler et al. 2011). By interacting 
with the PB1 subunit, PB1-F2 was shown to up-regulate the PR8 polymerase activity (Mazur, 
Anhlan et al. 2008) and, more recently, the highly pathogenic H5N1 (McAuley, Zhang et al. 
2010) and pH1N1 (Chen, Chen et al. 2010). Importantly, PB1-F2 expression results in 
enhanced apoptotic-cell death in immune cells, viral pathogenicity in mice, and 
immunopathology (Chen, Calvo et al. 2001; Zamarin, Ortigoza et al. 2006; Conenello, 
Zamarin et al. 2007; McAuley, Hornung et al. 2007; McAuley, Chipuk et al. 2010). Intranasal 
administration of PB1-F2 peptides derived from the 20th century pandemic strains (1918 
H1N1, 1957 H2N2, 1968 H3N2) and H5N1 led to acute lung injury, elevation of pro-
inflammatory cytokines, and the influx of inflammatory cells to the lungs of mice (McAuley, 
Chipuk et al. 2010). However, this effect seems to be lost in recently circulating human 
H3N2 strains through accumulations of point mutations in the PB1-F2 protein (Alymova, 
Green et al. 2011). A rare polymorphism (N66S) in PB1-F2 has been associated with high 
lethality of the 1918 IAV and certain highly pathogenic H5N1strains (Conenello, Zamarin et 
al. 2007; Schmolke, Manicassamy et al. 2011). Overall, the effects of PB1-F2 in relation to 
influenza-host interaction are not completely understood and seem to be cell-type, virus 
strain, and even host-specific. Nevertheless, the contribution of PB1-F2 to the virulence of 
IAV to its natural hosts has been limited to avian species (Marjuki, Scholtissek et al. 2010; 
Schmolke, Manicassamy et al. 2011) and, to our knowledge, no studies have determined its 
role in the context of IAV infection of TR H3N2 in swine. 
In this study, we compared the effects of PB1-F2 expression in the background of 
two TR H3N2 IAVs different pathotypes in pigs. We sought to delineate PB1-F2 contribution 
to viral polymerase activity measured in vitro, as well as its role in viral replication and cell 
death using ex vivo infected porcine tissues. Finally, we addressed whether the presence of 
PB1-F2 or the N66S polymorphism would translate into changes in pathogenicity, and host 





 5.3. Material and Methods 
5.3.1. Ethics Statement 
Swine pathogenicity studies were conducted in the high containment facilities at the 
National Animal Disease Center in Ames, IA under protocol 3950 "Influenza A virus 
pathogenesis and host response in swine" approved by the USDA- ARS Animal Care and Use 
Committee. Porcine explants were prepared according to protocol R-08-16 “Transmissibility 
of Influenza A Viruses in Swine" approved by the Institutional Animal Care and Use 
Committee, University of Maryland, College Park. Animal studies adhered strictly to the US 
Animal Welfare Act (AWA) laws and regulations. 
5.3.2. Cell lines and virus strains 
Human embryonic kidney cells (293-T) were cultured in OptiMEM I (GIBCO, Grand 
Island, NY) containing 10% FBS and antibiotics. Madin-Darby canine kidney (MDCK) cells 
were maintained in modified Eagle's medium (MEM) (Sigma-Aldrich, St. Louis, MO) 
supplemented with 5% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), L-
glutamine.and antibiotics. A/swine/Wisconsin/14094/99 (H3N2) (Genbank taxonomy 
136472) was a kind gift from Dr. Sagar Goyal, University of Minnesota. 
A/turkey/Ohio/313053/04 (Genbank taxonomy ID 533026) was kindly provided by Dr. Yehia 
Saif, Ohio State University. Both viruses were successfully rescued from cloned cDNAs as 
described below and amplified in either MDCK cells (Sw/99 ) or embryonated eggs (Ty/04) 
following the same substrates used for isolation of the WT viruses. Sw/99 and Ty/04 bearing 
mutations in PB1-F2 were generated by reverse genetics and are described below. All 
recombinant viruses were amplified in MDCK cells to produce viral stocks. 
5.3.3. Reverse genetics and mutagenesis 
The eight-plasmid-based reverse genetics (RG) system was used to rescue WT 
A/swine/Wisconsin/14094/99 (H3N2) (Sw/99), A/turkey/Ohio/313053/04 (H3N2) (Ty/04) 
and recombinants thereof.  Each of the eight viral gene segments were amplified by RT-PCR 
and cloned in the bidirectional reverse genetics (RG) plasmid derived from pHW2000 
(Hoffmann, Neumann et al. 2000). The QuikChange II site-directed mutagenesis kit 




PB1-F2 ORF of both Sw/99 and Ty/04, which display a low and high virulent phenotype for 
pigs, respectively (Pena et al., manuscript in preparation). To ensure complete abolition of 
PB1-F2 translation, we mutated the ATG start codon to ACG and introduced 2 stop codons at 
amino acid positions 12 (c153g) and 58 (g291a) as previously described by Zamarin et al. 
(Zamarin, Ortigoza et al. 2006). All the three above mutations were silent in the PB1 ORF. 
Since the Sw/99 virus is of low virulence to pigs, we introduced the virulence marker N66S 
to assess wheather this polymorphism is implicated in the high severity of TR H3N2-induced 
disease in pigs (Conenello, Zamarin et al. 2007). Viruses used in this study are summarized in 
table 1. All RG plasmids and recovered recombinant viruses were fully sequenced to confirm 
their identity. The recombinant viruses were generated by transfecting co-cultured 293-T and 
MDCK cells as previously described (Hoffmann, Neumann et al. 2000).  
5.3.4. Sequence alignment 
The Sw/99 and Ty/04 WT PB1-F2 gene products were aligned with the 20th century 
pandemic strains (1918 H1N1, 1957 H2N2, and 1968 H3N2), and some previously 
characterized PB1-F2 proteins. Alignment was carried out using ClustalW method in 
MegAlign (Lasergene v.8.1.5., DNAStar, Madison, WI). 
5.3.5. Viral ribonucleoprotein (vRNP) reconstitution assay 
In order to study the effects of PB1-F2 on polymerase activity, a previously 
developed viral ribonucleoprotein (vRNP) reconstitution assay was used (Pena, Vincent et 
al.). Briefly, 1 µg of the plasmid encoding the influenza virus-like NS vRNA carrying the 
Gaussia Luciferase (GLuc) reporter gene was transfected in 293-T cells along with 1 µg of 
each of the RG plasmids encoding PB2, PB1, PA and NP plasmids using the TransIT-LT1 
(Mirus, Madison, WI) reagent following the manufacturer’s recommendations. The PB1 
plasmid encoded either the WT PB1-F2 or knockout (KO); or, in the case of Sw/99, the PB1-
F2 gene with the N66S mutation. The pCMV/SEAP (SEAP) plasmid, which expresses the 
secreted alkaline phosphatase, was co-transfected into cells to normalize the transfection 
efficiency. At 24 hours post-transfection, supernatant from transfected cells was harvested 
and assayed for both luciferase and secreted alkaline phosphatase activities using the 
BioLux™ Gaussia Luciferase Assay Kit (NEB, Ipswich, MA) and the Phospha-Light™ 
Secreted Alkaline Phosphatase Reporter Gene Assay System (A&D, Foster City, CA) 
according to the manufacturers’ instructions. Relative polymerase activity was calculated as 




5.3.6. Isolation, infection, and viability of porcine alveolar macrophages 
Porcine alveolar macrophages (PAMs) were isolated from five healthy pigs. At 
necropsy, the trachea was sectioned and 50 mL MEM were dispensed into the lungs using a 
50 mL pipette. The fluid was withdrawn by aspiration and the procedure was repeated two 
times to maximize PAMs recovery. The retrieved bronchoalveolar lavage fluid (BALF) was 
placed on ice until centrifugation (500 g, 5 min, 4°C). The cell pellet was resuspended in 20 
mL of PAMs complete media, which consisted of phenol red-free MEMα (Gibco, Grand 
Island, NY) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO) and antibiotics. 
PAMs were purified by adhesion. PAMs suspension derived from each donor was plated on 
75 cm2 tissue culture flasks (Corning, Lowell, MA) and incubated for 4 h at 37°C in 5% CO2. 
The flasks were gently rocked at hourly intervals during incubation. Nonadherent cells were 
removed and adherents PAMs were harvested with a cell scraper. The cells were then 
collected, washed once, and counted using an automated cell counter PAMs were seeded at a 
density of 1x105 cells per well in a 96-well flat-bottom plate with a final volume of 100 µl of 
PAMs complete media. At 24 h after plating, the media was removed and PAMs were 
infected with 100 µl of the recombinant viruses diluted in PAMs media at a multiplicity of 
infection (MOI) of 2 or 10.  PAMs viability was measured by the XTT colorimetric method 
using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN) 
according to the manufacturer’s protocol. At the indicated time points, 20 µl of XTT working 
solution (1 mg/mL), prepared immediately before use, were added to each well and the 
microplate was incubated for an additional 2 h at 37°C and read using an ELISA plate reader 
(SpectraMax M5, Molecular Devices, Sunnyvale, CA) at a wavelength of 650 nm. PAMs 
viability was determined as a relative percentage of the mock-treated non-infected control.  
To determine the infectivity of PB1-F2 recombinant viruses in freshly isolated 
alveolar macrophages, PAMs were isolated from five healthy pigs as above, and seeded on a 
6-well plate in a volume of 3 mL of MEMα supplemented with 10% fetal bovine serum and 
antibiotics. PAMs were incubated overnight and infected at MOI 2 with MEM without 
trypsin. Following 1 h adsorption at 37°C, PAMs were washed three times with PBS and the 
culture was replenished with 3 mL MEMα supplemented with 10% fetal bovine serum and 
antibiotics. At the indicated time points, 300 µl of supernatant was collected to assess virus 





5.3.7. TUNEL assay in ex vivo infected porcine alveolar macrophages 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) 
was used to quantify the levels of apoptotic-cell death induced by PB1-F2 recombinant 
viruses in ex vivo infected PAMs. Apoptotic cells were detected using the In Situ Cell Death 
Detection Kit, Fluorescein (Roche Applied Science, Indianapolis, IN) according to the 
manufacturer’s instructions. Briefly, PAMs were infected as described above at MOI of 2 and 
at 72 hpi cells were fixed with 4% paraformaldehyde and permeabilized in PBS containing 
0.1% Triton X-100 and 0.1% sodium citrate. Cells were then incubated in the TUNEL 
reaction mixture in the dark at 37°C for 60 min followed by detection of DNA strand breaks 
in apoptotic cells by fluorescence microscopy. A minimum of 600 cells was counted in a 
blinded-fashion from more than 10 random microscopic fields and the percentage of cell 
apoptosis was determined. 
 
5.3.8. Isolation, culture, and infection of porcine respiratory explants 
Porcine nasal turbinates, tracheal, and lung explants were prepared as described 
previously (Van Poucke, Nicholls et al. 2010), with some modifications. All respiratory 
explants were cultivated according to the air-liquid interface principle in an incubator at 37°C 
and 5% CO2. NT and trachea explants were cultivated in 50% DMEM (Gibco)/50% RPMI 
(Gibco) media supplemented with 100 U/mL penicillin (Gibco), 100 µg/mL of streptomycin 
(Gibco), 0.1 mg/mL gentamycin (Gibco), 25 µg/mL Amphotericin B (Gibco), 0.3 mg/mL 
glutamine (BDH Biochemical) and nonessential amino acids (Sigma). Media for lung 
explants consisted of M199 (Sigma) containing the same antibiotics as above, nonessential 
amino acids (Sigma). Vitamin supplement (ATCC, Rockville, MD), 0.5 µg/mL 
hydrocortisone and ITS supplement (Insulin, Transferrin, Selenium) added at 10 mL/L 
medium. A five-week-old swine donor obtained from a high-health status farm whose 
animals are negative for IAV was used for this study. The animal was humanely euthanized 
with Beuthanasia®-D (Intervet/Schering-Plough, Summit, NJ) at a dosage of 1 mL/4.5 Kg of 
body weight and the respiratory tissues were collected. NT and trachea explants were 
dissected and washed 10 times with PBS containing antibiotics to remove bacterial 
contamination. Tissues were then cut into squares of 25 mm2 each and placed with the 
epithelial surface upwards onto the filter membrane of the polyester tissue culture-treated 




lower compartment was filled with 1 mL of explant media. The right apical lung lobe was 
expanded with a 1% type VII-A low gelling temperature agarose solution (Sigma, St. Louis, 
MO) that had been dissolved in lung explants media and cooled down to 37°C. The expanded 
lung was placed at 4°C for 10 min in a sterile container until the agarose solidified. The 
embedded lung tissue was then cut into 1 mm thick slices using a microtome blade and hand 
microtome. Two sections of the lungs were obtained: the proximal lung (close to the start of 
bronchial tree) and distal lung (close to the lung alveoli). The procedure for cultivation of 
lung explants was similar to the procedure used for the NT and tracheal explants. After 24 h, 
lung explants were washed with warm PBS to remove most of the agarose before infection. 
At 24 h of culture, explants were washed with PBS and 106 tissue culture infectious dose 50% 
(TCID50) of the recombinant viruses diluted in 500 µl of explants media were deposited in the 
upper compartment of Transwells® for 1 h. After the 1 h adsorption at 37°C, explants were 
washed three times with PBS and the culture replenished with 500 µl of explants media. One 
hundred µl of upper compartment explant bathing media was collected at 24, 48, and 72 h 
post inoculation to assess virus yields. Virus titers in respiratory explants were determined by 
standard TCID50 in MDCK cells. 
 
5.3.9. Virus titration 
Viral stocks and virus present in biological samples were titrated on MDCK cells and 
the TCID50/mL was determined by the Reed and Muench method (Reed and Muench 1938). 
Briefly, samples were serially diluted 10-fold in serum-free media containing antibiotics and 
1 µg/mL TPCK-trypsin (SIGMA) and 100 or 200 µl of the inoculum were overlaid onto 
confluent monolayers of MDCK cells seeded in 96-well plates. The cells with the sample 
were incubated for 3 days and the endpoint viral titer was determined by an HA assay using 
0.5% turkey red blood cells. 
5.3.10. Swine pathogenicity experiment  
Three-week-old cross-bred pigs were obtained from a high-health herd free of SIV 
and porcine reproductive and respiratory syndrome virus. All pigs were treated with ceftiofur 
crystalline free acid (Pfizer Animal Health, New York, NY) to reduce bacterial contaminants 
prior to the start of the experiment. Fifty pigs were randomly divided in five groups (n=10) 




of each of the PB1-F2 recombinant viruses diluted in 2 mL of MEM using previously 
described protocols (Vincent, Lager et al. 2010). Following inoculation, pigs were monitored 
daily for clinical signs of disease and nasal swabs were collected to measure viral shedding. 
Five pigs from each group were euthanized on day 1 and the remaining five animals were 
euthanized at 3 dpi for evaluation of viral lung load, pathology, and host response to 
infection. Five additional pigs were inoculated with 2 mL MEM as above and served as 
mock-controls. Control pigs were euthanized at 3 days post infection (dpi). 
5.3.11. Pathologic examination of swine lungs 
At necropsy, lungs were removed in toto and evaluated to determine the percentage 
of the lung affected by purple-red, consolidated lesions that are typical of influenza virus 
infection in pigs. The percentage of the surface affected with pneumonia was visually 
estimated for each lobe, and a total percentage for the entire lung was calculated based on 
weighted proportions of each lobe to the total lung volume as previously described (Halbur, 
Paul et al. 1995). Each lung was then lavaged with 50 mL MEM to obtain bronchoalveolar 
lavage fluid (BALF). A single veterinary pathologist scored all lungs and was blinded to the 
treatment groups.   
5.3.12. Histopathology and immunohistochemistry 
Tissue samples from the trachea and right middle lung lobe were taken and fixed in 
10% buffered formalin for histopathological examination. Tissues were routinely processed 
and stained with hematoxylin and eosin. A board-certified veterinary pathologist blinded to 
treatment groups evaluated microscopic lesions.  Scoring of lesions was based on scales 
adapted from Gauger et al (Gauger, Vincent et al. 2011). Individual scores were assigned to 
four parameters: bronchial and bronchiolar epithelial changes, bronchitis/bronchiolitis, 
peribronchiolar lymphocytic cuffing and interstitial pneumonia.  Scores were based on 
percentage of airways with lesions that included epithelial changes and inflammation on a 5-
point scale: 0: No lesions, 1: 1-25%, 2: 26 to 50%, 3: 51-75%, 4: greater than 75% of airways 
affected with airway epithelial damage and inflammation.  Peribronchiolar cuffing by 
lymphocytes was graded on a 4-point scale:  0: None, 1: Mild, loosely formed cuff, 2:  
Moderate, well formed cuffs,, and 3:  Prominent, thick well formed cuffs.  Interstitial 
pneumonia was graded on 5-point scale based on severity and distribution:  0:  No lesions, 1:  
Mild, focal to multifocal, 2:  Moderate, locally extensive to multifocal, 3:  Moderate, 




Trachea sections were scored similar to the bronchi and bronchioles and were based 
on epithelial changes and degree of inflammation. Tracheal epithelial changes were graded on 
a 5-point scale: 0:  No lesions, 1:  Early epithelial changes characterized by focal to 
multifocal loss of cilia and epithelial degenerative changes, 2:  Mild epithelial flattening with 
loss of cilia and goblet cells, 3:  Moderate epithelial flattening with decreased thickness of 
respiratory epithelium, loss of cilia and goblet cells, 4:  Flattened epithelium with areas of 
mucosa covered by a single layer of cuboidal epithelium and epithelial loss (necrosis).  
Degree of tracheitis was graded on a simple 4-point scale:  0: None, 1: Mild, 2: Moderate, 
and 3: Severe. 
  Influenza virus Type A-specific antigen was detected in lung tissues using a 
previously described immunohistochemical (IHC) method with minor modification (Vincent, 
Janke et al. 1997). Briefly, tissue sections were deparaffinized and hydrated in distilled water. 
Slides were quenched in 3% hydrogen peroxide for 10 min, rinsed three times in de-ionized 
water and treated in 0.05% protease for 2 min. Slides were then rinsed three times in de-
ionized water and once in Tris-buffered saline (TBS). Influenza A virus-specific monoclonal 
antibody (MAb) HB65 (ATCC, Manassas, VA), specific for the nucleoprotein (NP) of 
influenza A viruses, was applied at 1:100 dilution and slides were incubated at room 
temperature for 1 h.  Bound MAbs were stained with peroxidase-labeled anti-mouse IgG 
followed by chromogen using the DAKO LSAB2-HRP Detection System (DAKO, 
Carpinteria, CA) according to the manufacturer’s instructions. The slides were rinsed in 
deionized water and counterstained with Gill’s hematoxylin.  Antigen detection was given 
two scores:  1) airway epithelial labeling and 2) alveolar/interstitial labeling.  In airway 
epithelium a 5-point scale was used:  0:  None, 1:  Few  cells with positive labeling, 2:  Mild 
scattered labeling, 3:  Moderate scattered labeling, 4:  Abundant scattered labeling (greater 
than 50% epithelium positive in affected airways).  In the interstitium/alveoli, a 4-point scale 
was used:  0:  None, 1:  Minimal focal signals, 2:  Mild multifocal signals, 3:  Abundant 
signals. 
 
5.3.13. Quantification of cytokine/chemokine protein levels in bronchoalveolar 
lavage fluid  
Levels of nine porcine cytokines/chemokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 




manufacturer’s recommendations (SearchLight, Aushon Biosystems). Levels of IFN-α 
protein were measured by ELISA using F17 monoclonal antibody, K9 MAb and recombinant 
porcine IFN-α (R&D Systems Inc., Minneapolis, MN) as previously described (Brockmeier, 
Lager et al. 2009). 
5.3.14. Statistical analysis 
All statistical analyses were performed using GraphPad Prism Software Version 5.00 
(GraphPad Software Inc., San Diego, CA). Comparison between two treatment means was 
achieved using a two-tailed Student t-test, whereas multiple comparisons were carried out by 
analysis of variance (ANOVA) using Dunnett’s post hoc test, unless otherwise specified. The 
differences were considered statistically significant at p< 0.05. 
 
 




 5.4. Results 
5.4.1. Generation of PB1-F2 recombinant influenza viruses 
In this study, we sought to understand how PB1-F2, the 11th defined IAV gene 
product, modulates the replication and virulence of triple reassortant influenza viruses in pigs. 
The sequences of the Sw/99 and Ty/04 PB1-F2 proteins are 90 amino acid (aa) long and 
differ only at four amino acid positions from each other. The Ty/04 contains the following 
mutations compared to sw/99: S23N, R44K F57S, and F83S. The functional roles of these 
polymorphisms have not been established. The Ty/04 PB1-F2 is 54.4 % divergent from the 
1918 H1N1 PB1-F2 at the amino acid level. Compared with previously characterized human 
H3N2 IAV PB1-F2 proteins, the Ty/04 presents 74.4 % and 86.6 % of aa identity with 1968 
pandemic strain A/Hong Kong/1/68 (H3N2) and with the seasonal human H3N2 
A/Wuhan/359/95 (H3N2) isolate, respectively (Fig. 5.1). 
 
Figure 5.1. Alignment triple reassortant H3N2 PB1-F2 used in this study.  Sw/99 and 
Ty/04 PB1-F2 ORF were aligned to those of the 20th century pandemic strains (1918 H1N1, 
1957 H2N2, and 1968 H3N2), other H3N2 swine IAV strains, and the previously 
characterized PB1-F2 proteins. Boxed residue highlights amino acid residues that have been 
associated with increased virulence of 1918 and highly pathogenic H5N1 strains: 51(T), 
56(V), 66(S), and 87(E). Asterisks indicated the positions in which pro-inflammatory 
mutations (P62L, H75R, Q79R, and S82L) have been found in the human H3N2 PB1-F2 




In order to study the PB1-F2 proteins expressed by either Sw/99 or Ty/04, we first 
established a reverse-genetics (RG) system for these viruses using a previously published 
approach (Hoffmann, Neumann et al. 2000). PB1-F2 translation from the segment 2 RNA 
was completely abolished by mutating the ATG start codon to ACG and introducing 2 stop 
codons downstream of the gene. Since Sw/99 virus is of low virulence to pigs, we introduce 
the N66S mutation in its PB1-F2, an important mutation for the virulence H5N1 and 1918 
influenza viruses in the mouse model of infection (Conenello, Zamarin et al. 2007). The 
viruses used herein are summarized in Table 1. Each viral gene was cloned into the pDP-
2002 vector and the WT RG viruses were rescued by transfection of 293-T and MDCk co-
cultures. Because the presence of PB1-F2 in certain virus strains has been shown increase 
polymerase activity, we next assessed whether this phenotype could be recapitulated in 
viruses containing the TRIG cassette. We found no difference in polymerase activity between 
the WT and PB1-F2 mutants from the two different strains chosen for this study (Fig. 5.2), 
suggesting that PB1-F2 does not affect polymerase activity of the TR H3N2 influenza viruses 
studied herein. 
 
Table 5.1.  Influenza viruses used in this study.  
 
Viruses Acronym in main text 
A/turkey/Ohio/313053/04 (H3N2) Ty/04 WT 
A/turkey/Ohio/313053/04 (H3N2) PB1-F2 knockout Ty/04 KO 
A/swine/Wisconsin/14094/99 (H3N2) Sw/99 WT 
A/swine/Wisconsin/14094/99 (H3N2) PB1-F2 knockout Sw/99 KO 











Figure 5.2. PB1-F2 derived from TR H3N2 does not influence polymerase activity. 293-
T cells were transfected with plasmids encoding the minimal components required for viral 
transcription and replication (PB2, PB1, and PA polymerase subunits, NP and a vRNA 
influenza driven-luciferase reporter replicon expressing GLuc) derived from either Sw/99 
(A), Ty/04(B). The pCMV/SEAP, plasmid was used to normalize transfection efficiency as 
previously described (Pena, Vincent et al.). At 24 hours post transfection, the supernatant was 
harvested and assayed for both luciferase and phosphatase activities. Data are expressed as 






5.4.2. PB1-F2 affects both the infectivity and viability of porcine alveolar 
macrophages in a strain-dependent fashion 
Since PB1-F2 has been shown to induce cell death in immune cells (Chen, Calvo et 
al. 2001; McAuley, Chipuk et al. 2010), we investigated whether the presence of PB1-F2 
affects the infectivity and the viability of freshly isolated porcine alveolar macrophages 
(PAMs). The purity of PAMs preparations was over 98%, as determined by flow cytometry 
using anti-porcine CD163 antibody (data not shown). PAMs derived from 5 healthy pigs 
were infected at MOI of 2 with each of the PB1-F2 recombinant viruses and viral yields in 
PAM supernatant were determined by standard TCID50 in MDCK cells. Disruption of PB1-
F2 expression significantly reduced viral yields in PAMs from 6-48 hpi, although the 
presence of N66S mutation had no effect in viral replication in these cells (Fig.5.3A). The 
impact of Sw/99 PB1-F2 in PAMs viability as well as in apoptotic cell death correlated with 
the replication ability of these viruses. The Sw/99 WT caused more cytotoxicity to PAMs 
compared to Sw/99 KO, whereas the N66S mutation had an intermediate effect (Fig. 5.3B 
and 5.3C). Ty/04 WT replicated to lower levels in PAMs compared to Sw/99 WT and 
knocking out PB1-F2 had no effect in virus growth. Overall PAMs viability was reduced 
upon infection with the Ty/04 isogenic viruses. Although Ty/04 KO had lower levels of 
apoptotic cell death as determined by TUNEL assay, overall PAM viability was not affected 
as assessed by the XTT method (Fig. 5.3B and 5.3C). It should be noted that cytotoxicity 
measured by the XTT assay was only detected when PAMs were infected at high MOI (10). 
Taken together, these data suggest that PB1-F2 affects the replication and viability of PAMs 








Figure 5.3. Infectivity and viability of porcine alveolar macrophages upon infection with 
PB1-F2 recombinant viruses. (A) Porcine alveolar macrophages (PAMs) derived from five 
healthy pigs were infected at MOI of 2 with each of the recombinant viruses and viral yields 
were determined by standard TCID50 in MDCK cells. (B) Toxic effects induced by PB1-F2. 
PAMs were mock-infected or infected with PB1-F2 recombinant viruses at an MOI of 10 and 
cell viability was measured by the XTT assay at 24, 48 and 72 hpi. (C) PAMs were mock-
infected or infected at MOI of 2 with the PB1-F2 recombinant viruses and assayed for 
apoptotic-cell death using the in situ TUNEL assay at 72 hpi. Each data point represents the 
mean ± SEM. Asterisks indicate that the differences are statistically significant (p< 0.05) 




5.4.3. PB1-F2 enhances replication of TR H3N2 IAV in porcine respiratory explants 
It has been demonstrated that PB1-F2 increase replication of certain IAV isolates in 
tissue culture (McAuley, Zhang et al. 2010; Smith, Adler et al. 2011). However, cell lines do 
not exhibit the natural physiological conditions and cellular complexity present in the 
respiratory tract. In order to study the replication of PB1-F2 recombinant viruses in a relevant 
biological system, we developed an ex vivo organ culture model of the pig respiratory tract 
maintained an air–liquid interface. Tissue explants were prepared from nasal turbinates, 
trachea, proximal (close to the bronchi), and distal lung (close to the alveoli) from healthy 
swine donor. Knocking out PB1-F2 from Ty/04 caused mild but significant decrease in virus 
replication in respiratory explants. The presence of PB1-F2 (or the N66S mutation) had no 
impact on the replication of Sw/99 in this system (Fig. 5.4A-D). Collectively, these data 
indicate that PB1-F2 can modulate viral production in swine respiratory tissues but its 
function may be unnecessary for some SIV strains, which is consistent with the observation 






Figure 5.4. Replication of PB1-F2 recombinant viruses in porcine respiratory explants. 
Nasal turbinates (A), tracheal (B), proximal (C), and distal lung (E) explants were infected 
with 106 TCID50 of each  viruses, The bathing media was collected at the indicated time 
points and titrated by the TCID50 method in MDCK cells. Values shown are the mean ± SEM 




5.4.4. Deletion of PB1-F2 increases the virulence of Ty/04 to swine without 
affecting viral load 
We next evaluated the effects of PB1-F2 in the virulence of TR H3N2 IAVs in vivo. 
Three-week old cross bred pigs were obtained from a high-health herd and separately in five 
groups of 10 pigs each and a control group containing 5 pigs. Animals were housed in 
separated isolation units and inoculated intratracheally with 105 TCID50/animal. The control 
group was inoculated with sterile tissue culture media. Five pigs from each of the infected 
group were euthanized at 24 hpi and the remaining five animals were euthanized at 3 dpi 
along with the control pigs. The expression PB1-F2 (or the N66S modification in sw/99) did 
not affect viral shedding in nasal secretions from either of the strains tested (Fig. 5.5A). 
Similarly, viral lung load was not affected by PB1-F2 in neither of the strains (Fig. 5.5B). At 
necropsy, PB1-F2 or N66S substitution had no effect in either the macroscopic (Fig.5C) or 
microscopic lung pathology (Fig. 5.5D) caused by sw/99. Surprisingly, knocking out PB1-F2 
from the Ty/04 strain significantly increased the macroscopic and microscopic pneumonia of 
this virus at 3dpi (Fig. 5.5C-D), indicating that PB1-F2 is a modulator of virulence of certain 




Figure 5.5. Replication and pathology induced by PB1-F2 recombinant viruses in swine. 
Groups of pigs (n=10) were infected with 105 TCID50 of PB1-F2 recombinant viruses and 
nasal swabs were collected from 1-3 dpi for measuring virus shedding. Five animals from 
each group were euthanized either at 1 or 3 dpi. The lungs were collected and processed for 
virus titration and pathological analysis. (A) Viral shedding in nasal secretions of pigs. (B) 
Pulmonary replication of PB1-F2 isogenic viruses in pigs. Values are mean ± SEM of virus 
titer (log10 TCID50/mL) in bronchoalveolar lavage fluid (BALF) collected at the indicated 
time points. (C) Percentage of macroscopic lung lesions (D) Histopathologic scores in the 




5.4.5. PB1-F2 modulates the innate immune response in swine lungs 
It has been shown that PB1-F2 strongly influences the early host response during 
IAV infection (McAuley, Hornung et al. 2007; Le Goffic, Leymarie et al. 2011). To further 
characterize the effect of PB1-F2 in the pathological manifestations during infection with TR 
H3N2 IAV in swine, we measured the protein levels of ten porcine cytokines/chemokines 
(IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNF-α, and IFN-α, and IFN-γ) in BALF 
collected at 1 and 3 dpi necropsies. The amounts of the cytokines/chemokines IL-1β, IL-2, 
IL-4, IL-10, IL-12p70, TNF-α, and IFN-α were not affected by the PB1-F2 in either of the 
strains (Fig. 5.6, and data not shown). However, increased pulmonary levels of IL-6 were 
seen early (1 dpi) during the infection with Sw/99 WT as compared to Sw/99 KO, suggesting 
that PB1-F2 differentially regulates these cytokines in pigs infected with Sw/99 virus. The 
presence of N66S change increased the levels of IL-8 at 1 dpi compared to WT virus. 
Interestingly, knocking out PB1-F2 from Ty/04 augmented the pulmonary levels of IL-8 and 
IFN-γ at 3 dpi, which was concomitant with the development of the enhanced pneumonia in 
this group. Collectively, these results indicate that PB1-F2 differentially modulates the local 
levels cytokines and chemokines during infection with TR H3N2 in pigs and this heightened 
production of IL-8 and IFN-γ pro-inflammatory mediators correlated with the lung pathology 






Figure 5.6. PB1-F2 modulates the innate immune response in swine lungs. Groups of pigs 
(n=10) were infected intratracheally with 105 TCID50 of PB1-F2 recombinant viruses. On 
days 1 and 3 post-infection, animals from each group were euthanized and the 
cytokines/chemokines levels in BALF were determined by ELISA. Data are shown as mean ± 
SEM of five animals in each challenge group. A one-way analysis of variance (ANOVA) was 






Triple reassortant (TR) IAVs have become endemic in swine populations in North 
American since their first introduction in 1998 (Zhou, Senne et al. 1999). TR swine IAV have 
demonstrated remarkable ability to reassort with either classical swine H1N1 or human H1N1 
and H3N2 viruses, generating several different virus reassortants in the last decade. 
Remarkably, the 2009 pandemic H1N1 (pH1N1) resulted from genetic reassortment between 
TR swine IAV circulating in North America and Eurasia swine H1N1 IAV (Garten, Davis et 
al. 2009). In the US, pH1N1 has been reassorting with endemic TR strains at an alarming 
rate, emphasizing the epidemiological importance of viruses harboring the TRIG cassette 
(Ducatez, Hause et al. 2011).  
The phenotypes associated with the presence of PB1-F2 proteins derived from TR 
H3N2 IAVs have not yet been elucidated. Here, we created PB1-F2 null viruses in the 
background of two representative lineages of swine-origin North American TR H3N2 
viruses: sw/99, which belongs to the phylogenetic cluster III; and Ty/04, a representative 
swine-origin TR H3N2 IAV belonging to cluster IV. These viruses were chosen because they 
are genetically related and the Ty/04 virus is thought to have originated from the Sw/99 strain 
following interspecies transmission event(s). Since Sw/99 is low virulent for pigs (Pena et al, 
manuscript in preparation), we also studied the effects of the virulence marker N66S in the 
PB1-F2 of this strain. We focused in swine systems to evaluate the role of PB1-F2 in the 
context of isogenic viruses whose differences were limited to the PB1-F2 gene product. In 
addition to the impact of influenza infection on the swine industry and the epidemiology of 
IAV, conducting pathogenesis studies in pigs also offers the possibility of extrapolating the 
findings to humans, since there are important similarities between the two species regarding 
the distribution of sialic acid receptors, cytokine production, and clinical-pathological 
outcomes after influenza infection (Van Reeth, Van Gucht et al. 2002; Barnard 2009; Barbe, 
Atanasova et al. 2010; Barbe, Saelens et al. 2010; Nelli, Kuchipudi et al. 2010). 
Alveolar macrophages are located at the air-tissue interface in the lungs and are the 
initial cells that combat inhaled microorganisms and particulate matter (Coleman 2007). IAV 
have been shown to infect alveolar macrophages in a variety of species, including mice, 
swine, and humans (Rodgers and Mims 1982; Reading, Miller et al. 2000; Seo, Webby et al. 




alveolar macrophages by chemical treatment unveiled that these cells are indispensable for 
controlling IAV infection (Kim, Lee et al. 2008). Since its original discovery, PB1-F2 has 
been suggested to play a role in influenza virulence by destroying host immune cells such as 
macrophages (Chen, Calvo et al. 2001; Lamb and Takeda 2001; Zamarin, Garcia-Sastre et al. 
2005). We addressed this question by infecting freshly isolated porcine alveolar macrophages 
(PAMs) ex vivo with PB1-F2 recombinant viruses. We found that the presence of PB1-F2 
was required from optimal replication of the Sw/99 strain, whereas its presence did not affect 
Ty/04 replication in these cells (Fig. 5.3). Consistent with its enhanced replication, the 
viability of PAMs infected ex vivo was affected by the presence of PB1-F2 in the Sw/99 
strain. Differences in apoptotic cell death were detected by TUNEL assay when PAMs were 
infected at MOI 2, but this effect was only quantifiable by XTT when PAMs were infected at 
MOI 10. There was no correlation between the ability of PB1-F2 recombinant viruses to 
replicate in PAMs and the virulence of these viruses to pigs. Disruption of PB1-F2 ORF had 
no effect in Sw/99 virulence as measured by viral shedding, viral lung load, and lung 
pathology. These results are in accordance with previous reports that showed a lack of 
correlation between macrophage infectivity and/or cell death in vitro and the course of IAV 
disease in mouse models (McAuley, Chipuk et al. 2010; Tate, Pickett et al. 2010). In the 
background of Ty/04, PB1-F2 had no effect on viral replication, apoptosis or viability of 
PAMs.  
Expression of full-length PB1-F2 as well as the N66S substitution has been shown to 
increase replication of certain IAV isolates in tissue culture (McAuley, Zhang et al. 2010; 
Schmolke, Manicassamy et al. 2011; Smith, Adler et al. 2011). Because cell lines lack the 
cellular complexity and natural physiological conditions of the respiratory tract, we studied 
the replication of PB1-F2 recombinant viruses in porcine respiratory explants. Different 
groups have shown that respiratory explants are a valuable system to study influenza-host 
interaction in a scalable, well-defined experimental setting (Chan, Chan et al. 2010; Nunes, 
Murcia et al. 2010; Van Poucke, Nicholls et al. 2010), although no study has compared side-
by-side viral replication ex vivo versus in vivo. Our results supported the hypothesis that PB1-
F2 modulates viral replication in a strain-dependent manner. Although Ty/04 PB1-F2 did not 
affect polymerase activity, higher viral yields were observed in respiratory explants infected 
with Ty/04 WT relative to Ty/04 KO. In the backbone of Sw/99 viruses, neither PB1-F2 
deletion nor N66S mutation affected viral growth kinetics in this system (Fig.6.4). 




the levels of viral shedding in nasal secretions and lung viral load in vivo.  On the other hand, 
we found no differences between Ty/04 WT and Ty/04 KO regarding viral shedding in the 
upper respiratory tract and BALF titers, suggesting that results obtained from ex vivo and in 
vivo results not always correlate with each other. Even though tissue culture explants preserve 
the normal tissue cytoarchitecture, it must be noted that these cells are removed from their 
normal in vivo environment and may thus behave different and may not reflect the effects of 
in vivo systemic factors present during infection (Grivel and Margolis 2009). These 
limitations should be considered when using ex vivo models to extrapolate conclusions 
obtained in these systems to in vivo settings. 
McAuley et al. demonstrated that PB1-F2 proteins from human H3N2 IAV differ 
profoundly in their ability to induce inflammatory responses and pathology in lungs. They 
found that PB1-F2 derived from the 1968 pandemic strain A/Hong Kong/1/68 (H3N2) exerts 
robust pro-inflammatory effects in vivo, whereas a later seasonal H3N2 isolate was not 
capable of triggering this response (McAuley, Chipuk et al. 2010). Recently, the same group 
demonstrated that PB1-F2 from recent H3N2 isolates lost the immunostimulatory activity 
through truncation or accumulations of point mutations, presumably during viral adaptation 
in humans. The authors mapped the pro-inflammatory mutations in PB1-F2 to P62L, H75R, 
Q79R, and S82L (Alymova, Green et al. 2011). Interestingly, the PB1-F2 sequences of both 
Sw/99 and Ty/04 presents conserved residues in these positions, which include a mix of the 
pro-inflammatory motifs 62(L) and 82(L) as well as the non-inflammatory mutations 75(H), 
79(Q). In our swine pathogenicity studies, PB1-F2 deletion or N66S substitution in the 
background of Sw/99 did not alter viral-induced pneumonia in these animals. Unexpectedly, 
disruption of PB1-F2 ORF from the Ty/04 strain significantly aggravated both the 
microscopic and macroscopic pneumonia caused by this virus at 3 dpi. The degree of 
pneumonia in Ty/04 KO cannot be explained by improved replication efficiency of this virus 
since no replication variation was observed between the two Ty/04 isogenic viruses 
The pro-inflammatory cytokine response is critical for recruiting effector cells to the 
site of an infection. However, elevated or prolonged cytokine production can also contribute 
to the pathological changes observed during infection. Thus, a fine balance between 
inflammation and immunity must be achieved in order to successfully counteract IAV 
infection. To better understand the mechanism of enhanced pneumonia in Ty/04 KO-infected 
pigs, we measured the pulmonary concentration of ten cytokines/chemokines early during the 




there was a significant increase in the pulmonary levels of IL-8 and IFN-γ at 3 dpi as 
compared to the group infected with Ty/04 WT virus.  
IL-8 is a major chemokine involved in neutrophil recruitment to infection sites, a 
vital mechanism for elimination of the assaulting microorganism. Nevertheless, this process 
must be tightly regulated to ensure a beneficial outcome to the host since uncontrolled 
neutrophil recruitment can lead to harmful release of enzymes, reactive oxygen species, and 
increase vascular permeability in the lungs (Dallegri and Ottonello 1997). Importantly, 
elevated level of IL-8 has been implicated in the pathogenesis of viral-induced bronchiolitis 
in humans (Koh, Jung da et al. 2007).  
IFN-γ is an important immunoregulatory cytokine, which is produced by T cells, NK 
cells, and macrophages. IFN-γ has pleiotropic effects on various cells of the immune systems 
and plays an important role in T-cell–mediated lung injury (Bruder, Srikiatkhachorn et al. 
2006). Influenza virus infection induces local production of IFN-γ in the respiratory tract. 
Experiments in gene-targeted mice showed that IFN-γ plays no significant role in protection 
from lethal infection (Graham, Dalton et al. 1993) and IAV has developed mechanisms to 
evade its antiviral activity by disrupting intracellular signaling pathways (Uetani, Hiroi et al. 
2008). In vivo neutralization of IFN-γ with monoclonal antibodies demonstrated that this 
cytokine plays crucial role in the recruitment and/or retention of leucocytes in the inflammed 
lung parenchyma during IAV infection (Baumgarth and Kelso 1996). Recently, Le Goffic et 
al. reported that infection with the laboratory strain A/WSN/1933 (H1N1) in mice resulted in 
higher levels of IFN-γ relative to infection with an isogenic virus lacking PB1-F2 (Le Goffic, 
Leymarie et al. 2011). These results are in disagreement with our findings in pigs using a TR 
H3N2 AIV, in which deletion of PB1-F2 led to enhanced IFN-γ concentrations in BALF. The 
reason for this discrepancy is unclear, but it might be due to differences in viral strains and 
host system used in each study. In fact, there have been conflicting reports of the role of PB1-
F2 in modulating type I interferons, suggesting that the exact role of PB1-F2 in influencing 
the host innate immune response remains unresolved (Le Goffic, Bouguyon et al. 2010; 
Dudek, Wixler et al. 2011; Varga, Ramos et al. 2011). Thus, it is possible that deregulation of 
the innate host defense through IL-8 and IFN-γ pathways might have played a role in the 
exacerbated immunopathology induced by PB1-F2 null Ty/04 virus.  Should Ty/04 PB1-F2 
have a direct effect in blocking or downregulating IL-8 and IFN-γ expression, this effect 
would explain the lessened pulmonary lesions developed in the Ty/04 WT group. These 




research efforts focusing on the modulation of the porcine immune system by PB1-F2 and its 
interaction with host factors should shed light into the molecular mechanisms of PB1-F2 in 
strain and host-dependent manner. 
In conclusion, we have shown that PB1-F2 has pleiotropic effects in the swine host, 
which are expressed in a strain-dependent manner. We demonstrated that PB1-F2 is an 
important viral component implicated in orchestrating innate immune responses in the 
infected lungs. For the first time, PB1-F2 has been shown to play a detrimental role in AIV 
pathogenesis in mammals.  This study fills a critical gap regarding the virulence determinants 
of influenza virus for swine. Our studies provide important insights into the impact of PB1-F2 









Chapter 6: Modifications in the Polymerase Genes of a Swine-
Like Triple-Reassortant Influenza Virus To Generate Live 
Attenuated Vaccines Against 2009 Pandemic H1N1 Viruses 
6.1. Abstract 
On June 11, 2009 the World Health Organization (WHO) declared that the outbreaks 
caused by novel swine-origin influenza A (H1N1) virus had reached pandemic proportions. 
The pandemic H1N1 (H1N1pdm) is the predominant influenza strain in the human 
population. It has also crossed the species barriers and infected turkeys and swine in several 
countries. Thus, the development of a vaccine that is effective in multiple animal species is 
urgently needed. We have previously demonstrated that introduction of temperature-sensitive 
mutations in the PB2 and PB1 genes of an avian H9N2 combined with the insertion of an HA 
tag in PB1 resulted in an attenuated (att) vaccine backbone for both chickens and mice. 
Because the new pandemic strain is a triple reassortant (TR) virus, we chose a swine-like TR 
virus isolate, A/turkey/OH/313053/04 (H3N2) (ty/04), to introduce the double attenuating 
modifications with the goal of producing live attenuated influenza vaccines (LAIV). This 
genetically modified backbone had impaired polymerase activity and restricted virus growth 
at elevated temperatures. In vivo characterization of two H1N1 vaccine candidates generated 
using the ty/04 att backbone demonstrated that this vaccine is highly attenuated in mice as 
indicated by the absence of signs of disease, limited replication and minimum 
histopathological alterations in the respiratory tract. A single immunization with the ty/04 att-
based vaccines conferred complete protection against a lethal H1N1pdm infection in mice. 
More importantly, vaccination of pigs with a ty/04 att-H1N1 vaccine candidate resulted in 
sterilizing immunity upon an aggressive intratracheal challenge with the 2009 H1N1 
pandemic virus. Our studies highlight the safety of the ty/04 att vaccine platform and its 
potential as a master donor strain for the generation of live attenuated vaccines for humans 







In the spring of 2009, the Centers for Disease Control and Prevention (CDC) of the 
United States of America announced the identification of a novel H1N1 strain (H1N1pdm) of 
influenza A virus causing an acute respiratory disease in humans (Dawood, Jain et al. 2009). 
The virus spread easily and sustainably among humans throughout the world, prompting the 
World Health Organization (WHO) to declare on June11th, 2009 the first influenza pandemic 
of the 21st century (Enserink and Cohen 2009; Al Hajjar and McIntosh 2010). This new 
isolate was identified as a swine-origin influenza virus (S-OIV) because its RNA segments 
were most closely related to influenza viruses isolated from pigs in North America and 
Eurasia (Garten, Davis et al. 2009; Gibbs, Armstrong et al. 2009). Specifically, six of its 
genomic segments (PB2, PB1, PA, HA, NP, and NS) are most similar to those of triple-
reassortant (TR) influenza viruses currently circulating in North American pigs, whereas the 
NA and M gene segments are related to prevalent Eurasian H1N1 swine influenza strains. 
This particular gene constellation has never been described among swine or human influenza 
isolates from anywhere in the world and the precise evolutionary pathway in the genesis of 
the pandemic H1N1 is currently unknown (Dawood, Jain et al. 2009; Garten, Davis et al. 
2009; Gibbs, Armstrong et al. 2009; Smith, Vijaykrishna et al. 2009). Since 1998, the 
emergence of TR influenza viruses, which have their genes derived from human, swine and 
avian strains, have caused a dramatic change in the epidemiology of influenza in pigs in 
North America (Zhou, Senne et al. 1999; Karasin, Olsen et al. 2000; Karasin, Schutten et al. 
2000; Olsen 2002; Karasin, Carman et al. 2006; Olsen, Karasin et al. 2006). Prior to 1997-98, 
swine influenza in North America was caused almost exclusively by infection with classical 
H1N1 viruses, a derivate of the 1918 Spanish flu that was initially isolated from pigs in 1930 
(Shope 1931). Since their introduction in the late 90’s, TR swine influenza viruses have 
become endemic in North American swine. TR strains of the H3N2, H1N2, and H1N1 
subtypes predominate in the US swine population (Vincent, Ma et al. 2008). TR swine 
viruses have demonstrated remarkable reassortment ability with either classical swine H1N1 
and human H1N1 and H3N2 viruses, generating at least seven different reassortant lineages 
in the last decade (Karasin, Olsen et al. 2000; Karasin, Schutten et al. 2000; Richt, Lager et 
al. 2003; Webby, Rossow et al. 2004; Karasin, Carman et al. 2006; Lekcharoensuk, Lager et 
al. 2006; Ma, Gramer et al. 2006; Olsen, Karasin et al. 2006; Ma, Vincent et al. 2007). A 
unique feature shared by all of these novel reassortants is the maintenance of the so-called 




genes, the human-like PB1 gene and the classical swine NP, M and NS genes (Vincent, Ma et 
al. 2008; Ma, Lager et al. 2009). The TRIG cassette appears to accept multiple HA and NA 
types, which could provide a selective advantage to swine viruses possessing this internal 
gene constellation (Vincent, Ma et al. 2008; Ma, Lager et al. 2009). Although there have been 
sporadic human infections in the United States with the H1 TR swine influenza viruses, none 
of these events led to sustained human-to-human transmission, until the emergence of the 
H1N1pdm virus (Neumann, Noda et al. 2009; Shinde, Bridges et al. 2009; Vincent, Lager et 
al. 2010). Outbreaks of H1N1pdm in pigs in commercial swine operations have been reported 
in several countries, such as Canada, Argentina, Australia, Singapore, UK, Ireland, Norway, 
USA, Japan, and Iceland. In all incidents, epidemiological investigations have linked humans 
as the possible source of the infection to the pigs (Hofshagen, Gjerset et al. 2009; Howden, 
Brockhoff et al. 2009). Experimentally, it was established that the virus is pathogenic and 
transmits readily in pigs (Brookes, Irvine et al. 2009; Itoh, Shinya et al. 2009; Lange, 
Kalthoff et al. 2009; Weingartl, Albrecht et al. 2009; Vincent, Lager et al. 2010). It also 
induces clinical signs of disease and respiratory tract pathology similar to other influenza A 
viruses of swine (Brookes, Irvine et al. 2009; Itoh, Shinya et al. 2009; Lange, Kalthoff et al. 
2009; Weingartl, Albrecht et al. 2009; Vincent, Lager et al. 2010). The natural outbreaks of 
H1N1pdm and laboratory studies underscore the threat that the virus poses to the swine 
industry.  
 The rapid spread of the H1N1pdm virus around the globe and its ability to cross the 
species barrier highlight the need for developing effective control strategies. In this regard, 
the development of safe and potent vaccines that are effective in more than one animal 
species would be highly desirable. LAIVs closely mimic natural infection and have several 
advantages over inactivated vaccines. LAIVs trigger cell-mediated immunity and mucosal 
immune responses, thereby providing longer-lasting immunity and broader antigenic 
coverage than conventional inactivated vaccines (Cox, Brokstad et al. 2004; He, Holmes et al. 
2006; Horimoto and Kawaoka 2009). In the United States, a trivalent live attenuated 
influenza vaccine (FluMist®) containing two type A viruses (H1N1 and H3N2) and a type B 
virus has been licensed for use in humans since 2003 (Ambrose, Luke et al. 2008; Ambrose, 
Yi et al. 2008). Moreover, LAIV human influenza vaccines have been used for many years in 
Russia without the emergence of new influenza virus reassortants, thus demonstrating the 
stability of these attenuating phenotypes (Klimov, Egorov et al. 1995; Marsh, Watson et al. 
2003; Ambrose, Luke et al. 2008; Ambrose, Yi et al. 2008; Chen and Subbarao 2009). In 




Intervet) has been developed for horses and is available commercially in North America 
(Paillot, Hannant et al. 2006). Field experience with both the human and the equine influenza 
live vaccines have demonstrated the safety, effectiveness, and the genetic and phenotypic 
stability of these vaccine platforms (Chambers, Holland et al. 2001; Lunn, Hussey et al. 2001; 
Townsend, Penner et al. 2001; Paillot, Hannant et al. 2006; Belshe, Ambrose et al. 2008; 
Block, Yogev et al. 2008; Chen and Subbarao 2009; Rhorer, Ambrose et al. 2009; Talaat, 
Karron et al. 2009).  
 In swine medicine, however, temperature-sensitive LAIVs have not yet been 
developed, despite their demonstrated safety and efficacy for other animal vaccines. More 
recently, live attenuated vaccines based on deletions in the NS1 viral protein have been 
shown to provide protection in swine (Richt, Lekcharoensuk et al. 2006; Vincent, Ma et al. 
2007). Currently, commercially available swine influenza vaccines are based on inactivated 
whole virus preparations of the H1N1 and H3N2 subtypes. The use of vaccination has 
become a common practice to control swine influenza in the US. Nonetheless, these 
commercially available vaccines provide limited protection against the antigenically diverse 
influenza viruses that circulate in North American pigs, and consequently, forced swine 
producers to use autogenous inactivated vaccines with the hope of achieving better antigenic 
matching (Vincent, Lager et al. 2007). However, it is important to note that the use of 
inactivated vaccines has been associated with enhanced pneumonia when immunized pigs 
were challenged with divergent viruses (Vincent, Lager et al. 2007). Thus, the development 
of LAIV swine influenza vaccines has the potential to circumvent the drawbacks associated 
with commercial vaccines and improve both the homotypic and heterosubtypic protection in 
pigs against this important swine pathogen. Furthermore, the testing of newly developed 
LAIV influenza vaccines in swine offers the possibility of translating the findings to human 
medicine, given the similarity of influenza clinical signs, pathology and distribution of sialic 
acid receptors between the two species (Barnard 2009; Nelli, Kuchipudi et al. 2010). 
 With the aim of developing LAIV temperature-sensitive influenza vaccines against 
the H1N1pdm virus, we have used reverse genetics to introduce attenuation markers in the 
polymerase genes of a swine-like TR H3N2 influenza virus, A/turkey/Ohio/313053/04 
(H3N2) (ty/04) (Tang, Lee et al. 2005). We chose this isolate because it grows well in both 
eggs and cell culture-based substrates, displays a broad host range and has internal genes 
similar to the H1N1pdm virus. These features highlight the potential of this backbone to 
induce strong immune responses in multiple animal species and possible cross-protection to 




att) had impaired polymerase activity and viral growth at elevated temperatures. In vivo 
characterization in mice of two H1N1 vaccine candidates generated using this backbone 
demonstrated that this vaccine is attenuated as indicated by the absence of any signs of 
disease upon vaccination, absent or limited replication in the respiratory tract, and minimum 
histopathological alterations in the lungs. More importantly, a single low dose of the H1N1 
ty/04 att-based vaccines provided complete protection against a lethal H1N1pdm challenge in 
mice. Subsequently, we chose one of the ty/04 att-H1N1 vaccine candidates for further 
testing in swine and found that the vaccine was safe and conferred sterilizing immunity upon 
an aggressive intratracheal challenge of pigs with the 2009 H1N1 pandemic virus. Thus, 
introduction of genetic signatures for att in the backbone of a swine-like TR influenza virus 
resulted in highly attenuated and efficacious live influenza vaccines with promising 






6.3. Material and Methods 
6.3.1. Ethics Statement 
 Animal studies were conducted under ABSL-3 conditions approved by USDA 
and performed according to protocols R-09-93 "Transmissibility of Influenza A Viruses", R-
08-16 Transmissibility of Influenza A Viruses in Swine", R-09-55 "Evaluation of attenuation 
and protection efficiency of live attenuated influenza vaccines", and R-09-68 "Evaluation of 
the pathogenesis of swine-like human H1N1 and live attenuated vaccines in a mouse model" 
approved by the Institutional Animal Care and Use Committee of the University of Maryland. 
In addition, swine studies were performed under Animal Care and Use Protocol 3950 
"Influenza A virus pathogenesis and host response in swine" approved by the USDA-ARS 
Animal Care and Use Committee, Ames, Iowa. Animal studies adhere strictly to the US 
Animal Welfare Act (AWA) laws and regulations. 
6.3.2. Cell lines and virus strains 
             Human embryonic kidney cells (293-T) were cultured in OptiMEM I (GIBCO, Grand 
Island, NY) containing 5% FBS and antibiotics. Madin-Darby canine kidney (MDCK) cells 
were maintained in modified Eagle's medium (MEM) (Sigma-Aldrich, St. Louis, MO) 
supplemented with 5% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO) and 
antibiotics.  A/turkey/Ohio/313053/04 (H3N2) (ty/04) has been previously described and it 
was kindly provided by Yehia Saif, Ohio State University, Wooster, OH) (Tang, Lee et al. 
2005). A/California/04/09 (H1N1) (Ca/04) was kindly provided by the Centers for Disease 
Control and Prevention (CDC), Atlanta, Georgia. The lethal mouse-adapted Ca/04 (ma-
Ca/04) was generated in our laboratory by adapting the wild type Ca/04 in both DBA/2 and 
BALB/c mice through two serial lung passages (Ye, Sorrell et al. 2010). Recombinant viruses 
used in this paper were generated from cloned cDNAs and are described below and in Table 
6.1. All experiments using the pandemic H1N1 or its wild type reassortants were performed 







Table 6.1.  Influenza viruses used in this study.  
 
Viruses Acronym in main text 
A/California/04/09 (H1N1) a Ca/04 
mouse-adapted A/California/04/09 (H1N1) ma-Ca/04 
A/turkey/Ohio/313053/04 (H3N2) c ty/04 WT 
Reverse genetics A/turkey/Ohio/313053/04 (H3N2) d ty/04 RG 
A/turkey/Ohio/313053/04 (H3N2) att  e OH 2:6 ty/04 att 
Surface genes from A/New York/18/09 (H1N1) in ty/04 att backbone f NY 2:6 ty/04 att  
Surface genes from A/Netherlands/602/09 (H1N1) in ty/04 att backbone g NL 2:6 ty/04 att   
Surface genes from A/Netherlands/602/09 (H1N1) in ty/04 WT backbone h NL 2:6 ty/04 WT  
A/Netherlands/602/09 (H1N1) NL WT 
 
a  Genbank taxonomy ID2:641501 
b  Mouse-adapted A/California/04/09 (H1N1) that is lethal for BALB/c mice. 
c  Genbank taxonomy ID: 533026 
d  A/turkey/Ohio/313053/04 (H3N2) entirely generated from cloned cDNA. 
e  A/turkey/Ohio/313053/04 (H3N2) carrying temperature sensitive mutations in both PB2 and PB1 and 
an HA tag in the carboxyl-terminus of  PB1 
f   2:6 reassortant containing the surface genes of A/New York/18/09 (H1N1) (genbank taxonomy 
ID2:643545) and the internal genes from the attenuated ty/04 att. 
g  2:6 reassortant containing the surface genes of A/Netherlands/602/09 (H1N1) (genbank taxonomy 
ID2:643212) and the internal genes from the attenuated ty/04 att. 
h  2:6 reassortant containing the surface genes of A/Netherlands/602/09 (H1N1) (genbank taxonomy 
ID2:643212) and the internal genes from unmodified  ty/04 WT. 






6.3.3. Generation of recombinant viruses 
The A/turkey/Ohio/313053/04 (H3N2) (ty/04) strain was generated by reverse 
genetics (RG) using a previously described method (Hoffmann, Neumann et al. 2000). 
Briefly, viral RNA was extracted from stock virus using the RNeasy kit (Qiagen, Valencia, 
CA, USA) according to manufacturer's instructions. Reverse transcription was carried out 
with the uni-12 primer (5′-AGCAAAAGCAAAGG-3′) and AMV reverse transcriptase 
(Promega, Madison, WI, USA) and the viral genes were PCR amplified using a set of 
universal primers (Hoffmann, Stech et al. 2001). Purified PCR products were digested with 
either BsaI or BsmBI and cloned into the pDP2002 vector, which is derived from the pHW-
2000 vector (26) in which a spacer sequence of 444 base pairs was cloned between the two 
BsmBI sites to allow visual monitoring of vector digestion efficiency through agarose gel 
electrophoresis.The resulting clones were fully sequenced and compared to the WT viral 
consensus sequence. Primer sequences are available upon request. The entire plasmid set for 
the A/Netherlands/602/09 (H1N1) (NL WT) was kindly provided by Ron A. Fouchier, 
Erasmus Medical Center, Rotterdam, The Netherlands, whereas the HA and the NA RG 
plasmids for the A/New York/18/09 (H1N1) (NY) were kindly provided by Ruben Donis, 
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA.  
 The genetic signatures for attenuation of an avian influenza virus were previously 
described (Song, Nieto et al. 2007). Here, the same modifications were introduced into the 
PB2 and PB1 genes of ty/04. Briefly, the ts mutations in PB1 and PB2 were introduced by 
site-directed mutagenesis using a commercially available kit (Stratagene, La Jolla, CA), 
whereas the HA tag epitope was introduced by subcloning this sequence from the WF10 att 
(Song, Nieto et al. 2007) into the PB1 gene of ty/04 to generate ty/04 att. The recombinant 
WT viruses as well as the 2:6 surface gene reassortants were generated by transfecting the 
RG plasmids into co-cultured 293T and MDCK cells as previously reported (Hoffmann, 
Neumann et al. 2000). NL 2:6 ty/04 WT is a 2:6 reassortant with the surface genes from the 
NL virus and the internal genes from ty/04 wild type virus. NY 2:6 ty/04 att and NL 2:6 ty/04 
att are surface gene reassortants between the NY and NL viruses, respectively and the ty/04 






6.3.4. Viral ribonucleoprotein (vRNP) reconstitution assay to study polymerase 
activity 
A model viral RNA (vRNA), consisting of the Gaussia Luciferase (GLuc) open 
reading frame flanked by the non-coding regions of the influenza NS segment (pGLuc-NS) 
was used to assess polymerase activity in a minigenome reconstitution assay (Fig. 1A). 
Briefly, 293T cells were seeded in 6-well plates and transfected with 1 µg of the reporter 
plasmid along with 1 µg of each of the pDP2002 plasmids encoding PB2, PB1, PA and NP 
using the TransIT-LT1 (Mirus, Madison, WI) reagent following the recommendations of the 
manufacturer. In addition, the pCMV/SEAP plasmid, which encodes a secreted alkaline 
phosphatase gene, was cotransfected into the cells to normalize the transfection efficiency. At 
the indicated time points, supernatant from transfected cells were harvested and assayed for 
both luciferase and secreted alkaline phosphatase activities using the BioLux™ Gaussia 
Luciferase Assay Kit (NEB, Ipswich, MA) and the Phospha-Light™ Secreted Alkaline 
Phosphatase Reporter Gene Assay System (A&D, Foster City, CA) according to the 
manufacturers’ protocol. Relative polymerase activity was calculated as the ratio of luciferase 
and SEAP luminescence for three independent experiments. 
6.3.5. Replication of recombinant viruses at different temperatures 
The temperature sensitive (ts) phenotypes of wt and att viruses were evaluated by 
titrating the stock viruses at 33, 35, 37, 39, and 41°C by the TCID50 method in MDCK cells as 
previously described (Jin, Lu et al. 2003; Joseph, McAuliffe et al. 2008; Chen, Santos et al. 
2009). Replicates of 10 wells were used for each dilution. Cells were incubated at the 
respective temperatures for 3 days and the presence of virus in each well was determined by 
HA assay. The ts phenotype of a virus was defined by a 2 log10 reduction in titer at 39°C 










6.3.6. Immunization and challenge studies in mice 
Seven-week-old female BALB/c mice (Charles River Laboratories, Frederick, MD) 
were anaesthetized with isofluorane prior to intranasal inoculation. Mice were inoculated 
with 50 µl 105 tissue culture infectious dose 50 (TCID50) of the recombinant viruses in 
PBS/mouse. Each experimental group contained 10 animals. Group 1 received PBS alone as a 
vaccine negative control. Groups 2, 3, 4 and 5 were inoculated with NY 2:6 ty/04 att ; NL 2:6 
ty/04 att; NL 2:6 ty/04 WT; and NL WT, respectively. Groups 4 and 5 served as positive 
controls for the vaccine and as a reference to evaluate the attenuation of the ty/04 att-based 
vaccines. Mice were bled using the submandibular bleeding method (Golde, Gollobin et al. 
2005) prior to inoculation and at days 7, 21, 28 and 42 after immunization.  At 3 days post-
inoculation (dpi), 3 animals from each group were humanely euthanized and tissues were 
harvested for virus titration and histopathologic evaluation. 
 Mice (n=7) were challenged at 21 dpi with 20 mouse lethal dose 50 (MLD50) of the 
lethal ma-Ca/04 by the intranasal route. At 5 days post challenge (5 dpc), 3 mice from each 
group were euthanized and their lungs collected for histopathologic analysis and to measure 
levels of challenge virus. Tissue homogenates were prepared in PBS, clarified by 
centrifugation, and stored at -70ºC until use. Clinical signs of disease, body weight, and 
mortality were monitored daily in the remaining mice.  
6.3.7. Attenuation phenotype and efficacy of ty/04 att-based vaccines in swine 
Swine studies were conducted in the high-containment facilities of the National 
Animal Disease Center (NADC), Ames, IA following protocols approved by the NADC and 
University of Maryland Animal Care and Use Committees. In both studies, three-week old 
cross bred pigs were obtained from a high-health herd free of SIV and porcine reproductive 
and respiratory syndrome virus. All pigs were treated with ceftiofur crystalline free acid 
(Pfizer Animal Health, New York, NY) to reduce bacterial contaminants prior to the start of 
the experiment. Animals that received the inactivated Ca/04 vaccine were housed under 
biosafety level 2 (ABSL2) conditions and those that received the NY 2:6 ty/04 att vaccine or 





6.3.8. Safety of ty/04 att-based vaccines in pigs 
25 pigs were randomly divided into five treatment groups (n=5) and housed in 
separate isolation rooms. To further evaluate the safety of the ty/04 att backbone in swine, 
groups of pigs were intranasally inoculated with 105 TCID50/animal of either OH 2:6ty/04 att 
(a virus that carries the surface genes of ty/04 WT and ty/04 att internal genes) or with NY 
2:6ty/04 att vaccines diluted in 2ml of MEM. Two other groups were similarly inoculated 
with ty/04 WT and ty/04 RG and served as controls for comparing the attenuation phenotype 
of the modified ty/04 att backbone, whereas a fifth group was mock-vaccinated with PBS 
alone. Clinical observations and rectal temperatures were recorded individually on day −2 
through day 0 in order to establish normal baseline values for each animal. Nasal swabs were 
collected before vaccination and daily during three days as previously described (Vincent, 
Ciacci-Zanella et al. 2010; Vincent, Lager et al. 2010). Following inoculation, rectal 
temperature and clinical signs of disease were monitored daily until the terminus of the 
experiment (3 dpi) when the animals were humanely euthanized and necropsy was 
performed.  
6.3.9. Efficacy of H1N1 ty/04 att vaccine in pigs 
40 pigs were randomly divided in four groups of ten pigs each (Table 4). Group 1 
was vaccinated with 105 TCID50/animal of NY 2:6 ty/04 att through intranasal route whereas 
group 2 was vaccinated intramuscularly with 2 ml of an adjuvanted UV-inactivated Ca/04 
vaccine (UVadj-Ca/04) as previously described (Vincent, Ciacci-Zanella et al. 2010). Briefly, 
the inactivated experimental vaccine was prepared from the WT Ca/04 at 8 HA units per 50 
µL (or 105 TCID50/ml) with inactivation by ultraviolet irradiation and addition of a 
commercial adjuvant (Emulsigen D, MVP Labs) at a v:v ratio of 4:1 virus to adjuvant. Group 
3, non-vaccinated and challenged (NV+Ca/04), and group 4, non-vaccinated, mock-
challenged (NV+Mock), were also included in the vaccine trial. At two-weeks after primary 
immunization, pigs were boosted using the same vaccines, dose and route as described for 
primary vaccination. Fourteen days post boost (dpb), pigs from groups 1-3 were challenged 
intratracheally with 2 ml of 1×105 TCID50 of Ca/04 as previously described (Vincent, Ciacci-
Zanella et al. 2010). Following challenge, pigs were monitored daily for hyperthermia and 




necropsied. Virus shedding in nasal secretions was measured at 3 and 5 dpc. Blood samples 
were collected at day -3 (pre-bleed), at 14 dpv, at 0 dpc and 5 dpc for analysis of the humoral 
antibody response against Ca/04. 
6.3.9. Pathologic examination of swine lungs after vaccination and challenge 
At necropsy, lungs were removed in toto and evaluated to determine the percentage 
of the lung affected with purple–red, consolidated lesions that are typical of influenza virus 
infection in pigs. The percentage of the lung affected with pneumonia was visually estimated 
for each lobe, and a total percentage for the entire lung was calculated based on weighted 
proportions of each lobe to the total lung volume as previously described (Halbur, Paul et al. 
1995). Each lung was then lavaged with 50 ml MEM to obtain bronchoalveolar lavage fluid 
(BALF). Tissue samples from the trachea and right cardiac lung lobe and other affected lobes 
were taken for histopathologic examination. Lung sections were given a score from 0 to 3 to 
reflect the severity of bronchial epithelial injury using previously described methods (Richt, 
Lager et al. 2003). 
6.3.10. Hemaglutination inhibiton (HI) assay 
Serum samples were treated with receptor-destroying enzyme (Accurate Chemical 
and Scientific Corp., Westbury, NY) to remove nonspecific inhibitors and the anti-viral 
antibody titers were evaluated using the HI assay method outlined by the WHO Animal 
Influenza Training Manual (WHO/CDS/CSR/NCS/2002.5). HI assays were performed using 
turkey red blood cells (RBC) and NY 2:6 ty/04 att and the wild type Ca/04 as the HI antigens. 
Log2 transformations were analyzed and reported as geometric mean of titers (GMT). 
6.3.11. Quantification of antibody isotypes in porcine BALF samples 
The presence of Ca/04-specific IgG and IgA antibodies in porcine BALF was 
detected by ELISA assays as previously described (Vincent, Ciacci-Zanella et al. 2010). 
Briefly, concentrated Ca/04 virus was resuspended in Tris–EDTA basic buffer, pH 7.8, and 
diluted to an HA concentration of 100 HA units/50 µl. Immulon-2HB 96-well plates (Dynex, 
Chantilly, VA) were coated with 100 µl of antigen solution and incubated at room 
temperature overnight. Plates were blocked for 1 h with 100 µl of 10% BSA in PBS and 
washed three times with 0.05% Tween 20 in PBS prior to addition of test BALF. The assays 
were performed on each BALF sample in triplicate. Antibody levels are reported as mean 




triplicate sample of each animal. Peroxidase-labeled goat anti-swine IgA (Bethyl, 
Montgomery, TX) or IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD) were used as 
secondary antibodies. Secondary antibodies were peroxidase-labeled goat anti-swine IgA 
(Bethyl, Montgomery, TX) or IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD) 
Secondary antibodies were peroxidase-labeled goat anti-swine IgA (Bethyl, Montgomery, 
TX) or IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD). 
6.3.12. Titration of virus stocks and virus present in biological samples 
Viral stocks and virus present in animal samples (clarified tissue homogenates, nasal 
swabs or BALF) were titrated on MDCK cells and the TCID50/ml was determined by the 
method of Reed and Muench (Reed and Muench 1938). Briefly, samples were serially diluted 
10-fold in serum-free media containing antibiotics and 1 µg/ml TPCK-trypsin (SIGMA, Saint 
Louis, MO). Next, 100 or 200 µl of the inoculum was overlaid onto confluent monolayers of 
MDCK cells seeded in 96-well plates. The cells with sample were incubated for 3 days and 
the endpoint viral titer was determined by an HA assay or immunostaining with an anti-
influenza A nucleoprotein monoclonal antibody as previously described (Vincent, Ciacci-
Zanella et al. 2010). 
6.3.13. Histopathology 
Lung and trachea samples were fixed in 10% buffered formalin and embedded in 
paraffin following standard histopathologic procedures. Sections of 5-µm thickness were cut 
from the lung and stained with hematoxylin and eosin (H&E). The degree of microscopic 
lesions was determined and representative pictures were taken from each slide.  
6.3.14. Statistical analysis 
All statistical analyses were performed using GraphPad Prism Software Version 5.00 
(GraphPad Software Inc., San Diego, CA). Comparison between two treatment means was 
achieved using a two-tailed Student t-test, whereas multiple comparisons were carried out by 
analysis of variance (ANOVA) using Tukey’s post hoc test, unless otherwise specified. 
Correlations were determined with bivariate correlations procedures (Pearson’s correlation 







6.4.1. Swine-like TR influenza att backbone has impaired polymerase activity at 
elevated temperatures 
The molecular features that control the ts phenotype of the master donor virus 
(MDV) A/Ann Arbor/6/60 (H2N2) have been mapped to five mutations distributed in the 
PB2 (N265S), PB1 (K391E, E581G and A661T), and NP (D34G) segments (Jin, Lu et al. 
2003). In previous studies, we showed that these genetic signatures can be transferred to an 
H9N2 avian influenza virus and impart the same ts phenotype. However, the ts avian 
influenza virus was not sufficiently attenuated in chickens, which raised potential safety 
concerns (Song, Nieto et al. 2007). Thus, an additional genetic modification, an HA tag 
epitope in the C-terminus of the PB1 gene was introduced to enhance the ts phenotype in 
vitro and the att phenotype in birds and mammals (Song, Nieto et al. 2007; Hickman, Hossain 
et al. 2008). Moreover, viruses carrying the ts loci along with the HA tag, herein named as 
att, were both genetically and phenotypically stable, a critical feature in the development of 
live att influenza vaccines. 
 In this study, we wanted to ascertain whether our dual attenuation approach could be 
introduced into the swine-like TR genetic backbone of A/turkey/Ohio/313053/04 (H3N2) 
(ty/04) strain. The ty/04 strain is an ideal candidate for an att vaccine backbone because the 
virus has been shown to replicate in several animal species such as chickens, turkeys and 
swine (Yassine, Al-Natour et al. 2007). We altered the PB2 and PB1 genes of ty/04 by 
incorporating ts mutations in both genes and also incorporated the HA tag into PB1 (Fig.6.1A 
and B). Additionally, the WT ty/04 PB1 contains aspartic acid at position 581, in contrast to 
the WT PB1 of A/Ann Arbor/6/60, which encodes glutamic acid. 
 The ts effect of mutations in the polymerase complex of ty/04 was analyzed at 
different temperatures, using a viral ribonucleoprotein (vRNP) reconstitution assay as 
previously described (Fig.6.1A). 293-T cells were co-transfected with plasmids encoding the 
ty/04 PB2, PB1, PA, and NP genes and the influenza replicon carrying a secreted luciferase 
(GLuc). Transfection efficiency was normalized using a plasmid encoding the secreted 
alkaline phosphatase (SEAP) gene. The extent of influenza polymerase activity is expressed 




temperatures (33, 35, 37, 39, and 41°C) and the supernatants were harvested 24 hours post-
transfection for quantification of reporter gene expression. Introduction of ts and att 
mutations in the PB2 and PB1 genes of ty/04 led to significantly lower polymerase activities 
than that of WT genes at non-permissive temperatures (Fig.6.1C). In addition, the 
temperature in which the different backbones reached maximal polymerase activity, as 
indicated by luciferase activity also differed among the different constructs. The highest 
polymerase activity of the ty/04 att was detected at 35°C, whereas the peak for the ty/04 WT 
was at 39°C and the ts was between 35-37°C (Fig.6.1C). More importantly, introduction of 
the HA epitope in PB1 had a combined deleterious effect in combination with the four ts 
mutations in PB1 and PB2 since the att backbone had the most marked reduction in 
polymerase activity at temperatures above 37°C. Taken together, these results indicate that 
the ts phenotype displayed by the modified human and avian influenza strains can be 
transferred to a swine-like TR backbone and that inclusion of an HA epitope in PB1 enhances 







Figure 6.1.Viral ribonucleoprotein reconstitution assay to study the polymerase 
activities of ty/04 WT and its mutants. (A) 293-T cells were transfected with plasmids 
encoding the minimal components required for viral transcription and replication (the PB1, 
PB2, and PA polymerase subunits, NP, and a vRNA influenza virus-driven luciferase reporter 
replicon). The influenza virus reporter plasmid contains the open reading frame of Gaussia 
luciferase (GLuc) flanked by the 5' and 3' untranslated regions (UTR) of the influenza virus 
NS segment. This cassette was inserted between the human polymerase I promoter (Pol I) and 
terminator (tI) sequences. The presence of luciferase protein in the supernatant is measured 
by a luciferase assay. (B) Schematic representation of the ty/04 PB2 and PB1 constructs for 
the generation of ts and att mutant viruses. Site-directed mutagenesis was used to introduce 1 
temperature-sensitive (ts) mutation into the PB2 gene (N265S) and 3 ts mutations into the 
PB1 gene (K391E, D581G, and A661T) of A/turkey/Ohio/313053/04 (H3N2) to generate 
ty/04 ts. The PB1 gene was further modified by incorporating an HA tag into the carboxy 
terminus of PB1 to generate ty/04 att. (C) Polymerase activities of WT ty/04 and its mutants 
at different temperatures. 293-T cells were transfected with 1 µg each of the influenza virus-
driven luciferase reporter plasmid and the PB2, PB1, PA, and NP plasmids and were 
incubated at different temperatures as shown. pCMV/SEAP, which encodes secreted alkaline 




posttransfection, the supernatant was harvested and assayed for both luciferase and 
phosphatase activities. Normalized polymerase activities (means ± standard errors) were 
determined from three independent experiments. 
 
 
6.4.2. Genetically modified ty/04 att vaccines display restricted growth at non-permissive 
temperatures 
In order to study the effects of the att mutations in the context of the viral life cycle, 
we compared the replication of WT and att H1N1pdm viruses in MDCK cells at different 
temperatures. Four different 2:6 reassortant viruses were tested: NY 2:6 ty/04 att, NL 2:6 
ty/04 att, NL 2:6 ty/04 WT, and NL WT (Table 2). The NL 2:6 ty/04 WT and NL WT viruses 
replicated equally well at temperatures ranging from 33° to 39°C (Table 6.2). In agreement 
with the minigenome assay, the two H1N1 ty/04 att viruses had at least a 100-fold reduction 
in virus titers at 39°C compared to 33°C, confirming the ts phenotype of this genetically 
modified vaccine backbone. In addition, the ty/04 att viruses were unable to replicate at 41°C 
in contrast to the NL 2:6 ty/04 WT, and NL WT which showed significant growth at 41ºC 
(about 4-5 log10 lower than at 33ºC). Thus, the two H1N1 ty/04 att-vaccines displayed the 
expected ts phenotypes in a canine cell line. 
 
Table 6.2. Replication of recombinant viruses at different temperatures. 
 
MDCK cells were inoculated with WT or att viruses and incubated for 3 days at increasing 
temperatures (33, 35, 37, 39, and 41°C). The presence of the virus in each well was detected by an HA 
assay and the log10 titer was determined by TCID50. Shown are representative data of two 
independent experiments.  Values in bold indicate that the virus is temperature sensitive (100-fold 
Viruses 33°C 35°C 37°C 39°C 41°C 
 


















































reduction in virus titer at 39°C as compared to 33°C). BLD: below the detection limit (0.6 log10 
TCID50/ml).  
6.4.3. Genetically modified ty/04 att vaccines are attenuated in mice 
To evaluate whether the reduction in polymerase activity and virus replication at non-
permissive temperatures by the ty/04 att-based viruses would translate into an attenuated 
phenotype in vivo, we assessed weight loss, the levels of viral replication in the respiratory 
tract and the extent of pulmonary pathology in BALB/c mice inoculated with these viruses. 
Groups of ten mice were inoculated with 105 TCID50 of the recombinant viruses (Fig 6.2) 
through the intranasal route. At 3 dpi, 3 animals from each group were humanely euthanized 
and organs were collected for virus titration and histopathology. Body weight changes during 
12 dpi were monitored daily as a parameter of influenza morbidity. The 2 ty/04 att vaccines 
were highly attenuated in mice as demonstrated by the absence of clinical disease signs and 
no changes in body weight. Conversely, mice inoculated with the WT ty/04 backbone (NL 
2:6 ty/04 WT) showed significant body weight loss (≤20%) by 7 dpi, although they 
eventually recovered. As expected, noticeable reduction in body weight was also observed 
when mice received the NL WT, and recovery was slightly delayed in comparison to the NL 
2:6 ty/04 WT group (Fig.2 A). In examining tissue tropism and viral replication, the NY 2:6 
ty/04 att virus was not detected in any of the organs sampled (nasal cavity, trachea, and 
lungs). Lung sections from the NY 2:6 ty/04 att group were indistinguishable from the mock-
inoculated controls at the microscopic level, corroborating that the ty/04 att LAIV is highly 
attenuated (Fig. 6.2C, D). Although mice inoculated with NL 2:6 ty/04 att showed no signs of 
disease upon vaccination, there was limited viral replication in the lower respiratory tract of 
these animals. However, replication in the trachea was detected only in a single individual 
(17 TCID50/g of tissue) and the titers in the lungs were significantly lower than from those 
obtained in the NL 2:6 ty/04 WT group (Fig. 6.2B). Only mild histopathological alterations 
were detected in the lungs of a single mouse inoculated with the NL 2:6 ty/04 att virus, 
suggesting that pulmonary replication of this att vaccine virus does not lead to significant 
pathological damage in the lungs (Fig 6.2B, E). In contrast, mice inoculated with NL 2:6 
ty/04 WT had high viral replication (104 to 106 TCID50) in the entire respiratory tract and 
moderate histopathological alterations in the lungs characterized by necrotizing bronchitis, 
bronchiolitis and varying degrees of hemorrhage (Fig. 6.2B, F). Infection with NL WT 
resulted in 10 to 100-fold higher viral titers in the respiratory tract (105 to 107 TCID50) 




group showed more severe pathology in the lungs as compared to NL 2:6 ty/04 WT (Fig. 
6.2G), suggesting that the internal genes from the H1N1pdm are more virulent in mice than 
the internal genes from the North American TR viruses. Together, the double attenuation 
strategy resulted in a swine-like TR backbone that displayed desirable safety properties in the 






Figure 6.2.Safety of ty/04 att H1N1 vaccines in BALB/c mice. Groups of 10 mice each 
were inoculated intranasally with 105 TCID50s of the recombinant virus. One group received 
PBS and served as a vaccine negative control. (A) Percentage of change in body weight as a 
measure of morbidity following intranasal inoculation of mice with either a ty/04 WT or a 
ty/04 att virus. Mice were weighed daily for 12 days. (B) Replication and tissue tropism of 
WT and att H1N1 viruses in the respiratory tracts of mice. At 3 dpi, three animals from each 
group were euthanized, and virus titers in the respiratory tract were determined by standard 
TCID50 in MDCK cells. Log10 titers for each group are plotted as means ± standard errors. *, 
P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant. (C, D, E, F, and G) Lung 
histopathology of mice inoculated with ty/04 WT or ty/04 att viruses at 3 dpi. A 
representative image from each treatment group is shown. (C) Lung of a control mouse 
showing normal bronchiole and alveoli. (D and E) Lungs from animals inoculated with NY 
2:6 ty/04 att or NL 2:6 ty/04 att, respectively, are indistinguishable from those of mock-
infected animals. (F) Lung of a mouse infected with the NL 2:6 ty/04 WT virus, showing 
moderate histopathological lesions, including necrotizing bronchiolitis, the presence of cell 
debris, and various degrees of hemorrhage. (G) Lung of a mouse infected with NL WT, 
displaying more-severe histopathology characterized by necrotizing bronchiolitis, the 
presence of cell debris and inflammatory infiltrates, hyperemia, and hemorrhage. 
 
6.4.4. The ty/04 att-based vaccines are attenuated in swine 
In order to further evaluate the safety of the ty/04 att vaccine backbone, groups of 
pigs (n=5) were inoculated intranasally with ty/04 att vaccines containing either H1N1 or 
H3N2 surfaces. The H1N1 surface genes were derived from the A/New York/18/09 (H1N1), 
whereas the H3N2 genes were from the A/turkey/Ohio/313053/04 (H3N2) isolate (Table 6.1). 
Ty/04 WT and ty/04 RG viruses were included as non-attenuated virus controls. Clinical 
signs of disease and rectal temperatures were monitored and nasal swabs were collected daily 
to quantify virus shedding in nasal secretions. At 3 dpi, pigs were euthanized, the degree of 
lung pathology was determined and the presence of virus in BALF samples titrated. Pigs 
inoculated with non-attenuated ty/04 viruses developed a febrile response (> 40° C) that 
peaked 24 hpi (Fig. 6.3A) and shed large amounts of virus (3-5 log10 TCID50/ml) in nasal 
secretions (Fig. 6.3B). Similarly, viral titers in BALF collected at 3 dpi ranged from 105 to 
106 TCID50/ml (Fig. 6.3C). At necropsy, the lungs from animals inoculated with these viruses 
had up to 15% of the total lung area (mean % pneumonia of 7.5 and 7.4 for ty/04 WT and 
ty/04 RG, respectively) displaying pneumonic lesions typical of influenza infection in pigs 
(Fig. 6.3D). In general, the gross lesions were marked, plum-colored consolidated areas 
located mainly in the cranioventral lobes of the lung. Microscopically, lesions in lungs were 
typical of influenza virus infection in pigs and were characterized by multifocal to 




cuffing, and mild multifocal interstitial pneumonia and varying degrees of alveolar 
involvement (Fig. 6.3E). Clinical signs of disease, lung pathology and viral replication in 
biological samples were indistinguishable between the Ty/04 WT and RG viruses, confirming 
that the ty/04 generated through RG displays a phenotype identical to WT virus. In contrast, 
none of the animals inoculated with H3N2 or H1N1 ty/04 att viruses developed fever, cough 
or other clinical signs following vaccination, indicating that the ty/04 att viruses were safe for 
administration to pigs (Fig. 6.3A). Correspondingly, there was 100-1,000 fold less virus 
shedding from the nose of pigs vaccinated with ty/04 att viruses as compared to unmodified 
ty/04 viruses. In general, NY 2:6 ty/04 att–vaccinated pigs shed less virus than H3N2:6 ty/04 
att inoculated pigs (Fig. 6.3B). In addition, viral titers in BALF were significantly reduced 
(p< 0.01) in ty/04 att-vaccinated pigs as compared to ty/04 WT-infected pigs (Fig. 6.3C). 
Although both vaccines caused mild gross and microscopic lesions in the lungs, the 
percentage of lung involvement was not significantly different from mock-vaccinated pigs 
(p> 0.05, Dunnett’s test), corroborating the clinical findings that these vaccines are 
sufficiently attenuated in pigs (Fig. 6.3D, E). Histopathologically, nasal turbinates and 
trachea obtained from pigs immunized with either vaccine were similar to control animals, as 
opposed to the WT-inoculated pigs (Fig. 6.3E). Thus, modified ty/04 viruses displayed att 



















































Figure 6.3. Attenuation phenotype of H1N1 and H3N2 ty/04 att viruses in swine. Groups 
of pigs (n=5) were randomly divided into five treatment groups and inoculated intranasally 
with 105 TCID50/animal of either H3N2:6ty/04 att or with NY 2:6 ty/04 att vaccines diluted 
in 2 ml of MEM. Two other groups were similarly inoculated with either ty/04 WT or with a 
WT virus generated from plasmid DNA (ty/04 RG) to compare the attenuation phenotype of 
the modified ty/04 att backbone. A fifth group was mock vaccinated with PBS alone (Mock). 
Nasal swabs and rectal temperature readings were taken daily. At 3 dpi, all animals were 
euthanized to measure viral replication and lung pathology. (A) Daily mean rectal 
temperatures of pigs following inoculation with WT or ty/04 att viruses. (B) Viral shedding 
in nasal secretions of pigs. (C) Viral titers in bronchoalveolar lavage fluid (BALF) collected 
at necropsy.  Viral titers in nasal swabs and BALF were determined by TCID50 on MDCK 
cells. Values are shown as the mean ± SEM. * p< 0.05 ; ** p< 0.01; *** p< 0.001 as 
compared to ty/04 WT control by Dunnett’s test. (D) Percentage of macroscopic lung lesions 
and (E) Histopathologic scores of nasal turbinates, trachea and lungs of swine inoculated with 
WT or ty/04 att viruses at 3 dpi. Lesions were compared to sham inoculated group by 








6.4.5. Vaccination with H1N1 ty/04 att-based vaccines confers complete protection in mice 
against a lethal H1N1pdm challenge 
Recent pathology studies have shown that H1N1pdm infections can lead to fatal viral 
pneumonia in a small percentage of cases (Perez-Padilla, de la Rosa-Zamboni et al. 2009; 
Soto-Abraham, Soriano-Rosas et al. 2009; Gill, Sheng et al. 2010). Thus, we have developed 
a lethal mouse model of H1N1pdm (Ye, Sorrell et al. 2010) that recapitulates the severe viral 
pneumonia induced by the novel H1N1 in human patients. Hence, we used this lethal model 
of H1N1 severe pneumonia to test whether the ty/04 att vaccines can induce protective 
immunity against lethal H1N1pdm infection. To determine the robustness of protection 
induced by the two H1N1 ty/04 att vaccines, mice were intranasally challenged with 20 
MLD50 of the lethal mouse-adapted Ca/04 at 21 dpv. Groups of mice immunized with WT 
H1N1 viruses (NL WT and NL 2:6 ty/04 WT) were also included as a positive control for the 
vaccine. Again, body weights were measured prior to challenge infection and daily after 
challenge. At 5 dpc, the lungs from three animals of each group were collected for 
histopathology and virus titration. All the H1N1 ty/04 att-vaccinated animals were 
completely protected against the lethal ma-Ca/04 infection as demonstrated by the absence of 
clinical signs of disease and no changes in body weight after challenge (Fig. 4A, B). More 
importantly, mice vaccinated with NL 2:6 ty/04 att had neither lung pathology nor detectable 
replication of the challenge virus (Fig. 6.4A, B, C, D). The group that received the NY 2:6 
ty/04 att vaccine showed a significant reduction in the level of challenge virus isolated from 
lungs by 5 dpc in contrast to the mock-vaccinated mice (Fig. 6.4C). Additionally, pulmonary 
histopathology was detected only in one individual in this group, which agreed with the 
clinical findings (Fig 4E). As expected, the groups that were immunized with the WT H1N1 
viruses were completely protected from challenge (Fig 6.4A, B, C) and had neither viral 
replication nor pathological alterations in the lungs (Fig. 6.4F, G). In contrast, all 
unvaccinated control mice developed severe signs of disease such as lethargy, rough coat, 
dehydration, and up to 25 % of body weight loss. The control mice died within 5-6 dpc (Fig. 
6.4A, B). Examination of the lungs of the mock-immunized group revealed severe pneumonia 
characterized by extensive hemorrhagic lesions, necrotizing bronchitis and bronchiolitis, 
interstitial edema, and the presence of cell debris and inflammatory infiltrates in the alveoli 
(Fig. 6.4H). Infection by the ma-Ca/04 caused much more severe bronchopneumonia as 
compared with the lesions induced by the NL WT or the NL 2:6 ty/04 WT upon 




















Figure 6.4. Protective efficacy of ty/04 att H1N1 vaccines against lethal H1N1pdm 
challenge in mice. Groups of mice (n=7) were vaccinated with H1N1 recombinant viruses 
containing either att or WT backbones. A control group was mock vaccinated with PBS. All 
animals were challenge 21 days later with 20 MLD50 of the lethal mouse-adapted Ca/04 by 
the intranasal route. At 5 dpc, the lungs from three animals were collected and processed for 
virus titration and histopathology. (A) Percent body weight change of naïve and vaccinated 
mice after lethal challenge. (B) Survival rates of naïve and vaccinated mice after lethal 
challenge. (C) Pulmonary replication of the challenge virus in the lungs of mice. Values are 
mean ± SEM. *** p< 0.001 between PBS and NY 2:6 ty/04 att. (D, E, F, G, and H) Lung 
pathology following a lethal ma-Ca/04 challenge. Immunized animals showed no significant 
histopathological changes. D) Mice immunized with NL 2:6 ty/04 att. E) Mice immunized 
with NY 2:6 ty/04 att. F) Mice immunized with NL 2:6 ty/04WT. G) Mice immunized with 
NL WT.  H) Mock vaccinated mice had severe bronchopneumonia after lethal challenge that 




interstitial edema, and the presence of cell debris and inflammatory infiltrates in the alveoli 
and airways.  
 
In order to evaluate the immune responses induced by the ty/04 att vaccines that 
protected mice against lethal H1N1pdm challenge, we measured the levels of anti-Ca/04 
antibodies in the sera of immunized mice using a HI assay (Table 6.3). In general, the 
protection rate correlated with the level of the HI antibody titer measured on the day of 
challenge (21 dpv). At 0 dpc, the geometric mean titer (GMT) against Ca/04 was slightly 
lower in the NY 2:6 ty/04 att vaccine as compared to the NL 2:6 ty/04 att group, though the 
difference was not statistically significant. As expected, the highest GMT was induced by the 
non-attenuated viruses NL 2:6 ty/04 WT and NL WT. Mock-vaccinated animals had 
undetectable HI antibodies. We also found a positive correlation (Pearson’s correlation, 
r2=0.82, p<0.05) between the invasiveness of the vaccines/viruses, i.e. the ability of the 
H1N1 ty/04 att or WT viruses to replicate in the respiratory tract, and the levels of circulating 
HI antibodies. The least invasive vaccine, NY 2:6 ty/04 att, induced lower HI antibodies as 
compared with the more invasive NL 2:6 ty/04 att vaccine. The highest HI titer was elicited 
by the NL WT.  Based on this correlation analysis, 82% of the variance in HI titers at 21 dpv 
could be explained by variation in the ability of the viruses to replicate in the lungs. 
Collectively, these results suggested that a single low dose inoculation of the ty/04 att LAIV 
could prevent histopathological alterations in the lungs and provide complete protection 
































Hemagglutination inhibiton (HI) titers are given as the reciprocal of the highest dilution of serum that 
showed activity against the A/CA/04/09(H1N1). Values are given as the geometric mean titer (GMT. 
N/A: not applicable-animals were dead at this time point. 
 
6.4.6. Vaccination with H1N1 ty/04 att-based vaccines provides sterilizing immunity 
against an aggressive H1N1pdm challenge in pigs 
The NY 2:6 ty/04 att was selected for a vaccination/challenge trial in swine because 
it was the most attenuated vaccine in mice and had limited shedding in pigs after vaccination. 
Because only inactivated influenza vaccines are currently licensed for use in the U.S. swine 
industry, we also compared side-by-side the efficacy of the NY 2:6 ty/04 att with an 
experimental Ca/04 inactivated adjuvanted vaccine (UVAdj-Ca/04). Thus, at two weeks after 
boost immunization, pigs were challenged with 105 TCID50 of the virulent Ca/04 by 
intratracheal inoculation and followed for 5 days. The clinical performance in pigs of the 
H1N1 vaccines is summarized in Table 4.  Non-vaccinated and challenged (NV+Ca/04) 
animals developed clinical signs of disease after challenge and typical macroscopic lung 
lesions of influenza infection by 5 dpc. In addition, all 10 pigs from this group shed virus in 
the nose at both 3 and 5 dpc and replicated virus in BALF at 5 dpc. Two doses of the UVAdj-
Ca/04 vaccine provided satisfactory protection as determined by the reduced lung pathology 
and limited challenge virus replication in both the upper and lower respiratory tract. 
 Groups      0 dpv       21 dpv       21 dpc 
PBS <10 <10 N/A 
NY 2:6 ty/04 att   <10 25 1076 
NL 2:6 ty/04 att   <10 89 1810 
NL 2:6 ty/04 WT   <10 718 2560 




However, 2 pigs in this group did shed virus in the nose at day 5 and 1 animal had detectable 
virus in BALF. Remarkably, none of the animals vaccinated with NY 2:6 ty/04 att had 
detectable infectious virus in nasal secretions or in the lungs, suggesting that replication of 
the challenge virus was abolished at the site of infection. Macroscopically, discrete lung 
lesions were detected in 50% of the animals immunized with NY 2:6 ty/04 att vaccine, 
however the percentage was lower than the group immunized with the inactivated vaccine in 
which 90% of the animals developed limited gross pulmonary pathology upon challenge. 
Nevertheless, in both vaccine groups there was a significant reduction (p<0.001) in the 
percentage of macroscopic lung pathology compared to the NV+Ca/04 group. Microscopic 
changes associated with influenza infection in the lungs were reflective of the macroscopic 
pneumonia. As expected, non-vaccinated, mock-challenged (NV+Mock) controls remained 
healthy throughout the study and had neither significant macroscopic nor microscopic lesions 
in the lungs. 
 Serum samples were also collected at the day of challenge and Ca/04-specific 
antibodies were examined by an HI assay. All pigs were negative for antibodies (HI titer <10) 
at the start of the experiment. At the day of challenge, 8 out of 10 pigs had detectable HI 
antibodies against Ca/04 in the inactivated vaccine group, whereas 7 out of 10 animals were 
HI positive in NY 2:6 ty/04 att group. The mean HI antibody titers measured at the day of 
challenge in both vaccine groups were approximately the same (Table 6.4).  
Table 6.4. Clinical performance of H1N1 ty/04 att-based vaccine in swine after challenge 
with pandemic H1N1 
 
NV+Ca/04, non-vaccinated, challenged positive control group; NV+Mock, non-vaccinated, non-
challenged negative control group. 
a Geometric mean HI titer against Ca/04 at the day of challenge. Numbers within parenthesis represents 
the number of animals that seroconverted/total animals per group. 
b Percentage of macroscopic lung lesions given as mean score ± SEM.  
c Microscopic pneumonia scores given as mean score ± SEM.  
Group HI titer a Macroscopic 
pneumonia b 
Microscopic 
pneumonia (0-3) c 
Nasal swabs d BALF 5 
dpc e 
    3 dpc 5 dpc  
NY 2:6 ty/04 att   16.2 (7/10) 0.3 ± 0.1* 0.5 ± 0.1* 0 ± 0 * 0 ± 0* 0 ± 0* 
UVAdj-Ca/04 20.0 (8/10) 1.2 ± 0.6* 0.3 ± 0.2* 0 ± 0 * 0.4 ± 0* 0.3 ± 
0.3* 
NV+Ca/04 <10 (0/10) 5.5 ± 1.3 1.5 ± 0.4 2.2 ± 0.4 2.8 ± 0.2 3.9 ± 0.2 




d  Average viral titer (log10) measure as TCID50 per ml of fluid present in nasal swabs collected at 3 and 
5 days post-challenge (dpc) 
e  Average viral titer (log10) measure as TCID50 per ml of bronchoalveolar lavage fluid (BALF) 
collected at 5 days post-challenge (dpc).   




To characterize the immunoglobulins present in the lower respiratory tract of swine, 
total levels of Ca/04-specific IgG or IgA isotype antibodies were measured by ELISA in 
BALF samples collected at necropsy (5 dpi). The data presented in Fig. 6.5 shows the mean 
of the isotype response in each group. Levels of Ca/04-specific IgG were similar between the 
two vaccinated groups (Fig. 6.5A). In contrast, IgA levels in BALF from pigs in the NY 2:6 
ty/04 att group were significantly higher than in the inactivated vaccine group (Fig. 6.5B). 
Taken together, these results suggest that NY 2:6 ty/04 att vaccine is immunogenic in pigs 
and provides sterilizing immunity against pandemic H1N1 challenge. 
Figure 6.5. Antibody isotype profiles in BALF samples of vaccinated pigs after challenge 
with H1N1pdm. The levels of Ca/04-speficic IgG (A) and IgA (B) antibodies present in 
BALF samples were quantified by ELISA. Groups of pigs (n=10) were vaccinated twice with 
either the NY 2:6 ty/04 att or with an inactivated Ca/04 vaccine, challenged with H1N1pdm 
at 2 weeks post-boost and necropsied at 5 dpi when BALF was collected. Non-vaccinated 
pigs challenged with the Ca/04 virus (NV+Ca/04) and non-vaccinated mock challenge pigs 
(NV+Mock) were included as controls. Results are given as the mean OD ±standard error of 










The 2009 H1N1 pandemic caused by a triple reassortant influenza virus has spread 
worldwide and caused profound economic, health, and social impacts. This virus is the 
predominant circulating influenza virus among people in both northern and southern 
hemispheres (Al Hajjar and McIntosh 2010) and has the ability to infect pigs experimentally 
and under natural conditions (Brookes, Irvine et al. 2009; Howden, Brockhoff et al. 2009; 
Lange, Kalthoff et al. 2009; Weingartl, Albrecht et al. 2009; Vincent, Lager et al. 2010). 
Therefore, the development of alternative influenza vaccines for use in humans and animals 
would play an important role in mitigating the effects of the evolving H1N1 pandemic. 
Inactivated swine influenza vaccines are available for pigs; however, they do not provide 
either adequate immunity or cross-protection (Vincent, Lager et al. 2008). This poor cross-
protection associated with the use of inactivated vaccines was highlighted in a recent study, 
which reported only limited serologic cross-reactivity between sera from pigs vaccinated with 
contemporary H1 swine influenza viruses and the pandemic H1N1 2009 isolates (Vincent, 
Ciacci-Zanella et al. 2010). These findings are of major significance for the current scenario, 
given the possibility that 2009 H1N1 viruses could become established in swine. In the 
present study, we addressed this issue and developed temperature-sensitive LAIV Influenza 
vaccines for use in pigs. Moreover, we used mouse and swine models to test the efficacy of 
our vaccine platform in protecting against severe H1N1pdm-induced pneumonia that has 
been reported in some human fatalities (Perez-Padilla, de la Rosa-Zamboni et al. 2009; Soto-
Abraham, Soriano-Rosas et al. 2009; Gill, Sheng et al. 2010). 
 In this study, we have used reverse genetics and molecular biology techniques to 
modify the polymerase genes of a swine-like TR influenza virus with the goal of developing 
alternative influenza vaccines for use in more than one animal species. We have previously 
shown that attenuation of an avian influenza strain required both the ts mutations found on 
the PB2 and PB1 genes of the A/Ann Arbor/6/60 (H2N2) human strain and incorporation of 
an HA tag epitope in the carboxy-terminus of PB1 (Song, Nieto et al. 2007). Here, we studied 
the effects of the ts and att (ts+ HA tag) mutations in the polymerase activity of a triple 
reassortant influenza virus whose polymerase genes are from avian (PB2 and PA), human 
(PB1) and swine (NP) origin. We demonstrated that introduction of ts mutations into the PB2 
and PB1 subunits of a TR influenza virus severely impaired polymerase activity in human 




enhanced by the covalent attachment of an HA epitope in PB1. These results are in agreement 
with our previous studies in which incorporation of an HA tag in PB1 synergistically 
enhances the attenuating effects of the ts mutations in the context of an avian influenza strain 
(Song, Nieto et al. 2007; Hickman, Hossain et al. 2008). It is unclear how the ts loci 
combined with the HA tag modulates polymerase activity in elevated temperatures. In 
addition, the mechanisms responsible for the restricted replication of the ts influenza viruses 
at the non-permissive temperature have not been completely elucidated. A recently proposed 
mechanism to explain the ts phenotype involves multiple defects in replication of the MDV 
A/Ann Arbor/6/60 harboring the ts loci. These defects include decreased vRNA synthesis, 
blockage of viral RNP export from nucleus, reduced incorporation of M1, and production of 
virions with irregular morphology at 39º C (Chan, Zhou et al. 2008).  
 To gain further insight into the phenotypic alterations caused by the att mutations in 
viruses containing the TRIG cassette, we investigated the replication of WT and att H1N1 
viruses at different temperatures. In agreement with the RNP reconstitution assay and our 
previous reports (Song, Nieto et al. 2007; Hickman, Hossain et al. 2008), the growth of the 
ty/04 att viruses was highly restricted at the non-permissive temperatures. Thus, introducing 
the double mutations from H9N2 avian virus into a divergent TR influenza strain was 
sufficient to transfer the ts phenotype.  
 The next step for evaluating live att influenza vaccines would be to test whether the 
vaccines were safe for use in mice and other animal models. Consistent with our in vitro data, 
all the H1N1 ty/04 att-based vaccines were sufficiently attenuated in mice, unlike their WT 
H1N1 counterparts that caused clinical disease and pulmonary pathology. However, there 
were differences in the extent of attenuation depending on the origin of the surface protein 
genes. Although none of the ty/04 att vaccines caused clinical disease or major 
histopathological changes in mice, animals inoculated with NL 2:6 ty/04 att had higher levels 
of replication of vaccine virus in the lungs as compared with the group immunized with NY 
2:6 ty/04 att. These findings were not unexpected since our group and others have reported 
limited replication of LAIV (att or ts) upon intranasal inoculation of mice and ferrets 
(Hickman, Hossain et al. 2008; Joseph, McAuliffe et al. 2008; Chen and Subbarao 2009; 
Chen, Santos et al. 2009). The difference in attenuation between the two vaccines suggests 
that the surface genes from A/Netherlands/602/09 carry virulent markers that might be absent 
in A/New York/18/09. In fact, a recent study reported a difference in virulence between 




(Manicassamy, Medina et al. 2010). These authors reported that A/Netherlands/602/09 was 
lethal to C57B/6 mice as opposed to Ca/04, even though their genomes differ only in eight 
amino positions. Future studies investigating the contributions of individual amino acids for 
the delayed clearance of the NL 2:6 ty/04 att as compared to NY 2:6 ty/04 att will help to 
pinpoint virulence determinants in surface glycoproteins of the H1N1pdm viruses.  
 We next evaluated the safety and the efficacy of the double-mutant live att influenza 
vaccines in pigs. Although other strategies such as truncations of NS1 (Solorzano, Webby et 
al. 2005; Richt, Lekcharoensuk et al. 2006; Vincent, Ma et al. 2007) and elastase growth-
restriction (Masic, Babiuk et al. 2009; Masic, Booth et al. 2009) have been developed for 
attenuating live influenza viruses for use in swine, these technologies are relatively new and 
are not as well-characterized as the ts vaccines. In addition to the impact of influenza 
infection on the swine industry, testing influenza vaccines in pigs also offers the possibility of 
extrapolating the findings to humans, since there are important similarities between the two 
species regarding the distribution of sialic acid receptors, cytokine production, and clinical-
pathological outcomes after influenza infection (Van Reeth, Van Gucht et al. 2002; Barnard 
2009; Barbe, Atanasova et al. 2010; Barbe, Saelens et al. 2010; Nelli, Kuchipudi et al. 2010). 
Data from our safety studies showed that both the H3N2 and H1N1 ty/04 att vaccines were 
attenuated in pigs as evidenced by the absence of clinical signs of disease upon intranasal 
vaccination, reduced viral replication in the respiratory tract and minimal pathological 
changes in the lungs. The decreased replication of the ty/04 att vaccines in the upper 
respiratory tract of pigs is consistent with previous reports showing that the cold-adapted, 
temperature sensitive A/Ann Arbor/6/60 influenza vaccines replicate to moderate levels in the 
nasal cavities of ferrets (Joseph, McAuliffe et al. 2008; Chen and Subbarao 2009; Chen, 
Santos et al. 2009; Chen, Lamirande et al. 2010) and with NS1-truncated H3N2 influenza 
vaccines in pigs that also had limited replication in the nasal cavity (Solorzano, Webby et al. 
2005). Although the ty/04 att vaccines were detected in BALF samples, the level of viral 
replication was significantly reduced in comparison to unmodified virus and, more 
importantly, caused no overt clinical signs and only minimal pathology in the lungs. A 
minimal amount of replication is likely beneficial for eliciting T-cell responses to internal 
genes that may provide heterologous cross-protection. These findings are also consistent with 
safety studies of truncated NS1-based vaccines in swine that showed limited replication and 
pathology in the lower respiratory tract (Solorzano, Webby et al. 2005). Moreover, a detailed 




ferrets showed that the virus replicated in the lungs and caused discrete to moderate 
bronchointerstitial inflammation at 3 dpv after intranasal administration and these adverse 
effects correlated with the origin of the surface genes, the dose and the volume of the vaccine 
(Jin, Manetz et al. 2007). Since we used a large volume (2 ml) in our vaccination 
experiments, the present study confirms and extends the safety studies of Jin and colleagues 
in ferrets (Jin, Manetz et al. 2007). It has been shown that intranasal administration of 
volumes larger than 0.2 ml results in replication of the LAIV A/Ann Arbor/6/60 vaccine in 
the lower respiratory tract of ferrets (Jin, Manetz et al. 2007), but the authors also highlighted 
that the ferrets studies did not accurately reflect the administration of this vaccine in humans, 
in which intranasal delivery of 0.5 ml inoculum containing radiolabeled albumin failed to 
reach the lower respiratory tract (Bryant, Brown et al. 1999). Thus, our safety studies in 
swine could be more relevant than the ferret model to evaluate adverse effects of live att 
influenza vaccines for use in humans. 
 One of the most challenging tasks in producing effective live attenuated vaccines is 
to achieve an adequate balance between safety and efficacy. By introducing the att 
modifications into the polymerase genes of a swine-like TR strain, this desirable balance was 
achieved. The vaccines were attenuated in both mice and pigs and, more importantly, elicited 
protective immunity in both species. In mice, the ty/04 att-based H1N1 proved to be 
efficacious against a lethal infection with H1N1pdm. The mice challenge model used in our 
vaccine trials attempted to recapitulate the severe pneumonia induced by the pandemic H1N1 
in certain human patients. All vaccinated animals survived the lethal challenge and had no 
signs of morbidity following challenge; even though one vaccinated group had limited viral 
replication in the lungs. The incomplete clearance of challenge virus in the lungs of the 
immunized mice was not unexpected. Previously, we reported that mice vaccinated with the 
avian att backbone and challenged with a lethal dose of H5N1 had viral replication in the 
lungs, although the animals were completely protected from disease (Hickman, Hossain et al. 
2008). Our results are in agreement with this report, and of note, the limited pulmonary 
replication of the challenge virus did not cause significant pathologic changes, correlating 
with the clinical findings. The ty/04 att-based H1N1 vaccine was also immunogenic in swine 
and provided sterilizing immunity upon an aggressive challenge with pandemic H1N1 as 
opposed to an experimental Ca/04 inactivated vaccine, which elicited protective but not 
sterilizing immunity in all animals. Although serum HI antibody titers were modest in the att 




were detected in the lungs of all pigs in the group.  The local antibody response is likely 
correlated with the protection from challenge with Ca/04, although we cannot exclude the 
contribution of T-cell mediated responses to the sterilizing immunity provided by vaccination 
with the live att H1N1 virus. 
 In the face of influenza pandemics that have the ability to overcome the species 
barriers such as the 2009 H1N1, the supply of vaccines for use in agriculture could be 
jeopardized. Our cell culture-based live att H1N1 vaccines could be an attractive alternative 
for this possible pandemic vaccine shortage. Because the ty/04 att live vaccines developed 
here are efficacious in multiple species, are easier to manufacture than inactivated vaccines 
and do not require adjuvants, our study represents a major advance in vaccine development 
for the 2009 H1N1 pandemic. 
 In conclusion, we demonstrated that the double attenuating mutations first 
implemented for an H9N2 avian influenza strain could be successfully transferred to a 
heterologous nonattenuated swine-like triple reassortant influenza virus. Thus our second 
generation of live att influenza vaccines based on modifications of the PB2 and PB1 genes of 
ty/04 expresses desirable biological traits in vitro, retains its safety properties in vivo, and can 
induce excellent protection against aggressive H1N1 challenges in more than one animal 
species. Our studies highlight the attenuation of the ty/04 att vaccine platform and its 
potential as a master donor strain for the generation of live attenuated vaccines with 






Chapter 7: Shuffling of the Influenza Genome: A Novel 




H5N1 and H9N2 avian influenza subtypes top the World Health Organization’s 
(WHO) list with the greatest pandemic potential. Inactivated H5N1 vaccines have induced 
limited immune responses and, in the case of live attenuated vaccines, there are safety 
concerns regarding the possibility of reassortment between the H5 gene with other circulating 
influenza viruses. In this study, we shuffled the genome of an avian H9N2 influenza virus, 
A/Guinea Fowl/Hong Kong/WF10/99 (H9N2), to allow insertion and expression of foreign 
genes. Subsequently, this strategy was used to generate an influenza-vectored H5 vaccine to 
address the limitations of H5N1 vaccines. Shuffling of the influenza genome was achieved by 
expressing the NEP/NS2 gene from a single open reading frame (ORF) downstream of the 
PB1 gene, and the transgene was cloned downstream of a truncated form of the NS1 protein. 
Avian influenza viruses (H9N2) expressing reporter genes and the entire ORF of the H5 
hemagglutinin were generated by reverse genetics. In vitro studies demonstrated that these 
vectors had impaired polymerase activity and viral replication. Further in vivo 
characterization of the shuffled influenza virus vector showed that this strategy completely 
attenuated a ressortant virus containing 6 genes from a highly pathogenic H5N1 and the 2 
modified segments from the shuffled vector (PB1-NEP/NS2 and NS1-GFP) in chickens. 
More importantly, immunization with the H9N2-H5 virus protected against lethal H5N1 
challenges in both mice and ferrets, whereas the H9N2-GFP control vector did not. Taken 
together, our results demonstrate that the shuffled influenza virus vector is highly attenuated 
in vivo and provides efficient protection against lethal H5N1 virus challenges. These vectors 
have great potential for the development of improved vaccines against influenza as well as 





 7.2. Introduction 
The use of viral vectors for the delivery of traceable reporter genes and bioactive 
molecules has broad applications in the fields of gene therapy and infectious disease. A 
number of live recombinant viral vectored vaccines have been licensed for veterinary use and 
many are in clinical development for humans (Draper and Heeney 2010). These vaccines 
combine some of the positive features of DNA vaccines with those of live attenuated 
vaccines. Similar to DNA vaccines, viral vectors deliver the nucleic acid encoding protein 
immunogens into target host cells, but with the added advantage of inducing more robust 
immune responses, which are elicited by replication of the viral entity (Draper and Heeney 
2010). Since the development of reverse genetic methods for segmented negative sense RNA 
viruses, influenza A viruses (IAV) have also been considered as potential vaccine vectors 
(Hoffmann, Neumann et al. 2000). 
 IAV are single-stranded RNA viruses with negative polarity belonging to the family 
Orthomyxoviridae. Its genome contains eight RNA segments which encode 10-12 viral 
proteins. During viral assembly, the vRNAs are selectively packaged into virions in the form 
of viral ribonucleoprotein complexes. The packaging signals in each of the vRNAs consist of 
the untranslated regions (UTR) at both the 3’ and 5’ terminal sequences, and regions of the 
adjacent coding sequence. Two major viral glycoproteins, the hemagglutinin (HA) and the 
neuraminidase (NA), are present in the viral envelope (Hutchinson, von Kirchbach et al. 
2010).  
The engineering of IAV as vaccine vectors offers several advantages: (i) IAV induce 
strong cellular and humoral immune responses both systemically and at the mucosal 
surfaces(Garulli, Kawaoka et al. 2004), (ii) influenza does not have a DNA phase during 
replication, eliminating safety concerns regarding integration of viral DNA into the host 
genome, (iii) IAV have 16 different HA and 9 different NA surface protein genes, which 
readily permits reconstitution of the vector surface proteins, making boost vaccinations 
feasible(Fouchier, Munster et al. 2005), and (iv) IAV are well characterized with attenuated 
strains already used as vaccines for humans and livestock (Belshe, Edwards et al. 2007).  
However, most of the IAV vectors developed to date have either been unstable or tolerated 
only short gene inserts(Manicassamy, Manicassamy et al. 2010). Thus, both the instability of 
the transgene and the insert size limitation has prevented IAV vectors from being used as 




H9N2 avian influenza virus and highly pathogenic avian influenza virus (HPAIV) 
H5N1 subtypes top the World Health Organization’s (WHO) list with the greatest pandemic 
potential. The development of effective vaccines against these subtypes is an essential 
component of the WHO’s global strategy for pandemic preparedness (WHO 2010). 
Furthermore, with the emergence of the swine-origin pandemic H1N1 in the spring of 2009, 
there is heightened concern that these viruses may reassort with the pandemic virus to 
produce a highly pathogenic virus or a novel strain that readily infects and transmits in 
humans.  Inactivated vaccines, particularly in the context of HPAIV H5N1 are poorly 
immunogenic and often require the addition of an adjuvant and/or boosting to induce an 
immune response. LAIV vaccines provide broad cross-protective responses and do not 
require the use of adjuvants as they mimic a natural infection (Johnson, Feldman et al. 1985; 
Belshe, Mendelman et al. 1998). However, with respect to the development of vaccine 
candidates against H5N1 influenza strains, live-attenuated vaccines (LAIV) have the potential 
to reassort with seasonal influenza viruses (Suguitan, McAuliffe et al. 2006; Treanor, 
Campbell et al. 2006). This creates a significant safety concern as vaccination may 
inadvertently result in the generation of novel pandemic viruses of the H5 subtype on a 
seasonal virus background.   
In this study, we used reverse genetics to rearrange the IAV genome and generate 
influenza vectors that stably express foreign genes. Specifically, the NEP/NS2 protein was 
expressed as a discrete single open reading frame (ORF) downstream of the PB1 gene, and 
the foreign gene of interest was cloned downstream of the NS1 gene under the transcriptional 
control of the NS promoters. We have successfully rescued avian IAV (H9N2) expressing 
enhanced green-fluorescent protein (GFP), secreted Gaussia Luciferase (GLuc), and the 
entire ORF of the HA from a prototypic highly pathogenic H5N1 virus A/Viet Nam/1203/04 
(H5N1) strain. Expression of the transgenes was maintained during serial passages in 
mammalian cells, confirming the stability of the engineered vectors. Importantly, high levels 
of expression of both HA proteins (H9 and H5) were detected in cells infected with the H9N2 
virus expressing the H5 ORF (H9N2-H5). In vitro studies demonstrated that these vectors had 
impaired polymerase activity and viral replication. In vivo characterization of the shuffled 
influenza virus vector demonstrated that this strategy was able to attenuate a ressortant virus 
containing six genes from a highly pathogenic H5N1 and the two modified segments from the 
shuffled vector in chickens. More importantly, immunization of mice and ferrets with the 




vector did not. Our results demonstrate that the shuffled influenza virus vector is highly 
attenuated in vivo and provides efficient protection against lethal H5N1 virus challenges. 
Furthermore, because the H5 ORF expressed in this construct does not code for a functional 
genomic RNA, reassortment of the influenza H5 HA is very unlikely to occur. Therefore, 
these vectors have great potential for the development of improved vaccines against influenza 






 7.3. Material and Methods 
7.3.1. Ethics Statement 
 Vaccination studies were conducted under BSL-2 condition, whereas virus 
challenge with HPAIV H5N1 was performed under Animal Biosafety Level 3 (ABSL-3) 
conditions approved by USDA. Animal studies were performed according to protocols R-09-
93 "Transmissibility of Influenza A Viruses", and R-09-55 "Evaluation of attenuation and 
protection efficiency of live attenuated influenza vaccines", approved by the Institutional 
Animal Care and Use Committee of the University of Maryland. Animal studies adhere 
strictly to the US Animal Welfare Act (AWA) laws and regulations. 
7.3.2. Viruses and cell lines 
 Human embryonic kidney cells (293-T) were cultured in OptiMEM I (GIBCO, 
Grand Island, NY) containing 10% FBS and antibiotics. Madin-Darby canine kidney 
(MDCK) cells were maintained in modified Eagle's medium (MEM) (Sigma-Aldrich, St. 
Louis, MO) supplemented with 5% fetal bovine serum (FBS) (Sigma-Aldrich) and 
antibiotics. 
The avian influenza virus, A/Guinea fowl/Hong Kong/WF10/99 (H9N2) [hereafter 
H9N2 WT], has been previously described (Song, Nieto et al. 2007). The HPAIV A/Viet 
Nam/1203/04 (H5N1) [hereafter H5N1 WT] was a kind gift from the Centers for Disease and 
Control (CDC). 
Recombinant viruses used in this paper were generated from cloned cDNAs and are 
described below and in Table 1.All the viruses were propagated in 7-10 day old embryonated 
hens eggs and titrated by at least one of the following methods: egg infectious dose 50% 




7.3.3. Generation of recombinant viruses by reverse genetics 
The eight plasmid reverse genetic system for H9N2 WT has been previously 




2007). The HA and NA genes from the H5N1 WT strain were cloned into pDP2002 vector. 
The ΔH5 HA plasmid encodes the HA segment from H5N1 WT, which has been further 
modified by the removal of the encoded polybasic cleavage site. To generate H9N2 WT with 
ΔNS1, the NS segment was modified so it encodes a carboxy-terminal-truncated NS1 protein 
product comprising amino acids 1 to 99 and an unmodified NEP/NS2 protein.  
Shuffling of the influenza genome was accomplished by expressing the NEP/NS2 
protein from a single polypetide downstream of the PB1 gene. Foreign genes of interest are 
cloned downstream of a full-length or truncated NS1 gene between two AarI cloning sites (or 
other compatible type III restriction endonucleases) so that there is no introduction of 
exogenous sequences. Processing of the PB1-NEP/NS2 and NS1-foreign gene proteins is 
achieved by the in frame incorporation of the foot-and-mouth disease virus (FMDV) 2A cis-
acting hydrolase elements (CHYSEL) (de Felipe 2004) downstream of PB1 and NS1, 
respectively. The corresponding packaging signals previously determined for RNA segments 
2 and 8 were maintained to achieve efficient vRNA incorporation into virions (Fujii, Fujii et 
al. 2005; Liang, Hong et al. 2005). All the plasmid constructs and recovered recombinant 
viruses were fully sequenced to confirm their identity.  
 
7.3.4. Minigenome assay 
The minigenome assay was performed as described previously (Pena, Vincent et al.). 
The PB1 attenuated plasmid (PB1 att) used here as a control, has been previously published 
and contains the K391E, E581G, and A661T mutations and an HA tag sequence fused in 
frame with the C-terminus of the PB1 protein (Song, Nieto et al. 2007). 
7.3.5. Growth kinetics 
MDCK cells were seeded in 6-well plates and infected in triplicate with each of the 
viruses described in Table 1 at a multiplicity of infection (MOI) of 0.01. Following 1 hour 
adsorption, the monolayers were washed 3 times with PBS and 2 mL of OptiMEM media 
containing 1 µg/ml TPCK-trypsin was added. Plates were incubated at 37°C and cell culture 
supernatant was harvested at 0, 12, 24, 48, 72, and 96 hours post-infection (hpi). The titer of 
virus released into the cell culture supernatant at each time point was determined by TCID50 






7.3.6. Immunoelectron microscopy 
Recombinant viruses were purified by sucrose density gradient centrifucation. 
Purified viruses were adsorbed to formvar/ silicon monoxide-coated nickel grids (Electron 
Microscopy Sciences, Hatfield, PA). The grids were blocked in PBS containing 0.2% BSA 
and incubated with in-house produced mouse monoclonal antibodies specific for the H5 or 
H9 HA. Grids were washed in blocking solution and incubated in goat anti-mouse IgG 
antiserum conjugated to 6 nm gold beads (Aurion, Costerweg 5, The Netherlands). The grids 
were then negatively stained with 2 % phosphotungstic acid (PTA) for 3 min, dried, and 
examined under a transmission electron microscope. 
7.3.7. Mouse studies 
Five-week-old female BALB/c mice (Charles River Laboratories, Frederick, MD) 
were anaesthetized with isofluorane prior to intranasal inoculation. Mice were inoculated 
with 50 µl 105 egg infectious dose 50 (EID50) of the recombinant viruses diluted in PBS. A 
boost immunization was given in half of the animals two weeks after the first inoculation. 
Each experimental group contained 30 animals. Mice were divided into 4 groups as follows: 
a) PBS (negative control) ; b) H9N2-GFP(vector control) ; c) H9N2-H5 (test vaccine); and d) 
ΔH5N1(positive control for the H5N1 vaccine). At 2 weeks post-vaccination (or 2 weeks 
post-boost for animals immunized twice), each group was divided into 3 subgroups (n=10) 
and intranasally challenged with either 20, 200, or 2000 mouse lethal dose 50% (MLD50) of 
the highy pathogenic A/Viet Nam/1203/04 (H5N1) strain. Mice were bled using the 
submandibular bleeding method (Golde, Gollobin et al. 2005) prior to inoculation and at 
several time points after immunization to evaluate the immunogenicity of the vaccines. At 5 
days post challenge (5 dpc), 3 mice from each subgroup were euthanized and their lungs were 
collected for histopathologic analysis and to measure levels of challenge virus. Tissue 
homogenates were prepared in PBS, clarified by centrifugation, and stored at -70ºC until use. 
Clinical signs of disease, body weight, and mortality were monitored daily throughout the 
experiment to evaluate vaccine safety and efficacy. Mice presenting ≥25% body weight loss 
were humanely euthanized and counted as have succumbed from the infection. 
To assess the ability of the viruses to replicate in the respiratory tract of mice, 16 




days post-inoculation (dpi), all animals were euthanized and their tissues were harvested for 
virus titration and histopathologic evaluation. 
 
7.3.8. Ferret studies 
Twelve female Fitch ferrets, 3 to 6 months-old, were purchased from Triple F Farms 
(Sayre, PA) and randomly divided in four groups of three animals each. Animals were 
seronegative for IAV, as determined by blocking NP ELISA. Prior to vaccination, ferrets 
were housed in a BSL2 facility and monitored for 5 to 7 days to measure body weight and 
establish baseline body temperatures. A subcutaneous implantable temperature transponder 
(Bio Medic Data Systems,Seaford, DE) was placed in each ferret for identification and 
temperature readings. Ferrets were intranasally immunized twice two weeks apart with 500 µl 
containing 105 EID50 of the recombinant viruses diluted in PBS, using the same viruses as for 
murine.  At 2 weeks after boost, ferrets were lethally challenged with 106 EID50 of the 
HPAIV H5N1 A/Viet Nam/1203/2004 strain. Body weight changes, clinical signs of disease 
including fever and mortality were monitored daily throughout the experiment as parameters 
for vaccine evaluation. Nasal washes were collected for seven days after each vaccination and 
for nine days post-challenge to quantify virus shedding. Blood samples were collected at 
0,14, and at 28 dpv and a final bleed was performed at 15 dpc. 
 
7.3.9. Chicken studies 
To determine the pathogenicity of a shuffled HPAIV H5N1 (Table 7.1) was 
evaluated in chickens. Two-week-old specific-pathogen-free leghorn chickens were 
inoculated intravenously (n=2) or through a combination of natural routes (intranasal, 
intraocular, oral, and intratracheal) [n=5] with a total of 107 EID50 of the shuffled HPAIV 
H5N1 and morbidity and mortality was followed for 10 days after inoculation. 
 7.3.10. Serological analysis 
Serum samples were treated with receptor-destroying enzyme (Accurate Chemical 
and Scientific Corp., Westbury, NY) to remove nonspecific receptors and the anti-viral 




laboratory diagnosis and virological surveillance of influenza (WHO 2011). H9N2 WT and 
ΔH5N1 were used in these assays. 
7.3.11. Stability of shuffled vectors 
The stability of the shuffled H9N-GFP virus was assessed by serially passaging the 
virus in MDCK cells at a low MOI. Viruses obtained from MDCK passages 1, 5, and 10 were 
further amplified in embryonated eggs, and used infect fresh MDCK cells with each passage 
at 1:100 dilution and measuring the levels of  GFP transgene expression by fluorescence 
microscopy.   
7.3.12. Statistical analysis 
All statistical analyses were performed using GraphPad Prism Software Version 5.00 
(GraphPad Software Inc., San Diego, CA). Comparison between two treatment means was 
achieved using a two-tailed Student t-test, whereas multiple comparisons were carried out by 
analysis of variance (ANOVA) using Tukey’s post hoc test, unless otherwise specified. The 







7.4.1. Generation of shuffled influenza virus vectors expressing reporter genes 
The IAV RNA segment 8 codes for two proteins: NS1, a nonstructural protein that 
inhibits the host’s antiviral response, and NEP/NS2, an structural component of the viral 
particle. NEP/NS2 interacts with the cellular export machinery, participates in the assembly 
of virus particles, and is involved in the regulation of IAV transcription and replication. 
While NS1 is produced from unspliced RNA, NEP/NS2 is expressed from spliced mRNA 
(Robb, Smith et al. 2009). In this study, we used reverse genetics to rearrange the genome of 
an avian IAV, A/Guinea Fowl/Hong Kong/WF10/99 (H9N2) (Song, Nieto et al. 2007). We 
chose this strain because it grows well in eggs and tissue culture and has been shown to 
replicate in several animal species such as mice, chicken and ferrets without previous 
adaptation (Song, Nieto et al. 2007; Hickman, Hossain et al. 2008).  
Shuffling of the influenza genome was accomplished by expressing the NEP/NS2, an 
essential viral protein, from a single polypetide downstream of the PB1 gene and introducing 
the foot and mouth disease virus (FMDV) 2A autoproteolytic cleavage site between them to 
allow cotranslational release of a processed NEP/NS2 from the upstream PB1-2A 
polyprotein. Removing NEP/NS2 from RNA segment 8 resulted in additional cloning space 
in this segment. The expression of the transgenes of interest was achieved by cloning their 
gene downstream of NS1 protein. The FMDV 2A was cloned between NS1 and the transgene 
to enable discrete expression of the foreign protein. The corresponding packaging signals 
previously determined for RNA segments 2 and 8 were maintained to optimize incorporation 
of the modified vRNA into virions (Fujii, Fujii et al. 2005; Liang, Hong et al. 2005). As proof 
of principle for this technology, the secreted Gaussia luciferase (GLuc), the enhanced green 
fluorescent protein (GFP) (Fig. 7.1A, and Table 7.1) was cloned into this vector and 
successful virus rescue was achieved for all these transgenes. Recombinant IAV virus vectors 
reached titers in the order of 6-7 Log10 EID50/mL after amplification in embryonated hens 
eggs. Expression of both GFP and GLuc reporter genes was readily detected either in the 












Kong/WF10/99 (H9N2) a 
none none H9N2 H9N2 WT 
A/Viet Nam/1203/04 (H5N1) b none none H5N1 H5N1 WT 
Unshuffled H9N2-ΔNS1 c NS1 truncation none H9N2 ΔH9N2 
Shuffled H9N2-ΔNS1-GFP d NS1 truncation and shufflng GFP H9N2 H9N2-GFP 
Shuffled H9N2-ΔNS1-GLuc e NS1 truncation and shufflng GLuc H9N2 H9N2-GLuc 
Shuffled H9N2-ΔNS1-ΔH5 Orf f NS1 truncation, shufflng, and 




Surface genes from ΔH5N1 in 
unshuffled H9N2-ΔNS1 
backbone g 
NS1 truncation and  
modified cleavage site in HA 
none H5N1 ΔH5N1 
Shuffled H5N1 WT h shufflng GFP H5N1 none 
 
a  Genbank taxonomy ID: 221116 
b  Genbank taxonomy ID: 284218 
c  A/Guinea fowl/Hong Kong/WF10/99 (H9N2) with NS1 truncation at position 99. 
d  A/Guinea fowl/Hong Kong/WF10/99 (H9N2) with NS1 truncation at position 99 with 
genome shuffling and expressing GFP. 
e A/Guinea fowl/Hong Kong/WF10/99 (H9N2) with NS1 truncation at position 99 with 
genome shuffling and expressing GLuc. 
f A/Guinea fowl/Hong Kong/WF10/99 (H9N2) with NS1 truncation at position 99 with 
genome shuffling and expressing H5 HA ORF derived from A/Viet Nam/1203/04 (H5N1) . 
The polybasic cleavage site present in the H5 HA was modified.  
g  2:6 reassortant containing the surface genes of A/Viet Nam/1203/04 (H5N1)  and the 
internal genes A/Guinea fowl/Hong Kong/WF10/99 (H9N2) with NS1 truncation at position 
99. The polybasic cleavage site present in the H5 HA was modified.  
h 2:6 reassortant containing 6 genes of  A/Viet Nam/1203/04 (H5N1) and the segment 2 and 8 
derived from the shuffled A/Guinea fowl/Hong Kong/WF10/99 (H9N2). Shuffled segment 2 










Figure 7.1. Shuffled H9N2 influenza A viruses expressing reporter genes. (A) Schematic 
representation of shuffled influenza viruses. NEP/NS2 protein is expressed from a single ORF (solid box) 
downstream of the PB1 gene, whereas the foreign antigen of interest is expressed downstream of the NS1 
gene. The packaging signals span both the untranslated region (solid line) and a part of the ORF at both 
ends each RNA segment. Two recombinant viruses were made expressing either eGFP (A), GLuc (B) 
downstream of a truncated NS1 gene. The viruses were rescued by reverse genetics and used to infect 
MDCK cells. At 24 hpi, GFP expression was detected by confocal microscopy (A) and GLuc was detected 





7.4.2. The H5 hemagglutinin expressed from segment 8 is incorporated into the 
envelope of a shuffled H9N2 virus 
With the goal of developing shuffled influenza virus as a vaccine vector, the HA 
ORF, a type I membrane protein, from the A/Viet Nam/1203/04 (H5N1) isolate was cloned 
downstream of a truncated NS1 gene in the background of an H9N2 virus. The H5 HA was 
genetically modified to remove its multi-basic cleavage site, a domain associated with high 
pathogenicity phenotype of the HPAIV (Basler and Aguilar 2008). Similarly to the viruses 
expressing reporter genes, the recombinant H9N2-H5 virus was successfully rescued and 
propagated in embryonated eggs, a substrate approved for human vaccines. To our 
knowledge, this is the first report that successfully recovered an eight-segmented IAV 
expressing two different HA proteins. Cells infected with the H9N2-H5 virus expressed high 
levels of both HA subtypes as determined by IFA using monoclonal antibodies (mAb) against 
the H5 and H9 HA, respectively (Fig. 7.2).  
Previous studies have demonstrated the surface incorporation of two different HAs 
(H1 and H3) by a recombinant influenza virus containing nine RNA segments (Gao, Lowen 
et al. 2010). We next sought to determine whether the H5 HA could be incorporated into our 
eight –segmented H9N2 shuffled influenza vector. The H9N2-H5 virus showed typical 
influenza virus morphology, consistent of pleomorphic particles and roughly spheroidal 
virions with approximately 100 nm in diameter (Fig. 7.2 and data not shown). Immunogold 
electron microscopy using an anti-H5 and anti-H9 specific mAb revealed that the H5 and the 
H9 HAs were incorporated into virus (Fig 7.2, small insets). As expected, H5 and H9 control 
virus only reacted with the respective mAb. These results indicate that shuffled IAV vectors 
retained the typical virion morphology and that the H5 HA expressed from segment 8 was 






ΔH5N1 H9N2-H5 H9N2 WT 
Figure 7.2. Novel influenza vector expressing H9 and H5 HA proteins on viral 
surface. A recombinant H9N2 virus was made expressing the H5 HA ORF and rescued 
by reverse genetics and used to infect MDCK cells. Expression of the H9 and the H5 
HA was confirmed by IFA and TEM (small insets) using monoclonal antibodies specific 
for these antigens and compared to either a H5N1 or H9N2 wild type virus. TEM, black 
dots correspond to immunogold reactions for either H5 or H9 HA proteins, please note 




7.4.3. Genome shuffling leads to impaired polymerase activity and reduced viral 
growth in vitro 
In order to study the effects of the incorporation of FMDV 2A and NEP/NS2 
downstream of the PB1 gene in viral polymerase activity, we performed viral 
ribonucleoprotein (vRNP) reconstitution assay to measure polymerase activity at different 
temperatures (33, 35, 37, 39, and 41°C) as previously described (Pena, Vincent et al.). 293-T 
cells were co-transfected with plasmids encoding the wild type PB2, PB1 (or PB1-2A-
NEP/NS2), PA, and NP genes and the influenza vRNA reporter construct carrying a secreted 
luciferase (GLuc). Transfection efficiency was normalized using a plasmid encoding the 
secreted alkaline phosphatase (SEAP) gene. Polymerase activity was monitored by the ratio 
of Gluc/SEAP. These experiments revealed that the presence of PB1-2A-NEP/NS2 led to 
significantly lower polymerase activities than that of WT genes at the different temperatures 
studied (Fig. 7.3A). These results suggested that the strategy used to rearrange the IAV 
genome decreases viral polymerase activity. 
To evaluate whether the reduction in polymerase activity viruses would translate into 
attenuated viral replication, the growth properties of the shuffled vectors H9N2-GFP and 
H9N2-H5 were evaluated in MDCK cells infected at MOI 0.01. In agreement with the 
minigenome assay, shuffled viruses harboring a truncated NS1 had 10-100 fold reductions in 
virus titer as compared to unshuffled viruses containing the same NS1 modification. Both 
WT and shuffled viruses reached maximum viral titers at 24 hours postinfection (Fig. 7.3B). 
Together, these results indicate that shuffled viruses can undergo multiple cycles of 
replication in MDCK cells, although the maximum virus titer is reduced by 10 fold as 





Figure 7.3. In vitro characterization of shuffled influenza vectors. (A) Minigenome assay.  
293-T cells were transfected with 1 µg each of the influenza driven-luciferase reporter plasmid 
and PB2, PB1, PA and NP plasmids and incubated at different temperatures as shown. 
pCMV/SEAP, which encodes secreted alkaline phosphatase was cotransfected into the cells to 
normalize transfection efficiency. The WT PB1 and an attenuated PB1 gene (PB1 att) were used 
here as a controls. At 24 hours post-transfection, the supernatant was harvested and assayed for 
both luciferase and phosphatase activities. Normalized polymerase activities (mean ± SE) were 
determined from three independent experiments. (B) Multicycle step growth curve. MDCK cells 
were seeded in 6-well plates and infected in triplicates with each of the viruses described in table 
1 at a multiplicity of infection (MOI) of 0.01. Supernatants were harvested at the indicated time 




7.4.4. Stability of shuffled influenza vectors 
 
We next examined the stability of the H9N2-GFP during serial passage of this vector 
in MDCK cells at a low MOI. Because of the low titers obtained from MDCK cells, viruses 
obtained at passages 1, 5, and 10 were further amplified in embryonated eggs, and evaluated 
for stability. The phenotypic stability was assessed by infecting MDCK cells with 1:100 
dilution of each viral passage and measuring the levels of GFP transgene expression. High 
expression levels of GFP were detected up to 10 passages, suggesting that shuffled IAV 
maintains foreign gene transcripts after several passages in tissue culture. 
  
Figure 7.4. Stability of shuffled influenza 
vectors. Stability of shuffled H9N2-GFP was 
assessed by serially passaged in MDCK cells 
and using the viruses from passages 1 (A), 5 
(B) and 10 (C) to infect MDCK cells at 1:100 
dilution and measuring the levels of GFP 





7.4.5. Genome shuffling strongly attenuates influenza vectors in vivo 
To evaluate the safety profile of shuffled IAV vectors, we tested these vectors in 
mice, ferrets, and chickens. BALB/c mice (n=14) were intranasally inoculated with 105 EID50 
/mouse of either H9N2-GFP or H9N2-H5 shuffled vectors. Body weight loss and the levels of 
viral replication in the respiratory tract were used as parameters of morbidity.  An additional 
group was mock vaccinated with PBS alone, and a fourth group was inoculated with virus 
containing the surface genes derived from a low pathogenic A/Viet Nam/1203/04 (which had 
the polybasic cleavage site in HA removed) in the backbone of the H9N2 virus containing a 
truncated NS1 (hereafter referred to as ΔH5N1) as non-shuffled virus control.  
  The ability of the viruses to replicate in the respiratory tract of mice was assessed by 
measuring viral load from the lungs of mice (4 from each group) at 3 dpi. The shuffled H9N2 
vectors were highly attenuated in mice as demonstrated by the absence of clinical disease 
signs and no change in body weight after vaccination. Conversely, mice inoculated with the 
ΔH5N1 unshuffled virus showed significant body weight loss (≤ 20%) by 8 dpi, although 
they eventually recovered. (Fig.7.5A). In examining tissue tropism and viral replication, the 
shuffled H9N2 vectors viruses were not detected in any of the organs sampled (nasal cavity, 
trachea, and lungs). Consistent with the clinical data, mice inoculated with the ΔH5N1 had 
high virus titers in the respiratory tract (Fig.7.5B). 
To obtain more detailed information about the safety of the shuffled IAV vectors, an 
attenuation study was conducted in ferrets (n=3) using the same treatment groups and viral 
doses used for the mice studies. Clinical evaluations performed after vaccination indicated no 
clinical signs of disease, no body weight changes, or no fever in the vaccinated groups 
relative to mock animals (Fig.7.5C-D), confirming the safety features of shuffled viruses in 
the ferret model. Virus shedding was not detected in any of the ferrets groups after 
vaccination or boost (data not shown). 
As the H5 HA is expressed from the shuffled H9N2-H5 virus as a chimeric HA 
segment with the packaging signals of the NS gene, the possibility of reassortment of the H5 
HA is remote (Gao and Palese 2009). Nevertheless, genetic ressortment could take place if a 
circulating IAV exchanges both RNA segments 2 and 8 with the shuffled IAV. Therefore, we 
addressed this question by rescuing an H5N1 virus containing 6 WT RNA segments 
(1,3,4,5,6, and 7) from the HPAIV A/Viet Nam/1203/04 (H5N1) strain and 2 segments (PB1-




H9N2 virus. The A/Viet Nam/1203/04 (H5N1) strain was isolated from a fatally infected 
human patient and is one of the most virulent HPAIV isolated to date (Govorkova, Rehg et al. 
2005). The pathogenicity of shuffled HPAIV H5N1 was evaluated in chickens, a highly 
susceptible host for the HPAIV. Two-week-old specific-pathogen-free leghorn chickens were 
inoculated intravenously or through all natural routes at once (intranasal, intraocular, oral, 
and intratracheal) with a total of 107 EID50 of the shuffled HPAIV H5N1 and morbidity and 
mortality was followed for 10 days after inoculation. Remarkably, none of the chickens died 
or developed clinical signs of disease upon inoculation (Fig.7.5E and data not shown),. This 
suggests that even if the shuffled virus reassorted with a HPAIV H5N1, the resulting virus 
would be completely attenuated. Taken together, these results indicate that shuffled-based 








Figure 7.5. In vivo attenuation of shuffled influenza viruses. (A) Safety studies in mice. Body weight 
changes following intranasal inoculation of BALB/c mice (n=10) with 105 EID50 /mice of the 
recombinant viruses. (B) Viral replication in the respiratory tract of mice. BALB/c mice (n=4) were 
inoculated with 105 EID50 and viral titers in the indicated organs at 3 dpi were determined by TCID50 . 
The lower limit of detection (0.6 TCID50 /mL) of the assay is indicated by the dashed horizontal line. (C 
and D) Attenuation in ferrets. Ferrets (n=3) were intranasally inoculated with 105 EID50 /animal with the 
recombinant viruses and body temperature(C) and body weight (D) were recorded daily. (E) Safety 
studies in chickens. SPF leghorn chickens were inoculated intravenously (n=2) or through natural routes 
(intranasal, intraocular, oral, and intratracheal) [n=5] with 107 EID50 of the shuffled HPAIV H5N1 and 





7.4.6. Shuffled H9N2-H5 virus vector provides protection against highly 
pathogenic H5N1 challenges in mammals  
Given the epidemiological relevance of HPAIV H5N1 virus for public health and the fact that 
vaccination is a mainstay of WHO’s pandemic preparedness plan, we assessed the ability of 
the shuffled H9N2-H5 virus to induce a protective immune response against one of the 
world’s toughest pathogen: the HPAIV H5N1.  
Protective efficacy in mice. Groups of BALB/c mice (n=30) were intranasally 
vaccinated once or twice with 105 EID50/animal with the following: a) PBS (negative 
control); b) H9N2-GFP (vector control) ; c) H9N2-H5 (test vaccine); and d) ΔH5N1(positive 
control for the H5N1 vaccine). At 2 weeks post-vaccination (or 2 weeks post-boost for 
animals immunized twice), each group (n=30) was divided into 3 subgroups (n=10) and 
challenged with either 20, 200, or 2000 mouse lethal dose 50% (MLD50) of the virulent 
A/Viet Nam/1203/04 (H5N1) strain. Clinical signs of disease, weight loss and survival were 
monitored for 15 days post-challenge (dpc). At 5 dpc, three mice from each group were 
euthanized and their lungs collected for histopathologic analysis and to measure levels of the 
H5N1 challenge virus.  
A single dose of the H9N2-H5 vector provided complete protection from morbidity 
and mortality following lethal challenges with 20 and 200 MLD50 of HPAIV H5N1. The 
results are summarized in Fig. 7.6. The subgroup challenged with 2000 MLD50 lost an 
average of ≤10% of body weight by 7 dpc, but all the animals recovered with the exception of 
a single mouse that succumbed to infection. This was in contrast to the outcome observed in 
the group immunized with the H9N2-GFP vector control. In this group, a single 
immunization was not fully protective since all animals developed clinical disease and lost 
body weight with all challenge doses. The mortality rate in the singly immunized H9N2-GFP 
group was 14.3%, 85.7%, and 100% for the 20, 200, or 2000 MLD50 challenge doses, 
respectively. Additionally, protection against pulmonary viral replication mirrored the clinical 
performance of the vaccines. All the H9N2-GFP inoculated mice that received a single 
vaccine dose had high virus titers in the lungs across all challenge doses, whereas the H9N2-
H5 vaccine provided sterilizing immunity against 20 MLD50 challenge and only 1, and 2 
individuals had detectable virus replication in the lungs following 200, or 2000 MLD50 
challenges, respectively.  Nevertheless, viral titers in these groups were lower than in the 




rates in the H9N2-GFP was indistinguishable from the PBS inoculated group, demonstrating 
that the cross-protective immunity elicited by H9N2-GFP control, but not by H9N2-H5, 







Figure 7.6. Protective efficacy of H9N2-H5 shuffled vector in mice after a single 
immunization. BALB/c mice (n=30) were inoculated with 105 EID50 /mice of the recombinant 
viruses. At 2 weeks post-vaccination, each treatment group was divided into 3 subgroups (n=10) 
and challenged with either 20, 200, or 2000 mouse lethal dose 50% (MLD50) of the virulent A/Viet 
Nam/1203/04 (H5N1) strain by the intranasal route. Clinical outcome in animals receiving one 
dose of the H9N2-H5 vaccine. Percent body weight change (upper panels), survival (middle 






Importantly, a second dose of H9N2-H5 vaccine resulted in complete clinical protection and 
sterilizing immunity in all individuals regardless of the challenge dose used. The results from 
this trial are summarized in Fig. 7.7. In the H9N2-GFP group boost vaccination elicited 
protection from morbidity against 20 MLD50 challenge. However, these animals were not 
protected from replication of the H5N1 virus. The mean viral titer in this group was 
approximately 103 TCID50/g of lung tissue. Challenge with 200 and 2000 MLD50 overcame 
the cross-protective immunity induced by the H9N2-GFP vector as indicated by 28.5% and 
71.5% mortality rates, respectively, and high levels of replicating challenge virus in the lungs 
(105 to 106 TCID50/g of lung). Collectively, these results demonstrated that the shuffled 
H9N2-H5 vector is suitable for prime/boost vaccination protocols as boost vaccination 
enhanced protection. The PBS control mice had high viral lung load (105.5 to 107 TCID50/g) 
and all animals died within 7-10 dpc, depending on the challenge dose used.  As expected, 
immunization with the ΔH5N1 induced sterilizing immunity irrespective of the challenge 
dose. However, the protective immunity induced by ΔH5N1 needs to be counterbalanced by 
the pathogenicity of this virus to BALB/c mice, which almost reached the humane endpoint 
for euthanasia (25% body weight loss) upon immunization. 






Figure 7.7. Protective efficacy of H9N2-H5 shuffled vector in mice after a boost 
immunization. BALB/c mice (n=30) were inoculated twice with 105 EID50 /mice of the 
recombinant viruses. At 2 weeks post-boost, each treatment group was divided into 3 
subgroups (n=10) and challenged with either 20, 200, or 2000 mouse lethal dose 50% 
(MLD50) of the virulent A/Viet Nam/1203/04 (H5N1) strain by the intranasal route. Clinical 
outcome in animals receiving two dose of the H9N2-H5 vaccine. Percent body weight change 





Protective efficacy in ferrets. To gain more insight into the efficacy of the H9N2-
H5 vector, we conducted a vaccine-challenge study in ferrets, an established outbred model 
of IAV (Matsuoka, Lamirande et al. 2009),  using the same treatment groups as for the mouse 
studies. The ferrets (n=3) were vaccinated intranasally twice on days 0 and 14 with 105 
EID50/animal and challenged at 2 weeks post-boost with a lethal dose (106 EID50/ferret) of 
A/Viet Nam/1203/2004 (H5N1) strain. This challenge was extremely severe (equivalent to 
10,000 ferret lethal dose 50% for this H5N1 strain (Mahmood, Bright et al. 2008)) and was 
chosen with the objective to discriminate the protective responses induced by the H9N2-H5 
vector from the cross-protection induced by the H9N2-GFP vector control. Virus shedding 
post-challenge was measured in nasal washes collected from 1-9 dpc. Following challenge, 2 
out of 3 ferrets vaccinated with the H9N2-H5 virus were completely protected against death 
and disease. In contrast, 3 out of 3 ferrets in the H9N2-GFP group developed severe clinical 
manifestations of infection and succumbed between 9-13 dpc (Fig. 7.7A). In the H9N2-H5 
group, the single ferret (# 426) that succumbed to infection showed initially no clinical 
disease, but shed high amounts of virus, which eventually led to development of clinical 
signs, and required euthanasia by 13 dpc. Even though the protected H9N2-H5 ferrets were 
co-housed with the unprotected ferret, these animals had an average of 10-fold reduction in 
viral shedding compared to the ferrets from the H9N2-GFP group. PBS-inoculated animals 
had 2-3 log higher viral titer in nasal wash samples than H9N2-H5 (Fig. 7.7B). These animals 
developed severe clinical disease, which characterized by fever, lethargy, anorexia, body 
weight loss and diarrhea. PBS-inoculated animals had uncontrolled viral replication from 1-9 
dpi and the animals either succumbed to infection or were euthanized at the humane 
endpoints. ΔH5N1 vaccinated ferrets did not show any clinical signs of disease after the 
challenge, although low levels virus shedding was detected in nasal washes collected from 2 
ferrets between 1 and 3 dpc (Fig. 7.7B). Collectively, these results suggest that the shuffled 
H9N2-H5 vector can protect mice and ferrets against severe HPAIV H5N1challenges and 





 Figure 7.8. Protective efficacy of H9N2-H5 shuffled vector in ferrets. 6-8 months old 
female ferrets (n=3) were vaccinated with 105 EID50 of the recombinant viruses and 
boosted 2 weeks later using the same virus and dose. Two weeks after boost, ferrets 
were challenged with 106 EID50 /ferret (10,000 FLD50) of A/Viet Nam/1203/2004 
(H5N1) and protection was evaluated. Nasal washes were collected for nine days post-
challenge to assess challenge virus shedding (A) Survival upon challenge (B) Virus 
shedding in nasal secretions.  The lower limit of detection (0.6 TCID50 /mL. Names on 




7.4.7. Serum antibody responses against H9N2 vector and H5 HA transgene 
 
The ability of sera from vaccinated ferrets to neutralize H5N1 and H9N2 viruses was 
assessed by HI tests. No detectable HI antibody titers against the H5N1 virus were detected 
prior to challenge in any of the groups (Table 7.2). Interestingly, when the humoral response 
was evaluated against the H9N2 virus, all animals inoculated with the H9N2-GFP vector 
control had high HI titers, whereas only a single animal from H9N2-H5 virus seroconverted 
against H9N2. Neither PBS nor ΔH5N1 inoculated ferrets had detectable antibody titers 
against the H9N2 virus (Table 7.3). 
Table 7.2. Immunogenicity in ferrets of shuffled influenza vaccines against H5N1 virus.  
 
Hemagglutination inhibiton (HI) titers are given as the reciprocal of the highest dilution of 
serum that showed activity against the ΔH5N1 virus. HI titers for each animal are shown.. 
The limit of the detection of this technique is 10. N/A: not applicable-animals were dead at 
this time point. 
  Groups 0 dpv 14 dpv 14 dpb/0 dpc 15 dpc 
PBS <10,<10,<10 <10,<10,<10 <10,<10,<10 N/A, N/A, N/A 
H9N2-GFP   <10,<10,<10 <10,<10,<10 <10,<10,<10 N/A, N/A, N/A 
H9N2-H5   <10,<10,<10 <10,<10,<10 <10,<10,<10 40,20, N/A 





Table 7.3. Immunogenicity in ferrets of shuffled influenza vaccines against H9N2 virus.  
 
Hemagglutination inhibiton (HI) titers are given as the reciprocal of the highest dilution of 
serum that showed activity against the H9N2 WT virus. HI titers for each animal are shown.. 
The limit of the detection of this technique is 10. N/A: not applicable-animals were dead at 
this time point. 
  Groups 0 dpv 14 dpv 14 dpb/0 dpc 15 dpc 
PBS <10,<10,<10 <10,<10,<10 <10,<10,<10 N/A, N/A, N/A 
H9N2-GFP   <10,<10,<10 320,320,160 160,160,160 N/A, N/A, N/A 
H9N2-H5   <10,<10,<10 <10,<10,<10 <10,40,<10 <10,40, N/A 





With the advent of reverse genetics system for IAV, several groups have devised 
strategies to express foreign peptides or proteins from the IAV genome. Among all the viral 
proteins, the surface glycoproteins HA and NA have been successfully engineered for 
expression of small protein epitopes (Li, Mueller et al. 2005; Martínez-Sobrido and García-
Sastre 2007; Martina, van den Doel et al. 2011). Nevertheless, neither HA nor NA 
glycoproteins are optimal targets for the insertion of foreign sequences because of insert size 
constraints and the fact that boost immunizations could be limited by pre-existing immunity 
to the vector or the transgene itself. Additionally, expression of foreign genes has also been 
achieved by fusion or co-expression of foreign proteins downstream of the NS1 protein, but 
expression of NEP/NS2 is still dependent of splicing of segment 8 RNA (Ferko, Stasakova et 
al. 2001; Kittel, Ferko et al. 2005; Sereinig, Stukova et al. 2006; Wolschek, Samm et al. 
2011). Recently, Manicassamy and collaborators adapted a previously developed strategy to 
express NEP/NS2 as a single ORF (Basler, Reid et al. 2001) and constructed IAV expressing 
GFP reporter gene fused to viral NS1 protein via a linker sequence. However, the stability of 
the GFP-expressing virus was compromised during multicycle replication (Manicassamy, 
Manicassamy et al. 2010). 
 In this study, we rearranged or shuffled the genome of IAV with the goal of 
expanding its genome coding capacities and improving the stability of the IAV vector. Using 
this strategy, rescue of shuffled IAV carrying up to 1.7 Kb of foreign sequences (H5 ORF) 
downstream of a truncated NS1 protein was successfully carried out. Interestingly, viruses 
expressing GFP and GLuc from full-length NS1 were effectively recovered, but it was not 
possible to rescue a virus that stably maintained the H5 ORF cloned downstream of full-
length NS1, indicating that the maximum packaging capacity of the shuffled IAV may have 
been reached. By cloning GFP and the secreted Gluc reporter genes it was possible to 
demonstrate that both the cytosolic and secretory pathways can be accessed using this 
technology. The high levels of GLuc expression in tissue culture supernatant suggested that 
shuffled IAV might have the potential to deliver soluble molecules secreted by pathogenic 
microorganisms, such as bacterial toxins.  
As a proof of principle for the shuffled influenza-based vector platform, we 
expressed the entire H5 HA ORF in the eighth segment of shuffled H9N2 IAV vector and 
tested the safety and the efficacy of this vector against a prototypical HPAIV H5N1 viruse, 




administration in two mammalian species. More importantly, inoculation of chickens with a 
shuffled virus rescued in the background of the wild type A/Viet Nam/1203/04 (H5N1) was 
completely attenuated in chickens, a highly susceptible host for HPAIV H5N1 viruses. The 
H9N2-H5 vaccine proved to be very efficacious against robust challenges with HPAIV H5N1 
in both mice and ferrets. Unlike LAIV that are currently licensed in the USA, that rely on a 
small number of attenuating mutations (Jin, Lu et al. 2003), genome shuffling may allow a 
more stable attenuation phenotype since it involves more dramatic changes in the structure of 
IAV genome. In fact, we have previously demonstrated that transferring the genetic 
signatures from the LAIV A/Ann Arbor/6/60 (H2N2) to the H9N2 avian influenza virus used 
in the current study imparted the temperature sensitive (ts) phenotype but the vaccine was not 
sufficiently attenuated in mice or chickens, which raises potential safety concerns (Song, 
Nieto et al. 2007; Hickman, Hossain et al. 2008). 
To gain further insight into the phenotypic alterations caused by the genome 
shuffling, we evaluated growth characteristics and polymerase activity derived from these 
viruses.  Comparison of growth curves of the recombinant virus showed that shuffled virus 
grew to substantially lower levels than isogenic virus without NEP/NS2 shuffling. The 
incorporation of the H5 HA did not enhance virus replication since H9N2-GFP and H9N2-H5 
had similar titers and growth kinetics. The impaired growth of shuffled viruses could be 
explained mechanistically by lower polymerase activity displayed by the PB1-2A-NEP/NS2 
as compared to the WT PB1 gene in a side-by-side vRNP reconstitution assay. The 
mechanisms responsible for the decreased activity of shuffled polymerase complex as well as 
the impaired virus growth are not completely understood. Nevertheless, we have previously 
shown that incorporating an eight amino acid HA tag epitope in the C-terminus of PB1 
reduced viral replication and polymerase activity (Pena, Vincent et al. ; Song, Nieto et al. 
2007). Thus, it is possible that the 18 amino acid long FMDV 2A tag in PB1 contributes to 
the attenuated polymerase activity and viral growth. Additionally, the expression of NEP/NS2 
from a single ORF in segment 2 may alter the levels of transcription and replication of the 
shuffled virus relative to their WT counterparts. NEP/NS2 has been shown to modulate the 
relative amounts of cRNA, vRNA, and mRNA in vRNP reconstitution assays and in the 
context of viral infection (Robb, Smith et al. 2009). Furthermore, the effect that the FMDV 
2A fused to the carboxyl terminus of NS1 have in viral replication and the ability of the IAV 
to counteract the host innate response still need to be explored. Lastly, the exact boundaries 
of the packaging signals for IAV are not yet properly defined and may be subtype or even 




length of packaging signals previously reported for H1N1 strains (Liang, Hong et al. 2005). 
Fine mapping of the optimum cis-acting sequences required for H9N2 vRNA incorporation 
into influenza virus particles may allow improvements in virus yield and stability of foreign 
genes. Hence, the phenotypic alterations exhibited by shuffled vectors may be caused by 
multiple defects in several steps of the viral life cycle. Further study of the mechanisms of 
attenuation of shuffled IAV may shed light onto basic molecular constraints that control IAV 
replication.  
The use of replication-competent vectors mirrors the natural infection and has the 
advantage of a prolonged transgene expression profile and the possibility of amplifying the 
infection, and consequently transgene delivery, to neighboring cells. However, a significant 
concern with the administration of replication-competent virus vectors derived from known 
human pathogens, such as the IAV, is the risk of residual virulence due to incomplete 
attenuation of the wild type virus. Thus, stringent safety requirements must be met for the 
application of replication competent vectors in human medicine. The pathogenicity of the 
shuffled IAV developed here was evaluated in three established animal models for IAV: 
mice, ferrets, and chickens.  In mice, resistance to IAV is partially controlled by alleles at the 
Mx locus on chromosome 16. The Mx protein is an interferon-induced guanosine 
triphosphatase that confers variable levels of resistance to orthomyxoviruses infection. The 
Mx allele is absent in influenza virus-susceptible mice strains such as BALB/c because of 
frameshift mutation or premature truncation of the Mx protein (Staeheli, Grob et al. 1988). 
Because of its high susceptibility, we chose this strain to evaluate the safety profile of the 
shuffled IAV. Single nucleotide polymorphisms (SNPs) in the Mx gene have been reported in 
humans and were associated with increased susceptibility to viral infection (Suzuki, Arase et 
al. 2004; He, Feng et al. 2006; Yin, Peng et al. 2006), highlighting the relevance of our safety 
studies for patients harboring these SNPs. When administered to BALB/c mice, the 
unshuffled ΔH5N1 virus raised some safety concerns in this highly susceptible mouse strain 
since the animals developed significant disease and the virus replicated to high titers in the 
respiratory tract. In contrast, the shuffled IAV vectors, which had the truncation in the 
interferon antagonist NS1 protein as in the ΔH5N1, were completely attenuated in mice. This 
was demonstrated by the absence of clinical signs of disease upon vaccination and the 
undetectable virus replication and pathology in the respiratory tract. The pathogenicity of the 
ΔH5N1 virus in BALB/c mice is in agreement with previous studies that demonstrated 




(Talon, Salvatore et al. 2000). Correspondingly, immunization of ferrets with shuffled vectors 
resulted in asymptomatic infection of the respiratory tract with no virus shedding. In order for 
shuffled vectors to reassort with WT IAV, both RNA segments 2 and 8 must be exchanged 
with the circulating virus. We foresaw a worst-case scenario in which this reassortment event 
would occur with a HPAIV H5N1 strain containing, among other virulent motifs, the 
polybasic cleavage site in the HA. Nevertheless, our data in chickens suggest that genome 
shuffling results in an H5N1 virus completely innocuous to this highly susceptible natural 
host. These preclinical studies performed in three highly susceptible animal species indicate 
that shuffled IAV vectors are highly attenuated in vivo and may be suitable for people bearing 
immune deficiencies as well as for the young and the elderly. 
One of the challenges in developing viral-vectored vaccines is to sufficiently 
attenuate the virus without seriously affecting its ability to function as a useful viral vector, 
e.g. being immunogenic against the target pathogen. Using aggressive HPAIV H5N1 
challenges in mice and ferret models, the efficacy of shuffled vectors was established. In 
mice, a single low dose of the H9N2-H5 vaccine provided complete clinical protection 
against challenges with up 200 MLD50. When the group was challenged with 2,000 MLD50, 
this vaccine decreased viral lung load by 10,000 fold as compared to the H9N2-GFP vector 
control and just one individual out of seven died. Subjects immunized with the vector control 
and challenged with the same dose experienced 100% mortality. A second administration of 
the H9N2-H5 vector provided sterilizing immunity irrespective of the challenge dose. In 
ferrets, the limited number of animals used and an individual animal variation appears to have 
influenced the capability of the H9N2-H5 vaccined group to resist the challenge. One animal 
developed clinical disease and shed large amounts of virus, albeit onset of shedding was 
delayed by one day in this individual relative to the other unprotected ferrets. This animal 
remained in the same isolator with the 2 other animals in this group during 12 of the15 day-
experiment. Although the active dissemination of virus by this ferret may have overwhelmed 
the protective efficacy of the H9N2-H5 vaccine, its cage-mates were completely protected 
from clinical disease and shed lower amounts of viruses relative to PBS and H9N2-GFP 
vector control groups. Even though ferrets used in this study were obtained from the same 
supplier and were age, and sex-matched, genetic and environmental elements may have been 
influenced the ability of this particular subject to respond to vaccination. 
The mechanisms responsible for the lower anti-H9 immunity after immunization with 




agreement with findings reported by Nayak and colleagues (Nayak, Rout et al. 2009). These 
authors used a Newcastle disease virus (NDV)-vectored H5 vaccine and found that, even 
though the NDV-H5 replicated to similar levels to the NDV vector control in vitro, lower 
antibodies titers against NDV was observed in animals vaccinated with NDV-H5  as 
compared to recipients of the NDV vector control (Nayak, Rout et al. 2009).  
Since its emergence in the human population in 1997, HPAIV H5N1 have been 
considered an imminent threat to public health. Besides H5N1, WHO currently recognizes 
the avian influenza H7 and H9 subtypes as viruses with pandemic potential. Furthermore, 
with the emergence of the swine-origin pandemic H1N1 in the spring of 2009, there is 
heightened concern that these highly pathogenic viruses may reassort with the pandemic virus 
to produce a highly pathogenic viruses.  Should these viruses acquire the ability to spread 
sustainably among human, a prophylactic vaccine will be the mainstay in the global combat 
to these infections. A novel pandemic strain must be immunologically distinct from 
circulating viruses with respect to the HA to be able to spread in the naïve human population 
throughout the world. In naïve populations, LAIV had significantly better efficacy than 
inactivated vaccine, which would result in more rapid herd immunity and require fewer 
vaccine doses as compared to inactivated vaccines (Johnson, Feldman et al. 1985; Belshe, 
Mendelman et al. 1998). Our shuffled-based IAV vaccines might be an appropriate 
alternative to conventional inactivated and LAIV in case of a pandemic due to its safety 
profile and robust efficacy.  
In summary, we demonstrated, for the first time, that influenza viruses are amenable 
to genome rearrangement and can satisfactorily accommodate large pieces of additional 
genetic material while preserving replication and immunogenicity. This vaccine does not 
require expensive high-containment manufacturing facilities and can be grown in eggs; so far 
the substrate of choice for producing IAV vaccines.  Furthermore, development of this 
technology may pave the way to a novel class of influenza vectors that can provide immunity 





Chapter 8: Conclusions and future prospects 
 
8.1. Conclusions  
The overall objectives of this dissertation work were to determine the molecular basis 
of virulence of the influenza A viruses (IAV) for the swine host and to develop live 
attenuated influenza vaccines and influenza-based vectors for their use in multiple species.  
Here, we determined that the surface glycoproteins and the PB1-F2 protein are 
virulence determinants of IAV for pigs. We focused on swine because of the economical 
importance of this species for the livestock industry, its epidemiological relevance in IAV 
ecology, and the fact that swine influenza mirrors the human disease regarding the 
distribution of sialic acid receptors, cytokine production, and clinical-pathological outcomes 
after influenza infection. We consider these studies to be very timely considering the current 
scenario of IAV infection with triple reassortant viruses in both the human and swine 
population. 
In the second part of this study, we developed temperature-sensitive live attenuated 
influenza vaccines that are safe and efficacious in pigs. These studies highlighted the safety 
of a live attenuated vaccine platform and its potential as a master donor strain for the 
generation of efficacious vaccines with applications in both human and veterinary medicine. 
Lastly, we rearranged the genome of an avian H9N2 influenza virus to generate 
replication-competent influenza virus vectors that provide a robust system for expression and 
delivery of foreign genes. As a proof-of-principle, we expressed the hemagglutinin from a 
prototypical highly pathogenic avian influenza virus (HPAIV) H5N1 and shown that this 
vectored H5 vaccine retained its safety properties in avian and mammalian species, and 
induced excellent protection against aggressive HPAIV H5N1 challenges in mice and ferrets.  
To our knowledge, the studies completed in this dissertation are the first to define 
molecular markers in the AIV genome that contributes to its virulence in pigs. In addition, the 
influenza-based vaccines and viral vectors engineered in this research are novel in the field of 
influenza virus research. These studies provided novel insights for understanding influenza 







Based on the results presented in chapters 3 to 7, the general conclusions from this 
study are:  
 
1) Role of surface glycoproteins in the pathogenesis of triple reassortant H3N2 
influenza viruses in swine (Chapter 3): 
a) We have successfully established a reverse genetics system for generation of 
triple reassortant H3N2 influenza A viruses (sw/99 and ty/04) from cloned 
cDNAs 
b) We have developed a swine model of infection that reproduces clinical signs 
of disease under experimental condition. 
c) Genetically related triple reassortant H3N2 IAV display different pathotypes 
in the swine host. 
d) Surface glycoproteins are necessary and sufficient for the lung pathology 
induced by these viruses 
e) The internal genes from triple reassortant H3N2 IAV play a major role in 
induction of the febrile response 
f) Influenza virus virulence in swine is polygenic. Other genes in addition to 
HA and NA are required for reversion of the clinical disease phenotype. 
 
2) Role of PB1-F2 in the virulence of triple reassortant H3N2 and pandemic 
H1N1 influenza viruses in swine (Chapters 4 and 5): 
 
a) PB1-F2 in the context of the sw/99 strain impacts macrophage viability and 
viral yields in PAM, as well as IL-6 in vivo. 
b) In the context of ty/04, PB1-F2 increases its replication in explants but not in 
vivo. 
c) Knocking out PB1-F2 from ty/04 enhances pulmonary lesions in pigs, as 




d) In the context of pH1N1, PB1-F2 increases polymerase activity and its 
replication in respiratory explants and in lungs of infected swine.  
e) Restoring PB1-F2 in pH1N1 enhances microscopic pneumonia and the 
pulmonary levels of IFN-α and IL-1β. 
f) In swine, PB1-F2 proteins derived from triple reassortant IAVs exhibit the 
following effects in vivo: no effect in the context of sw/99 strain; increases 
the virulence of pH1N1; and decreases the virulence of ty/04. 
g) Overall, PB1-F2 has pleiotropic effects in the swine host, which are 
expressed in a strain-dependent manner. 
 
3) Modifications in the polymerase genes of a swine-like triple reassortant 
influenza virus to generate live attenuated vaccines for humans and livestock (Chapter 
6): 
 
a) The double attenuating mutations first implemented for an H9N2 avian 
influenza strain could be successfully transferred to a heterologous 
nonattenuated swine-like triple reassortant influenza virus. 
b) We have successfully developed a viral ribonucleoprotein (vRNP) 
reconstitution assay to study polymerase activity based on the secreted 
Gaussia luciferase 
c) The live attenuated influenza vaccine (LAIV) based on ty/04 strain expresses 
desirable biological traits in vitro. 
d) The ty/04-based LAIV rescued with H3N2 and pH1N1 surfaces retain their 
safety properties in vivo (mice and swine).  
e) The ty/04-based LAIV induces excellent protection against aggressive 
pH1N1 challenges in both mice and swine. 
f) The ty/04-based LAIV is cell-culture based, which makes it an attractive 





g) The ty/04-based LAIV has the potential for the prevention of influenza 
across species 
 
4) Shuffling of the influenza genome to engineer vectors stably expressing foreign 
genes (Chapter 7): 
 
a) The vector allows for both cytosolic and ER bound translation. 
b) The H5 hemagglutinin expressed from segment 8 is incorporated into the 
envelope of a shuffled H9N2 virus. 
c) Shuffled vectors have impaired polymerase activity and viral replication in 
vitro. 
d) At least 1.7kb can be expressed from an eight-segmented influenza virus 
vector. 
e) Genome rearrangement was able to completely attenuate a ressortant virus 
containing 6 genes from a highly pathogenic H5N1 and the 2 modified 
segments from the shuffled vector (PB1-NEP/NS2 and NS1-GFP) in 
chickens. 
f) The shuffled vector is highly attenuated in vivo and provides efficient 





 8.2. Future prospects 
Based on the findings from this dissertation research, the following studies are suggested: 
 
1) Role of surface glycoproteins in the pathogenesis of triple reassortant H3N2 
influenza viruses in swine (Chapter 3): 
a) Test 7:1 reassortant with just HA gene to assess if the HA is sufficient for the 
lung pathology. 
b) Test 5:3 reassortant (HA,NA,NS) to assess if these gene combination can 
revert  the clinical disease phenotype. 
c) Characterize other gene combinations to determine the molecular 
constellation that contributes to the high virulence of ty/04 relative to sw/99 
in pigs. 
d) Characterize the receptor binding profile of the sw/99 and ty/04 HA using 
glycan arrays and correlate that with the receptors in the pig. 
e) Study the effects of glycosylation site at position 246 in both sw/99 and ty/04 
with respect to virus infectivity, receptor binding, pathogenicity, and 
transmissibility. The mutation N246S arouse during amplification of the 
sw/99 in eggs. The presence of this mutation changes the reactivity of sw/99 
in HA assays using either turkey or chicken RBCs. These mutations have 
already been introduced in both sw/99 and ty/04 and the viruses have been 
successfully recovered. 
f) Study reassortment events and transmissibility of sw/99 and ty/04 with other 
IAV that exhibit pandemic potential such H2N2, H5N1, H7N1, and H9N2. 
g) Characterize the transmissibility and pathogenesis of triple reassortant IAVs 
in ferrets and evaluate their pandemic potential upon adaptation and 
reassortment with other IAVs in both pigs and ferrets. Do the triple 
reassortants H3N2 IAVs have zoonotic or pandemic potential? If so, are 







2) Role of PB1-F2 in the virulence of triple reassortant H3N2 and pandemic 
H1N1 influenza viruses in swine (Chapters 4 and 5): 
a) Determine the molecular and cellular mechanisms responsible for PB1-F2 
strain-specific effects in swine. 
b) Test the PB1-F2 recombinant viruses generated herein in post-influenza 
secondary pneumonia in murine and swine models. 
c) Use the PB1-F2 recombinant viruses rescued herein to evaluate the effects of 
PB1-F2 in other animal models such as chickens, turkeys, and ferrets. 
d) Determine if the surface proteins contribute to the strain-specificity of PB1-F2 
proteins derived from triple reassortant IAVs. 
e) Determine if the PB1-F2 proteins studied here have a direct effect on cellular 
pathways involved in innate immune responses and cell death. 
f) Test whether the PB1-F2 used herein have direct antibacterial effect and 
whether they have pro- or anti-inflammatory potential upon administration of 




3) Modifications in the polymerase genes of a swine-like triple reassortant 
influenza virus to generate live attenuated vaccines for humans and livestock (Chapter 
6): 
 
a) Test the effects of the T6D mutation in the ty/04 PB1 att gene. This mutation 
interferes with PB1-PA interaction and is expected to attenuate further the 
ty/04 att vaccine. Ty/04 att viruses containing the T6D mutation has already 
been rescued. 
b) Test the effects of introducing the H6 cleavage site (PQIET motif) into the 
HA cleavage site of the H3 (ty/04) and H1 (pH1N1) virus subtypes. These 
modifications have already been made and the viruses have been rescued. 




d) Compare inactivated vaccines and ty/04 LAIV vaccines in a swine model of 
vaccine-induced enhanced pneumonia 
e) Characterize, in depth, both the cellular and humoral immune responses 
induced by ty/04 LAIV in pigs. 
f) Safety and efficacy studies of ty/04 LAIV in the field 
g) Test the ty/04 vaccine in other species such as ferrets, turkeys and chickens. 
h) Test the ty/04 att pH1N1 and H3N2 vaccines containing the elastase motif in 
the HA. These vaccines have already been made and their sequences were 
confirmed. These vaccines are expect to improve the safety profile of the 
original ty/04 LAIV. 
i) Test the ty/04 att vaccines in which the pH1 and the H3 cleavage sites in the 
HA were replaced by the H6 cleavage site (PQIET motif) in the HA. These 
vaccines are expect to improve the safety profile of the original ty/04 LAIV. 
j) Test alternative routes of immunization such as intradermal for delivery of 
ty/04 LAIV. 
k) License the vaccine for field use in swine and turkey populations. 
 
 
4) Shuffling of the influenza genome to engineer vectors stably expressing foreign 
genes (Chapter 7): 
a. Use the shuffled vector to express molecular adjuvants in vaccine/challenge 
studies against influenza and other diseases. 
b. Evaluate the safety and efficacy of the shuffled H9N2-H5 in the young and 
the elderly (mouse models).  
c. Test shuffled H9N2 vectors expressing soluble H5 HA and headless H5 to 
evaluate whether these constructs improve the immunogenicity and the 




d. Use the GLuc-based vector developed herein to measure influenza-specific 
neutralizing antibodies in biological samples. 
e. Study the types of cells infected by IAV and virus reassortment using the 
GFP and RFP reporters already generated. 
f. Rearrange other genes in order to restore polymerase activity and virus 
growth. Then, perform pathogenesis studies using in vivo bioluminescence 
imaging systems. 
g. Use the shuffled vectors for genome-wide RNA interference (RNAi) screens 
to identify host factors that are required for influenza replication. 
a. Adapt the shuffled vector for high growth in Vero cells, which is an 
approved substrate to produce human vaccines. 
b. Use the vector against other pathogens and cancer. 
c. Product development and licensure for agriculture and human use. 
 
These studies will advance the scientific knowledge in the influenza field and will 
hopefully shed light for the rational development of vaccines and other intervention strategies 

































Al Hajjar, S. and K. McIntosh (2010). "The first influenza pandemic of the 21st 
century." Annals of Saudi medicine 30(1): 1-10. 
Al Hajjar, S. and K. McIntosh (2010). "The first influenza pandemic of the 21st 
century." Ann Saudi Med 30(1): 1-10. 
Ali, A., R. T. Avalos, et al. (2000). "Influenza virus assembly: effect of influenza 
virus glycoproteins on the membrane association of M1 protein." Journal of 
virology 74(18): 8709-8719. 
Alymova, I. V., A. M. Green, et al. (2011). "Immunopathogenic and anti-bacterial 
effects of the H3N2 influenza A virus PB1-F2 map to amino acid residues 62, 
75, 79, and 82." Journal of virology. 
Ambrose, C. S., C. Luke, et al. (2008). "Current status of live attenuated influenza 
vaccine in the United States for seasonal and pandemic influenza." Influenza 
Other Respi Viruses 2(6): 193-202. 
Ambrose, C. S., T. Yi, et al. (2008). "Duration of protection provided by live 
attenuated influenza vaccine in children." Pediatr Infect Dis J 27(8): 744-748. 
Angata, T. and A. Varki (2002). "Chemical diversity in the sialic acids and related 
alpha-keto acids: an evolutionary perspective." Chemical reviews 102(2): 439-
469. 
Baigent, S. J. and J. W. McCauley (2003). "Influenza type A in humans, mammals 
and birds: determinants of virus virulence, host-range and interspecies 
transmission." BioEssays : news and reviews in molecular, cellular and 
developmental biology 25(7): 657-671. 
Barbe, F., K. Atanasova, et al. (2010). "Cytokines and acute phase proteins associated 
with acute swine influenza infection in pigs." Vet J. 
Barbe, F., K. Atanasova, et al. (2011). "Cytokines and acute phase proteins associated 
with acute swine influenza infection in pigs." Veterinary journal 187(1): 48-
53. 
Barbe, F., X. Saelens, et al. (2010). "Role of IFN-alpha during the acute stage of a 
swine influenza virus infection." Res Vet Sci 88(1): 172-178. 
Barclay, W. S. and P. Palese (1995). "Influenza B viruses with site-specific mutations 
introduced into the HA gene." Journal of virology 69(2): 1275-1279. 
Barnard, D. L. (2009). "Animal models for the study of influenza pathogenesis and 
therapy." Antiviral research 82(2): A110-122. 
Barnard, D. L. (2009). "Animal models for the study of influenza pathogenesis and 
therapy." Antiviral Res 82(2): A110-122. 
Basler, C. F. and P. V. Aguilar (2008). "Progress in identifying virulence 
determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A 
viruses." Antiviral research 79(3): 166-178. 
Basler, C. F., A. H. Reid, et al. (2001). "Sequence of the 1918 pandemic influenza 
virus nonstructural gene (NS) segment and characterization of recombinant 
viruses bearing the 1918 NS genes." Proceedings of the National Academy of 




Baumgarth, N. and A. Kelso (1996). "In vivo blockade of gamma interferon affects 
the influenza virus-induced humoral and the local cellular immune response in 
lung tissue." Journal of virology 70(7): 4411-4418. 
Bean, W. J., M. Schell, et al. (1992). "Evolution of the H3 influenza virus 
hemagglutinin from human and nonhuman hosts." Journal of virology 66(2): 
1129-1138. 
Belshe, R. B. (2004). "Current status of live attenuated influenza virus vaccine in the 
US." Virus research 103(1-2): 177-185. 
Belshe, R. B., C. S. Ambrose, et al. (2008). "Safety and efficacy of live attenuated 
influenza vaccine in children 2-7 years of age." Vaccine 26 Suppl 4: D10-16. 
Belshe, R. B., K. M. Edwards, et al. (2007). "Live attenuated versus inactivated 
influenza vaccine in infants and young children." The New England journal of 
medicine 356(7): 685-696. 
Belshe, R. B., P. M. Mendelman, et al. (1998). "The efficacy of live attenuated, cold-
adapted, trivalent, intranasal influenzavirus vaccine in children." The New 
England journal of medicine 338(20): 1405-1412. 
Block, S. L., R. Yogev, et al. (2008). "Shedding and immunogenicity of live 
attenuated influenza vaccine virus in subjects 5-49 years of age." Vaccine 
26(38): 4940-4946. 
Bourmakina, S. V. and A. Garcia-Sastre (2003). "Reverse genetics studies on the 
filamentous morphology of influenza A virus." The Journal of general 
virology 84(Pt 3): 517-527. 
Britton, A. P., K. R. Sojonky, et al. (2010). "Pandemic (H1N1) 2009 in skunks, 
Canada." Emerging infectious diseases 16(6): 1043-1045. 
Brockmeier, S. L., K. M. Lager, et al. (2009). "Adenovirus-mediated expression of 
interferon-alpha delays viral replication and reduces disease signs in swine 
challenged with porcine reproductive and respiratory syndrome virus." Viral 
immunology 22(3): 173-180. 
Brookes, S. M., R. M. Irvine, et al. (2009). "Influenza A (H1N1) infection in pigs." 
Vet Rec 164(24): 760-761. 
Brown, I. H., S. H. Done, et al. (1993). "Pathogenicity of a swine influenza H1N1 
virus antigenically distinguishable from classical and European strains." The 
Veterinary record 132(24): 598-602. 
Brown, I. H., P. A. Harris, et al. (1998). "Multiple genetic reassortment of avian and 
human influenza A viruses in European pigs, resulting in the emergence of an 
H1N2 virus of novel genotype." The Journal of general virology 79 ( Pt 12): 
2947-2955. 
Bruder, D., A. Srikiatkhachorn, et al. (2006). "Cellular immunity and lung injury in 
respiratory virus infection." Viral immunology 19(2): 147-155. 
Bryant, M. L., P. Brown, et al. (1999). "Comparison of the clearance of radiolabelled 
nose drops and nasal spray as mucosally delivered vaccine." Nucl Med 
Commun 20(2): 171-174. 
Castrucci, M. R. and Y. Kawaoka (1995). "Reverse genetics system for generation of 
an influenza A virus mutant containing a deletion of the carboxyl-terminal 




Centanni, E. and E. Savonuzzi (1901). "La peste aviaria " Communicazione fatta 
all'Accademia delle Scienze mediche e naturali di ferrara. 
Chambers, T. M., R. E. Holland, et al. (2001). "A new modified live equine influenza 
virus vaccine: phenotypic stability, restricted spread and efficacy against 
heterologous virus challenge." Equine Vet J 33(7): 630-636. 
Chan, M. C., R. W. Chan, et al. (2010). "Tropism and innate host responses of the 
2009 pandemic H1N1 influenza virus in ex vivo and in vitro cultures of 
human conjunctiva and respiratory tract." The American journal of pathology 
176(4): 1828-1840. 
Chan, W., H. Zhou, et al. (2008). "The cold adapted and temperature sensitive 
influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated 
influenza vaccines, has multiple defects in replication at the restrictive 
temperature." Virology 380(2): 304-311. 
Chen, B. J., G. P. Leser, et al. (2008). "The influenza virus M2 protein cytoplasmic 
tail interacts with the M1 protein and influences virus assembly at the site of 
virus budding." Journal of virology 82(20): 10059-10070. 
Chen, C. J., G. W. Chen, et al. (2010). "Differential localization and function of PB1-
F2 derived from different strains of influenza A virus." Journal of virology 
84(19): 10051-10062. 
Chen, G. L., E. W. Lamirande, et al. (2010). "Safety, immunogencity, and efficacy of 
a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets." 
Virology 398(1): 109-114. 
Chen, G. L. and K. Subbarao (2009). "Live attenuated vaccines for pandemic 
influenza." Curr Top Microbiol Immunol 333: 109-132. 
Chen, H., R. A. Bright, et al. (2007). "Polygenic virulence factors involved in 
pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice." Virus 
research 128(1-2): 159-163. 
Chen, W., P. A. Calvo, et al. (2001). "A novel influenza A virus mitochondrial 
protein that induces cell death." Nat Med 7(12): 1306-1312. 
Chen, Z., C. Santos, et al. (2009). "Evaluation of live attenuated influenza a virus h6 
vaccines in mice and ferrets." Journal of virology 83(1): 65-72. 
Chen, Z., C. Santos, et al. (2009). "Evaluation of live attenuated influenza a virus h6 
vaccines in mice and ferrets." J Virol 83(1): 65-72. 
Choi, Y. K., J. H. Lee, et al. (2004). "H3N2 influenza virus transmission from swine 
to turkeys, United States." Emerg Infect Dis 10(12): 2156-2160. 
Choi, Y. K., T. D. Nguyen, et al. (2005). "Studies of H5N1 influenza virus infection 
of pigs by using viruses isolated in Vietnam and Thailand in 2004." Journal of 
virology 79(16): 10821-10825. 
Chou, Y. Y., R. A. Albrecht, et al. (2011). "The M Segment of the 2009 New 
Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission 
Efficiency in the Guinea Pig Model." Journal of virology 85(21): 11235-
11241. 
Clouthier, S. C., T. Rector, et al. (2002). "Genomic organization of infectious salmon 
anaemia virus." The Journal of general virology 83(Pt 2): 421-428. 
Coleman, J. R. (2007). "The PB1-F2 protein of Influenza A virus: increasing 




Conenello, G. M. and P. Palese (2007). "Influenza A virus PB1-F2: a small protein 
with a big punch." Cell Host Microbe 2(4): 207-209. 
Conenello, G. M., D. Zamarin, et al. (2007). "A single mutation in the PB1-F2 of 
H5N1 (HK/97) and 1918 influenza A viruses contributes to increased 
virulence." PLoS Pathog 3(10): 1414-1421. 
Copeland, C. S., R. W. Doms, et al. (1986). "Assembly of influenza hemagglutinin 
trimers and its role in intracellular transport." The Journal of cell biology 
103(4): 1179-1191. 
Cox, R. J., K. A. Brokstad, et al. (2004). "Influenza virus: immunity and vaccination 
strategies. Comparison of the immune response to inactivated and live, 
attenuated influenza vaccines." Scand J Immunol 59(1): 1-15. 
Crawford, P. C., E. J. Dubovi, et al. (2005). "Transmission of equine influenza virus 
to dogs." Science 310(5747): 482-485. 
Cross, K. J., L. M. Burleigh, et al. (2001). "Mechanisms of cell entry by influenza 
virus." Expert reviews in molecular medicine 3(21): 1-18. 
Da Silva, E. V., A. P. Da Rosa, et al. (2005). "Araguari virus, a new member of the 
family Orthomyxoviridae: serologic, ultrastructural, and molecular 
characterization." The American journal of tropical medicine and hygiene 
73(6): 1050-1058. 
Dallegri, F. and L. Ottonello (1997). "Tissue injury in neutrophilic inflammation." 
Inflammation research : official journal of the European Histamine Research 
Society ... [et al.] 46(10): 382-391. 
Dawood, F. S., S. Jain, et al. (2009). "Emergence of a novel swine-origin influenza A 
(H1N1) virus in humans." N Engl J Med 360(25): 2605-2615. 
Dawood, F. S., S. Jain, et al. (2009). "Emergence of a novel swine-origin influenza A 
(H1N1) virus in humans." The New England journal of medicine 360(25): 
2605-2615. 
de Felipe, P. (2004). "Skipping the co-expression problem: the new 2A "CHYSEL" 
technology." Genetic vaccines and therapy 2(1): 13. 
de Jong, J. C., D. J. Smith, et al. (2007). "Antigenic and genetic evolution of swine 
influenza A (H3N2) viruses in Europe." Journal of virology 81(8): 4315-4322. 
de Jong, M. D., C. P. Simmons, et al. (2006). "Fatal outcome of human influenza A 
(H5N1) is associated with high viral load and hypercytokinemia." Nature 
medicine 12(10): 1203-1207. 
De Vleeschauwer, A., K. Atanasova, et al. (2009). "Comparative pathogenesis of an 
avian H5N2 and a swine H1N1 influenza virus in pigs." PloS one 4(8): e6662. 
de Wit, E., V. J. Munster, et al. (2010). "Molecular determinants of adaptation of 
highly pathogenic avian influenza H7N7 viruses to efficient replication in the 
human host." Journal of virology 84(3): 1597-1606. 
de Wit, E., M. I. Spronken, et al. (2007). "A reverse-genetics system for Influenza A 
virus using T7 RNA polymerase." The Journal of general virology 88(Pt 4): 
1281-1287. 
Desselberger, U., V. R. Racaniello, et al. (1980). "The 3' and 5'-terminal sequences of 
influenza A, B and C virus RNA segments are highly conserved and show 




Dias, A., D. Bouvier, et al. (2009). "The cap-snatching endonuclease of influenza 
virus polymerase resides in the PA subunit." Nature 458(7240): 914-918. 
Draper, S. J. and J. L. Heeney (2010). "Viruses as vaccine vectors for infectious 
diseases and cancer." Nature reviews. Microbiology 8(1): 62-73. 
Ducatez, M. F., B. Hause, et al. (2011). "Multiple Reassortment between Pandemic 
(H1N1) 2009 and Endemic Influenza Viruses in Pigs, United States." 
Emerging infectious diseases 17(9): 1624-1629. 
Dudek, S. E., L. Wixler, et al. (2011). "The influenza virus PB1-F2 protein has 
interferon-antagonistic activity." Biological chemistry. 
Dundon, W. G., P. De Benedictis, et al. (2010). "Serologic evidence of pandemic 
(H1N1) 2009 infection in dogs, Italy." Emerging infectious diseases 16(12): 
2019-2021. 
Easterday, B. C. a. V. R., K. (1999). " Swine Influenza." Diseases of Swine Iowa 
state University Press, Ames, Iowa, USA: 277-290. 
Ekiert, D. C., R. H. Friesen, et al. (2011). "A highly conserved neutralizing epitope on 
group 2 influenza A viruses." Science 333(6044): 843-850. 
Elleman, C. J. and W. S. Barclay (2004). "The M1 matrix protein controls the 
filamentous phenotype of influenza A virus." Virology 321(1): 144-153. 
Enami, M., W. Luytjes, et al. (1990). "Introduction of site-specific mutations into the 
genome of influenza virus." Proceedings of the National Academy of Sciences 
of the United States of America 87(10): 3802-3805. 
Enami, M. and P. Palese (1991). "High-efficiency formation of influenza virus 
transfectants." Journal of virology 65(5): 2711-2713. 
Enami, M., G. Sharma, et al. (1991). "An influenza virus containing nine different 
RNA segments." Virology 185(1): 291-298. 
Enserink, M. and J. Cohen (2009). "Virus of the year. The novel H1N1 influenza." 
Science 326(5960): 1607. 
Ferko, B., J. Stasakova, et al. (2001). "Hyperattenuated recombinant influenza A 
virus nonstructural-protein-encoding vectors induce human immunodeficiency 
virus type 1 Nef-specific systemic and mucosal immune responses in mice." 
Journal of virology 75(19): 8899-8908. 
Fernandez-Sesma, A., S. Marukian, et al. (2006). "Influenza virus evades innate and 
adaptive immunity via the NS1 protein." Journal of virology 80(13): 6295-
6304. 
Fodor, E., L. Devenish, et al. (1999). "Rescue of influenza A virus from recombinant 
DNA." Journal of virology 73(11): 9679-9682. 
Fouchier, R. A., V. Munster, et al. (2005). "Characterization of a novel influenza A 
virus hemagglutinin subtype (H16) obtained from black-headed gulls." 
Journal of virology 79(5): 2814-2822. 
Fouchier, R. A., P. M. Schneeberger, et al. (2004). "Avian influenza A virus (H7N7) 
associated with human conjunctivitis and a fatal case of acute respiratory 
distress syndrome." Proceedings of the National Academy of Sciences of the 
United States of America 101(5): 1356-1361. 
Fujii, K., Y. Fujii, et al. (2005). "Importance of both the coding and the segment-
specific noncoding regions of the influenza A virus NS segment for its 




Fujii, K., M. Ozawa, et al. (2009). "Incorporation of influenza A virus genome 
segments does not absolutely require wild-type sequences." The Journal of 
general virology 90(Pt 7): 1734-1740. 
Fukuyama, S. and Y. Kawaoka (2011). "The pathogenesis of influenza virus 
infections: the contributions of virus and host factors." Current opinion in 
immunology 23(4): 481-486. 
Gagneux, P., M. Cheriyan, et al. (2003). "Human-specific regulation of alpha 2-6-
linked sialic acids." The Journal of biological chemistry 278(48): 48245-
48250. 
Gambaryan, A. S., A. I. Karasin, et al. (2005). "Receptor-binding properties of swine 
influenza viruses isolated and propagated in MDCK cells." Virus research 
114(1-2): 15-22. 
Gao, Q., A. C. Lowen, et al. (2010). "A nine-segment influenza a virus carrying 
subtype H1 and H3 hemagglutinins." Journal of virology 84(16): 8062-8071. 
Gao, Q. and P. Palese (2009). "Rewiring the RNAs of influenza virus to prevent 
reassortment." Proceedings of the National Academy of Sciences of the 
United States of America 106(37): 15891-15896. 
Garcia-Sastre, A., T. Muster, et al. (1994). "Use of a mammalian internal ribosomal 
entry site element for expression of a foreign protein by a transfectant 
influenza virus." Journal of virology 68(10): 6254-6261. 
Garten, R. J., C. T. Davis, et al. (2009). "Antigenic and genetic characteristics of 
swine-origin 2009 A(H1N1) influenza viruses circulating in humans." Science 
325(5937): 197-201. 
Garulli, B., Y. Kawaoka, et al. (2004). "Mucosal and systemic immune responses to a 
human immunodeficiency virus type 1 epitope induced upon vaginal infection 
with a recombinant influenza A virus." Journal of virology 78(2): 1020-1025. 
Gauger, P. C., A. L. Vincent, et al. (2011). "Enhanced pneumonia and disease in pigs 
vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and 
challenged with pandemic 2009 H1N1 influenza virus." Vaccine 29(15): 
2712-2719. 
Gibbs, A. J., J. S. Armstrong, et al. (2009). "From where did the 2009 'swine-origin' 
influenza A virus (H1N1) emerge?" Virology journal 6: 207. 
Gibbs, A. J., J. S. Armstrong, et al. (2009). "From where did the 2009 'swine-origin' 
influenza A virus (H1N1) emerge?" Virol J 6: 207. 
Gibbs, E. P. and T. C. Anderson (2010). "Equine and canine influenza: a review of 
current events." Animal health research reviews / Conference of Research 
Workers in Animal Diseases 11(1): 43-51. 
Gill, J. R., Z. M. Sheng, et al. (2010). "Pulmonary pathologic findings of fatal 2009 
pandemic influenza A/H1N1 viral infections." Arch Pathol Lab Med 134(2): 
235-243. 
Golde, W. T., P. Gollobin, et al. (2005). "A rapid, simple, and humane method for 
submandibular bleeding of mice using a lancet." Lab Anim (NY) 34(9): 39-
43. 
Gomez-Puertas, P., C. Albo, et al. (2000). "Influenza virus matrix protein is the major 




Gong, J., W. Xu, et al. (2007). "Structure and functions of influenza virus 
neuraminidase." Current medicinal chemistry 14(1): 113-122. 
Govorkova, E. A., J. E. Rehg, et al. (2005). "Lethality to ferrets of H5N1 influenza 
viruses isolated from humans and poultry in 2004." Journal of virology 79(4): 
2191-2198. 
Graef, K. M., F. T. Vreede, et al. (2010). "The PB2 subunit of the influenza virus 
RNA polymerase affects virulence by interacting with the mitochondrial 
antiviral signaling protein and inhibiting expression of beta interferon." 
Journal of virology 84(17): 8433-8445. 
Graham, M. B., D. K. Dalton, et al. (1993). "Response to influenza infection in mice 
with a targeted disruption in the interferon gamma gene." The Journal of 
experimental medicine 178(5): 1725-1732. 
Gramer, M. R., J. H. Lee, et al. (2007). "Serologic and genetic characterization of 
North American H3N2 swine influenza A viruses." Canadian journal of 
veterinary research = Revue canadienne de recherche veterinaire 71(3): 201-
206. 
Gray, G. C., T. McCarthy, et al. (2007). "Swine workers and swine influenza virus 
infections." Emerging infectious diseases 13(12): 1871-1878. 
Greninger, A. L., E. C. Chen, et al. (2010). "A metagenomic analysis of pandemic 
influenza A (2009 H1N1) infection in patients from North America." PloS one 
5(10): e13381. 
Grivel, J. C. and L. Margolis (2009). "Use of human tissue explants to study human 
infectious agents." Nature protocols 4(2): 256-269. 
Guo, J., L. Yao, et al. (2010). "[Immunological evaluation of vector-expressed M2 
and HA genes of H5N1 influenza virus in mice]." Sheng wu gong cheng xue 
bao = Chinese journal of biotechnology 26(5): 649-656. 
Hai, R., M. Schmolke, et al. "PB1-F2 expression by the 2009 pandemic H1N1 
influenza virus has minimal impact on virulence in animal models." J Virol 
84(9): 4442-4450. 
Halbur, P. G., P. S. Paul, et al. (1995). "Comparison of the pathogenicity of two US 
porcine reproductive and respiratory syndrome virus isolates with that of the 
Lelystad virus." Veterinary pathology 32(6): 648-660. 
Halbur, P. G., P. S. Paul, et al. (1995). "Comparison of the pathogenicity of two US 
porcine reproductive and respiratory syndrome virus isolates with that of the 
Lelystad virus." Vet Pathol 32(6): 648-660. 
Hale, B. G., R. E. Randall, et al. (2008). "The multifunctional NS1 protein of 
influenza A viruses." The Journal of general virology 89(Pt 10): 2359-2376. 
Harder, T. C. and T. W. Vahlenkamp (2010). "Influenza virus infections in dogs and 
cats." Veterinary immunology and immunopathology 134(1-2): 54-60. 
Hatta, M., P. Gao, et al. (2001). "Molecular basis for high virulence of Hong Kong 
H5N1 influenza A viruses." Science 293(5536): 1840-1842. 
Hayden, F. G., R. Fritz, et al. (1998). "Local and systemic cytokine responses during 
experimental human influenza A virus infection. Relation to symptom 





He, J., D. Feng, et al. (2006). "Association of SARS susceptibility with single nucleic 
acid polymorphisms of OAS1 and MxA genes: a case-control study." BMC 
infectious diseases 6: 106. 
He, X. S., T. H. Holmes, et al. (2006). "Cellular immune responses in children and 
adults receiving inactivated or live attenuated influenza vaccines." J Virol 
80(23): 11756-11766. 
Hensley, S. E., S. R. Das, et al. (2009). "Hemagglutinin receptor binding avidity 
drives influenza A virus antigenic drift." Science 326(5953): 734-736. 
Hickman, D., M. J. Hossain, et al. (2008). "An avian live attenuated master backbone 
for potential use in epidemic and pandemic influenza vaccines." J Gen Virol 
89(Pt 11): 2682-2690. 
Hirst, G. K. (1941). "The Agglutination of Red Cells by Allantoic Fluid of Chick 
Embryos Infected with Influenza Virus." Science 94(2427): 22-23. 
Hoffmann, E., G. Neumann, et al. (2000). "A DNA transfection system for generation 
of influenza A virus from eight plasmids." Proceedings of the National 
Academy of Sciences of the United States of America 97(11): 6108-6113. 
Hoffmann, E., G. Neumann, et al. (2000). "A DNA transfection system for generation 
of influenza A virus from eight plasmids." Proc. Natl. Acad. Sci. U S A. 
97(11): 6108-6113. 
Hoffmann, E., J. Stech, et al. (2001). "Universal primer set for the full-length 
amplification of all influenza A viruses." Arch Virol 146(12): 2275-2289. 
Hoffmann, E., J. Stech, et al. (2001). "Universal primer set for the full-length 
amplification of all influenza A viruses." Arch Virol 146(12): 2275-2289. 
Hofshagen, M., B. Gjerset, et al. (2009). "Pandemic influenza A(H1N1)v: human to 
pig transmission in Norway?" Euro Surveill 14(45). 
Horimoto, T. and Y. Kawaoka (1994). "Reverse genetics provides direct evidence for 
a correlation of hemagglutinin cleavability and virulence of an avian influenza 
A virus." Journal of virology 68(5): 3120-3128. 
Horimoto, T. and Y. Kawaoka (2009). "Designing vaccines for pandemic influenza." 
Curr Top Microbiol Immunol 333: 165-176. 
Howard, W. A., S. C. Essen, et al. (2011). "Reassortant Pandemic (H1N1) 2009 Virus 
in Pigs, United Kingdom." Emerging infectious diseases 17(6): 1049-1052. 
Howden, K. J., E. J. Brockhoff, et al. (2009). "An investigation into human pandemic 
influenza virus (H1N1) 2009 on an Alberta swine farm." Can Vet J 50(11): 
1153-1161. 
Howden, K. J., E. J. Brockhoff, et al. (2009). "An investigation into human pandemic 
influenza virus (H1N1) 2009 on an Alberta swine farm." The Canadian 
veterinary journal. La revue veterinaire canadienne 50(11): 1153-1161. 
Huang, I. C., W. Li, et al. (2008). "Influenza A virus neuraminidase limits viral 
superinfection." Journal of virology 82(10): 4834-4843. 
Hughes, M. T., M. Matrosovich, et al. (2000). "Influenza A viruses lacking sialidase 
activity can undergo multiple cycles of replication in cell culture, eggs, or 
mice." Journal of virology 74(11): 5206-5212. 
Hulse, D. J., R. G. Webster, et al. (2004). "Molecular determinants within the surface 
proteins involved in the pathogenicity of H5N1 influenza viruses in chickens." 




Hutchinson, E. C., J. C. von Kirchbach, et al. (2010). "Genome packaging in 
influenza A virus." The Journal of general virology 91(Pt 2): 313-328. 
Ibricevic, A., A. Pekosz, et al. (2006). "Influenza virus receptor specificity and cell 
tropism in mouse and human airway epithelial cells." Journal of virology 
80(15): 7469-7480. 
Ito, T., J. N. Couceiro, et al. (1998). "Molecular basis for the generation in pigs of 
influenza A viruses with pandemic potential." Journal of virology 72(9): 
7367-7373. 
Ito, T. and Y. Kawaoka (2000). "Host-range barrier of influenza A viruses." 
Veterinary microbiology 74(1-2): 71-75. 
Itoh, Y., K. Shinya, et al. (2009). "In vitro and in vivo characterization of new swine-
origin H1N1 influenza viruses." Nature 460(7258): 1021-1025. 
Iwatsuki-Horimoto, K., T. Horimoto, et al. (2006). "The cytoplasmic tail of the 
influenza A virus M2 protein plays a role in viral assembly." Journal of 
virology 80(11): 5233-5240. 
Jackson, D., M. J. Hossain, et al. (2008). "A new influenza virus virulence 
determinant: the NS1 protein four C-terminal residues modulate 
pathogenicity." Proceedings of the National Academy of Sciences of the 
United States of America 105(11): 4381-4386. 
Jiao, P., G. Tian, et al. (2008). "A single-amino-acid substitution in the NS1 protein 
changes the pathogenicity of H5N1 avian influenza viruses in mice." Journal 
of virology 82(3): 1146-1154. 
Jin, H., G. P. Leser, et al. (1997). "Influenza virus hemagglutinin and neuraminidase 
cytoplasmic tails control particle shape." The EMBO journal 16(6): 1236-
1247. 
Jin, H., B. Lu, et al. (2003). "Multiple amino acid residues confer temperature 
sensitivity to human influenza virus vaccine strains (FluMist) derived from 
cold-adapted A/Ann Arbor/6/60." Virology 306(1): 18-24. 
Jin, H., S. Manetz, et al. (2007). "Toxicological evaluation of live attenuated, cold-
adapted H5N1 vaccines in ferrets." Vaccine 25(52): 8664-8672. 
Johnson, P. R., Jr., S. Feldman, et al. (1985). "Comparison of long-term systemic and 
secretory antibody responses in children given live, attenuated, or inactivated 
influenza A vaccine." Journal of medical virology 17(4): 325-335. 
Joseph, T., J. McAuliffe, et al. (2008). "A live attenuated cold-adapted influenza A 
H7N3 virus vaccine provides protection against homologous and heterologous 
H7 viruses in mice and ferrets." Virology 378(1): 123-132. 
Karasin, A. I., S. Carman, et al. (2006). "Identification of human H1N2 and human-
swine reassortant H1N2 and H1N1 influenza A viruses among pigs in Ontario, 
Canada (2003 to 2005)." J Clin Microbiol 44(3): 1123-1126. 
Karasin, A. I., C. W. Olsen, et al. (2000). "Genetic characterization of an H1N2 
influenza virus isolated from a pig in Indiana." J Clin Microbiol 38(6): 2453-
2456. 
Karasin, A. I., M. M. Schutten, et al. (2000). "Genetic characterization of H3N2 
influenza viruses isolated from pigs in North America, 1977-1999: evidence 




Kawaoka, Y., C. W. Naeve, et al. (1984). "Is virulence of H5N2 influenza viruses in 
chickens associated with loss of carbohydrate from the hemagglutinin?" 
Virology 139(2): 303-316. 
Kay, R. M., S. H. Done, et al. (1994). "Effect of sequential porcine reproductive and 
respiratory syndrome and swine influenza on the growth and performance of 
finishing pigs." Vet Rec 135(9): 199-204. 
Kida, H., T. Ito, et al. (1994). "Potential for transmission of avian influenza viruses to 
pigs." The Journal of general virology 75 ( Pt 9): 2183-2188. 
Kim, H. M., Y. W. Lee, et al. (2008). "Alveolar macrophages are indispensable for 
controlling influenza viruses in lungs of pigs." Journal of virology 82(9): 
4265-4274. 
Kimble, B., G. R. Nieto, et al. (2010). "Characterization of influenza virus sialic acid 
receptors in minor poultry species." Virology journal 7: 365. 
Kimble, J. B., E. Sorrell, et al. (2011). "Compatibility of H9N2 avian influenza 
surface genes and 2009 pandemic H1N1 internal genes for transmission in the 
ferret model." Proceedings of the National Academy of Sciences of the United 
States of America 108(29): 12084-12088. 
Kittel, C., B. Ferko, et al. (2005). "Generation of an influenza A virus vector 
expressing biologically active human interleukin-2 from the NS gene 
segment." Journal of virology 79(16): 10672-10677. 
Kittel, C., S. Sereinig, et al. (2004). "Rescue of influenza virus expressing GFP from 
the NS1 reading frame." Virology 324(1): 67-73. 
Klimov, A. I., A. Y. Egorov, et al. (1995). "Genetic stability of cold-adapted 
A/Leningrad/134/47/57 (H2N2) influenza virus: sequence analysis of live 
cold-adapted reassortant vaccine strains before and after replication in 
children." J Gen Virol 76 ( Pt 6): 1521-1525. 
Kobasa, D., A. Takada, et al. (2004). "Enhanced virulence of influenza A viruses with 
the haemagglutinin of the 1918 pandemic virus." Nature 431(7009): 703-707. 
Koh, Y. Y., E. Jung da, et al. (2007). "Bronchoalveolar cellularity and interleukin-8 
levels in measles bronchiolitis obliterans." Chest 131(5): 1454-1460. 
Kothalawala, H., M. J. Toussaint, et al. (2006). "An overview of swine influenza." 
The Veterinary quarterly 28(2): 46-53. 
Krumbholz, A., A. Philipps, et al. (2011). "Current knowledge on PB1-F2 of 
influenza A viruses." Medical microbiology and immunology 200(2): 69-75. 
Kumar, S. R., L. Deflube, et al. (2011). "Genetic characterization of swine influenza 
viruses (H3N2) isolated from Minnesota in 2006-2007." Virus genes 43(2): 
161-176. 
Kwon, T. Y., S. S. Lee, et al. (2011). "Genetic characterization of H7N2 influenza 
virus isolated from pigs." Veterinary microbiology 153(3-4): 393-397. 
Lamb, R. A. and M. Takeda (2001). "Death by influenza virus protein." Nature 
medicine 7(12): 1286-1288. 
Lamb, R. A., S. L. Zebedee, et al. (1985). "Influenza virus M2 protein is an integral 





Lange, E., D. Kalthoff, et al. (2009). "Pathogenesis and transmission of the novel 
swine-origin influenza virus A/H1N1 after experimental infection of pigs." J 
Gen Virol 90(Pt 9): 2119-2123. 
Lazarowitz, S. G. and P. W. Choppin (1975). "Enhancement of the infectivity of 
influenza A and B viruses by proteolytic cleavage of the hemagglutinin 
polypeptide." Virology 68(2): 440-454. 
Le Goffic, R., E. Bouguyon, et al. (2010). "Influenza A virus protein PB1-F2 
exacerbates IFN-beta expression of human respiratory epithelial cells." 
Journal of immunology 185(8): 4812-4823. 
Le Goffic, R., O. Leymarie, et al. (2011). "Transcriptomic Analysis of Host Immune 
and Cell Death Responses Associated with the Influenza A Virus PB1-F2 
Protein." PLoS pathogens 7(8): e1002202. 
Lear, J. D. (2003). "Proton conduction through the M2 protein of the influenza A 
virus; a quantitative, mechanistic analysis of experimental data." FEBS letters 
552(1): 17-22. 
Lee, J. H., P. N. Pascua, et al. (2009). "Isolation and genetic characterization of H5N2 
influenza viruses from pigs in Korea." Journal of virology 83(9): 4205-4215. 
Lekcharoensuk, P., K. M. Lager, et al. (2006). "Novel swine influenza virus subtype 
H3N1, United States." Emerg Infect Dis 12(5): 787-794. 
Leser, G. P. and R. A. Lamb (2005). "Influenza virus assembly and budding in raft-
derived microdomains: a quantitative analysis of the surface distribution of 
HA, NA and M2 proteins." Virology 342(2): 215-227. 
Li, S., J. Schulman, et al. (1993). "Glycosylation of neuraminidase determines the 
neurovirulence of influenza A/WSN/33 virus." Journal of virology 67(11): 
6667-6673. 
Li, Z., Y. Jiang, et al. (2006). "The NS1 gene contributes to the virulence of H5N1 
avian influenza viruses." Journal of virology 80(22): 11115-11123. 
Li, Z. N., S. N. Mueller, et al. (2005). "Chimeric influenza virus hemagglutinin 
proteins containing large domains of the Bacillus anthracis protective antigen: 
protein characterization, incorporation into infectious influenza viruses, and 
antigenicity." Journal of virology 79(15): 10003-10012. 
Liang, Y., Y. Hong, et al. (2005). "cis-Acting packaging signals in the influenza virus 
PB1, PB2, and PA genomic RNA segments." Journal of virology 79(16): 
10348-10355. 
Lipatov, A. S., S. Andreansky, et al. (2005). "Pathogenesis of Hong Kong H5N1 
influenza virus NS gene reassortants in mice: the role of cytokines and B- and 
T-cell responses." The Journal of general virology 86(Pt 4): 1121-1130. 
Lipatov, A. S., Y. K. Kwon, et al. (2008). "Domestic pigs have low susceptibility to 
H5N1 highly pathogenic avian influenza viruses." PLoS pathogens 4(7): 
e1000102. 
Lorusso, A., K. S. Faaberg, et al. (2010). "One-step real-time RT-PCR for pandemic 
influenza A virus (H1N1) 2009 matrix gene detection in swine samples." 
Journal of virological methods 164(1-2): 83-87. 
Loving, C. L., S. L. Brockmeier, et al. (2010). "Influenza virus coinfection with 
Bordetella bronchiseptica enhances bacterial colonization and host responses 




Lu, B., H. Zhou, et al. (2005). "Improvement of influenza A/Fujian/411/02 (H3N2) 
virus growth in embryonated chicken eggs by balancing the hemagglutinin 
and neuraminidase activities, using reverse genetics." Journal of virology 
79(11): 6763-6771. 
Lunn, D. P., S. Hussey, et al. (2001). "Safety, efficacy, and immunogenicity of a 
modified-live equine influenza virus vaccine in ponies after induction of 
exercise-induced immunosuppression." J Am Vet Med Assoc 218(6): 900-
906. 
Luoh, S. M., M. W. McGregor, et al. (1992). "Hemagglutinin mutations related to 
antigenic variation in H1 swine influenza viruses." Journal of virology 66(2): 
1066-1073. 
Luytjes, W., M. Krystal, et al. (1989). "Amplification, expression, and packaging of 
foreign gene by influenza virus." Cell 59(6): 1107-1113. 
Ma, K., A. M. Roy, et al. (2001). "Nuclear export of influenza virus 
ribonucleoproteins: identification of an export intermediate at the nuclear 
periphery." Virology 282(2): 215-220. 
Ma, W., M. Gramer, et al. (2006). "Isolation and genetic characterization of new 
reassortant H3N1 swine influenza virus from pigs in the midwestern United 
States." J Virol 80(10): 5092-5096. 
Ma, W., K. M. Lager, et al. (2009). "The role of swine in the generation of novel 
influenza viruses." Zoonoses and public health 56(6-7): 326-337. 
Ma, W., K. M. Lager, et al. (2009). "The Role of Swine in the Generation of Novel 
Influenza Viruses." Zoonoses Public Health. 
Ma, W., A. L. Vincent, et al. (2007). "Identification of H2N3 influenza A viruses 
from swine in the United States." Proc Natl Acad Sci U S A 104(52): 20949-
20954. 
Maes, L., Haesebrouck, F. and Pensaert, M (1984). "Experimental reproduction of 
clinical disease by intratracheal inoculation of fattening pigs with swine 
influenza virus isolates." Proc. Int. Congr. Pig Vet. Soc 8: 60. 
Mahmood, K., R. A. Bright, et al. (2008). "H5N1 VLP vaccine induced protection in 
ferrets against lethal challenge with highly pathogenic H5N1 influenza 
viruses." Vaccine 26(42): 5393-5399. 
Manicassamy, B., S. Manicassamy, et al. (2010). "Analysis of in vivo dynamics of 
influenza virus infection in mice using a GFP reporter virus." Proceedings of 
the National Academy of Sciences of the United States of America 107(25): 
11531-11536. 
Manicassamy, B., R. A. Medina, et al. (2010). "Protection of mice against lethal 
challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine 
H1N1 based vaccines." PLoS Pathog 6(1): e1000745. 
Marjuki, H., C. Scholtissek, et al. "Three amino acid changes in PB1-F2 of highly 
pathogenic H5N1 avian influenza virus affect pathogenicity in mallard 
ducks." Arch Virol 155(6): 925-934. 
Marjuki, H., C. Scholtissek, et al. (2010). "Three amino acid changes in PB1-F2 of 
highly pathogenic H5N1 avian influenza virus affect pathogenicity in mallard 




Marsh, G. A., J. M. Watson, et al. (2003). "An evaluation of the genetic stability and 
pathogenicity of the Russian cold-adapted influenza A donor strains 
A/Leningrad/134/17/57 and A/Leningrad/134/47/57 in ferrets." J Virol 
Methods 107(1): 63-69. 
Martina, B. E., P. van den Doel, et al. (2011). "A recombinant influenza A virus 
expressing domain III of West Nile virus induces protective immune 
responses against influenza and West Nile virus." PloS one 6(4): e18995. 
Martínez-Sobrido, L. and A. García-Sastre (2007). "Recombinant influenza virus 
vectors." Future Virology 2(4): 401-416. 
Masic, A., L. A. Babiuk, et al. (2009). "Reverse genetics-generated elastase-
dependent swine influenza viruses are attenuated in pigs." J Gen Virol 90(Pt 
2): 375-385. 
Masic, A., J. S. Booth, et al. (2009). "Elastase-dependent live attenuated swine 
influenza A viruses are immunogenic and confer protection against swine 
influenza A virus infection in pigs." Journal of virology 83(19): 10198-10210. 
Masic, A., J. S. Booth, et al. (2009). "Elastase-dependent live attenuated swine 
influenza A viruses are immunogenic and confer protection against swine 
influenza A virus infection in pigs." J Virol 83(19): 10198-10210. 
Mathieu, C., V. Moreno, et al. (2010). "Pandemic (H1N1) 2009 in breeding turkeys, 
Valparaiso, Chile." Emerging infectious diseases 16(4): 709-711. 
Matrosovich, M., A. Tuzikov, et al. (2000). "Early alterations of the receptor-binding 
properties of H1, H2, and H3 avian influenza virus hemagglutinins after their 
introduction into mammals." Journal of virology 74(18): 8502-8512. 
Matrosovich, M. N., T. Y. Matrosovich, et al. (2004). "Neuraminidase is important 
for the initiation of influenza virus infection in human airway epithelium." 
Journal of virology 78(22): 12665-12667. 
Matsuoka, Y., E. W. Lamirande, et al. (2009). "The ferret model for influenza." 
Current protocols in microbiology Chapter 15: Unit 15G 12. 
Matsuoka, Y., D. E. Swayne, et al. (2009). "Neuraminidase stalk length and 
additional glycosylation of the hemagglutinin influence the virulence of 
influenza H5N1 viruses for mice." Journal of virology 83(9): 4704-4708. 
Mazur, I., D. Anhlan, et al. (2008). "The proapoptotic influenza A virus protein PB1-
F2 regulates viral polymerase activity by interaction with the PB1 protein." 
Cell Microbiol 10(5): 1140-1152. 
McAuley, J. L., J. E. Chipuk, et al. (2010). "PB1-F2 proteins from H5N1 and 20 
century pandemic influenza viruses cause immunopathology." PLoS 
pathogens 6(7): e1001014. 
McAuley, J. L., F. Hornung, et al. (2007). "Expression of the 1918 influenza A virus 
PB1-F2 enhances the pathogenesis of viral and secondary bacterial 
pneumonia." Cell Host Microbe 2(4): 240-249. 
McAuley, J. L., F. Hornung, et al. (2007). "Expression of the 1918 influenza A virus 
PB1-F2 enhances the pathogenesis of viral and secondary bacterial 
pneumonia." Cell host & microbe 2(4): 240-249. 
McAuley, J. L., K. Zhang, et al. (2010). "The effects of influenza A virus PB1-F2 
protein on polymerase activity are strain specific and do not impact 




Melen, K., R. Fagerlund, et al. (2003). "Importin alpha nuclear localization signal 
binding sites for STAT1, STAT2, and influenza A virus nucleoprotein." The 
Journal of biological chemistry 278(30): 28193-28200. 
Mitnaul, L. J., M. N. Matrosovich, et al. (2000). "Balanced hemagglutinin and 
neuraminidase activities are critical for efficient replication of influenza A 
virus." Journal of virology 74(13): 6015-6020. 
Moreno, A., L. Di Trani, et al. (2011). "Novel H1N2 swine influenza reassortant 
strain in pigs derived from the pandemic H1N1/2009 virus." Veterinary 
microbiology 149(3-4): 472-477. 
Murakami, S., T. Horimoto, et al. (2008). "Establishment of canine RNA polymerase 
I-driven reverse genetics for influenza A virus: its application for H5N1 
vaccine production." Journal of virology 82(3): 1605-1609. 
Muraki, Y. and S. Hongo (2010). "The molecular virology and reverse genetics of 
influenza C virus." Japanese journal of infectious diseases 63(3): 157-165. 
Myers, K. P., C. W. Olsen, et al. (2007). "Cases of swine influenza in humans: a 
review of the literature." Clinical infectious diseases : an official publication 
of the Infectious Diseases Society of America 44(8): 1084-1088. 
Myers, K. P., C. W. Olsen, et al. (2006). "Are swine workers in the United States at 
increased risk of infection with zoonotic influenza virus?" Clin Infect Dis 
42(1): 14-20. 
Naffakh, N., A. Tomoiu, et al. (2008). "Host restriction of avian influenza viruses at 
the level of the ribonucleoproteins." Annual review of microbiology 62: 403-
424. 
Nagarajan, M. M., G. Simard, et al. (2010). "Single-step multiplex conventional and 
real-time reverse transcription polymerase chain reaction assays for 
simultaneous detection and subtype differentiation of Influenza A virus in 
swine." Journal of veterinary diagnostic investigation : official publication of 
the American Association of Veterinary Laboratory Diagnosticians, Inc 22(3): 
402-408. 
Nayak, B., S. Kumar, et al. (2010). "Contributions of the avian influenza virus HA, 
NA, and M2 surface proteins to the induction of neutralizing antibodies and 
protective immunity." Journal of virology 84(5): 2408-2420. 
Nayak, B., S. N. Rout, et al. (2009). "Immunization of chickens with Newcastle 
disease virus expressing H5 hemagglutinin protects against highly pathogenic 
H5N1 avian influenza viruses." PloS one 4(8): e6509. 
Nayak, D. P., E. K. Hui, et al. (2004). "Assembly and budding of influenza virus." 
Virus research 106(2): 147-165. 
Nelli, R. K., S. V. Kuchipudi, et al. (2010). "Comparative distribution of human and 
avian type sialic acid influenza receptors in the pig." BMC veterinary research 
6: 4. 
Nelli, R. K., S. V. Kuchipudi, et al. (2010). "Comparative distribution of human and 
avian type sialic acid influenza receptors in the pig." BMC Vet Res 6: 4. 
Nermut, M. V. and H. Frank (1971). "Fine structure of influenza A2 (Singapore) as 
revealed by negative staining, freeze-drying and freeze-etching." The Journal 




Neumann, G., K. Fujii, et al. (2005). "An improved reverse genetics system for 
influenza A virus generation and its implications for vaccine production." 
Proceedings of the National Academy of Sciences of the United States of 
America 102(46): 16825-16829. 
Neumann, G. and G. Hobom (1995). "Mutational analysis of influenza virus promoter 
elements in vivo." The Journal of general virology 76 ( Pt 7): 1709-1717. 
Neumann, G., T. Noda, et al. (2009). "Emergence and pandemic potential of swine-
origin H1N1 influenza virus." Nature 459(7249): 931-939. 
Neumann, G., T. Watanabe, et al. (1999). "Generation of influenza A viruses entirely 
from cloned cDNAs." Proceedings of the National Academy of Sciences of 
the United States of America 96(16): 9345-9350. 
Neumann, G., A. Zobel, et al. (1994). "RNA polymerase I-mediated expression of 
influenza viral RNA molecules." Virology 202(1): 477-479. 
Newman, A. P., E. Reisdorf, et al. (2008). "Human case of swine influenza A (H1N1) 
triple reassortant virus infection, Wisconsin." Emerging infectious diseases 
14(9): 1470-1472. 
Nfon, C., Y. Berhane, et al. (2011). "Molecular and Antigenic Characterization of 
Triple-Reassortant H3N2 Swine Influenza Viruses Isolated from Pigs, Turkey 
and Quail in Canada." Transboundary and emerging diseases 58(5): 394-401. 
Nicholson, T. L., D. Kukielka, et al. (2011). "Utility of a panviral microarray for 
detection of swine respiratory viruses in clinical samples." Journal of clinical 
microbiology 49(4): 1542-1548. 
Nidom, C. A., R. Takano, et al. (2010). "Influenza A (H5N1) viruses from pigs, 
Indonesia." Emerging infectious diseases 16(10): 1515-1523. 
Noble, S., M. S. McGregor, et al. (1993). "Antigenic and genetic conservation of the 
haemagglutinin in H1N1 swine influenza viruses." The Journal of general 
virology 74 ( Pt 6): 1197-1200. 
Nofs, S., M. Abd-Eldaim, et al. (2009). "Influenza virus A (H1N1) in giant anteaters 
(Myrmecophaga tridactyla)." Emerging infectious diseases 15(7): 1081-1083. 
Nunes, S. F., P. R. Murcia, et al. (2010). "An ex vivo swine tracheal organ culture for 
the study of influenza infection." Influenza and other respiratory viruses 4(1): 
7-15. 
O'Neill, R. E., J. Talon, et al. (1998). "The influenza virus NEP (NS2 protein) 
mediates the nuclear export of viral ribonucleoproteins." The EMBO journal 
17(1): 288-296. 
OIE. (2008, 2008). "Swine influenza." World Organization for Animal Health (OIE). 
Manual of diagnostic tests and vaccines for terrestrial animals 2008. Retrieved 
10/10/11, from http://www.oie.int/eng/normes/mmanual/2008/pdf/2.08.0. 
Olsen, C. W. (2002). "The emergence of novel swine influenza viruses in North 
America." Virus Res 85(2): 199-210. 
Olsen, C. W. (2002). "The emergence of novel swine influenza viruses in North 
America." Virus research 85(2): 199-210. 
Olsen, C. W., A. I. Karasin, et al. (2006). "Triple reassortant H3N2 influenza A 
viruses, Canada, 2005." Emerg Infect Dis 12(7): 1132-1135. 
Osterhaus, A. D., G. F. Rimmelzwaan, et al. (2000). "Influenza B virus in seals." 




Ozawa, M., S. Basnet, et al. (2011). "Impact of amino acid mutations in PB2, PB1-
F2, and NS1 on the replication and pathogenicity of pandemic (H1N1) 2009 
influenza viruses." Journal of virology 85(9): 4596-4601. 
Ozawa, M., S. T. Victor, et al. (2011). "Replication-incompetent influenza A viruses 
that stably express a foreign gene." The Journal of general virology. 
Paillot, R., D. Hannant, et al. (2006). "Vaccination against equine influenza: quid 
novi?" Vaccine 24(19): 4047-4061. 
Palese, P. and M. Shaw (2007). Orthomyxoviridae: the viruses and their replication. 
Fields Virology. Philadelphia, PA, Lippincott Williams & Wilkins. 2: 1647-
1689. 
Pappas, C., P. V. Aguilar, et al. (2008). "Single gene reassortants identify a critical 
role for PB1, HA, and NA in the high virulence of the 1918 pandemic 
influenza virus." Proceedings of the National Academy of Sciences of the 
United States of America 105(8): 3064-3069. 
Pena, L., A. L. Vincent, et al. "Modifications in the polymerase genes of a swine-like 
triple reassortant influenza virus to generate live attenuated vaccines against 
2009 pandemic H1N1 viruses." J Virol. 
Pena, L., A. L. Vincent, et al. (2011). "Modifications in the polymerase genes of a 
swine-like triple-reassortant influenza virus to generate live attenuated 
vaccines against 2009 pandemic H1N1 viruses." Journal of virology 85(1): 
456-469. 
Percy, N., W. S. Barclay, et al. (1994). "Expression of a foreign protein by influenza 
A virus." Journal of virology 68(7): 4486-4492. 
Pereda, A., J. Cappuccio, et al. (2010). "Pandemic (H1N1) 2009 outbreak on pig 
farm, Argentina." Emerging infectious diseases 16(2): 304-307. 
Pereda, A., A. Rimondi, et al. (2011). "Evidence of reassortment of pandemic H1N1 
influenza virus in swine in Argentina: are we facing the expansion of potential 
epicenters of influenza emergence?" Influenza and other respiratory viruses. 
Perez-Padilla, R., D. de la Rosa-Zamboni, et al. (2009). "Pneumonia and respiratory 
failure from swine-origin influenza A (H1N1) in Mexico." N Engl J Med 
361(7): 680-689. 
Perez, D. R. and R. O. Donis (2001). "Functional analysis of PA binding by influenza 
a virus PB1: effects on polymerase activity and viral infectivity." Journal of 
virology 75(17): 8127-8136. 
Perez, J. T., A. Varble, et al. (2010). "Influenza A virus-generated small RNAs 
regulate the switch from transcription to replication." Proceedings of the 
National Academy of Sciences of the United States of America 107(25): 
11525-11530. 
Perroncito, E. (1878). "Epizoozia tifoide neigalliancei." Annali della Academia 
d'agricoltora di Torino 21: 87-126. 
Ping, J., S. K. Dankar, et al. (2010). "PB2 and hemagglutinin mutations are major 
determinants of host range and virulence in mouse-adapted influenza A virus." 
Journal of virology 84(20): 10606-10618. 
Pleschka, S., R. Jaskunas, et al. (1996). "A plasmid-based reverse genetics system for 




Portela, A. and P. Digard (2002). "The influenza virus nucleoprotein: a 
multifunctional RNA-binding protein pivotal to virus replication." The Journal 
of general virology 83(Pt 4): 723-734. 
Presti, R. M., G. Zhao, et al. (2009). "Quaranfil, Johnston Atoll, and Lake Chad 
viruses are novel members of the family Orthomyxoviridae." Journal of 
virology 83(22): 11599-11606. 
Racaniello, V. R. and D. Baltimore (1981). "Cloned poliovirus complementary DNA 
is infectious in mammalian cells." Science 214(4523): 916-919. 
Ramakrishnan, M. A., P. Wang, et al. (2010). "Triple reassortant swine influenza A 
(H3N2) virus in waterfowl." Emerging infectious diseases 16(4): 728-730. 
Reading, P. C., J. L. Miller, et al. (2000). "Involvement of the mannose receptor in 
infection of macrophages by influenza virus." Journal of virology 74(11): 
5190-5197. 
Reed, L. J. and H. Muench (1938). "A simple method for estimating 50 percent 
endpoints." Am J Hyg 37: 493. 
Rhorer, J., C. S. Ambrose, et al. (2009). "Efficacy of live attenuated influenza vaccine 
in children: A meta-analysis of nine randomized clinical trials." Vaccine 
27(7): 1101-1110. 
Richt, J. A., K. M. Lager, et al. (2004). "Real-time reverse transcription-polymerase 
chain reaction assays for the detection and differentiation of North American 
swine influenza viruses." Journal of veterinary diagnostic investigation : 
official publication of the American Association of Veterinary Laboratory 
Diagnosticians, Inc 16(5): 367-373. 
Richt, J. A., K. M. Lager, et al. (2003). "Pathogenic and antigenic properties of 
phylogenetically distinct reassortant H3N2 swine influenza viruses 
cocirculating in the United States." J Clin Microbiol 41(7): 3198-3205. 
Richt, J. A., K. M. Lager, et al. (2003). "Pathogenic and antigenic properties of 
phylogenetically distinct reassortant H3N2 swine influenza viruses 
cocirculating in the United States." Journal of clinical microbiology 41(7): 
3198-3205. 
Richt, J. A., P. Lekcharoensuk, et al. (2006). "Vaccination of pigs against swine 
influenza viruses by using an NS1-truncated modified live-virus vaccine." J 
Virol 80(22): 11009-11018. 
Robb, N. C., M. Smith, et al. (2009). "NS2/NEP protein regulates transcription and 
replication of the influenza virus RNA genome." The Journal of general 
virology 90(Pt 6): 1398-1407. 
Robertson, J. S. (1979). "5' and 3' terminal nucleotide sequences of the RNA genome 
segments of influenza virus." Nucleic acids research 6(12): 3745-3757. 
Robertson, J. S., M. Schubert, et al. (1981). "Polyadenylation sites for influenza virus 
mRNA." Journal of virology 38(1): 157-163. 
Robinson, J. L., B. E. Lee, et al. (2007). "Swine influenza (H3N2) infection in a child 
and possible community transmission, Canada." Emerging infectious diseases 
13(12): 1865-1870. 
Rodgers, B. C. and C. A. Mims (1982). "Influenza virus replication in human alveolar 




((Rossman, J. S. and R. A. Lamb (2011). "Influenza virus assembly and budding." 
Virology 411(2): 229-236. 
Rott, R., H. D. Klenk, et al. (1995). "Influenza viruses, cell enzymes, and 
pathogenicity." American journal of respiratory and critical care medicine 
152(4 Pt 2): S16-19. 
Ruigrok, R. W., P. J. Andree, et al. (1984). "Characterization of three highly purified 
influenza virus strains by electron microscopy." The Journal of general 
virology 65 ( Pt 4): 799-802. 
Ruigrok, R. W., E. A. Hewat, et al. (1992). "Low pH deforms the influenza virus 
envelope." The Journal of general virology 73 ( Pt 4): 995-998. 
Salomon, R., J. Franks, et al. (2006). "The polymerase complex genes contribute to 
the high virulence of the human H5N1 influenza virus isolate 
A/Vietnam/1203/04." The Journal of experimental medicine 203(3): 689-697. 
Schafer, W. (1955). "Vergleichende sero-immunologische untersuchungen uber die 
viren der influenza unf klassichen geflugelpest. ." Z Naturforsch 10B: 81-91. 
Schmitt, A. P. and R. A. Lamb (2005). "Influenza virus assembly and budding at the 
viral budozone." Advances in virus research 64: 383-416. 
Schmolke, M., B. Manicassamy, et al. (2011). "Differential Contribution of PB1-F2 
to the Virulence of Highly Pathogenic H5N1 Influenza A Virus in 
Mammalian and Avian Species." PLoS pathogens 7(8): e1002186. 
Scholtissek, C. (1995). "Molecular evolution of influenza viruses." Virus genes 11(2-
3): 209-215. 
Scholtissek, C., H. Burger, et al. (1983). "Genetic relatedness of hemagglutinins of 
the H1 subtype of influenza A viruses isolated from swine and birds." 
Virology 129(2): 521-523. 
Scholtissek, C., H. Burger, et al. (1985). "The nucleoprotein as a possible major 
factor in determining host specificity of influenza H3N2 viruses." Virology 
147(2): 287-294. 
Scholtissek, C., I. Koennecke, et al. (1978). "Host range recombinants of fowl plague 
(influenza A) virus." Virology 91(1): 79-85. 
Schotsaert, M., M. De Filette, et al. (2009). "Universal M2 ectodomain-based 
influenza A vaccines: preclinical and clinical developments." Expert review of 
vaccines 8(4): 499-508. 
Schulman, J. L. and P. Palese (1977). "Virulence factors of influenza A viruses: WSN 
virus neuraminidase required for plaque production in MDBK cells." Journal 
of virology 24(1): 170-176. 
Seo, S. H., R. Webby, et al. (2004). "No apoptotic deaths and different levels of 
inductions of inflammatory cytokines in alveolar macrophages infected with 
influenza viruses." Virology 329(2): 270-279. 
Sereinig, S., M. Stukova, et al. (2006). "Influenza virus NS vectors expressing the 
mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune 
response and protect animals against tuberculosis challenge." Clinical and 
vaccine immunology : CVI 13(8): 898-904. 
Shaw, M. L., K. L. Stone, et al. (2008). "Cellular proteins in influenza virus 




Sheerar, M. G., B. C. Easterday, et al. (1989). "Antigenic conservation of H1N1 
swine influenza viruses." The Journal of general virology 70 ( Pt 12): 3297-
3303. 
Shih, S. R. and R. M. Krug (1996). "Novel exploitation of a nuclear function by 
influenza virus: the cellular SF2/ASF splicing factor controls the amount of 
the essential viral M2 ion channel protein in infected cells." The EMBO 
journal 15(19): 5415-5427. 
Shih, S. R., M. E. Nemeroff, et al. (1995). "The choice of alternative 5' splice sites in 
influenza virus M1 mRNA is regulated by the viral polymerase complex." 
Proceedings of the National Academy of Sciences of the United States of 
America 92(14): 6324-6328. 
Shimizu, T., N. Takizawa, et al. (2011). "Crucial role of the influenza virus NS2 
(NEP) C-terminal domain in M1 binding and nuclear export of vRNP." FEBS 
letters 585(1): 41-46. 
Shinde, V., C. B. Bridges, et al. (2009). "Triple-reassortant swine influenza A (H1) in 
humans in the United States, 2005-2009." N Engl J Med 360(25): 2616-2625. 
Shinya, K., M. Ebina, et al. (2006). "Avian flu: influenza virus receptors in the human 
airway." Nature 440(7083): 435-436. 
Shinya, K., Y. Fujii, et al. (2004). "Characterization of a neuraminidase-deficient 
influenza a virus as a potential gene delivery vector and a live vaccine." 
Journal of virology 78(6): 3083-3088. 
Shope, R. E. (1931). "The Etiology of Swine Influenza." Science 73(1886): 214-215. 
Shope, R. E. (1931). "Swine Influenza : Iii. Filtration Experiments and Etiology." The 
Journal of experimental medicine 54(3): 373-385. 
Siebler, J., O. Haller, et al. (1996). "Thogoto and Dhori virus replication is blocked by 
inhibitors of cellular polymerase II activity but does not cause shutoff of host 
cell protein synthesis." Archives of virology 141(8): 1587-1594. 
Smith, A. M., F. R. Adler, et al. (2011). "Effect of 1918 PB1-F2 expression on 
influenza A virus infection kinetics." PLoS computational biology 7(2): 
e1001081. 
Smith, G. J., J. Bahl, et al. (2009). "Dating the emergence of pandemic influenza 
viruses." Proceedings of the National Academy of Sciences of the United 
States of America 106(28): 11709-11712. 
Smith, G. J., D. Vijaykrishna, et al. (2009). "Origins and evolutionary genomics of 
the 2009 swine-origin H1N1 influenza A epidemic." Nature 459(7250): 1122-
1125. 
Smith, W., Andrewes C. H., and Laidlaw P. P. (1933). "A virus obtained from 
influenza patients." Lancet 2: 66-68. 
Snyder, M. H., A. J. Buckler-White, et al. (1987). "The avian influenza virus 
nucleoprotein gene and a specific constellation of avian and human virus 
polymerase genes each specify attenuation of avian-human influenza 
A/Pintail/79 reassortant viruses for monkeys." Journal of virology 61(9): 
2857-2863. 
Solorzano, A., R. J. Webby, et al. (2005). "Mutations in the NS1 protein of swine 
influenza virus impair anti-interferon activity and confer attenuation in pigs." 




Song, H., G. R. Nieto, et al. (2007). "A new generation of modified live-attenuated 
avian influenza viruses using a two-strategy combination as potential vaccine 
candidates." Journal of virology 81(17): 9238-9248. 
Song, H., G. R. Nieto, et al. (2007). "A new generation of modified live-attenuated 
avian influenza viruses using a two-strategy combination as potential vaccine 
candidates." J Virol 81(17): 9238-9248. 
Song, J., H. Feng, et al. (2011). "The PA protein directly contributes to the virulence 
of H5N1 avian influenza viruses in domestic ducks." Journal of virology 
85(5): 2180-2188. 
Song, J. M., N. Van Rooijen, et al. (2011). "Vaccination inducing broad and 
improved cross protection against multiple subtypes of influenza A virus." 
Proceedings of the National Academy of Sciences of the United States of 
America 108(2): 757-761. 
Song, M. S., J. H. Lee, et al. (2010). "Evidence of human-to-swine transmission of 
the pandemic (H1N1) 2009 influenza virus in South Korea." Journal of 
clinical microbiology 48(9): 3204-3211. 
Sorrell, E. M., G. C. Ramirez-Nieto, et al. (2007). "Genesis of pandemic influenza." 
Cytogenetic and genome research 117(1-4): 394-402. 
Sorrell, E. M., H. Song, et al. (2010). "A 27-amino-acid deletion in the neuraminidase 
stalk supports replication of an avian H2N2 influenza A virus in the 
respiratory tract of chickens." Journal of virology 84(22): 11831-11840. 
Soto-Abraham, M. V., J. Soriano-Rosas, et al. (2009). "Pathological changes 
associated with the 2009 H1N1 virus." N Engl J Med 361(20): 2001-2003. 
Sovinova, O., B. Tumova, et al. (1958). "Isolation of a virus causing respiratory 
disease in horses." Acta virologica 2(1): 52-61. 
Sponseller, B. A., E. Strait, et al. (2010). "Influenza A pandemic (H1N1) 2009 virus 
infection in domestic cat." Emerging infectious diseases 16(3): 534-537. 
Staeheli, P., R. Grob, et al. (1988). "Influenza virus-susceptible mice carry Mx genes 
with a large deletion or a nonsense mutation." Molecular and cellular biology 
8(10): 4518-4523. 
Starick, E., E. Lange, et al. (2011). "Reassorted pandemic (H1N1) 2009 influenza A 
virus discovered from pigs in Germany." The Journal of general virology 
92(Pt 5): 1184-1188. 
Steel, J., A. C. Lowen, et al. (2010). "Influenza virus vaccine based on the conserved 
hemagglutinin stalk domain." mBio 1(1). 
Strobel, I., M. Krumbholz, et al. (2000). "Efficient expression of the tumor-associated 
antigen MAGE-3 in human dendritic cells, using an avian influenza virus 
vector." Human gene therapy 11(16): 2207-2218. 
Subbarao, E. K., Y. Kawaoka, et al. (1993). "Rescue of an influenza A virus wild-
type PB2 gene and a mutant derivative bearing a site-specific temperature-
sensitive and attenuating mutation." Journal of virology 67(12): 7223-7228. 
Subbarao, E. K., W. London, et al. (1993). "A single amino acid in the PB2 gene of 
influenza A virus is a determinant of host range." Journal of virology 67(4): 
1761-1764. 
Subbarao, K. and T. Joseph (2007). "Scientific barriers to developing vaccines against 




Sugita, Y., T. Noda, et al. (2011). "Ultracentrifugation Deforms Unfixed Influenza A 
Virions." The Journal of general virology. 
Suguitan, A. L., Jr., J. McAuliffe, et al. (2006). "Live, attenuated influenza A H5N1 
candidate vaccines provide broad cross-protection in mice and ferrets." PLoS 
medicine 3(9): e360. 
Suzuki, F., Y. Arase, et al. (2004). "Single nucleotide polymorphism of the MxA 
gene promoter influences the response to interferon monotherapy in patients 
with hepatitis C viral infection." Journal of viral hepatitis 11(3): 271-276. 
Suzuki, Y., T. Ito, et al. (2000). "Sialic acid species as a determinant of the host range 
of influenza A viruses." Journal of virology 74(24): 11825-11831. 
Swenson, S. L., L. G. Koster, et al. (2010). "Natural cases of 2009 pandemic H1N1 
Influenza A virus in pet ferrets." Journal of veterinary diagnostic investigation 
: official publication of the American Association of Veterinary Laboratory 
Diagnosticians, Inc 22(5): 784-788. 
Tada, T., K. Suzuki, et al. (2011). "NP body domain and PB2 contribute to increased 
virulence of H5N1 highly pathogenic avian influenza viruses in chickens." 
Journal of virology 85(4): 1834-1846. 
Takano, R., C. A. Nidom, et al. (2009). "A comparison of the pathogenicity of avian 
and swine H5N1 influenza viruses in Indonesia." Archives of virology 154(4): 
677-681. 
Talaat, K. R., R. A. Karron, et al. (2009). "A live attenuated H7N3 influenza virus 
vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults." 
Vaccine 27(28): 3744-3753. 
Talon, J., M. Salvatore, et al. (2000). "Influenza A and B viruses expressing altered 
NS1 proteins: A vaccine approach." Proceedings of the National Academy of 
Sciences of the United States of America 97(8): 4309-4314. 
Tang, Y., C. W. Lee, et al. (2005). "Isolation and characterization of H3N2 influenza 
A virus from turkeys." Avian Dis 49(2): 207-213. 
Tang, Y., C. W. Lee, et al. (2005). "Isolation and characterization of H3N2 influenza 
A virus from turkeys." Avian diseases 49(2): 207-213. 
Tate, M. D., D. L. Pickett, et al. (2010). "Critical role of airway macrophages in 
modulating disease severity during influenza virus infection of mice." Journal 
of virology 84(15): 7569-7580. 
Taubenberger, J. K. and J. C. Kash (2010). "Influenza virus evolution, host 
adaptation, and pandemic formation." Cell host & microbe 7(6): 440-451. 
Thompson, C. I., W. S. Barclay, et al. (2004). "Changes in in vitro susceptibility of 
influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution 
in the human host." The Journal of antimicrobial chemotherapy 53(5): 759-
765. 
Townsend, H. G., S. J. Penner, et al. (2001). "Efficacy of a cold-adapted, intranasal, 
equine influenza vaccine: challenge trials." Equine Vet J 33(7): 637-643. 
Townsend, H. G., S. J. Penner, et al. (2001). "Efficacy of a cold-adapted, intranasal, 





Treanor, J. J., J. D. Campbell, et al. (2006). "Safety and immunogenicity of an 
inactivated subvirion influenza A (H5N1) vaccine." The New England journal 
of medicine 354(13): 1343-1351. 
Trebbien, R., L. E. Larsen, et al. (2011). "Distribution of sialic acid receptors and 
influenza A virus of avian and swine origin in experimentally infected pigs." 
Virology journal 8(1): 434. 
Trifonov, V. and R. Rabadan (2009). "The Contribution of the PB1-F2 protein to the 
fitness of Influenza A viruses and its recent evolution in the 2009 Influenza A 
(H1N1) pandemic virus." PLoS Curr 1: RRN1006. 
Tscherne, D. M. and A. Garcia-Sastre (2011). "Virulence determinants of pandemic 
influenza viruses." The Journal of clinical investigation 121(1): 6-13. 
Tu, J., H. Zhou, et al. (2009). "Isolation and molecular characterization of equine 
H3N8 influenza viruses from pigs in China." Archives of virology 154(5): 
887-890. 
Uetani, K., M. Hiroi, et al. (2008). "Influenza A virus abrogates IFN-gamma response 
in respiratory epithelial cells by disruption of the Jak/Stat pathway." European 
journal of immunology 38(6): 1559-1573. 
Upham, J. P., D. Pickett, et al. (2010). "Macrophage receptors for influenza A virus: 
role of the macrophage galactose-type lectin and mannose receptor in viral 
entry." Journal of virology 84(8): 3730-3737. 
Van Poucke, S. G., J. M. Nicholls, et al. (2010). "Replication of avian, human and 
swine influenza viruses in porcine respiratory explants and association with 
sialic acid distribution." Virology journal 7: 38. 
Van Reeth, K. (2000). "Cytokines in the pathogenesis of influenza." Veterinary 
microbiology 74(1-2): 109-116. 
Van Reeth, K., I. H. Brown, et al. (2008). "Seroprevalence of H1N1, H3N2 and 
H1N2 influenza viruses in pigs in seven European countries in 2002-2003." 
Influenza and other respiratory viruses 2(3): 99-105. 
Van Reeth, K., G. Labarque, et al. (1999). "Differential production of 
proinflammatory cytokines in the pig lung during different respiratory virus 
infections: correlations with pathogenicity." Research in veterinary science 
67(1): 47-52. 
Van Reeth, K., S. Van Gucht, et al. (2002). "Correlations between lung 
proinflammatory cytokine levels, virus replication, and disease after swine 
influenza virus challenge of vaccination-immune pigs." Viral immunology 
15(4): 583-594. 
Van Reeth, K., S. Van Gucht, et al. (2002). "In vivo studies on cytokine involvement 
during acute viral respiratory disease of swine: troublesome but rewarding." 
Vet Immunol Immunopathol 87(3-4): 161-168. 
van Riel, D., L. M. Leijten, et al. (2011). "Highly Pathogenic Avian Influenza Virus 
H5N1 Infects Alveolar Macrophages without Virus Production or Excessive 
TNF-Alpha Induction." PLoS pathogens 7(6): e1002099. 
Varga, Z. T., I. Ramos, et al. (2011). "The influenza virus protein PB1-F2 inhibits the 
induction of type i interferon at the level of the MAVS adaptor protein." PLoS 




Vijaykrishna, D., L. L. Poon, et al. (2010). "Reassortment of pandemic H1N1/2009 
influenza A virus in swine." Science 328(5985): 1529. 
Vincent, A. L., J. R. Ciacci-Zanella, et al. (2010). "Efficacy of inactivated swine 
influenza virus vaccines against the 2009 A/H1N1 influenza virus in pigs." 
Vaccine 28(15): 2782-2787. 
Vincent, A. L., K. M. Lager, et al. (2010). "Experimental inoculation of pigs with 
pandemic H1N1 2009 virus and HI cross-reactivity with contemporary swine 
influenza virus antisera." Influenza Other Respi Viruses 4(2): 53-60. 
Vincent, A. L., K. M. Lager, et al. (2007). "Failure of protection and enhanced 
pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an 
inactivated classical swine H1N1 vaccine." Vet Microbiol. 
Vincent, A. L., K. M. Lager, et al. (2008). "Failure of protection and enhanced 
pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an 
inactivated classical swine H1N1 vaccine." Vet Microbiol 126(4): 310-323. 
Vincent, A. L., W. Ma, et al. (2008). "Swine influenza viruses a North American 
perspective." Adv Virus Res 72: 127-154. 
Vincent, A. L., W. Ma, et al. (2008). "Swine influenza viruses a North American 
perspective." Advances in virus research 72: 127-154. 
Vincent, A. L., W. Ma, et al. (2007). "Efficacy of intranasal administration of a 
truncated NS1 modified live influenza virus vaccine in swine." Vaccine 
25(47): 7999-8009. 
Vincent, A. L., S. L. Swenson, et al. (2009). "Characterization of an influenza A virus 
isolated from pigs during an outbreak of respiratory disease in swine and 
people during a county fair in the United States." Veterinary microbiology 
137(1-2): 51-59. 
Vincent, L. L., B. H. Janke, et al. (1997). "A monoclonal-antibody-based 
immunohistochemical method for the detection of swine influenza virus in 
formalin-fixed, paraffin-embedded tissues." Journal of veterinary diagnostic 
investigation : official publication of the American Association of Veterinary 
Laboratory Diagnosticians, Inc 9(2): 191-195. 
Waddell, G. H., M. B. Teigland, et al. (1963). "A New Influenza Virus Associated 
with Equine Respiratory Disease." Journal of the American Veterinary 
Medical Association 143: 587-590. 
Wan, H. and D. R. Perez (2006). "Quail carry sialic acid receptors compatible with 
binding of avian and human influenza viruses." Virology 346(2): 278-286. 
Wang, P., P. Palese, et al. (1997). "The NPI-1/NPI-3 (karyopherin alpha) binding site 
on the influenza a virus nucleoprotein NP is a nonconventional nuclear 
localization signal." Journal of virology 71(3): 1850-1856. 
Wang, Z. and G. M. Duke (2007). "Cloning of the canine RNA polymerase I 
promoter and establishment of reverse genetics for influenza A and B in 
MDCK cells." Virology journal 4: 102. 
Wasilenko, J. L., C. W. Lee, et al. (2008). "NP, PB1, and PB2 viral genes contribute 
to altered replication of H5N1 avian influenza viruses in chickens." Journal of 




Watanabe, T., S. Watanabe, et al. (2003). "Exploitation of nucleic acid packaging 
signals to generate a novel influenza virus-based vector stably expressing two 
foreign genes." Journal of virology 77(19): 10575-10583. 
Watanabe, T., S. Watanabe, et al. (2009). "Viral RNA polymerase complex promotes 
optimal growth of 1918 virus in the lower respiratory tract of ferrets." 
Proceedings of the National Academy of Sciences of the United States of 
America 106(2): 588-592. 
Webby, R. J., K. Rossow, et al. (2004). "Multiple lineages of antigenically and 
genetically diverse influenza A virus co-circulate in the United States swine 
population." Virus Res 103(1-2): 67-73. 
Webster, R. G., W. J. Bean, et al. (1992). "Evolution and ecology of influenza A 
viruses." Microbiological reviews 56(1): 152-179. 
Weingartl, H. M., R. A. Albrecht, et al. (2009). "Experimental infection of pigs with 
the human 1918 pandemic influenza virus." J Virol 83(9): 4287-4296. 
WHO. (2009). "Influenza (Seasonal)." Fact sheet n°211  Retrieved 10/10/11, 2011, 
from http://www.who.int/mediacentre/factsheets/fs211/en/. 
WHO. (2010). "Antigenic and genetic characteristics of influenza A(H5N1) and influenza 
A(H9N2) viruses and candidate vaccine viruses developed for potential use in 
human vaccines."   Retrieved 10/10/2011, 2011, from 
http://www.who.int/csr/disease/avian_influenza/guidelines/h5n1virus/en/index.html. 
WHO. (2011). "Manual for the laboratory diagnosis and virological surveillance of 
influenza "   Retrieved 10/10/2011, 2011, from 
http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf. 
Wise, H. M., A. Foeglein, et al. (2009). "A complicated message: Identification of a 
novel PB1-related protein translated from influenza A virus segment 2 
mRNA." Journal of virology 83(16): 8021-8031. 
Wolschek, M., E. Samm, et al. (2011). "Establishment of a chimeric, replication-
deficient influenza A virus vector by modulation of splicing efficiency." 
Journal of virology 85(5): 2469-2473. 
Wrammert, J., D. Koutsonanos, et al. (2011). "Broadly cross-reactive antibodies 
dominate the human B cell response against 2009 pandemic H1N1 influenza 
virus infection." The Journal of experimental medicine 208(1): 181-193. 
Wu, R., Y. Guan, et al. (2010). "A live bivalent influenza vaccine based on a H9N2 
virus strain." Vaccine 28(3): 673-680. 
Yassine, H. M., M. Q. Al-Natour, et al. (2007). "Interspecies and intraspecies 
transmission of triple reassortant H3N2 influenza A viruses." Virol J 4(1): 
129. 
Yassine, H. M., M. Q. Al-Natour, et al. (2007). "Interspecies and intraspecies 
transmission of triple reassortant H3N2 influenza A viruses." Virology journal 
4: 129. 
Yassine, H. M., M. Khatri, et al. (2011). "Potential role of viral surface glycoproteins 
in the replication of H3N2 triple reassortant influenza A viruses in swine and 
turkeys." Veterinary microbiology 148(2-4): 175-182. 
Yasuda, J., S. Nakada, et al. (1993). "Molecular assembly of influenza virus: 




Ye, J., E. M. Sorrell, et al. (2010). "Variations in the hemagglutinin of the 2009 H1N1 
pandemic virus: potential for strains with altered virulence phenotype?" PLoS 
pathogens 6(10): e1001145. 
Yen, H. L., C. H. Liang, et al. (2011). "Hemagglutinin-neuraminidase balance confers 
respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in 
ferrets." Proceedings of the National Academy of Sciences of the United 
States of America 108(34): 14264-14269. 
Yewdell, J. W., J. R. Bennink, et al. (1985). "Influenza A virus nucleoprotein is a 
major target antigen for cross-reactive anti-influenza A virus cytotoxic T 
lymphocytes." Proceedings of the National Academy of Sciences of the 
United States of America 82(6): 1785-1789. 
Yin, S. C., X. M. Peng, et al. (2006). "[MxA gene-88 G/T polymorphism influences 
the outcomes of HBV infection]." Zhonghua gan zang bing za zhi = Zhonghua 
ganzangbing zazhi = Chinese journal of hepatology 14(6): 418-421. 
Zamarin, D., A. Garcia-Sastre, et al. (2005). "Influenza virus PB1-F2 protein induces 
cell death through mitochondrial ANT3 and VDAC1." PLoS Pathog 1(1): e4. 
Zamarin, D., M. B. Ortigoza, et al. (2006). "Influenza A virus PB1-F2 protein 
contributes to viral pathogenesis in mice." J Virol 80(16): 7976-7983. 
Zell, R., A. Krumbholz, et al. (2007). "Prevalence of PB1-F2 of influenza A viruses." 
J Gen Virol 88(Pt 2): 536-546. 
Zhang, X., W. Kong, et al. (2009). "A one-plasmid system to generate influenza virus 
in cultured chicken cells for potential use in influenza vaccine." Journal of 
virology 83(18): 9296-9303. 
Zhou, N. N., D. A. Senne, et al. (1999). "Genetic reassortment of avian, swine, and 
human influenza A viruses in American pigs." J Virol 73(10): 8851-8856. 
Zhou, Y., M. Konig, et al. (1998). "Membrane-anchored incorporation of a foreign 
protein in recombinant influenza virions." Virology 246(1): 83-94. 
Zhu, H., B. Zhou, et al. (2011). "Novel reassortment of eurasian avian-like and 
pandemic/2009 influenza viruses in Swine: infectious potential for humans." 
Journal of virology 85(20): 10432-10439. 
 
 
